annual research report 2008 - princess alexandra hospital...4 centres for health research annual...

Princess Alexandra Hospital

Centres for Health Research

Annual Research Report 2008

©Centres for Health Research Annual Research Report 2008

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part of this publication may be reproduced by any process without prior written permission from the Princess Alexandra Hospital Centres for Health Research.

Enquiries should be directed to the Director, Research Development & Ethics, Centres for Health Research, Princess Alexandra Hospital.

ISSN 1833-6574

Leaders in Translational Research

Improved Medical Care

Clinical Problem

Basic science &/or clinical research

Evaluation of efficacy of research results on clinical problem

(including clinical trials)

Health Service Research (can the solution be applied to routine

practice?)

Clinical Solution

TRANSLATI

ONAL

RESEARCH

PEOPLEINVOLVED

Scientists and

Clinicians

Patients

Clinicians & Hospital

/ Health Managers

RegulatoryAuthority


Research - Key to Health Translating Science into Better Health 3

Message from the Clinical CEO . . . . . . 4

Chairman’s Report . . . . . . 6

Highlights . . . . . . 8

Australasian Kidney Trials Network . . . . . . 11

The University of Queensland at the Princess Alexandra Hospital . . . . . . 13

Queensland University of Technology at the Princess Alexandra Hospital . . . . . . 15

New Colleagues . . . . . . 18

Postgraduate Research Students . . . . . . 22

Committee Reports

Allied Health Research Committee . . . . . . 27

Cancer Collaborative Group . . . . . . 28

Human Research Ethics Committee . . . . . . 30

PA Foundation . . . . . . 32

Group Reports

Academic Unit in Geriatric Medicine . . . . . . 35

Acquired Brain Injury . . . . . . 38

Alcohol and Drug . . . . . . 40

Audiology . . . . . . 41

Brain Injury Rehabilitation . . . . . . 42

Cardiology . . . . . . 43

Cardiothoracic Surgery . . . . . . 45

Cardiovascular Imaging . . . . . . 47

Clinical Pharmacology . . . . . . 50

Dermatology . . . . . . 52

Diabetes and Endocrinology . . . . . . 55

Diamantina Institute for Cancer, Immunology and Metabolic Medicine . . . . . . 58

Ear Nose Throat . . . . . . 66

Emergency . . . . . . 67

Gastroenterology and Hepatology . . . . . . 68

Hypertension . . . . . . 71

Infection Management . . . . . . 74

Intensive Care . . . . . . 76

Internal Medicine & Clinical Epidemiology . . . . . . 79

Liver Research . . . . . . 81

Medical Oncology . . . . . . 83

Nephrology . . . . . . 86

Nursing Practice Development . . . . . . 92

Nutrition and Dietetics . . . . . . 93

Occupational Therapy . . . . . . 95

Older Persons Mental Health . . . . . . 97

Pathology Queensland . . . . . . 99

Pharmacy . . . . . . 101

Physiotherapy . . . . . . 103

Queensland Clinical Trials Centre - Biostatistics . . . . . . 104

Queensland Melanoma Project . . . . . . 107

Queensland Spinal Cord Injuries . . . . . . 109

Radiation Oncology (Mater) . . . . . . 112

Radiation Oncology (Princess Alexandra Hospital) . . . . . . 114

Respiratory and Sleep Medicine . . . . . . 117

Rheumatology . . . . . . 119

Social Work . . . . . . 120

Speech Pathology . . . . . . 122

Therapeutics Research . . . . . . 124

Upper Gastro-Intestinal . . . . . . 126

Publications - Major Grants - People

Summary of Publications & Students . . . . . . 130

Journal Articles . . . . . . 131

Book Chapters . . . . . . 144

Published Abstracts and Conference Proceedings . . . . . . 146

Accepted for Publication (in press) . . . . . . 150

Major Grants . . . . . . 155

Committees . . . . . . 160

Research Staff by Department . . . . . . 162

Postgraduate Students . . . . . . 176

Contents

4 Centres for Health Research Annual Research Report 2008

Message from the

Clinical CEOOver many years at the Princess Alexandra Hospital, I

have witnessed the development of a research ethos

and our researchers who have made and continue

to make impressive advances in basic, clinical and

translational research. These advances have directly

contributed to better healthcare delivery and practice

to our Queensland community. These breakthroughs

have been made possible because of the passion,

dedication, and commitment of our researchers. It

is important that we recognise the need to facilitate

and support imaginative and rigorous research –basic,

clinical, translational, policy-oriented - in all disciplines

and fields. It is also important that we recognise and

support, within major tertiary teaching hospitals, those

that undertake clinical and

translational research.

This year’s PAH Week

“Transplantation:

Now and in the

Future” was a great

success providing

an opportunity

to showcase and

celebrate our

advancements in

medical practice, delivery of clinical care, education

and research. There were many highlights during the

week including presentations by our young investigators

with more than 75 abstracts and 60 clinical posters

presented for judging.

The Translational Research Institute, which will be

located at the Princess Alexandra Hospital, is on

schedule and is expected to open in 2012. Brisbane

firms, Wilson Architects and Donovan Hill, were

successful in a bid for this new multi-million dollar

institute. The capability of the facility which will

include discovery, production, clinical testing and

manufacturing of new biopharmaceuticals will further

enhance Queensland’s research. The research milieu

and culture at the hospital will continue to increase

which is important for the translation of research and

integral to the development of the future generation of

scientists and clinician researchers.

The quality and impact of the research conducted at

the hospital is achieved as result of the commitment,

hard work and dedication of the entire research

community.

This report showcases the quality of the research

output and the many local, national and international

collaborations. Researchers at the Princess Alexandra

continue to attract substantial funding across a

range of specialties, including cancer, immunology,

cardiovascular, metabolic disorders, aged care and

telehealth, and therapeutics. We have seen a record

increase in research income, in research publications

and postgraduate student enrolment and completions.

4 Centres for Health Research Annual R


The report provides an overview of the multitude of

research achievements and documents many highlights,

including three significant grants awarded by the

Queensland Smart State to entities at PAH: $3million

towards scientific and analytical equipment for the

Molecular Cancer Research in Pathology; $2million

to establish the Australian-Canada Prostate Cancer

Research Alliance; and $1.25million Head and Neck

Cancer Centre of Excellence for Asia Pacific at the

Princess Alexandra Hospital for research into head and

neck cancers that severely affect people in developing

nations.

The report concludes with a list of publications, funding

and staff. Further details of the research conducted by

the Diamantina Institute for Cancer, Immunology and

Metabolic Medicine, The University of Queensland and

the Queensland University of Technology are contained

in their respective annual reports.

The Centres for Health Research under the leadership

of Professor John Prins and Ms Areti Gavrilidis is a vital

part of the Princess Alexandra Hospital’s commitment

to research. The Centres promotes, fosters and

facilitates excellence in research; provides advice on

strategic and operational policy on research direction;

oversees the process for effective management of

research infrastructure; and coordinates and facilitates

the administration of research activities and the

conduct of medical research within the hospital.

I congratulate and thank Professor John Prins for his

ongoing leadership and his contribution throughout

another successful year.

My appreciation goes to the entire research and clinical

community, the Human Research Ethics Committee,

to our donors, the PA Foundation, to our partners and

research collaborators whose tireless dedication and

commitment to the research endeavour continues to

shape the research and to contribute to delivery of

patient care at the Princess Alexandra Hospital and

Queensland.

Professor David Theile (Snr)District Chief Executive Officer

Metro South Health Service District

“The quality and impact of the research conducted at the hospital is achieved as result of the commitment, hard work and dedication of the entire research community.”


Chairman’sReport

2008 was again a highly successful year for research at

Princess Alexandra Hospital, evidenced by significant

increases in all standard indices and metrics. These

include publications, research grants, higher degree

students and applications to the Human Research Ethics

Committee.

The Human Research Ethics Committee warrants

special mention. Chaired by Dr Jennifer Fleming,

the Committee reviewed over 270 protocols in

2008 – representing the highest number of new

submissions and approximately a 7% increase over

2007. Particularly pleasing for me is the progressive

increase in the number of investigator-driven research

protocols whilst recognising the involvement in

industry-sponsored clinical trials. The committee has

substantially reduced time to approval throughout the

year through a combination of efficiencies within the

ethical and contractual review processes and in the

general administration of the applications, with reforms

directed by Ms Areti Gavrilidis.

The future of research on the campus bodes well, with a

number of exciting initiatives. Building work has begun

on the Pharmacy Australia Centre of Excellence (PACE),

due for completion at the end of 2009. This beautiful

building, fronting Cornwall St, will house The University

of Queensland Pharmacy School and its researchers in

addition to pharmacy-related commercial partners. It

will add significantly to research and education activity

on the campus, and contribute to the aim of complete

integration of clinical practice, teaching and research in

all disciplines. Planning for the Translational Research

Institute continues, with the majority of funds for

the proposed $350M budget already acquired from

State and Federal Governments and Universities. This

exciting venture will house over 600 Researchers from

the Princess Alexandra Hospital, The University of

Queensland, Queensland Institute of Technology and

the Mater Medical Research Institute in addition to the

PA-Southside Clinical School and substantial teaching

facilities. These initiatives, along with other precinct

developments including the Boggo Rd Development,

the Queensland Children’s Hospital and developments

within the PAH itself will position us as a lead player in

translational research.

Despite these enviable positives, we still need to work

to address some issues. We need to seek greater

uniformity of research

performance across the

campus. As is evident

from this report, we

have international-

standard research

in many disciplines.

However, some areas

are relatively less

productive,

despite a surfeit

of clinical

material and

a world class

research


facility and collaborative opportunities. The onus is on

individuals within the less productive areas to increase

their research performance – this is the responsibility

of a truly tertiary facility. Such improvement is also

highly achievable – evidenced by the tremendous

improvements in quality and quantity of research

in, for example, allied health research and trauma

research.

Finally, we need to ensure that management and

government processes keep pace with the increase in

research activity. We must ensure ongoing appropriate

ethical standards are applied, that we audit our

research activities and that we maximise funding

and collaborative opportunities. This is an essential

component of a world class research campus and

will ensure that we will be able to accommodate the

increasing levels of scrutiny. More importantly however,

such activities will facilitate ongoing efficient and

productive research, thus maximising the benefit to the

health of our community.

Professor John PrinsChair, Centres for Health Research


“These initiatives, along with other precinct developments including the Boggo Rd Development, the Queensland Children’s Hospital and developments within the PAH itself will position us as a lead player in translational research.”


HighlightsAnother successful year

Researchers at the Princess Alexandra Hospital have had a record year of achievements on a number of fronts

including number and total value of peer reviewed grants received, the number of students supervised and awarded

higher degree qualifications, and in the dissemination of knowledge through publication and presentations. A

number of researchers received awards including: Professor Ian Frazer received the Ramaciotti Medal for Excellence

in Biomedical Research, 2008 Prime Minister’s Prize for Science and the 2008 Balzan Prize for Preventive Medicine;

Professor Bryan Burmeister received the Queensland Health Australia Day award, Australia Day Certificate of

Achievement and a Certificate of Exemplary Service by Cancer Council Australia, and Professor David Johnson was

Queensland Finalist, Australian of the Year. Congratulations to the many clinician scientists, clinician researchers,

scientists and all those involved in supporting the research endeavours.

Diamantina Institute for Cancer, Immunology and Metabolic Medicine

The University of Queensland’s Diamantina Institute

for Cancer Immunology and Metabolic Medicine was

officially opened on Tuesday April 22, 2008 at the

Princess Alexandra Hospital. The Institute created

on January 1, 2007 through the amalgamation of the

Centre for Immunology and Cancer Research and the

Centre for Diabetes and Endocrinology Research, houses

approximately 200 researchers and students. There are

eleven research teams who work in areas of cancer cell

biology, immunology, and metabolic medicine.

The Diamantina Institute received a $3.2M grant from

the Australian Cancer Research Foundation (ACRF) to

undertake the creation of a unique, integrated genetics

and genomics facility on the PAH campus. This grant

was aimed at boosting and integrating cancer gene

discovery, gene characterisation and translation to

clinical practice. It has allowed researchers to buy the

latest high technology tools which will enable them

to sequence nearly a billion DNA bases per day, where

previously it took many months. The new centre is now

known as the ACRF Comprehensive Cancer Genomics

Facility.


Key research group highlights

Clinical Decision Making Tools for Older Patients

One of the key drivers of the research effort of the Academic Unit in Geriatric is

the desire to make specialist expertise available to all frail older people, including

in rural and remote communities. The team has developed and evaluated some

important service innovations which are likely to make this possible. Using

nursing assessors in rural settings to perform standardized assessments of older

people, and entering the information into a web-based “clinical decision support

system”, geriatricians in Brisbane are now able to provide reliable, safe and

effective assessments and management plans. This is unique world-wide.

A second innovation is to conduct ward rounds using mobile wireless video-

conferencing equipment. Brisbane based geriatricians are able to conduct full

ward rounds, interacting with staff, patients and family members at the bedside.

This approach is associated with considerable cost savings, and has been found

to be very acceptable to patients – in some respects even more satisfying than

traditional in person rounds. This work is ongoing, with plans to extend these

approaches to older people in nursing home and even in their own homes.

Professor Len Gray

Chronic Lymphocytic Leukaemia

Associate Professors Devinder Gill and

Nigel McMillan, along with the PAH and

UQ’s DICMM research teams, made two

significant breakthroughs in the world’s

most common form of leukaemia –

Chronic Lymphocytic Leukaemia (CLL).

The groundbreaking discovery that could

ultimately lead to a cure of CLL, could see a

new therapeutic agent trialed in patients in

about five years. The research breakthrough

included being able to keep CLL cells alive

for up to three months in culture flasks and

the discovery of two new growth factors

which keep the leukaemic cells alive.

Associate Professor Devinder Gill

Associate Professor Nigel McMillan


Test for Type 1 Diabetes

Professor Ranjeny Thomas and her team developed a simple test which could

allow for the early prediction of the onset of Type 1 diabetes in children, after

identifying a cellular pathway known as NF-kappa B that is activated in blood

cells of people with Type 1 diabetes.

Guidelines for Primary Aldosteronism

Associate Professor Stowasser served as one of seven members of an

international task force, sponsored by the US Endocrine Society, to develop a

practice guideline on case detection, diagnosis and management of primary

aldosteronism (the commonest potentially curable and specifically treatable

form of hypertension). These guidelines, which were published in The

Journal of Clinical Endocrinology & Metabolism and have since been widely

distributed and already frequently cited, marked a “coming of age” of the

concept that primary aldosteronism plays an important role in cardiovascular

disease states and should be systematically sought and specifically treated.

That the Unit was involved in their creation was a reflection of its reputation

as a world leader in this field.

Professor Thomas Marwick

Centre for Clinical Research Excellence in Cardiovascular and Metabolic Disease

Continuation of the second Centre for Clinical Research Excellence in

Cardiovascular and Metabolic Disease, by Professor Thomas Marwick. This

multidisciplinary group will undertake a series of unique studies aimed at

understanding and preventing early cardiovascular complications of several

metabolic conditions. Sensitive new cardiovascular imaging techniques will be

used to detect preclinical abnormalities in the structure, function and metabolism

of the heart and vasculature, facilitating the development of new strategies of

exercise and lifestyle intervention to prevent these complications. While built

on the successful initial CCRE in Cardiovascular and Metabolic Disease, including

multidisciplinary clinical research training, the new application involves major

new directions in the interface between the liver and metabolic syndrome, and

strategies for community-based prevention programs.

Associate Professor Michael Stowasser

Professor Ranjeny Thomas


Australasian Kidney Trials

NetworkThe Australasian Kidney Trials Network (AKTN) is a

resource which is inclusive of all researchers in the area

kidney disease within Australia and New Zealand. This

network was established to foster investigator initiated

trials in renal disease examining the efficacy and safety

of technologies, such as drug, or non-drug therapies

and diagnostic or screening tools, and in particular

to engage and enhance opportunities to improve

technology.

Prior to the establishment of the AKTN, there was

no formalised renal trials’ network operating within

Australia. In October 2003, a proposal led by Dr Carmel

Hawley, in response to a request by the ANZSN and KHA

for expressions of interest to run such a clinical trials

network, was developed and submitted. In August

2004, ANZSN and KHA endorsed this proposal to pursue

the initiation and running of the Australasian Kidney

Trial Network involving a Brisbane-based Operations

Secretariat with a successful NMRC Enabling Grant

awarded to the network. The group was supported

in early stages by staff from the Princess Alexandra

Hospital Centres for Health Research, Professor Don

Cameron AO, Chair and Ms Areti Gavrilidis, Director

Research Development and Ethics.

Research infrastructure has been established to

effectively connect Australian and New Zealand

researchers and the practising nephrology community.

The AKTN brings together critical mass of expertise

in trial design, obtaining research funding, electronic

data capture, data management, trial conduct, analysis

and reporting. The membership of the network is

diverse and includes physicians, epidemiologists,

biostatisticians, nurses, allied health professionals and

scientists involved in clinical and translational renal

research

Key achievements of the network include the

establishment of a vibrant clinical and translational

research network and infrastructure that fosters

collaborations between clinical research investigators

in Australia and New Zealand. Other achievements

include:

Success with competitive funding particular •

from Commonwealth funding opportunities and

international competitive grants.

Bilateral links with national organisations including •

the Queensland State Government, Queensland

Clinical Trials Network, Australia and New Zealand

Society of Nephrology, Kidney Health Australia,

ANZDATA Registry, CARI Guidelines, and Cochrane

Renal Group to ensure consensus in targeted

research strategies

Clinical trial initiation and development with •

a robust process for the development of trial

concepts into high quality clinical trials

The development of proposals for clinical trials •

with over 30 trials proposed to date

Successful patient recruitment (strategies have •

included extending invitations to participate in the

trials to all nephrology centres in Australia and New

Zealand thus establishing a link between practising

nephrologists and researchers)

Focusing on patient-centred outcomes in priority •

areas through an established rigorous peer-review


process of assessing all clinical trial proposals.

Strategy to successfully train, educate and mentor •

the next generation of clinician researchers.

Leading nephrologists provide key leadership to

enhance the clinical research capacity and expand

the critical mass of senior clinician mentors for

junior clinician researchers.

The network has been actively involved in discussions

with clinician researchers in Malaysia, China, United

Kingdom and Canada around collaborations in clinical

trials. The vision is to continue to consolidate on

current strengths and focus on key strategic scientific

and operational goals. These include:

Establishing of the AKTN as a key group in a •

Global Kidney Trials Consortium to not only

engage Australasian colleagues in international

projects, but to help Australasian researchers

and their clinical and translational research gain

international recognition.

Consolidating AKTN’s position as a national •

leader in renal research and broaden the range

of trials performed and forge closer links with

existing groups and infrastructure to maximise on

collaborations and efficiency.

Strengthening the Scientific Program and enable •

the development of new ideas, fill gaps in

translational research and evidence in the practice

of nephrology, widen focus of trials and to enhance

links with existing organisations in conducting

high priority studies for Indigenous communities

throughout Australia Indigenous health.

Developing early-career researchers by continuing •

to actively encourage and promote young

researchers, provide scholarships for PhD programs

and Masters Degree courses, and continue with

educational workshops on clinical trials design,

methods, analysis and conduct.

The group are currently running four trials, three

of which are being run in Australasia and one trial

involves Malaysia and the UK. Plans are underway to

commence a further Australasian trial in November.

The AKTN is continuing to forge its position as a leader

in clinical trials in nephrology. The next five years

promise to strengthen and diversity the activities of

AKTN and to deliver the results a number of trials

which will improve the outcomes of patients with

kidney disease.

Associate Professor Carmel HawleyChair, Operations Secretariat


The University of Queensland

at the Princess Alexandra Hospital

Faculty of Health Sciences

The University of Queensland’s Faculty of Health

Sciences (www.uq.edu.au/health) has strong ties with

multidisciplinary research groups at the Princess

Alexandra Hospital (PAH). The faculty comprises seven

schools: medicine; nursing and midwifery; population

health; pharmacy; human movement studies; dentistry

and health; and rehabilitation sciences.

There are many conjoint appointments and honorary

academic appointments across the hospital and the

University attached to these schools. Multidisciplinary

research is a key strength, including the new NHMRC

Program Grant awarded to Professor Tom Marwick and

his group.

A number of school research centres are based at the

hospital including the Endocrine Hypertension Research

Centre and the Renal Research Centre. There is a range

of less formal collaborations that combine clinical

expertise with patient-focused research in ground

breaking development activities. This innovative

research translates directly into optimal patient care.

In exciting developments, the Faculty of Health Sciences

will collaborate with the Diamantina Institute. The

School of Pharmacy will be increasing collaborations

across the campus with the ongoing development of

the Pharmacy Australia Centre of Excellence (PACE).

The PACE project is expected to be completed by 2010

with the relocation of the School of Pharmacy to the

site adjoining the hospital. PACE will also host the

professional pharmacy organisations and associated

health industries. It is planned that to increase links

with industry, the pharmacy profession and the hospital

and greatly expand the school’s research portfolio and

provide greater opportunities for postgraduate research

training.

The University of Queensland, especially the Faculty

of Health Sciences, look to increasing research ties

with this major hospital campus, with the focus on

improving health outcomes through excellence in

research.

School of Medicine, Faculty of Health Sciences

The University of Queensland’s School of Medicine is

recognised as one of four world-class medical schools

in the country and offers a variety of clinical rotations

within Australia and overseas. Most of its 1328 medical

students have rotated through clinical placements at

the PAH during their four years’ study.

The School of Medicine is currently composed of

10 clinical schools in Queensland, Brunei and New

Orleans; more than 60 research groups; and a medical

program at UQ’s Ipswich campus. Queensland Health

and private health service providers are the School’s

main partners and more than 1450 staff contribute to

its teaching and research activities.


More clinical schools are planned as student numbers

increase and teaching and research at the various

sites/hospitals support 11 academic disciplines:

anaesthesiology and critical care; molecular and

cellular pathology; general practice; paediatrics and

child health; medical education; psychiatry; medical

imaging; rural and remote medicine; medicine;

surgery; obstetrics and gynaecology.

As a tertiary-level facility with more than 700 beds, the

PAH facilitates research ranging from understanding

fundamental bodily processes to applying such

knowledge to improve clinical practice. Just over 100

School of Medicine staff were based at the PAH in 2008,

attracting $4.49M in research funding for the year.

School of Medicine groups represented at the PAH

include: the Cardiovascular Imaging Group, the

Academic Unit in Geriatric Medicine and the Endocrine

Hypertension Research Centre. Urology, liver and

ophthalmology research is also conducted by School

staff, along with studies in the clinical departments of

gastroenterology & hepatology; intensive care; ear, nose

& throat; the renal and respiratory units.

Many of the 700 plus PAH medical staff also hold joint

positions or academic titles with the School of Medicine

and multiple partnerships with research groups, other

universities and hospitals are also encouraged. There

are many collaborative studies underway, including

research into heart failure, liver disease, schizophrenia,

diabetes, geriatric medicine, psychiatry, hypertension

and clinical pharmacology.

The Professorial Chair of Dermatology was

implemented as a joint initiative of The University

of Queensland and the Queensland Skin and Cancer

Foundation to represent Queensland’s first professorial

research unit led by specialist dermatologists. The

Dermatology Group, is co-located at the hospital

dermatology department, is directed by renowned

Austrian clinical and academic dermatologist Professor

H. Peter Soyer. Their research primary objectives

are developing in focus particulary in the areas

of teledermatology, cutaneous bio-imaging and

cutaneous systems biology. The Head of the Mater

Clinical School, Professor David McIntyre has expanded

links between the hospital and the school’s research

groups. In collaboration with the Head of PA Southside

Clinical School, Professor John Prins, he has fostered

the development of the Princess Alexandra Hospital

Collaborative Organisation for Research and Education

which aims to further integrate the activities of these

groups. This group will form a major part of the

proposed Translational Research Institute to be based

at Princess Alexandra Hospital.

The School of Medicine also encourages staff and

graduates to conduct research relevant to communities

served by the School and to publish results in national

and international peer-reviewed journals. Such research

informs clinical academics’ teaching in the MBBS

Program and postgraduate courses, and is subject to

monitoring by the PAH and UQ’s human research ethics

committees. Research into effective education methods

is also a component of the MBBS Program.

Professor David Wilkinson


The University of Technology

at the Princess Alexandra Hospital

The current partnership between Queensland

University of Technology and the Princess Alexandra

Hospital will continue to expand. The opening of

the Translational Research Institute (TRI) in 2012 will

further foster and strengthen partnership arrangements

and collaborations in basic, clinical and translational

research. The TRI, which will combine research

groups from QUT’s Institute of Health and Biomedical

Innovation, brings together QUT, The University of

Queensland (Diamantina Institute and School of

Medicine), the Mater Medical Research Institute,

and the Princess Alexandra Hospital. Currently, QUT

research programs represented at the hospital include

trauma, wound healing, prostate cancer, and nursing

practice.’

Trauma

The QUT Trauma Research Group headed by Professor

Michael Schuetz, orthopaedic and trauma surgeon,

includes engineers and computer scientists, working

with surgeons, and emergency specialists at the PAH.

This Group improves community capacity to respond to

trauma and creates more effective clinical services for

severely injured patients. It focuses on bone fracture

healing through computer modelling, developing bone

substitutes and infection resistant implant coatings.

To date, the Group has had success creating new

models to help researchers better understand the

fracture healing process, how effective current surgical

interventions are in fracture healing, and better ways to

measure the fit of surgical implants.

In the future, the public will benefit from this planned

research into how diseases such as osteoporosis,

infections and drugs affect fracture healing. The

group plans to explore new ways of treating soft tissue

trauma.

Wound Healing

The QUT Wound Research Program is led by Professor

Helen Edwards and Professor Zee Upton. It is a

collaboration between scientists, engineers, nurses, and

surgeons from QUT and the Princess Alexandra Hospital

committed to the uptake of research into health

practice. The group advises governments, healthcare

providers and the community concerning improved

wound care. Clinical research includes development of

therapeutics and dressings, evaluation of bandaging

techniques, new devices and creating a DNA and

proteomics databank of wounds.

The Program’s discovery of a novel growth factor

complex VitroGro® led to the establishment of a start-

up company, Tissue Therapies Ltd. This company now

conducts clinical trials of VitroGro® in Australia and

Canada.


The public will benefit from the program’s continued

collaborative research into accelerated healing and

reduced scarring of wounds. The continued refinement

of the program’s human skin equivalent will also

dramatically improve the ability to test cosmetics and

pharmaceuticals without involving animals.

Prostate Cancer

The QUT Prostate Cancer Program, directed by Professor

Colleen Nelson and Professor Judith Clements, examines

therapeutic and biomarker development for prostate

cancer and involves geneticists, protein chemists,

urologists, oncologists and clinical pharmacologists.

It employs high throughput bioprofiling of prostate

cancer tissues to characterize the molecular

mechanisms underlying disease progression. The

research validates the relevance of potential targets

through the expression of candidate genes on tissue

microarrays elucidating pathways associated with poor

response to treatment.

The program is working collaboratively with

commercial partners in the United States and the

United Kingdom, and has established the national

Australian Prostate Cancer Bio-resource. In 2008 the

Australian-Canadian Prostate Cancer Research Alliance

was established, funded by a $2 million Smart State

National and International Research Alliance Program

grant. The alliance brings together specialists from

“Our major achievements during the year were the ACRF grant and the Australian-Canadian Prostate Cancer research Alliance funding (July) and First inaugural meeting in November with the PCFA”

the Institute of Health and Biomedical Innovation,

the Princess Alexandra Hospital Biomedical Precinct,

Vancouver, and 28 other partners throughout Australia

and Canada.

Professor Nelson was also named as a Chief Investigator

on the Australian Cancer Research Foundation

Comprehensive Cancer Genomics Facility, which

was awarded $3.2 million.. This award brought to

the Princess Alexandra Hospital research facility

a state of the art microarray scanner, genotyping

expansion, next generation sequencing, automated

immunohistochemistry staining and digital slide

scanning, and a scientific data management system.

These instruments and software are critical to the

ongoing developments of the translational Prostate

Cancer Research Centre.

The program aspires to trial new potential prognostic

biomarkers and therapeutics at the hospital, and is

poised to create and evaluate new methods for more

effective diagnosis and treatment of prostate cancer.

Nursing Practice

QUT is conducting multiple nursing-specific research

projects in collaboration with the Princess Alexandra

Hospital. Led by Professor Patsy Yates, the QUT School

of Nursing’s Director of Research, Professor Helen

Edwards, Head of School, and Dr Alexandra McCarthy,

Senior Lecturer, the collaboration incorporates various

projects examining key health issues. Projects include:

prevalence and determinants of health promotion


and risk reduction of younger female cancer survivors;

identifying the relationship between biochemical

markers and healing in chronic leg ulcers treated with

compression; evaluating novel methods for delivering

non-pharmacological interventions for dyspnoea

in cancer patients; evaluating a prescribed exercise

intervention for patients with venous leg ulcers;

cryotherapy for docetaxel-induced nail toxicities: Case

control study; health promotion and risk-reduction

behaviours of younger female survivors of breast and

haematological cancers.

A pilot study into the effects of exercise as a nursing

intervention to improve general physical health status

in haemodialysis patients has just been completed by

Dr McCarthy, who holds a joint appointment at QUT

and the PAH.

Significant developments particularly in trauma and

prostate cancer research were evident in 2008. The

goals for 2009-2011 relate to building a stronger

competitive grant base and stronger teams in our four

areas of expertise. A significant focus in 2009 will be in

prostate cancer.


New Colleagues

“Working at the PA provides an excellent opportunity to advance my research on the importance of sub-tropical grass pollens and IgE-producing B cells in hayfever and asthma.”

The theme of Dr Janet Davies’ research is antibody-

antigen interaction and the development of B cell

responses in autoimmunity and allergy. Her PhD

studies, with Professor Carnegie at Perth’s Murdoch

University, were on Lentivirus molecular mimicry

in models of the autoimmune diseases multiple

sclerosis and rheumatoid arthritis. During her post

doctoral studies with Professor Mackay at Melbourne’s

Monash University, Dr Davies mapped the binding

sites for several clinically important auto-antibodies

from patients with type 1 diabetes, primary biliary

cirrhosis and rheumatoid arthritis using phage display

technology and a novel data analysis protocol she had

developed.

Dr Davies spent nine years at the Alfred Hospital and

Dr Janet DaviesSenior Research Fellow

Monash University with Professors O’Hehir and Rolland

researching IgE producing B cells and grass pollen

allergy, an important contributing cause of asthma in

many cases. A 2005 grant from the Victorian Asthma

Foundation enabled cloning of the major allergen

of the subtropical Bahia grass pollen. The success

of this project lead to further development by the

CRC for Asthma and Airways Disease of the research

on Bahia grass pollen, an important allergen source

capable of triggering hayfever and asthma throughout

a prolonged season from spring to autumn. Under

her leadership the two major allergens of Bahia grass

have been characterised resulting in national and

international patents on use of Bahia grass pollen for

immunotherapy treatment of allergic diseases.

Dr Davies’ award-winning research has been recognised

by several leading institutions in her field. She has held

a honorary lectureship with Monash University since

2001, teaching immunology to undergraduate medical

students and training many research students and

visiting scientists in the laboratory preparing them for

their own successful research careers. She was the post-

doctoral representative to the executive committee of

the Department of Immunology and convened the the

departments’ research symposia in 2004 and 2005.

Dr Davies moved to Brisbane in July 2008 and joined

The Queensland University School of Medicine

Respiratory Medicine Research Group based at the

hospital and lead by Professor John Upham. She is

developing the group’s Smart State research into the

beneficial effects of bacterial lipopeptides in switching


off allergic responses to allergens, including house dust

mites and grass pollens.

She will continue investigating the immunological

relationship between pollen allergens of Bahia and

temperate grasses, as well as the prevalence of allergic

sensitization to subtropical grass pollens in different

climatic regions of Australia, especially in Brisbane

where these grasses predominate. With support from

The University of Queensland she will also pursue

research of grass pollen-specific IgE antibody producing

B cells and their role in triggering and perpetuating

allergic diseases.

“Having worked in Oncology since 1995, I’m pleased to be part of a multidisciplinary team at the PA committed to cancer research”

Dr McCarthy joined Cancer Services as Senior Research

Fellow in 2008, holding a joint appointment with QUT’s

School of Nursing and Midwifery and the Institute of

Health and Biomedical Innovation. She completed her

PhD in 2005. Her research to date has been in oncology

with a focus on the management of the acute and long-

term effects of cancer treatments in all domains of

health.

Current funded studies include a suite of projects

related to the long-term outcomes and behavioural

risks associated with cancer survivorship; including a

large study funded by the Department of Health and

Ageing lead by Professor Patsy Yates, Dr McCarthy, and

Associate Professor Debra Anderson. The outcome of

this work is an intervention to enhance cancer patients’

Dr Alexandra (Sandie) McCarthy

self-management of their health after discharge, which

is about to be trialled.

Other projects include an intervention to manage the

hand and nail toxicities associated with docetaxel,

undertaken in collaboration with researchers

and clinicians from Infection Control at PAH; an

investigation of evidence-based nursing management

of citrate toxicity during apheresis procedures; and

a project that examines issues related to health care

facility-acquired infection of central venous access

devices, again undertaken in conjunction with staff

from Infection Control.

A baseline study to assess the prevalence and nutrition

impact of chemotherapy-induced nausea and

vomiting is underway in collaboration with the PAH’s

nutrition and dietetics researchers and clinicians. This

multidisciplinary team have a suite of projects planned

with respect to the management of cancer-related

nausea and vomiting, once baseline data are collected.

Dr McCarthy is a medical sociologist by higher degree

training. As a result, many of these projects are

multimethod. They not only measure the effect of

nursing interventions, they often have an equally

interesting component addressing the quality of

life and sociocultural implications of cancer and

its treatments for the patients involved. Nursing

clinicians have key roles in these studies, providing the

opportunity to use relevant projects as a vehicle for the

thesis component of their higher degree studies.


“I’m delighted to be working with world-renown researchers at the Princess Alexandra Hospital while completing my postdoctoral research”

Originally from London, Dr Petchey trained in

Southampton and worked as a junior doctor in

various hospitals throughout the south of England.

After completing his MRCP he obtained a specialist

training in renal and general (internal) medicine at

Addenbrooke’s Hospital in Cambridge.

With special dispensation from Cambridge, Dr Petchey

came to Brisbane in late 2008 to undertake his PhD

with Professor David Johnson and Associate Professor

Nicole Isbel at the Princess Alexandra Hospital’s Renal

Research Department. Dr Petchey’s PhD examines the

pleiotropic action of vitamin D in patients with chronic

kidney disease, specifically its role in modulating

inflammatory burden, ameliorating insulin resistance

and its effects on cardiovascular structure and function.

Since joining the Princess Alexandra Hospital Dr

Petchey’s research has also included the Landmark

3 trial; a multidisciplinary approach to aggressive

Dr William PetcheyRenal Research Fellow

cardiovascular risk factor medication in patients with

chronic kidney disease; obesity, the relationship with

inflammatory burden and its predictive ability for

cardiovascular morbidity and mortality in the pre-

dialysis renal population; and, the role of vitamin K in

extra-osseous calcification.

Links with The University of Queensland’s Centre for

Clinical Research Excellence (CCRE) have also provided

Dr Petchey the opportunity to work with Professor

Tom Marwick (cardiology) and Professor John Prins

(endocrinology). He has had exposure to world-leading

cardiac imaging techniques, introduction to and

involvement with cutting-edge concepts such as the

role of bone in glucose metabolism. With Dr Hickman

of the Diamantina Institute he has established the

euglycaemic clamp technique locally, which is seen as

the gold-standard when measuring insulin resistance

and is only performed by a handful of research teams

world-wide.

Maintaining his enjoyment of medical education,

Dr Petchey teaches undergraduate medical students

regularly and was invited to join the Faculty of

Medicine as an Associate Lecturer. Highlights so far

have included seeing his first peer-reviewed journal

articles in press, presenting abstracts at the Australia

and New Zealand Society of Nephrology meeting and

being an invited speaker at the International Meeting

for the Joint Faculty of Intensive Care Medicine. He

secured competitive research funding from Roche and

the Princess Alexandra Hospital Foundation Trust, and

has received support from a CCRE scholarship towards

his PhD completion.


“Complementary medicines’ conjures up something that lacks evidence and queries as to its efficacy, while ‘alternative medicine’ hints at there being other alternatives to medicine. There should only be one medicine, and that is evidence-based medicine.”

Associate Professor Luis Vitetta, a graduate of The

University of Melbourne, was previously the Senior

Research Fellow with the Centre for Molecular Biology

and Medicine at Melbourne’s Epworth Medical Centre

and Deputy Head and Director of Research at the

Graduate School of Integrative Medicine at Swinburne

University.

His interests are in the areas of clinical epidemiology,

functional foods/immune function, mind body

medicine and cellular metabolism pro–oxidant

signalling systems. He has undertaken research aimed

at investigating the scientific evidence-base for a variety

of treatments commonly known as ‘complementary

medicine’ or ‘alternative medicine’. He dismisses

Associate Professor Luis VitettaPhoto by Stewart Gould, The University of Queensland

the myth that integrative medicine and alternative

medicine are synonymous, saying alternative medicine

comprises therapies not taught in conventional medical

schools, based on the ideas ranging from sensible (and

worth including in mainstream medicine) to those

that are extremely foolish and a few that are very

dangerous. His research is partly designed to prove to

the complementary medicine industry that it would be

better served by an integrative medical model.

A $660,000 grant from the National Institute of

Complementary Medicine (NICM) allowed him to

establish a NICM Collaborative Centre for Transitional

Preclinical and Clinical Research in Nutraceuticals and

Herbal Medicines. The Centre draws together leading

expertise in complementary and conventional medicine

to support complementary and alternative medicine

with evidence-based research.

Australia is one of the largest per capita users of

complementary medicines in the western world, and

Associate Professor Vitetta believes it is important

to thoroughly investigate the efficacy and safety of

practices and products that are not part of conventional

medicine. Such rigorous research may ultimately

replace terms such as ‘complementary medicines’

and perhaps lead to their inclusion into mainstream

medicine.

Associate Professor Vitetta’s area of interest emphasises

two key components being the scientific nature of the

work and the philosophy of recognising only one type

of medicine.


Postgraduate Research

“It has been a big change moving from clinical work to research, but I’ve developed many new skills and a different perspective on medicine already.“

Dr Barraclough completed her basic medical training

and first six months of nephrology training in

Melbourne, and then undertook a further 18 months’

training in Vancouver and New Delhi. She returned to

Australia in 2008 to complete her final year of advanced

training at the Princess Alexandra Hospital

Given Dr Baraclough’s long-term goal to work in renal

transplantation, she commenced a PhD focussing on

Dr Katherine Barraclough

BK nephropathy in adult kidney transplant recipients,

supervised by renal transplant physician Dr Nicole Isbel

(Department of Nephrology, PAH) and research fellow

Dr Christine Staatz (Department of Pharmacology, UQ).

BK nephropathy is caused by a polyoma virus called

‘BK’. It is an increasing problem for kidney transplant

recipients because it’s emerging as a cause of graft

loss. Knowledge regarding risk factors for the disease

is extremely limited and inconsistent. The aim of Dr

Barraclough’s PhD is to establish predictors for BK

nephropathy. Given that this virus really only leads to

clinical disease in the context of immunosuppression,

she will attempt to better characterise and quantify

overall immunosuppression burden and its relationship

to the appearance of post-transplantation BK viraemia.

Additionally the study will look into other novel donor,

recipient and viral determinants of disease.

Dr Barraclough has spent the first year of her PhD

planning an observational cohort study with a two-year

follow-up period. Patient recruitment has commenced.


“There is a wonderful thrill that goes with when the goal is reached knowing that whatever contribution you make will be stamped in the literature forever.“

Professor Bryan Burmeister was awarded a doctor of

medicine (MD) in July 2008. The title of his thesis was

‘The Role of Radiation Therapy in the Management of

Carcinoma of the Oesophagus - a personal experience

over 15 years’.

The thesis consisted of a review of 14 papers with

himself as the first author or as a contributing author.

The thesis was divided into three sections:

Definitive radiation therapy for oesophageal •

cancer;

Preoperative adjuvant radiation therapy for •

oesophageal cancer;

Palliative radiation therapy for oesophageal cancer. •

A clearer decision tree on management strategies for

oesophageal cancer now exists, as a result of the thesis.

Professor Burmeister believes that an MD is a wonderful

Professor Bryan Burmeister

challenge for a clinician as it provides a greater insight

into your area of expertise but also combining research

activity under one banner. Furthermore he believes

that research has various positive benefits to your

own personal and the hospital’s achievements, while

fostering research encourages staff at all levels to come

to the PAH.

Born in Zimbabwe and educated in South Africa, Bryan

has been at the PAH since 2002, and officially as the

Director of Radiation Oncology since 2004. He has

witnessed considerable change and development in the

radiation oncology field, particularly an increase in the

service commitments, techniques and technology.

Since the award of his MD, ongoing research has

included a published phase II trial using newer

chemotherapy regimens in oesophageal cancer

and a major PAH based randomised trial which has

been presented in abstract form and is currently

being prepared for formal publication. In future,

Bryan would like to devote more time to teaching

undergraduate and postgraduate students in the field

of radiation oncology.

The pot of gold at the end of the rainbow and the

subsequent flow on effects is what drives him to

continue with research. He has inspired colleagues to

pursue their own MD’s. His most recent achievement

is a prestigious invitation to present a plenary

presentation at the 2009 American Society for

Therapeutic Radiation Oncology meeting on a recently

completed randomised trial in melanoma which is his

other major interest.


Carolyn Lang was based at The University of

Queensland’s Diamantina Institute for Cancer,

Immunology and Metabolic Medicine. Her advisor

from UQ was Associate Professor Graeme Macdonald

and from QUT, Professor Michael Dunne. The focus

of Carolyn’s clinical epidemiology research was

investigating the contribution of host and virological

factors to symptoms of people living with chronic

hepatitis C infection.

Hepatitis C (HCV) is a major cause of cirrhosis and

liver-related deaths, and, for most people with HCV the

major impacts are due to symptoms and quality of life.

People living with HCV are interested in strategies that

will ameliorate their symptoms.

Quality of Life in individuals living with HCV infection

has been the subject of ongoing research. Two

important aspects emerged from an earlier qualitative

study: participants identified a variety of symptoms

Dr Carolyn Lang

they attributed to HCV; and several participants

reported episodic exacerbations with clustering of

physical symptoms. Carolyn sought to quantify these

symptoms and the phenomenon of clustering, and

further sought to determine if the symptoms and

symptom clusters were more prevalent and severe in

people living with HCV than in the general community

or among people living with other chronic liver

diseases; and, to investigate host and virological

correlates of these symptoms.

This research has provided greater understanding of the

nature of the symptoms experienced by people living

with HCV and has demonstrated that neuropsychiatric

symptoms were more likely to be reported by people

living with HCV than people with other liver diseases,

and more likely to report gastrointestinal symptoms

than people in the general community. Sleep problems

were significantly associated with inflammation of

the liver, the presence of steatosis in the liver, more

fibrosis and genotype 3 infection; while people with

increased fibrosis were more likely to report several

neuropsychiatric symptoms (depression, mental

tiredness and sleep problems).

Carolyn has presented her findings at International and

Australian conferences, Hepatitis Council of Queensland

support groups. Carolyn was awarded her PhD in 2008

and is currently an Epidemiologist with the Central

Population Health Services of Queensland Health.


“While working as an occupational therapist in Cancer Services, I was often involved with patients experiencing high levels of fatigue. Because traditional occupational therapy techniques have not been tested in cancer populations, there was limited information available to guide effective treatment of such patients”“

Amanda Purcell commenced her PhD at The University

of Queensland in 2006 with assistance from a dedicated

team of supervisors and co-investigators including Dr

Jenny Fleming, Dr Terry Haines, Dr Sally Bennett, Dr

Bryan Burmeister and Ms Kate McGuane. Her research

focused on cancer-related fatigue in radiotherapy

patients.

Amanda Purcell

An epidemiological study examining the contributing

factors to fatigue during radiotherapy identified

several behaviours, thereby supporting the concept of

cancer-related fatigue as a multidimensional construct.

The study was also used to help practitioners better

understand the significance of changes in scores on the

cancer-related fatigue assessment tool. Results of this

study have been accepted for publication in the British

Journal of Occupational Therapy, Supportive Care in

Cancer.

Initial findings were used to guide the development of

a second study: a randomised control trial examining

the effects of education and support in reducing

cancer-related fatigue and improving quality of life

in patients undergoing radiotherapy. Education and

support sessions developed by the multidisciplinary

radiotherapy team were trialled at different points

of radiotherapy treatment and were compared to

standard care. This study is progressing on target,

with recruitment finalised and data collection due for

completion by June 2009.

Her postdoctoral studies have been supported by

the radiation oncology and occupational therapy

departments. She has received financial assistance

from the Queensland Health Cancer Clinical Network,

the Princess Alexandra Hospital Cancer Collaborative

Group and Queensland Health’s Health Practitioner

Research Scheme.


Committee Reports


The Allied Health Research Collaborative includes health professionals

providing diagnostic, rehabilitative and clinical support to the hospital

and community through specialised services. It produces internationally-

relevant research on advanced health service delivery that is responsive to

personal and environmental contexts.

In 2008 the committee continued to facilitate, encourage and support

high quality research in allied health which has been nationally and

internationally recognized.

The committee also continued to: coordinate and advocate for the

dedicated allocation of resources to research in allied health; provide

the support to increase the number of research proposals, publications,

presentations and successful grant applications in allied health; increase

the profile of allied health involvement in research at PAH and the

community; ensure allied health research needs are represented and considered in strategic planning, encourage

networking and collaborations with nursing and medical researchers and universities and, liaise with the Clinical

Support Services Evidence Based Practice Network to encourage the uptake of research findings into clinical practice

and facilitate clinically relevant research.

Allied Health Research

Committee

AchievementsCoupled with an increase in interdisciplinary research projects and international collaboration, research productivity also increased. Over $1.5 million of funding was secured in the areas of falls, exercise therapy, spinal cord injury, brain injury rehabilitation, ageing, cancer services, indigenous health services, health related quality of life and nutrition.

Other key achievements included: a significant increase in postgraduate research participants with more than 20 full-time and part-time higher degree students enrolled; over 30 publications in refereed journals and book chapters; increase in national and international collaborations/linkages and, increase

in interdisciplinary and multidisciplinary research projects.

Other highlights included the development of an Allied Health Research and Evidence Based Practice Strategic Plan 2008-2010; the co-ordination of a Metro South District bid for Health Practitioner Research positions in a proposed Centre for Functioning, Disability and Health Research; the inaugural Division of Rehabilitation Research Symposium; a forum highlighting the evidence based practice and research relationship in the Division of Clinical Support Services; and intranet website development.



Cancer Collaborative GroupThe Cancer Collaborative model has successfully brought together scientists and clinicians to translate scientific

discoveries into clinical practice. The collaborative development grant from the Cancer Council Queensland in 2003

has contributed to an acceleration of cancer research and the application of such research in routine care through the

provision of training and equipment. It has provided support for new investigators from a variety of different medical

specialities to conduct translational research into different cancer types.

Summary of the achievements and some of the 2008 highlights are outlined below.

Discoveries in translational and clinical cancer research:

Over 60 collaborative cancer-related research projects were being conducted in 2008, with studies including biology of leukaemias, osteosarcomas, skin and breast cancers.

Gene expression profiling studies have shown a distinct pattern in chronic lymphocytic leukaemia (CLL) patients, differentiating between stable disease and progressive disease. Research data implicate one of the bone cells (osteoclast) in the spread of osteosarcoma, and cancer databases have been mined, producing 14 publications regarding lymphoma, head and neck cancer, leukaemia and oesophageal cancer.

Establishment of novel, broadly applicable approaches to cancer control:

Basic and clinical research altered clinical paradigms, which led to better treatment for people with cancer. Research was relevant to several cancers but notably in the management of post-transplant related lymphomas, oesophageal cancers, leukaemias and head and neck cancers.

New training and career development opportunities:

Career development is strongly valued by the Cancer Collaborative. Since 2003, six PhD scholarships were awarded in various specialties as well two practitioner

fellowships, one to an oncologist and another to allied health clinician. In addition, a post-doctoral scholarship was awarded to Dr Jennifer Fleming for tissue bank donor research. In 2008 a scholarship, jointly funded with the Australasian Research Management Society, was also awarded to Ms Gavrilidis to present a poster at the International Network of Research Management Societies 2008 Symposium in the UK. Ms Gavrilidis received special commendation on her poster.

Boost to collaborative use of facilities and expertise:

Microarray equipment has been incorporated into the genomic facility shared by researchers from the Diamantina Institute, QUT, Pathology Queensland, QIMR, Cancer Services Division, and IMVS (Adelaide). Tissue banks used by PAH clinicians are increasingly available to investigators in other institutions.

Researchers from the PAH campus, MMRI, QIMR, Griffith, ALLG, Peter MacCallum Cancer Centre and IMVS (Adelaide) now collaborate and the PAH/UQ Biostatistical Clinical Trials Centre has been established.

Significant funding has been leveraged:

In addition to financial and in kind support from the Cancer Council Queensland, the Princess Alexandra Hospital and the PA Foundation, the Cancer



Collaborative members secured substantial external funding. Major funding sources in 2008 include:

An NHMRC Major Equipment and Infrastructure •

grant of $584,700 (Gabrielli, Whitehead, Thomas,

McMillan, Saunders and Steptoe)

An Australian Cancer Research Foundation grant •

of $3.2M to establish a comprehensive cancer

genomics facility for the Diamantina Institute for

Cancer, Immunology and Metabolic Medicine, UQ,

on the PAH campus (Gonda, Brown, Nelson, Frazer

and Saunders)

A Pathology Queensland Smart State Equipment •

grant of $2.9M for clinical pathology research

laboratory equipment (Francis, Marlton and Gill).

Translating research into practice:

Several methods have been used to share research results within the medical field and the community during the year. These included:

The publication of 55 journal and 10 press articles; •

Three Cochrane reviews of which two related to •

breast cancer and one on radical prostatectomy for

prostate cancer;

Bi-monthly lunchtime seminars bringing together •

clinicians and scientists;

The Cancer Collaborative research website is accessible and continues to be improved and updated http://www.health.qld.gov.au/pahospital/research/ccg_defaul.asp


Human Research Ethics

Committee

The Princess Alexandra Hospital Human Research Ethics Committee held

11 meetings during the year and reviewed 273 new research protocols,

affirming the increasing volume and diversity of research being undertaken

within the district. There were 101 PAH investigators’ research protocols,

29 studies by students, 56 commercially-sponsored projects and a range

of collaborative and multidisciplinary projects with researchers at

affiliated teaching hospitals, research institutes and academic institutions

throughout Australia and internationally.

The Committee has continued its commitment to supporting the conduct

of highly ethical and robust health research. Reflecting the diversity of

research in the district, including the increase in early phase translational

research, there was a change in Committee membership during 2008 with

the appointment of Dr Jennifer Fleming as Chair in January and Dr Carl

Kirkpatrick as a pharmacology representative.

Mrs Jan Maxwell, lay female representative, retired after more than two years of dedicated contribution. The

Committee extended their appreciation and wished her well. Mrs Beverley Ryan was welcomed in her appointment as

lay female representative.

Significant Events The importance of professional development and training in research ethics and research practice for both HREC members and the research community is recognised and supported by the hospital.

Significant events during the year included the support of three committee members to attend the intensive research ethics course at Hepburn Springs, Victoria, organised by the Monash University’s Centre for Ethics in Medicine and Society.

Dr Fleming participated in the annual AHEC HREC Chairs Roundtable held at La Trobe University She was an invited speaker and co-presenter on the ethical

regulation of tissue banks at the Princess Alexandra Hospital Cancer Collaborative Group Seminar; the National Australasian Leukaemia and Lymphoma Group Conference held at Princess Alexandra Hospital, and the Australasian Biospecimens Network Annual Meeting held in Sydney.

The Chair and Ethics Manager presented at the PA Hospital Research Ethics Day, organised by the Centres for Health Research and the Nursing Research Development Unit.

New initiatives introduced during the year included the implementation of an expedited review process



New Protocol Submissions

January - December 2008

Clinical (Research

Trials)

Audit and Survey

Student Research

Other

Figure 1: New Protocol Submissions in 2008

13%

11%

26%

50%

New Protocol Submissions

2001-2008

300

250

200

150

100

50

02001 2002 2003 2004 2005 2006 2006

Year

Figure 2: New Protocol Submissions 2001-2008

No.

of

Subm

issi

ons

The number of new protocol submissions continues to increase, as depicted in figure 2.

2008

by a sub-committee to streamline approval of low and negligible risk research. This process is being further developed for implementation by Queensland Health and other state health bodies. Review and update of

the PAH Ethics Website continues, along with review of approval processes, management of research ethics and governance practices in keeping with state, national and global regulatory frameworks.


The PA Foundation

The PA Foundation is situated at the Princess Alexandra

Hospital and financially supports and promotes health

research conducted on the hospital campus. This

includes a research staff in excess of 600 people from

Queensland Health, The University of Queensland,

Queensland University of Technology and Griffith

University.

The Princess Alexandra Hospital is one of Australia’s

leading teaching and research hospitals and is the

tertiary referral centre for the Southern Zone of

Queensland Health and the

State centre for renal and liver

transplantation and spinal injuries.

Each year, over 5,500 staff care for

more than 61,000 inpatients and

310,000 out-patient and emergency

department patients.

The PA Foundation is a statutory

authority appointed under an Act

of Queensland Parliament and is

controlled and managed by an

independent Board of Directors.

The Directors are drawn from

the local business and medical

community and are appointed by the Governor of

Queensland.

Funds donated to and earned by the PA Foundation

are awarded annually by an independent team of

qualified health professionals, clinical and scientific

researchers who conduct their medical research on the

hospital campus. Each year, the PA Foundation invites

researchers and scientists on the hospital campus to

submit their application for research and/or project

grants. These applications undergo a rigorous process

and are assessed by the Research

Committee.

A special mention must be

made to welcome Professor John

Prins who has been appointed

as the new Chairman of the

Research Committee. This is in

addition to his responsibility

as one of the PA Foundation

Board of Directors. Professor

Prins has replaced Emeritus

Professor Kenneth Donald who

recently retired and we would

like to take this opportunity to

Mission Statement: To raise funds for health and medical research at the PAH campus for better treatment, prevention and cure of disease.

Vision Statement: To be the forefront provider of funds for collaborative world-class translational research, fostering and sustaining the next generation of science and clinical researchers.


thank Professor Donald for his immense support to the

foundation over the years.

The PA Foundation relies solely on donations from the general public, the business community, bequests and the thousands of patients and their families who have benefited from the outstanding medical treatment provided by the Princess Alexandra Hospital. There are also many PAH staff who donate a percentage of their salary through the foundation’s Workplace Giving Program.

For the financial year ending June 2008, the PA Foundation raised and awarded over $1.2 Million dollars including $350,000 from private practice grants. This is an outstanding record amount awarded to our sole objective of financially supporting world class medical researchers at the Princess Alexandra Hospital.

Michael T Wille OAM, Chairman


Group Reports

Research - Key to Health Translating Science into Better Health 35Research - Key to Health Translating Science into Better Health 35

The life expectancy of Australians is now among the highest in the world. While this is a wonderful achievement for

our nation, with it comes the consequence that increasingly people advance into very old age, with the attendant risks

of frailty, dementia, disability and dependence on others in the last few years of their lives. The future of the health

system will increasingly be shaped by growing numbers of older people seeking diagnostic advice, supervision of their

medical care and assistance with daily tasks.

The Academic Unit in Geriatric Medicine’s research and development program is targeted at this problem. Older

citizens deserve good quality health care, and it is the unit’s mission to make sure that they receive it.

The Unit had an exceptionally successful year, securing three new NHMRC grants, comprising $1.2 million, in addition

to $450,000 in other competitive grants. Using telemedicine and e-health strategies, the unit’s work focuses on

ensuring older people have good access to geriatric specialist expertise. Several new projects will develop quality

systems to ensure that hospital care for older people is at the highest possible standard.

Software systems developed by the Unit to support clinical care in hospitals are now implemented in seven hospitals.

Mobile video-conference ward rounds, pioneered by the unit, are now planned for implementation in several hospitals

across Queensland.

The Unit has grown to ten research staff and three PhD students, and will increase further into 2009.

Professor Len Gray Director, Academic Unit in Geriatric Medicine

Associate Professor, Centre for Online Health

Dr Paul VargheseDirector, Geriatric Medicine

Academic Unit in

Geriatric Medicine

Current Research Activities

Clinical TrialsTransition Care: Innovation and evidence (Cameron I, Crotty M, Gray L, et al.). This project will evaluate the efficacy of transition care (T-Care) models from a variety of clinical, economic and consumer perspectives. Several studies are planned: (i) An evaluation of in-home video-conference mediated T-Care; (ii) Development of Clinical Indicators for the T-Care

Program and (iii) Predictors of receipt of T-Care. This research is funded through an NHMRC Health Services Research Program.

Clinical outcomes, staff and carer perceptions of acute hospitalisation of patients with dementia (Gray L, Byrne G, Pachana N). This work addresses the problem of dementia in hospital, including how often people with


dementia are admitted, what happens to them, how hospitals respond to their needs, and how well carers perceive their needs are met. The key objective is to inform better design of hospital procedures in order to provide a basis for planning a logical, careful response for people with dementia. Funded by an NHMRC Dementia Research Grant.

Ambulatory monitoring of elderly patients in a rehabilitation setting (Gray L, Cheung V, Karunanithi M, Yelland C). Acceleration data is collected using an accelerometer with the aim of assessing the accuracy and practicality of an activity classification algorithm in detecting the position and movement of elderly patients with an accelerometer device attached to their waist. If viable, it could be useful to improve clinical monitoring and patient management, particularly in assessing and prescribing activities in rehabilitation programs.

Validation of an online geriatric assessment tool (Wong L, Martin-Khan M, Gray L). This research will determine the reliability of administering the Rowland Universal Dementia Assessment Scale (RUDAS) through videoconferencing as compared to the gold standard of face-to-face administration. It aims to extend existing knowledge by examining the practicability and reliability of administering the RUDAS in a telemedicine setting. In particular, its validity across the cut-point score of 22/30 will be studied.

Orthopaedic supplement to the interRAI AC (Pulle R, Gray L). This project aims to develop a set of supplementary data collection items to act as diagnostic screeners, inform clinical decision making and predict outcomes. The initial stage was a literature review that identified potential candidate items. The items have been peer reviewed by a panel of experts and the supplement is being trialled in an orthopaedic ward.

Evaluation of the impact of an online structured geriatric assessment system (Wright O, Varghese P, Wootton R, Scuffham P, et al.). An e-health supported, geriatrician-led comprehensive geriatric assessment service has been successfully implemented at three Queensland Health hospitals. Funding for a rigorous evaluation of these systems was awarded by a Queensland Health Private Practice Trust Fund grant. Evaluation shows positive benefits in improved access to formal geriatric assessment and trends of reduced waiting times for assessment by Aged Care Assessment Teams.

Validation of cognitive assessment using telecommunication (Gray L, Flicker L, Wootton R, Loh PK, Martin-Khan M, et al.). This project assesses the use of video conferencing to enable geriatricians to assess and diagnose memory problems including dementia. Establishing the reliability of diagnosis and related assessments, and identifying which functions can confidently be carried out via video conferencing, is one step towards extending the availability of this service to rural and remote communities. This is an NHMRC funded project.

Geriatric outcomes study in hospital (GOSH) (Gray L, Hirdes J, Wilson A, Beller E, Lakhan P, et al.). A prospective study aiming to identify predictors of adverse outcomes (delirium, falls, functional decline, pressure ulcer, etc) within hospital among older medical patients. Ultimately it is aimed to develop an omnibus screening strategy that will risk profile patients at admission with an aim to better target prevention and treatment strategies. There will be “validation” of the inbuilt screeners for dementia, delirium, depression and malnutrition. This project is partly funded by the JO and JR Wicking Trust.

Other ProjectsEffectiveness of adherence to dementia risk reduction in everyday practice (Martin-Khan M, Travers C, Lie D). This literature review will result in a report that will identify and summarise the current research evidence regarding the key outcome measures which demonstrate the effectiveness of strategies used to influence the translation of dementia risk reduction knowledge from the research arena into everyday clinical practice of Australian health professionals.

Duplication of documentation in hospital study (Pimm B, Wright O, Gray L). The aim of this study was to identify levels of documentation duplication and quality of data collected between health professionals for an acute admission episode for frail, aged clients. A retrospective audit of 100 medical charts has been completed and is currently being analysed.

STEADI (Lie D, Austin S). Streaming Technology as an Adjunct to Dementia Interventions (STEADI) is an intranet-based dementia resource trial. It will assess the utility of intranet based multi-media to assist dementia care in medical and surgical settings in a metropolitan teaching hospital. This project is funded for three years by the Dementia Collaborative Research Centre (Australian Government).


Awards & PrizesPrabha Lakhan

Best poster presentation at the 7th National Conference of Emerging Researchers in Ageing for a poster entitled The elderly at risk in hospital? Project: Geriatric outcomes study in hospital.

Best nursing poster presentation at the 7th National Conference of Emerging Researchers in Ageing for a poster entitled The elderly at risk in hospital? Project: Geriatric outcomes study in hospital.

National & International PresentationsLen Gray

Transition Care - What Method is Right for Whom? National Transition Care Forum, Melbourne.

Can We Really Make Bed Blocking Go Away? National Transition Care Forum, Melbourne.

Melinda Martin-Khan, Leon Flicker, et al.

Assessing cognitive function via tele-consultation. 7th Biennial International Dementia Conference, Conference and Exhibition Centre Darling Harbour, Sydney.

Major Grants & Financial Support Total NHMRC funding: $ 322,774

Other Competitive funding: $ 217,700

Funding from other sources: $ 175,818

38 Centres for Health Research Annual Research Report 200838 Centres for Health Research Annual Research Report 2008

Acquired Brain Injury

Outreach ServiceThe Acquired Brain Injury Outreach Service is a specialist community rehabilitation service for people with acquired

brain injury, their carers and service providers. The primary aim of the service is to facilitate successful community

integration for people with acquired brain injury. ABIOS also provides training and consultancy to service providers

and carers and conducts research and development activities to improve outcomes for people with acquired brain

injury and their families.

The Acquired Brain Injury Outreach Service research highlights during the year have related to both new and

concluding projects:

Implementing an ARC Linkage grant obtained for a collaborative study with University of Queensland, Griffith

University and Disability Services Queensland looking at the service and support needs of people with acquired brain

injury during the transition from hospital to home.

Successful completion and reporting of two applied research projects looking at the long term care needs of people

with acquired brain injury and the development of parenting supports for people with acquired brain injury

Ongoing funding for research into developing and sustaining models of service delivery for Aboriginal and Torres Strait

Islander people with acquired brain injury

New research investigating the processes of discharge from long term residential and slow-stream rehabilitation

facilities into the community for people with acquired brain injury

Raymund Quinn Manager


Other ProjectsImproving community-based rehabilitation for Aboriginal and Torres Strait Islander Queenslanders with Acquired Brain Injury (Gauld S, Smith S, Kendall M). This is an ongoing project that aims to develop and evaluate models of service delivery in community-based rehabilitation for people with acquired brain injury that are appropriate and relevant for Aboriginal and Torres Strait Islander communities. The project received funding in 2007 and 2008 and a submission has been made for 2009.

Determinants of successful community transition for individuals with acquired brain injury and their families (Fleming J, Worrall L, Cornwall P, Haines T, Ownsworth T, Kendall M, Chenoweth L). This ARC Linkage funded project involves a collaborative team of researchers from the University of Queensland, Griffith University and the Princess Alexandra Hospital. Industry partners include Disability Services Queensland and the Acquired Brain Injury Outreach Service. The project is a multisite project.


Understanding the changing community care needs of people with acquired brain injury (Kendall M, Quinn R). Data collection for this project was completed during 2008. The project utilised qualitative and quantitative methods to investigate the long term care needs of people with acquired brain injury. The project is now in the stage of manuscript preparation for publication.

Integrating individual parenting support into the community rehabilitation and case management context: A pilot study. (Black G, Kendall M, Roser J, Smith S, Wright S, Morriss E). Data collection from this pilot project was completed during 2008. The study involved the development and evaluation of a psychoeducational support for parents with acquired brain injury and their partners. The study is being funded internally by the Acquired Brain Injury Outreach Service to continue data collection during 2009.

Interventions for improving home and community re-engagement following traumatic brain injury (TBI) (Ownsworth T, Fleming J, Shum D, Kendall M). This study was completed and a manuscript prepared for publication in 2008. This study will form the basis of an application for a nationally competitive NHMRC grant in 2009. The study involved examining the effectiveness

of metacognitive skills training to improve error self-regulation during daily activities following acquired brain injury.

Discharge to the community: Factors contributing to successful community re-integration following prolonged hospital admission (Turner B, Wisniowski, C). This new research was developed during 2008 to examine the factors that contribute to successful transition to the community from prolonged hospital admission, including slow stream rehabilitation and residential care. The aim of the study is to inform and develop discharge guidelines for hospitals and institutions who are discharging people with acquired brain injury to the community after many years.

National & International PresentationsAreti Kennedy & Raymund Quinn

Brain Injury Association of Queensland Japan Study Tour, Brisbane.

Japanese Seikatsusha Network Study Tour, Brisbane.

Major Grants & Financial Support Other Competitive funding: $ 98,034


Alcohol and Drug Assessment

The Alcohol and Drug Assessment Unit is a small multidisciplinary unit based in the Division of Medicine. Clinical staff

include a Physician, Nurse, Social Worker and Clinical Psychologists. The unit provides outpatient treatment programs

for patients referred from the PAH and community. The main treatment approach is Cognitive Behavioural Therapy,

often supplemented with medication. Research conducted by the unit is undertaken to improve clinical outcomes.

Dr Gerald FeeneyMedical Director


Clinical ProjectsThe use of Naltrexone and Acamprosate combined with Cognitive Behavioural Therapy (CBT) in the treatment of alcohol dependence (Feeney GFX, Connor JP Young, RMcD). Naltrexone and Acamprosate both independently and combined significantly add to the efficacy of CBT to improve treatment outcomes.

The measurement of alcohol craving (Statham D, Connor JP, Feeney GFX, Young, RMcD). A new psychometric tool to more accurately assess alcohol craving has been developed. It is currently undergoing reliability and validity testing.

The application of non-linear statistical techniques as an adjunct to clinical decision making in alcohol dependence treatment. (Symons M, Connor, JP, Feeney GFX, Young RMcD). Based on 1200 patients that have received alcohol dependence treatment, non-linear statistical models have been developed to assess each new patient, identify excess and deficits and to provide a treatment prognosis.

Neuropsychological and psychosocial findings in liver transplantation for alcohol-related liver disease (Pegum N, Connor JP, Feeney GFX, Young RMcD). Ninety-two patients who underwent Orthotopic

Liver Transplantation were assessed with standard neuropsychological and psychosocial instruments pre and 12 months post transplantation. Transplantation significantly improved memory, visuomotor speed, complex attention, psychological distress and psychosocial functioning.

Alexithymia and interpersonal functioning in Alcohol Use Disorders (Thorberg F, Young RMcD, Feeney GFX, Connor JP). Data from 146 patients identified a relationship between anxious attachment and alexithymia, as well as significantly higher levels of insecure attachment in those with combined alexithymia and alcohol misuse, compared to those with alcohol misuse alone.

Awards & PrizesAssociate Professor Jason Connor

Australian Psychological Society Early Career Award.

National & International PresentationsAssociate Professor Jason Connor

Future Directions in Alcohol Use Disorder Research. 43rd Australian Psychological Society Annual Conference, Tasmania.


Research activity has reduced this year as a result of the conclusion of the projects relating to the management of

acoustic neuromas and the completion of the collaborative vestibular research with the University of Queensland.

Evelyn TowersDirector

Audiology


Clinical ProjectsSingle index measurement of hearing preservation following acoustic neuroma surgery (Brown-Rothwell D, Panizza B, Wilson W). Two surgical approaches were compared on a binaural single index of hearing and the change in the percentage loss of hearing calculated between the pre- and post-operative. The overall percentage difference between the approaches was not significant (N=39): 7.6% for the hearing preservation approach compared to 8.1% for the hearing sacrifice approach, but individual patients showed marked benefit. The finding showed the importance of individualising the approach for each patient.

National & International Presentations

David Brown-Rothwell

Preserving auditory function during skull base surgery, Auditory Brain Symposium, The University of Queensland, Brisbane.


Brain Injury Rehabilitation

The Brain Injury Rehabilitation Unit provides a tertiary assessment and rehabilitation service for those with acquired

brain injury in the broad working age group. Cases are referred from Queensland, Northern New South Wales and

interstate. The average age at admission to the inpatient environment was 36 years with 73% male and 65% of

traumatic brain origin. Outcome measures included the Functional Independence Measure (FIM, developed by Buffalo

University, New York State, USA) with the length of stay efficiency of 0.29 and an improvement in the Disability Rating

Score for severe head trauma patients of two points. The FIM is the standard assessment used by Queensland Health to

document a person’s basic functional level including ambulation, personal cares and basic cognition.

A number of improvements have been made to the service including: •

Development of a “family friendly area” within the ward •

Formation of a hypertonicity (spasticity) management group •

Implementation of electronic case conferencing. •

Dr R A HazeltonMedical Director

Major Grants & Financial SupportFunding from other sources: $ 10,000


The Cardiology Department is a tertiary referral unit offering a comprehensive cardiac service including

electrophysiology, invasive intervention, heart failure management and echocardiography. Supporting the

medical officers are registered nurse specialists in Cardiology Rehabilitation, Cardiac Resuscitation, Pacing and

Electrophysiology, Heart Failure and Cardiac Research, as well as Cardiac Scientists involved in echocardiography,

pacemakers, ECG, holter recordings, exercise and pharmacological stress testing. Cardiology nursing personnel offer

courses in cardiology and heart failure to city and country nurses.

The department offers a Cardiology Outreach Service to rural areas west and south of the district - Roma, Goondiwindi,

Kingaroy and Cherberg. These visits are staffed by a Cardiologist, Sonographer and Cardiac Nurse specialist and

provide clinical services to patients as well as specialist staff and patient education. Each rural region receives a visit

from each of the cardiology specialities - heart failure, resuscitation, cardiology and electrophysiology.

Research: Over the past 19 years the expertise of the Cardiology Research Department has secured a large number of

clinical trials from a variety of pharmaceutical companies as well as the National Institute of Health from the USA.

The department’s cardiologists initiate and participate in Investigator-driven research. Collaboration with the Cardiac

Surgery Department and the University of Queensland’s Cardiovascular Imaging Research Group ensures a wide range

of cardiology modalities can be offered to prospective research organisations. Research areas cover coronary artery

disease, cardiac arrhythmias, cardiac devices, acute/chronic systolic/diastolic heart failure, coronary angiography and

percutaneous transluminal coronary angioplasty, cardiac echocardiography, cardiac magnetic resonance imaging

and cardiac surgery. Full implementation of Good Clinical Research Practice and the high quality of source data is

paramount to the success of the department.

Dr Paul GarrahyDirector

Cardiology


Clinical ProjectsActive Study – Atrial fibrillation (Garrahy P)

Beautiful Study – Stable coronary artery disease and left ventricular systolic dysfunction (T Marwick)

Cardiome Study – Atrial fibrillation (Kaye G)

Champion Study – New reversible P2Y12 antagonist vs clopidogrel in subjects with Acute Coronary Syndrome undergoing PTCA (Garrahy P)

Danube Study – new drug vs placebo in subjects with chronic renal disease undergoing elective PTCA (Lim R)

Dionysis Study – new antiarrhythmic drug vs placebo in subjects with atrial fibrillation (Hill J)

Freedom Study (#1) – PTCA vs CABG in Diabetic Subjects. (Garrahy P)


Freedom Study (#2) – Cardiac device optimisation vs standard care, National Institute of Health, USA (Kaye G)

HAT Study – Anterior/lateral myocardial infarctions randomised to CPR or home automatic defibrillators (Marwick T)

I-Preserve Study – Heart Failure with diastolic dysfunction (Marwick T)

OAT Study – Myocardial infarction with occluded coronary artery > 3 days old, National Institute of Health, USA (Garrahy P)

Plato Study – New short-acting drug vs clopidogrel in subjects with Acute Coronary Syndrome (Garrahy P)

Red-HF Study – EPO vs placebo in subjects with anaemia associated with heart failure. (Marwick T)

dal-Outcomes Study – CEPT inhibition is Acute Coronary Syndrome (Garrahy P)

Rocket-AF Study – Warfarin vs. new drug in atrial fibrillation (Marwick T)

Shift Study – Congestive Heart Failure (Marwick T)

ZoMaxx II Study – Comparison of new drug-eluting stent vs TAXUS™ Express²™ Paclitaxel- Eluting Coronary Stent System in de novo coronary artery lesions (Garrahy P)

Other ResearchBurden of Care: The Support Needs of Carers of Cardiac Surgery Patients (Robinson R) Monash University. Protect Study: an international study into the outcomes of selective site cardiac pacing (Kaye G). Dr Gerald Kaye

is the international lead investigator and study chair. Professor Tom Marwick is Core Laboratory international lead investigator. The study commenced in 2007 and recruitment is currently 55% complete. Seventeen centres are involved internationally – 5 in Australia, 2 in New Zealand and 10 in the United Kingdom.

Study on the Comparison of Electrical Activation of the Left Ventricle with 3 Dimensional Echocardiographic Activation Mapping (Dauber K, Marwick T, Gould P).

Study on Changes in Stress and Strain in the Left Atrium and Cardiac Neurohormonal Function Post Ablation for Paroxysmal Atrial Fibrillation (Doneva S, Marwick T, Gould P).

National & International PresentationsCindy Hall

Patient Recruitment: Beyond the Poster, Association of Regulatory and Clinical Scientists, Sydney.

Dr Dariusz Korczyk

Heart Failure Epidemic, Annual Thai College of Physician Meeting, Papaya.

Heart Failure Epidemic, National Cardiac Forum, New South Wales

Dr Richard Lim

Do ACS Risk Scores Work in Clinical Practice? China Interventional Therapeutics Meeting, Beijing China.

Major Grants & Financial Support Other Competitive funding: $ 60,000


Current Research ActivitiesProspective randomized study to determine the clinical outcomes of tissue and mechanical aortic valve replacement in patients aged 55-70 years (Shah P, Mundy J, Marwick T). Tissue valves are increasingly used in the 55-70 age groups on the assumption that there are fewer valve related complications secondary to anticoagulation than with mechanical valves (1-2.5% per patient year). The disadvantage of tissue valves is that they require repeat open heart operation as the tissue valves degenerate with time (70% at 10 years and 90% at 15years). The advantage of mechanical valves is that no late reoperation is required and that of tissue valve is no anticoagulation is required. These traditional considerations are being questioned - modern mechanical valves are of low profile requiring less anticoagulation, while for tissue valves, reoperation risk is only slightly more then initial operation.

This prospective randomized study will be the first to address which is the optimal valve in 55-70 year-old patients undergoing aortic valve replacement. At present, every surgeon has their own preference, but there is no evidence base to make strong recommendation. In this study, the group will seek whether there is any difference in valve related complications (MAPE: major adverse postoperative events i.e. reoperation, endocarditis, major bleeding orthromboembolism) and short/long term survival

Cardiothoracic Surgery

The department has been involved in various aspects of research projects. Three presentations were made at the

annual national cardiothoracic meeting. One paper has been accepted in American journal of cardiology and three

papers are currently under review in various journals. Two ethics approved randomized studies have begun for which

a grant for $100,000 has been secured. Two part-time research nurses have been employed to assit with the projects.

Associate Professor Julie Mundy Director

between patients receiving tissue vsmechanical valves. It will be a prospective randomized study using the two most commonly used valves - St Jude Mechanical (St Jude Medical) and Mosaic tissue (Medtronic). Patients who give consent will be randomized to either having tissue or mechanical valves. They will be followed up during their stay in hospital and yearly thereafter to gather data to obtain the information described below. Data will be gathered to identify the following: predictors of early and late mortality, long term survival, freedom from reoperation, freedom from TIA, stroke and thromboembolic episodes, freedom from endocarditis, freedom from hemorrhagic complications, freedom from hospitalization, rate of readmission and freedom from valve failure.

Polyunsaturated fatty acid composition of epicardial adipose tissue in coronary heart disease (CHD) patients and controls (Kostner K, Peters P, Shah P). This research study is undertaken to investigate whether epicardial fat contains omega 3 fatty acids (which are the fatty acids found in fish). Fish consumption has been shown to be very beneficial for heart disease, since it may prevent sudden cardiac death. These benefits are due to so called long chain fatty acids in fish. These fatty acids get incorporated into membranes and protect them from oxidation as well as keep them fluid. In the present study the group will measure these fatty acids


in epicardial fat (fat around the heart) by taking a small amount of adipose tissue and blood during the planned surgery.

Dialysis and cardiac surgery (retrospective study in progress): To define the predictors of short and long-term mortality and morbidity, long term survival and quality of life of dialysis patients undergoing cardiac surgery.

Infective endocarditis (retrospective study in progress): Valves affected, pathogenesis, short term mortality, morbidity, their predictors and long term follow up.

Contemporary results following repair of acute type a aortic dissection (AAAD): A single centre experience (Campbell Lloyd A, Mundy J, Shah P)

Completed retrospective study: Patients who undergo full arch replacement are at higher risk of poor neurological outcome. From this series, the only useful predictor of mortality is low EF. Discharged patients have reasonable long-term survival and good quality of life.

Management approach and risk predictors for deep sternal wound infection (DSWI): After cardiac surgery at a tertiary medical centre (Sawhey R, Mundy J, Shah P). Completed retrospective study: Peri operative blood glucose management and limitation of transfusion may be the practises associated with reduced DSWI.

HbA1c: Is it a predictor of short term outcomes in diabetic patients undergoing primary CABG? (Strahan S, Mundy J, Shah P)

Completed retrospective study: HbA1c cannot be used as a single prognostic indicator of short-term outcomes in diabetic patients undergoing primary CABG

Cardiac tumours in adults: modes of presentations, surgical management and short term follow up results at a tertiary teaching hospital (Matebele M, Mundy J, Shah P)

Completed retrospective study. Echocardiogram is the principal mode of diagnosis for cardiac tumours. Surgical intervention is the treatment of choice for patients with benign cardiac tumours with very low morbidity and mortality and excellent long term survival. Surgical treatment of malignant tumours is associated with good local control and palliation but with very poor prognosis. Extending this study to other Australian institutions would give a more statistically significant result.

National and International Presentations (invited only)N Butler, Julie Mundy, Pallav Shah

Aortic surgery in gaint cell arteritis: A diagnostic and management dilemma. 2008 Australasian Conference of Cardio-thoracic Surgeons, Noosa.

P Wiemers, Julie Mundy, Pallav Shah

Post infarction V.S.D: Results and long term survival. 2008 Australasian Conference of Cardio-thoracic Surgeons, Noosa.

Major Grants & Financial SupportOther Competitive funding: $ 100,000


Cardiovascular Imaging

This group provides clinical and research capability in cardiac imaging and image processing. The Imaging group

has expertise in new echocardiographic imaging technologies, myocardial viability, early detection of atherosclerosis,

assessment of contractile reserve, and studies of how cardiac imaging techniques can influence patient outcomes and

cost-effectiveness of care. This work is carried out in the research echo/stress area in the Cardiology Department and an

image processing area in The University of Queensland Department of Medicine.

Highlights of 2008 were the preparation for the initiation of the National Health and Medical Research Council

(NHMRC) Program support (in collaboration with the Baker Institute), continuation of the second Centre of Clincial

Research Excellence award and Dr Jim Sharman’s NHMRC Project grant for central BP measurement (BP guide).

Professor Tom MarwickDirector

Current Research ActivitiesEvaluation of myocardial structure using ultrasound backscatter and tissue Doppler. Changes in the nature of the returning sound waves may be a marker of the underlying tissue characteristics. This work has been used to identify structural changes supporting the presence of a cardiomyopathy of diabetes and obesity, pre-clinical changes consistent with fibrosis in hypertensive patients, and evidence of ischemia (see below). This has generated unique diagnostic approaches and further developments seek to use these techniques to access the response of myocardium to various metabolic interventions including improved diabetic control.

Quantification of echo techniques for detection of myocardial ischemia, using tissue Doppler and speckle tracking techniques to measure myocardial strain and velocity.

Use of high frequency ultrasound to follow the progression of abnormal vascular structure and function.

The unique aspect of this work is the use of developmental edge-tracking software for objective quantification of vessel dimensions. These studies focus on patients with diabetes and renal disease as well as patients with heart failure. The group has recently completed two large-scale interventional studies that examine factors influencing vascular function and thereby progression of atherosclerosis. This work interfaces with Dr Kostner’s expertise in lipid management, especially novel plasma markers of atherosclerosis (lipoprotein (a), markers of complement activation and various apolipoproteins).

Evaluation of the incremental value of new imaging technologies (3D echo and strain) to clinical decision-making. A highlight of this work has been the completion of large-scale observational studies of the association of these measurements with outcomes.

Use of echocardiography to improve clinical decision-making (mitral regurgitation, peripheral vascular disease) has been augmented with a new collaboration


with Prof Paul Scuffham, a health economist from Griffith University.

Application of new techniques for central BP measurement to clinical decision-making.

Effects of aggressive lipid lowering on the progression of aortic sclerosis.

Measurement of omega 3 fatty acids and use of omega 3 fatty acids to prevent atrial fibrillation post CABG.

Metabolism of Lp(a) in hypertension

Effect of various newer lipid lowering agents.

Clinical ProjectsClinical Centres of Research Excellence in Cardiovascular and Metabolic Disease – studies of cardiovascular effects of lifestyle therapies:

LIFESTYLE-1 concluded, showing benefits of lifestyle change are limited to T2DM patients with the most severe metabolic disturbance

LIFESTYLE-2 is in preliminary stages, showing a significant prevalence of autonomic dysfunction – these patients will be randomized to exercise training and aldosterone blockade

OB-01 involved lifestyle change and metformin therapy in obesity – and is currently being analysed

OB-02 will involve lifestyle change and aldosterone blockade, and is currently in preparation

LANDMARK-2 (a lifestyle intervention trial in ESRF) was completed, and showed no benefit of therapy on cardiac or vascular function

STRATIFY Study: The initial phase showed equivalence of RN-supervised beta-blockade vs. selective therapy based on dobutamine stress echo results. The second phase (to be completed in 2009) will examine the impact of aspirin, statins and beta-blockers on cardiac risk at noncardiac surgery.

PROTECT-PACE Core Laboratory: This study of optimal pacing site for RV pacing is ongoing. Optimization of cardiac resynchronization therapy (CRT)

Use of perhexilene to improve cardiac function in viable myocardium

Importance of transmural distribution of scar to the diagnosis of myocardial viability

New techniques for quantitation of regional LV function

Raised LV filling pressure and hypertensive response to exercise – a study of echocardiographic and biochemical responses to anti-fibrotic therapy in LVH

Gold Coast Hyperlipidemia Atherosclerosis Regression trial

TARGET LDL Study

Atorvastatin Sepsis Trial

Various trials with Cordaptive (a new extended release nicotinic acid).

A multicenter, double-blind, randomized, 12-month, placebo-controlled study to evaluate the lipid-lowering effect, safety and tolerability of AVE5530 25 mg/day and 50mg/day when added to ongoing stable statin therapy (HMG-CoA reductase inhibitors) in patients with primary hypercholesterolemia. Sanofi Aventis

KOALA Study (RF management in obese children)

National & International PresentationsProfessor Tom Marwick

New technologies in assessment and follow-up of CRT, Assessment of myocardial viability (Invited speaker), Asia-Pacific Congress of Heart Failure, Melbourne.

Comparison of TVI and 2DS for viability assessment, Application of 2DS in the everyday clinical lab. (Invited speaker). Doppler myocardial imaging 2007. Leuven, Belgium.

Advanced Echo Symposium (Organizer), Sydney.

ASEANZ CV and Lipid Forum (Organizing committee), Melbourne.

2D and 3D echo for measuring LV volumes, EF and mass, Hypertensive LVH with normal EF, Type 2 DM and occult myocardial dysfunction (Invited speaker); Diastolic stress test Session moderator. Myocardial imaging is optional before CRT (Plenary – Debate). American Society of Echocardiography, Toronto.

Cardiac Imaging is required for CRT (Plenary – Debate). Heart Failure 2008, Milan.

New techniques for quantification of LV function, Echo in cardiac resynchronization therapy (Invited speaker). Diabetic cardiomyopathy (Lunchtime symposium) Contrast echocardiography Session moderator. Cardiac Society - New Zealand, Queenstown.


Asymptomatic aortic stenosis (Invited speaker); Systolic and diastolic function – Diabetes and Diastolic heart failure (Focus session); imaging in 2020 – Ultrasound will do it all (Plenary). European Society of Cardiology, Munich.

Stress echocardiography for assessment of hemodynamics and perfusion; Viability assessment with echocardiography (Invited speaker), What imaging test to do next (Moderator). AHA Scientific Sessions, New Orleans.

Strain indices for monitoring therapy; Stress echo vs nuclear (Invited speaker). EuroEcho, Lyon.

Interaction of LVH and ischemia in stress echo, Ventriculo-arterial interaction. (Invited speaker). Doppler myocardial imaging. Leuven, Belgium.

Associate Professor Karam Kostner

How to manage difficult lipids. 6th annual Toowoomba CV meeting. (Invited speaker)

Third international symposium on healthy aging, Hong Kong: Total CV risk management (Invited speaker). (Invited speaker)

Does dietary cholesterol play an important role in the prevention and treatment of CV disease? Natural Therapies and Health Expo, Brisbane. (Invited speaker)

Invited speaker, State of the Art BP and Lipid Lowering. 12th annual National Malaysian Heart Association Meeting, Kuala Lumpur. (Invited speaker)

Emerging Science of HDL. Atherosclerosis Expert Input Forum Hong Kong, Seoul, Korea. (Invited speaker)

Plenary Lecture: Novel HDL targeted therapies. Angioplasty Summit Seoul, Korea. (Invited speaker)

Managing hyperlipidemia in the context of absolute risk. Chalenges in Cardiology VIII, Royal Brisbane Hospital. (Invited speaker)

Organiser, Pfizer Controversies in Cardiology (Advisory Board Member) and talk: exercise and Evaluating and treating genetic dyslipidemias. ASEANZ Melbourne.

Organiser, Hands on session on CV investigations. Cardiology in Paradise, Gold Coast.

Major Grants & Financial SupportTotal NHMRC funding: $ 527,000




Clinical Pharmacology

The department continued to provide an expanded tacrolimus monitoring service for transplant centres throughout

the state, and maintained an active research program. Numerous collaborations have been established, including an

ongoing collaborative research agreement with Waters Corporation to investigate measurement of endogenous steroids

utilising the latest mass spectrometer technology. Paul Taylor has developed a highly accurate aldosterone assay, a

technique was developed for the measurement of oxypurinol, the active metabolite of allopurinol, for a collaborative

research project, and research continues with dosage individualisation of the newer immunosuppressant drugs.

Drug utilisation and pharmacovigilance studies have included reviews of off-label use of rituximab and national

reports of bleeding complications associated with antithrombotic drug combinations.

Associate Professor Peter PillansDirector


Clinical ProjectsReview of off-label use of rituximab (Butterly SJ, Pillans PI, Horn B, Miles R, Sturtevant J)

Bleeding complications associated with antithrombotic combinations (Ghiculescu RA, Pillans PI)

Other ProjectsOptimizing detection of curable hypertension by the development of a highly accurate method for measuring aldosterone concentrations in human blood and urine (Taylor PJ, Stowasser M, Gordon RD)

The effects of exercise induced dehydration and glycerol rehydration on aldosterone and cortisol (van Rosendal S, Taylor PJ, Coombes J, Gordon RD, Stowasser M)

Improved patient outcomes through dosage individualisation of the newer immunosuppressant drugs (Staatz CE, Tett SE, Taylor PJ, Johnson DW, Lynch SV)

The role of hepcidin in iron regulation (Hall S, Taylor PJ, Fletcher L, Bird R, Saal R, Mudge DW, Crawford D)

The preventative effects of omega-3 fatty acids on cardiovascular disease (Salm P, Taylor PJ, Kostner K)

Awards & PrizesPaul Taylor

Young Investigator Award, Best Clinical Oral Presentation, Princess Alexandra Hospital Week: A new, highly accurate method of measuring aldosterone in human plasma by semi-automated high performance liquid chromatography-tandem mass spectrometry: Towards improved detection of curable hypertension.

National & International PresentationsPaul Taylor

Regulated Research, Development and Manufacturing (RRDM) 2008, Australian Organisation for Quality.


Applying Quality Science in the Real World, The fitness of purpose of analytical methods, . Brisbane.

Therapeutic Drug Monitoring in Optimizing the Immunosuppressive Therapy., Introduction to high-performance liquid chromatography-tandem mass spectrometry: The gold standard for monitoring immunosuppressive drugs, Warsaw, Poland.

Major Grants & Financial SupportCompetitive funding: $ 30,000



DermatologyThe Dermatology Group underwent significant growth during the year which is reflected in the increased size of the

group and the research funding awarded. The group was awarded a seed grant of $46,000 from IVIMEDS (international

virtual medical school) for a Dermatology Content Development Project. This project involves collaborating with

academics from Dundee University, Barts and The London Medical School to develop an online teaching tool for

dermatology within Medical Schools. Funding has also been received from Epiderm for the purchase of a confocal

laser microscope and for a specialist operator. This microscope will be the third in Australia for the clinical use in in-

vivo imaging of neoplastic and inflammatory skin diseases.

Clinical research has also been supported with funding from the Gallipoli foundation to investigate morphological

characterisation of pre-cursor skin cancer lesions which may help to refine early detection techniques and lead to

improve patient outcomes. Scientific bench research has been given

a head start with a grant awarded by the Scientific Research Fund for

investigations into the genetic underpinnings of the inflammatory skin

disease, psoriasis.

Throughout the year the group established strong ties with the staff and

patients of the Princess Alexandra Hospital Dermatology Department,

and the group remains committed to further expansion and funding to

enable recognition as an internationally competitive group in dermatologic

research.

Professor H. Peter SoyerChair


Clinical ProjectsSkin Emergency Telemedicine Service (SETS) Study (Sinnott M, Xu C, Muir J, Soyer HP). Patients presenting to the PA emergency department with acute skin conditions have images taken and sent to a dermatologist for remote analysis. Treatment recommendations are carried out by emergency physicians and follow-up consultation performed in dermatology within two weeks. Initial case studies demonstrate the feasibility of teledermatology in a skin emergency service.

Tele-PASI-Assessment: A Feasibility Study Using Digital Camera and Mobile Phone Images (Soyer HP, Jakowenko J, Wu J, Singh P). A comparison of Psoriasis Area and Severity (PASI) Index accuracy among face-to-face observers and also between the face-to-face assessments and “image-only” assessments. Relevant for the documentation and management of psoriasis patients receiving biologics treatments especially those living in remote areas.


A feasibility study on consumer use of mobile phone cameras for capturing clinical images of nevi (Soyer HP, Jakowenko J, Hofmann-Wellenhoff R). Despite the variability in the quality of images taken by the different participants, there was very little image quality difference between mobile phone cameras and nevi types. New generation mobile phones may produce diagnostically acceptable clinical images.

In vivo Diagnosis of Neoplastic and Inflammatory Skin Diseases by Reflectance Confocal Microscopy (Soyer HP). The confocal laser microscope has been used to examine healthy and diseased skin (inflammatory and neoplastic) and compared with imaging done with the Multiphoton microscope housed in the Therapeutics Research Unit. Interesting morphological characteristics have been observed and path the way for more targeted and detailed research.

Other ProjectsIvimeds Seed Funded Content Development in Dermatology (Soyer HP, Wilkinson D, Ozolins I, Ferguson J, Ibbotson S, McGregor J, Hubbard V). The content is aimed at Year 2 medical students and covers the basics of dermatology in addition to the three most common neoplastic and inflammatory skin diseases. Virtual patients have been developed as representative cases in each area and short online videos detailing the patient experience are included.

National & International PresentationsProfessor H. Peter Soyer

Teledermatopathology. Telederm 2008, Chennai India.

Whither Teledermatology. Telederm 2008, Chennai India.

Mobile Teledermatology. Telederm 2008, Chennai India.

Skin Health, Skin Cancer and the Workplace. Sunsafe Workplace Program (Schools). Brisbane

Digital Dermatology. XXIX Symposium of the International Society of Dermatopathology, Graz

Dermoscopy Course. Maribor, Slovenia

Dysplastic nevus: Time for change? (Part 1). Course in Advanced Dermoscopy. EADV Congress, Paris

Mobile Teledermatology Coming of Age. Teledermatology Workshop. EADV Congress, Paris

The impact of clinical information in the histopathologic diagnosis of melanocytic skin

neoplasms. International Dermoscopy Society Dermoscopy Update, Paris

Certificate Advanced Dermoscopy and Dermal Imaging, Sydney

Academic Director, Dermoscopy by the Beach, Gold Coast

The clinic-pathologic dimension of melanocytic neoplasms. Skin Cancer Conference 2008, Gold Coast

Presentation at the Albinism Supporting Meeting, Brisbane

Melanocytic tumours: the case for a combined diagnostic approach of histopathologic and dermascopic evaluation. Australasian Dermatopathology Society 29th Annual Conference, Melbourne

Reflectance Confocal Microscopy: a new era of optical imaging in dermatology. Australian Dermatology Update Symposium, Sydney

Basics of dermoscopy: from the diagnostic criteria to their histopathologic correlates. International Short Course on Dermoscopy, Medical University of Graz

Dermoscopic-Pathologic Correlation. Dermoscopy Masterclass, Gold Coast

Dermatopathologic Correlation. Certificate Advanced Dermoscopy and Dermal Imaging Workshop, Gold Coast

Skin Health, Skin Cancer and the Workplace. Sunsafe Workplace Program (Schools), Brisbane

The morphologic dimension in dermatology – the role of dermoscopy and teledermatology. Clinical meeting of the Dermatology Department at Royal Perth Hospital and the Western Australian Faculty of College, Perth

Dermatoskopia Kursus. Society for Estonian Dermato-venereologists, Tallinn, Estonia

Unknown for Experts. Advanced Dermoscopy. American Academy of Dermatology 66th Annual Meeting, San Antonio Texas, USA

Population-based mole screening using telemedicine. International Society for Digital Imaging of the Skin Annual Meeting, San Antonio Texas, USA

Professor H. Peter Soyer and Muir J

Dermoscopy: A Users Guide Theory & Practice Beginners. Royal Australian College of General


Practitioners (RACGP) Gold Coast Clinical Update Weekend, Gold Coast

Dermoscopy: A Users Guide Theory & Practice Advanced. Royal Australian College of General Practitioners (RACGP) Gold Coast Clinical Update Weekend, Gold Coast

Test the Threshold – Biopsy or follow up. Dermoscopy Masterclass, Gold Coast




Diabetes & Endocrinology

The department continues with its strong tradition of conducting translational research in the areas of obesity, diabetes

and bone. The Centre of Clinical Research Excellence funded projects continue to provide strong collaborations with

cardiology, gastroenterology and nephrology. Through the Australian Osteoporosis Genetics Consortium, Dr Duncan

is establishing national and international partnerships. For her great research efforts, Dr Duncan has been awarded

a prestigious NHMRC Career Development Award. Further international collaborations are developing with Professor

Prins and Dr Russell working with Professor Nathan Efron from Queensland University of Technology and Professor

Boulton from Manchester, United Kingdom, on a Juvenile Diabetes Research Foundation funded project investigating

novel markers of diabetic peripheral neuropathy.

The department is now physically separated from the laboratory, hence greater efforts are required to maintain the

collaborations between the “scientists” and “clinicians”, but they continue.

Dr Anthony RussellDirector


Clinical ProjectsGenetics of High Bone Mass (Duncan EL)

Risedronate in Adults with Osteogenesis Imperfecta (Duncan EL). This study assessed the bone density response of adults with OI to oral risedronate at standard doses used for osteoporosis.

A pilot study to assess adrenal function after pulsed high dose glucocorticoids in cytotoxic chemotherapy regimens (Duncan EL). High dose glucocorticoids used for prolonged periods of time can suppress the hypothalamic/pituitary/adrenal axis. This project aims to assess the effect of extremely high doses of glucocorticoids given in short intermittent doses, as part of standard chemotherapy for haematological malignancies.

Glucocorticoid-Induced Bone Loss in Lymphoma (Duncan EL). Bone loss and fracture are common problems in patients given glucocorticoid therapy.

This project aims to quantify the effects of recurrent high dose glucocorticoids given as part of standard chemotherapy for haematological malignancies.

Osteoporosis Pharmacoepidemiology (Duncan EL). Osteoporosis is a costly disease – both in terms of consequences but also in terms of preventative therapies. This project looks at current osteoporosis prescribing in Australia.

Does Bone Regulate Energy Metabolism in Humans? Evidence from a Clinical Cohort of Obese and Non-Obese Individuals (Duncan EL, O’Moore-Sullivan TM, Prins JB)

The Inala Chronic Disease Management Project (Russell AW)A pilot project assessing an innovative model of care for the management of complex T2DM in the community by up-skilled general practitioners with the support of a specialist and a multi-disciplinary team.


Telephone Counselling For Maintenance Of Physical Activity, Weight Loss & Glycaemic Control In Type 2 Diabetes (O’Moore-Sullivan T, Russell AW)

A longitudinal study of nerve morphology in diabetic neuropathy using novel non-invasive ophthalmic surrogate markers (Prins JB, Russell AW)

Using conversational computer technology to improve diabetes management: A randomised controlled trial (Russell AW)

Obesity-related inflammation and insulin resistance in chronic liver disease: Exercise and diet as treatment options (Hickman IJ, Macdonald GA, Prins JB, O’Moore-Sullivan TM)

Investigation of the effects of improving insulin sensitivity by lifestyle interventions or drug therapies on markers of vascular and cardiac function, in patients with obesity, T2DM and after renal transplantation (Prins JB, O’Moore-Sullivan TM)

Investigations into the links between obesity and blood clotting (Sullivan C, Hickman IJ, Macdonald GA, O’Moore-Sullivan TM, Prins JB)

An investigation into the effect of improved insulin sensitivity, through the prescription of Metformin and lifestyle intervention, on cardiovascular structure and function, in non-diabetic, obese patients (O’Moore-Sullivan TM, Hickman I, Sullivan C, Wong C, Hukins C, Byrne N, Hills A, Prins J, Marwick T) An NHMRC Health Partnership Grant in Type 2 Diabetes.

Androgen status in obese men (Ong C, O’Moore-Sullivan TM, Liu P, Prins JB)

Investigation into cellular energy metabolism of muscle using Magnetic Resonance Spectroscopy (Ipavec Levasseur S, O’Moore-Sullivan TM, Hickman I, Cowin G, Byrne N, Prins JB)

Role of 11ββ-Hydroxysteroid Dehydrogenase (HSD) in Insulin Resistance (Prins JB, Nisbet J)

Drug elimination and clearance in obesity (Russell AW, O’Moore-Sullivan TM in collaboration with Dr Bruce Green (Pharmacy School) and Phd student Ms Phey Yen Han.)

Lifestyle interventions in obesity and diabetes (Prins, J). In these studies, we are comparing the effects of different lifestyle changes (e.g. diet vs. exercise) to improve diabetes, heart disease and to reduce weight. The aim is to develop a set of “designer”

lifestyle intervention programs that are tailor-made for individuals.

Obesity-related liver disease (Prins, J). Non-alcoholic fatty liver disease (NAFLD) is a common problem in individuals with obesity and/or type 2 diabetes. It has a significant risk of progression to liver failure and of liver cancer-development. The causes of NAFLD and the impact of lifestyle intervention and some therapies to reduce the severity and/or progression of the disease are being studied.

Other ProjectsAustralian Osteoporosis Genetics Consortium (Duncan EL). Bone density is a highly heritable trait. This national multicentre study aims to identify the genes underlying bone density employing an extreme truncate selection approach. Dr Duncan is the national coordinator and chief scientist running this project.

Genetics of High Bone Mass (Duncan EL). Patients with high bone mass may harbour anabolic (bone-building) genes. This project aims to identify the genes underlying high bone mass, and hopes to use this information to understand new methods of approaching osteoporosis.

Bone Regulation of Energy Metabolism in Humans (Duncan EL). Proteins secreted from bone regulate glucose and fat metabolism in mice. This study aims to look at obese and non-obese adult humans aiming to identify if these pathways are similarly regulated in humans.

An assessment of the mechanical properties of bone utilising nanoindentation (Russell AW, Huang H, Cribb B)

Investigation of the production of the peptide hormone, Adiponectin, by human fat cells (adipocytes) and its post-translational modification and multimerisation within the secretory pathway of cells (Prins JB)

Adiponectin’s role in modulating postprandial oxidative, inflammatory and cardiovascular stress (Prins JB)

Studies on regulation of fat cell growth (Prins JB). These studies on human fat cells are aimed at identifying key regulators of fat cell growth, a key component of the development of obesity. Once regulators are identified, it may be possible to develop drugs to interfere with the growth process, thus creating new treatments for obesity.


Mechanisms of steroid-induced diabetes (Prins JB). Steroids are commonly used drugs that have a major side effect of increasing blood sugar, causing diabetes. The group are investigating the way in which the drugs cause this effect, with a view to either developing new steroids without this side effect, or developing drugs to counteract this effect of steroids.

Awards & PrizesDr Emma Duncan

Career Development Award (NHMRC)

PA Foundation Grant

Postdoctoral Research Fellowship for Women, University of Queensland

National & International PresentationsDr Emma Duncan

International Transplantation Society Annual Scientific Meeting, Sydney

33rd European Symposium Calcified Tissues, Barcelona

Australian Gastroenterology Society Annual Scientific Meeting

Australian Association for Clinical Pharmacists Annual Scientific Meeting

Royal Australasian College of Physicians Queensland State Meeting

Professor David McIntyre

Session chair, International Association of Diabetes in Pregnancy Study Groups, Pasadena, USA

Identifying pre existing diabetes in the context of GDM

Overview of Diabetes in Pregnancy, Eli Lilly symposium for diabetes educators, Brisbane

The ADVANCE Study, Servier GP Information Evening, Noosa

DAFNE and intensive Type 1 diabetes care, Gympie general practice education group

Issues in Pre diabetes and diabetes, Frontier GP Education Meeting, Lindeman Island

Education in the Mater Clinical School, School of Medicine Colloquium, Brisbane

DAFNE in Type 1 diabetes care (public meeting), Diabetes Australia – Queensland, Brisbane

The DAFNE programme in Australia, Australian Diabetes Society Satellite Symposium, Melbourne

Obesity and Pregnancy Outcomes in HAPO, Australasian Diabetes in Pregnancy Society, Adelaide

Insulin analogues in pregnancy, Novo Nordisk meeting, Gold Coast

Dr Trisha O’Moore-Sullivan

Effective Clinical Interventions in the Treatment and Management of Obesity: Lifestyle Interventions, Invited symposium presentation Australian and New Zealand Obesity Society Annual Scientific Meeting, Brisbane

Earl use of insulin and antidiabetic drugs. National Prescribing Service Education Meeting, Brisbane





Research in the Diamantina Institute has been greatly boosted after receiving a $3.2M grant in March from the

Australian Cancer Research Foundation to investigate genes linked to cancer. The grant allowed researchers to buy the

latest high technology tools which will enable them to sequence nearly a billion DNA bases per day, where previously it

took many months.

Associate Professor Nigel McMillan and team made a groundbreaking

discovery that could ultimately lead to a cure of the world’s most common

form of leukaemia – Chronic Lymphocytic Leukaemia. In collaboration with

clinicians from the Princess Alexandra Hospital, they managed to identify

key growth factors that are essential for keeping the chronic lymphocytic

leukemia cells alive, enabling the research community to gain a greater

understanding of these cells. Research has previously been hindered

because of the difficulty of keeping cells alive once removed from the body.

Professor Ranjeny Thomas and team have developed a simple test which

should allow for the early prediction of the onset of Type 1 diabetes in

children. The team identified a cellular pathway known as NF-kappa B that

is activated in blood cells of people with Type 1 diabetes.

Professor Ian FrazerDirector


Clinical ProjectsStrategies for delivering vaccines in the developing world (Frazer I). Vaccines to prevent cervical cancer need to be given to 12 year olds, and three shots are required for effective immunisation. Even in the developed world, only about 80% of children return for their third shot – many just forget. Studies ar being conducted in Nepal and Vanuatu to find out whether distribution of a silicone wrist band printed with “remember your next vaccine shot” in the appropriate local language at the time of the first vaccine shot will enhance the rate of completion of the vaccine program.

Rheumatoid arthritis vaccine (Thomas R). Patients with rheumatoid arthritis (RA) are being enrolled in a phase I clinical trial of a modified dendritic cell vaccine, known as Rheumavax. The vaccine consists of dendritic cells, grown in the laboratory from the blood of the patient to be immunised, and an antigen relevant to the disease.

Vascular disease in rheumatoid arthritis (Thomas R). Researching into factors influencing the development and progression of cardiovascular disease in RA is underway. Atherosclerosis is measured using


ultrasound imaging of carotid and brachial arteries to examine whether plaque is present and to determine the elasticity of the vessel walls.

The group have found that changes in the lining of the blood vessel walls (the earliest signs of vascular disease) are reversible with suppression of inflammation in early RA. The immune system’s response to joint inflammation combines with factors traditionally associated with vascular disease, such as cholesterol, excessive weight and smoking, to accelerate vascular disease. The group are researching new molecules at the interface of these pathways which could determine a person’s risk for development of vascular disease.

Type 1 (Juvenile) diabetes (Thomas R). Studies by the group demonstrate high levels of systemic inflammation preceding the onset of type 1 diabetes in humans and mice. This includes increased levels of the cytokine interleukin-1 and activation of the NF-βB inflammatory pathway in blood cells. In humans this seems to be triggered by environmental factors in genetically susceptible individuals. The group have designed a blood test for early detection of Type 1 diabetes susceptibility. Children with an abnormal test will be followed for the next five years to determine the predictive value of the test. The next goal is to prevent disease in those whom the group identify as susceptible.

Lifestyle interventions in obesity and diabetes (Prins J). In these studies, the group are comparing the effects of different lifestyle changes (e.g. diet vs. exercise) to improve diabetes, heart disease and to reduce weight. The aim is to develop a set of “designer” lifestyle intervention programs that are tailor-made for individuals.

Obesity-related liver disease (Prins J). Non-alcoholic fatty liver disease (NAFLD) is a common problem in individuals with obesity and/or Type 2 diabetes. It has a significant risk of progression to liver failure and of liver cancer-development. The causes of NAFLD and the impact of lifestyle intervention and some therapies to reduce the severity and/or progression of the disease are being studied.

Other ProjectsIdentification and characterisation of MYB target genes (Gonda T) The MYB oncogene codes for a transcription factor – that is, a protein that turns other genes (“target genes”) on or off. Therefore the key to understanding how MYB functions is to identify those target genes.

The group are currently doing this using microarray expression profiling to measure changes in thousands of genes that occur when MYB itself is switched on or off, and will combine this with advanced technology called ChIP-Seq to map where the Myb protein binds across the whole genome.

Role of MYB in breast cancer (Gonda T). One of the key findings in recent years has been that MYB plays a key role in growth of the most common type of human breast cancer “oestrogen receptor positive”. The group now have evidence that MYB protects breast cancer cells against killing by certain drugs and thus that blocking MYB in combination with such drugs may be a valuable approach for developing new breast cancer treatments.

Development of approaches for therapeutic targeting of MYB (Gonda T). MYB is required for the growth and survival of most human leukaemia cells, in addition to many breast cancers and bowel cancers. Therefore blocking MYB or its action could have widespread implications for cancer treatment. The group are developing several approaches to this end, including blocking Myb’s interaction with essential partner proteins and looking for compounds that can switch the MYB gene off.

High-throughput discovery of novel cancer genes (Gonda T, Gabrielli B). This collaborative project aims to establish a facility (the ARVEC project) using robotics and advanced imaging technology to generate and screen large gene libraries. Specifically, the group will identify genes that can enhance or block cancer-associated properties in cultured cells as such genes may represent novel targets against which new cancer drugs could be developed.

Investigation into the alternative splicing of steroid hormone regulated genes in breast cancer (Dowhan D). The primary objective of the research is to investigate and understanding the role of steroid hormone signalling pathways and the alternative splicing of RNA in cancer initiation and progression. This will be achieved by studying the role of specific splicing proteins and protein methylation signalling pathways in the alternative splicing of genes related to the initiation and progression of hormone-dependent cancers.

The study of BEX2 pathway in breast cancer (Naderi A). The group are investigating a novel breast cancer gene, BEX2, which is highly expressed in a subset of breast tumours and exploring the functional significance of this gene in the biology of breast cancer.


The study of androgen signalling pathway in molecular apocrine breast cancer (Naderi A). The group are investigating a subtype of breast cancer which is characterised by the lack of oestrogen receptor and the presence of androgen receptor. Currently there are very limited options for the treatment of this subtype of breast cancer and therefore, the results can lead to the discovery of better treatments for this disease. A Phase 2 clinical trial to study a novel therapeutic approach for this subtype of breast cancer has been set up, which will begin in 2009.

Examining normal cell proliferative controls and how they go wrong in cancer (Gabrielli B). In the first theme there are three projects: Defining the role of cdk2/cyclin A in G2/M progression; defining the molecular mechanism of the cell cycle response to suberythemal doses of ultraviolet radiation; investigating a novel mechanism that links cell signalling to G2/M progression. These projects examine mechanisms that can contribute to regulating normal cell division. The work of the group is demonstrating that cyclin A/cdk2 and its upstream regulator, cdc25B, are critical components controlling cell division that respond to many different signals. This pathway appears to be defective in a number of different cancer types, including melanoma. The cell cycle response to ultraviolet radiation is often defective in melanomas, and is being investigated as a potential drug target. The group have found that its normal role is to ensure that all the DNA damage that occurs as a consequence of ultraviolet radiation exposure is fully repaired. Ultraviolet radiation-induced DNA damage is a source of many of the mutations associated with skin cancer, particularly melanomas.

Targeting defective controls to selectively destroy cancer cells with these defects (Gabrielli B). Work in this project is based on the anti-cancer drugs, the histone deacetylase inhibitors. The group have demonstrated that much of the tumour selective effect of these drugs is based on their ability to selectively target a defective cell cycle control in the cancer cells. Normal tissue is protected by their intact controls. Based on work on the ultraviolet radiation response, which is often defective in melanomas, the group are investigating components of this response pathway as potential targets for new drugs that specifically destroy melanomas with this defective mechanism.

Gene silencing as a cancer treatment (McMillan N). The laboratory focuses much of its efforts on developing gene silencing treatments for cancer. Interest is

around developing practical ways to implement this new technology. A major area the group have concentrated on is the ability of this technology to not only kill cancer cells but also to induce positive immune response in the animal models. This dual activity makes this treatment have the potential to be much more effective. Another major barrier in the use of this technology is the ability to deliver it in the bloodstream. Several projects, in collaboration with other researchers in the pharmacology area, are underway to develop novel delivery systems. The group are currently researching treatments for cervical cancer as well as melanoma.

Human papillomavirus in other cancers (McMillan N, Antonsson A) While human papillomavirus (HPV) is known to cause cervical cancer, we are unsure of its role in other common forms of cancer. The group have been investigating whether HPV can be found in both prostate and breast cancer using a novel test developed by Dr Annika Antonsson. She has found that HPV DNA is present in up to half of all breast and prostate cancers. In an extension of this work, she has found that HPV is present in the blood of normal healthy individuals. It appears that HPV is ubiquitous and its role of the development of other cancers is still uncertain.

Chronic lymphocytic leukaemia (McMillan N). Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. However, current treatments only reduce disease burden and there is at present no cure. In collaboration with haematologists at the Princess Alexandra Hospital, the group have been working on ways to investigate novel treatments for CLL. The major problem is the normal tools available to investigate cancers, such as cell lines and animal models, do not exist for CLL. New techniques to keep these cells alive for up to three months have been developed which allows the investigation into new treatments. The group found a critical set of growth factors required to keep the cells alive which may form the basis of a new treatment.

Development of novel therapies for cutaneous and oral squamous cell carcinoma (Saunders N). Squamous differentiation occurs in the external lining of the skin or the lining of the mouth, nose and throat. In normal states this process of differentiation is tightly regulated. However, in squamous cell carcinomas, the cells of the lining (keratinocytes) have become disrupted such that they no longer control growth, differentiation or cell death appropriately. Over the past few years


the group have demonstrated that a key controller of differentiation in normal keratinocytes are the E2F factors. They have shown these factors are disrupted in squamous cell carcinomas. Significantly, if we reinstate normal control of the E2F factors in squamous cell carcinoma cells it reinstates normal differentiation mechanisms. These experiments have proved that the E2F factors are a valid target in squamous cell carcinomas. The group are currently developing the E2Fs as potential drug targets in the laboratory and will start in vivo tests of their potential as an anti-cancer target. Recently the group completed their first trial in patients of an agent that showed some potential as an anti-E2F drug.

Identifying the biological basis for osteosarcoma metastasis (Saunders N). Osteosarcoma is the most common primary bone cancer in children and adolescents. Patients who do not have evidence of lung metastases have an approximately 80% chance of being cured. In contrast, those patients who have evidence of lung metastases have only a 20% chance of cure. In order to improve cure rates for this disease (currently approximately 50% overall), it will be important to develop selective cures or preventives for metastatic lung disease. We have completed a study of patient samples and have discovered that those patients who will develop lung metastases also have lost a particular cell type (osteoclast) in the bone where the cancer arises. We have now shown that the loss of the osteoclasts is a contributing factor in the causation of lung metastases. We are now conducting laboratory and in vivo tests of potential therapeutics that may prevent the loss of osteoclasts and hence prevent the development of lung metastases.

Genetics of ankylosing spondylitis (Brown M). Ankylosing spondylitis affects ~0.5% of white Europeans. We are part of an international consortium studying the genetic determinants of this disease, involving Australia, North American and British colleagues. The group is principally responsible for the genetics component of this study and is also involved in studies of how the genes involved actually operate to cause the condition. We are also part of the Wellcome Trust Case Control Consortium, and are performing genetic studies in association with this group particularly aiming to identify genes which affect the extent of bony fusion in ankylosing spondylitis, the main cause of disability in the disease. In association with colleagues based in Shanghai, China, the group are studying genetics of ankylosing spondylitis in Asian populations. 20% of Australians have some Chinese ancestry and the genes

involved in ankylosing spondylitis in this group differ from those in white Europeans, from which more will be learned about what leads to the condition.

Genetics of osteoporosis (Brown M). The group is the main centre for the Australian Osteoporosis Genetics Consortium, working together with leading Australian osteoporosis researchers to identify genes involved in bone thickness and thus fracture risk. There are collaborations with the European Union funded Genetic Factors for Osteoporosis study (GEFOS), which is the main osteoporosis genetics group internationally. In collaboration with English colleagues, the group are involved in a program developing new mouse models of osteoporosis, by ENU mutagenesis.

Genetics of multiple sclerosis (Brown M). As members of the ANZGene Multiple Sclerosis Consortium we have performed a genomewide association study in multiple sclerosis this year, particularly focusing on primary progressive multiple sclerosis. This study has identified new genes involved in this severe and disabling disease, which throw new light onto the diseases aetiopathogenesis.

Genetics of cervical cancer (Brown M). Cervical cancer is caused by chronic infection with human papillomavirus (HPV). Funded by the Australian Cancer Research Foundation, we are working to identify genes which affect an individual’s ability to clear the HPV infection. Identifying such genes may point to potential therapies aimed at preventing cervical cancer by enabling carriers to clear HPV infection.

The group also collaborates with others in studies of the genetics of rheumatoid arthritis, schizophrenia and pseudo-exfoliation syndrome (a cause of glaucoma). A program is being established in obesity genetics in children in and around Brisbane, testing the ability of genetic screening to identify those at risk of poor outcomes, and identifying further genes involved in the condition.

Overcoming local blocks to immunotherapy in skin (Frazer I). We can immunise people with tumour specific proteins and induce immune responses that can kill tumour cells in the lab. However, when the same experiment is done in a patient, the right immune responses are induced but the immune cells do not seem able to kill the cancer cells. A range of cells and signalling proteins, some naturally produced in skin, and some produced by skin tumours, that instruct killer cells not to work in their environment have been discovered. The group are now researching ways to


overcome the blocks that these cells produce, and testing these in animals with a view to their use in humans.

How we learn to live with ourselves (Frazer I). The protein building blocks of our body’s cells are not marked to distinguish them from foreign invader proteins that form part of a virus or bug. So how does the body tell the good self proteins from the bad invaders? The damage the invader causes alerts the immune system that action is needed. However self proteins and invader proteins tend to get mixed up at the sites where an invading organism is creating a problem, so a series of checks are put in place to make sure we generally don’t attack ourselves. We are studying the mechanisms by which one of these checks, a regulatory T cell that prevents damage to cells only expressing self protein, can get in the way of tumour specific responses against skin cancer cells that might otherwise be able to get rid of the skin cancer. Understanding of the mechanisms by which these regulatory T cells do their job will enable design of custom tricks for switching them off temporarily to enable cancer immunotherapy to work.

Rheumatoid arthritis vaccine (Thomas R). In mouse studies, the survival and migration of injected dendritic cells in this vaccine to the lymph glands in models of rheumatoid arthritis and of type 1 diabetes is being analysed. The group formulated a cell-free technology deriving from this vaccine as microparticles. The microparticles contain a natural inhibitor, known as curcumin (from the spice turmeric), deliver antigen, and are taken up by dendritic cells in the lymph glands. They are a versatile platform technology, which can deliver different antigens or inhibitors.

Cellular and molecular pathways of T-cell tolerance (Steptoe R). Diseases of immune dysregulation, such as autoimmunity and allergies, develop because the normal mechanisms that control the immune system fail. Retraining the immune system through induction of T-cell tolerance is seen as an attractive therapeutic for many of these diseases. In this project molecular, biochemical and cellular immunological approaches in conjunction with established models of tolerance to define key molecular pathways and cellular interactions that underlie the induction and maintenance of T-cell tolerance are being used.

Prevention and reversal of autoimmune diabetes (Steptoe R). The group have previously shown that autoimmune (type 1) diabetes can be prevented by expression of key disease targets in dendritic cells. The group are testing

in a range of models proof-of-principle studies that establish whether diabetes-causing immune responses can be terminated.

Novel methods of gene delivery for tolerance (Steptoe R). The group have developed substantial background expertise in the induction of antigen-specific tolerance in both naïve and memory T cells. Currently available methods limit the potential for clinical application of antigen-specific immunotherapeutic gene therapy. Ways to develop vaccine-like approaches to facilitate gene-therapeutic induction of tolerance for application to autoimmune diseases are being investigated.

Studies on regulation of fat cell growth (Prins JB). These studies on human fat cells are aimed at identifying key regulators of fat cell growth, a key component of the development of obesity. Once regulators are identified, it may be possible to develop drugs to interfere with the growth process, thus creating new treatments for obesity.

Mechanisms of steroid-induced diabetes (Prins JB). Steroids are commonly used drugs that have a major side effect of increasing blood sugar, causing diabetes. The group are investigating the way in which the drugs cause this effect, with a view to either developing new steroids without this side effect, or developing drugs to counteract this effect of steroids.

Awards & PrizesProfessor Ian Frazer

Ramaciotti Medal for Excellence in Biomedical Research ($50,000), in recognition of his work that contributed to the development of the world’s first cervical cancer vaccines.

2008 Prime Minister’s Prize for Science ($300,000), for his outstanding achievement in science benefiting society.

2008 Balzan Prize for Preventive Medicine (over $1.08 million), for his outstanding scientific achievement and lasting contribution to preventive medicine through his role in the development of a vaccine that promises to prevent virus-induced carcinoma of the cervix, which claims 250,000 lives every year.

National & International PresentationsProfessor Ian Frazer

Plenary Session, Specific Immunotherapy for skin disease: promises and pitfalls, American Academy of Dermatology, Texas, USA


Talk for World Cancer Day, Cancer Council, Canberra

Cancer Immunotherapy, Progress and Pitfalls, Lorne Cancer Conference, Melbourne

Research Launch – Importance of research, what CCA does Research Seminar. How research in Lab lead to Worldwide Programme, Cancer Council Tasmania, Tasmania

Talk about research and life in research and the trials and tribulations - as well as give an overview of vaccines in cancer prevention, Vaccine prevention symposium, Brisbane

Global Strategies for Cancer Reduction in the 21st Century, Medico-Legal Society Melbourne

Talk about the importance of an inquiry-based scientific methodology, the practices of scientists and the importance of scientific awareness in our current climate, Science 21 Teacher Conference, Brisbane

Plenary Address, Controlling Cancer through immunisation – a glass half full?, Sir Mark Oliphant Conference, Canberra

Australian Society of Gynaecologic Oncologists (ASGO). HPV vaccines – moving forwards, CSL, Hobart

Plenary Lecture IV, Immunotherapy for epithelial cancer: progress and pitfalls, Australasian Vaccines, Immuno Development Meeting, Gold Coast

Keynote Speaker, Is Cervical Cancer totally preventable?, AOGIN Bi-Annual Conference, Seoul

Cancer Immunology - why doesn’t immune surveillance work?, Visit to Queen Sirikit Centre for Breast Cancer, Bangkok

Vaccines to prevent and treat cervical cancer, Visit to Queen Siriki Centre for Breast Cancer, Bangkok

Never say Die – the solutions to cancer. What every WPO’er should know, World President’s Organisation, Sydney

The end of Cervical Cancer presentation, Infection & Immunity in Children 2008, England

Presentation about Leadership, Ethos Research Leaders Forum, Brisbane

General cancer prevention, the cervical cancer vaccine and the future, The Nationals Queensland Women’s Annual State Conference, Brisbane

HPV Vaccine Technology and Clinical Trial overview, Talk for South Australian Immunisation Network, Adelaide

By Teleconference, Advances in vaccine technology – where to next?, 6th Annual Australian Biotechnology Summit, Brisbane

Plenary 2, Preventing Cervical cancer - from bench to bedside and beyond, 2nd Clinical Research Excellence Conference, Brisbane

Microbiology and Immunology Department, University of Melbourne. Modelling immunotherapy for persistent viral infection Seminar. University of Melbourne, Melbourne

Presentation to Cancer Council Victoria on Cancer Council issues, Melbourne

Keynote Address, Harnessing the immune system to prevent cancer, Research Week 2008, St Vincent’s Hospital Research Meeting, Melbourne

Cervical Cancer: the place for Vaccination. Presenation on results of vaccination trials, UICC, Geneva

Lambie Dew Oration, Cancer and how to Avoid it, University of Sydney, Sydney

Symposium for CSL, Challenging our understanding of HPV Vaccines, PHAA Immunisation Conference, Gold Coast

Vaccines to prevent and to treat cervical cancer, Nambour Hospital

Seminar program at Tribhuvan University Teaching Hospital and luncheon address to Medical Practitioners, ACCF, Nepal

Opening Address, When can I expect a vaccine for Osteoporosis, 2008 Australian Orthopaedic Conference, Hobart

Using the immune system to prevent and control cervical cancer, Australian Society of Microbiology, Hobart

Keynote Address, Therapeutic Immunisation - where are we heading?, World Vaccine Congress 2008, Sydney

Opening Lecture, Cervical cancer prevention in the 21st century – is there still a place for the colposcope?, IFCPC World Congress, Auckland


Symposium on Vaccine Development for Cancer and Infectious Diseases, HPV Vaccines, Gairdner Foundation, Toronto

Lecture at Guelph University, Harnessing the Immune System to control Cancer - 50 minutes, Gairdner Foundation, Toronto

Immunology of HPV: Natural infection and Vaccines, MSD Scientific Symposium at the 12th Biennial Meeting of the International Gynaecologic Cancer Society 2008, Bangkok

New recipes for new vaccines, ADOL Health Conference, Gold Coast

Guest Speaker, Experience as AOY and of bringing lab research to commercialisation, Medical Staff Council of the Mater, Annual Dinner, Sydney

Hasting Memorial Lecture, Cancer Control in the 21st Century, Annual Medical Symposium, St George Hospital, Sydney

Cancer Wars: The return of the Immune System, MEPSA – mutation and experimental pathology society of Australia, Brisbane

New Therapies Seminar on vaccines in clinical practice - Will vaccines fulfil their promise?, COSA ASM, Sydney

Opening Speaker in the Frontiers of Science Services, Brisbane

Presented the Burnet Oration, ASI, Canberra


Fiftieth Australian Rheumatology Association Scientific Meeting (ASM), invited opening plenary speaker, Adelaide, SA. Antigen-specific therapy for rheumatoid arthritis. Describes development and current and future clinical translation of antigen-specific vaccine for rheumatoid arthritis. Clinical audience of >400. Also gave invited workshop talk at that meeting on The pleasures and pitfalls on a career in medical research.

Australasian Vaccines & Immunotherapeutics Development Meeting, invited plenary speaker, Gold Coast. Antigen-specific vaccination for rheumatoid arthritis.

Invited plenary, Australian Society for Immunology ASM, Canberra. Antigen-specific therapy for autoimmune disease. This is Australia’s most prestigious national immunology meeting. Few Australian speakers are asked to give plenary talks.

Professor Tom Gonda

Pre-ASH Myeloid Workshop, San Francisco, California USA

Genomics Institute of the Novartis Research Foundation, San Diego, California, USA

Institute for Molecular Medicine, Trinity College, Dublin Ireland

Professor Matt Brown

Australian Human Genetics Association, Genomewide association studies – the hope, hype and where to from here? Adelaide

Australian Rheumatology Association, Genetics of Inflammatory Arthritis, Adelaide

Clare Valley Bone Conference, Identifying Osteoporosis Genes, Clare Valley, South Australia

Endocrine Society of Australia, Identifying Osteoporosis Genes, Melbourne

Australian Society of Medical Research, Ian Frazer Oration - The Shock of the New, Brisbane

European Congress of Rheumatology, Genetics of ankylosing spondylitis, Paris

American College of Rheumatology, Genetic screening for ankylosing spondylitis, San Francisco

International Spondyloarthritis Congress, Genetics and genomics of ankylosing spondylitis, Ghent, Belgium

Associate Professor Nigel McMillan

Innate Sculpting of Adaptive Immunity, Hamilton Island

Discovery Science and Biotechnology, Brisbane

Merck Symposium on RNAi Delivery, AusBiotech

Epigenetics and RNA Biology, Sydney

Associate Professor Brian Gabrielli

Children’s Medical Research Institute, Westmead

Associate Professor Nicholas Saunders

E2Fs as anticancer targets. School of Pharmacy, University of Queensland, April.

The War on Cancer, Brisbane Institute, May.


Associate Professor Jon Whitehead

The Queenstown Signal Transduction Meeting, New players modulating adiponectin action, Queenstown, New Zealand

4th Scientific Meeting of the Asia-Pacific Diabetes and Obesity (APDO) Study Group, Mechanisms of Dex-induced inhibition of glucose uptake, Kobe, Japan

Australian Diabetes Society, New insights into adiponectin production, action and clearance, Melbourne

Associate Professor Edith Gardiner

Endocrine Society Meeting ENDO 2008, Symposium Presentation, Neural control of bone and fat, San Francisco, California

4th Australian Health and Medical Research Congress, Neural regulation of osteoblasts and adipocytes in skeletal tissue, Brisbane

Sydney University Tissue Engineering Network, Neural regulation of osteoblastic bone formation, Sydney

PatentsCompositions and methods for modulating immune responses. National Phase, 2007, Australia, US, Canada, Europe, India, China (Thomas R, O’Sullivan B)

A method for nucleic acid sequence analysis. National Phase, 1997, Eur, US (Frazer I)

A method for optimising gene expression. National Phase, 2002, Australia, US, Europe, Jap, NZ, (Frazer I)

Expression system. National Phase / Grant, 2002, Australia, Canada, China, Europe, Japan, South Korea, US (Frazer I)

Immunomodulating Compositions and Uses Therefor. National Phase, 2005, Australia, Canada, China, Europe, India, Japan, US (Frazer I)

Method and polynucleotides for determining translational efficiency of a codon. National Phase / Grant, 1999, Australia, Canada, Europe, Japan, NZ, US (Frazer I)

Modified papilloma virus L2 protein and VLPs formed therefrom. National Phase / Grant, 1994, Australia, Canada, Europe, Japan, NZ, US, Singapore, South Korea (Frazer I)

Novel compositions and uses therefor. National Phase / Grant, 2001, Australia, Canada, Europe, US (Frazer I)

Nucleic acid sequence & method for selectively expressing a protein in a target cell or tissue. National Phase / Grant, 1997, Australia, Canada, Europe, US, Japan (Frazer I)

Papilloma virus vaccine. National Phase / Grant, 1991, Australia, Brazil, Canada, Europe, Japan, US, Singapore, South Korea (Frazer I)

Papillomavirus polyprotein constructs. National Phase / Grant, 1995, Australia, Canada, Europe, HK, Japan, NZ, US, South Africa (Frazer I, McMillan N)

Recombinant papilloma virus L1. National Phase / Grant, 1994, Australia, Canada, Europe, Japan, NZ, Singapore, US, South Korea (Frazer I)

Subunit papilloma virus vaccine and peptides for use therein. National Phase / Grant, 1990, Australia, Canada, Europe, Japan, South Korea, US (Frazer I)

Treatment of papillomavirus infections. National Phase / Grant, 1998, Australia, Canada, Europe, Japan, NZ, South Korea, US, Singapore, South Africa (Frazer I)

Variants of human papillomavirus antigen. National Phase / Grant, 1994, Australia, Canada, Europe, Japan, NZ, US, South Africa (Frazer I)

Method of inducing an immune response. National Phase, 2007, US, Australia, Eur, Can (McMillan N, Leggatt G, Gu W)

Combination therapy. PCT, 2007 (Saunders N)

Diagnostic markers & uses therefor. PCT, 2007 (Brown M)

Diagnostic markers & uses therefor. PCT, 2008 (Brown M)

Diagnostic markers & uses therefor. Provisional, 2008 (Brown M)

Diagnostic markers & uses therefor II. Provisional, 2008 (Brown M)

Major Grants and Financial Support Total NHMRC funding: $ 5,184,202

Other Competitive funding: $ 5,326,740

Funding from commercial studies: $ 433,305

Funding from other sources: $ 15,160,165


Ear Nose Throat

The Ear Nose and Throat Department of the Princess Alexandra Hospital services the community nationally and

internationally. The well established Head and Neck Cancer Clinic caters for patients from all over Queensland,

interstate and internationally.

This department has built its reputation on its ability to obtain good results in patients with advanced head and neck

cancer.

Professor William B ComanDirector / Chair

Awards & PrizesProfessor William B Coman

Tianjin Medical University – 2nd Teaching Hospital School Of Medicine, Visiting Professor, Tianjin Medical University, 2008-2009.

National & International PresentationsInvited Speaker, Role of organ preservation in advance hypopharyngeal carcinoma, Pan Pacific – Honolulu Conference, Honolulu, HI

Conference Chairman, Upover Downunder V International ENT Meeting, Campitello, Italy

Invited Speaker, Melanoma, Melanoma Patients Australia Gala Dinner, Brisbane

Invited Panel Member, Management of Laryngeal Cancer T1-T4, ASOHNS, Sheraton Resort, Perth

Invited Speaker, Is there a role for organ preservation in advanced hypopharyngeal cancer, RACS – CASC 2008, Hong Kong

Invited Speaker, Update on NPC Vaccine, 12th International Congress on Oral Cancer, Shanghai, China

Invited Speaker, Young Surgeons in Research. The Royal Society of Medicine, Joint Anglo American Meet Dublin. Royal College of Surgeons, Ireland, Dublin, Ireland

Invited Speaker, Management by Conservation Partial Laryngectomy, 7th International Conference on Head and Neck Cancer, San Francisco USA

Invited Speaker, Quality of life, cost effectiveness, survival and functional outcomes following differential management of laryngeal cancer: Just how good are we at this stage?, The Garnat Passe and Rodney Williams Memorial Foundation Meeting, Noosa

Invited Speaker, Surgical Collaboration, The 2nd Australia-China Symposium on Science, Technology and Education, Gold Coast

Presenter, Christian Theodore Billroth – The Father of Modern Surgery, Princess Alexandra Hospital Surgical Grand Rounds, Brisbane


Emergency

The Emergency Department is a designated Level 6 Trauma centre with 46,205 attendances and 15,530 admissions in

2008. This represents an increase of 4.5% and 11%, respectively to the previous year. The admission rate is amongst

the highest in Australasia and demonstrates the high level of clinical acuity.

With the formation of the Queensland Emergency Medicine Research Fund the emergency department staff at the

hospital received funding for two research applications during the year. This will contribute to increasing the research

capacity.

Dr Phillip KayDirector


Clinical ProjectsImproving pain management of abdominal pain in Paediatric Emergency patients using a pre-post: interventional study (Williams S, Bonney D, Gilhotra Y, Pitt R, Holzhauser K)

NHMRC/NICS Emergency Care Community of Practice Pain Initiative – National Pain Audit. NHMRC/NICS (Clark D, Davis C (PAH))

Other ProjectsMathematical modelling of flows in Emergency Department (Kozan E, Collier J, Sinnott M)

Trauma Registry – Queensland Trauma Registry (Queensland Health and Conrod)

An exploratory study to examine the phenomenon of ambulance ‘ramping’ at hospitals within the Queensland Southern Health Districts and Queensland Ambulance Service (Rose E, Shaban R, Holzhauser K, Fitzgerald G, Finucane J, Crilly J, Eeles D, Tippet V)

Regulatory systems for occupational exposures in emergency health care: Contemporary challenges for the emergency physician in prevention, control and management (Sinnott M, Shaban R, Devereux J)

Awards & PrizesKerri Holzhauser & Julie Finucane

College of Emergency Nursing Australasia 2008 Philippa Moore Publication Prize for manuscript entitled Part A: Staff Attitudes to Family Presence during Resuscitation, an intervention study. Australasian Emergency Nursing Journal, 10(3), 124-133.

Major Grants and Financial Support Competitive funding: $ 144,878


Gastroenterology and Hepatology

In 2008 the Department of Gastroenterology had another productive year. One of the key highlights was that the

NHMRC funded a project grant to investigate ‘Pharmacodynamics in Liver disease and in Liver surgery’ with Dr

Macdonald and Dr Fletcher listed as Chief Investigators. The project will be led by Professor Michael Roberts and will

build on previous studies conducted at the Princess Alexandra Hospital. Other achievements include Carolyn Lang

being awarded her PhD for studies of Symptoms and quality of life in hepatitis C infection. The Clinical Trials Unit in

the department continued to grow and a number of phase II and III studies of new agents for the management of viral

hepatitis are underway. In addition, there are several long term studies nearing completion and it is anticipated there

will be a number of publications relating to these in 2009.

Associate Professor Graeme MacdonaldDirector


Clinical ProjectsClinical measures of obesity and risk of Barrett’s oesophagus (Macdonald GA, Whiteman DC, Kendall BJ). A study of the relationship between metabolic factors and obesity and risk of Barrett’s oesophagus. This is a follow on from work that demonstrated a link between serum leptin and risk of Barrett’s oesophagus in men.

CCRE in Cardiovascular and Metabolic Diseases (Marwick T, Prins JB, Macdonald G, Isbel N, Hegney D, Stowasser M). Collaborative study examining predictors of cardiovascular disease in a number of different disease states. In relation to liver disease the focus is on the prevalence of metabolic disturbance and cardiovascular disease following liver transplantation.

Obesity-related inflammation and insulin resistance in chronic liver disease (Macdonald GA, Hickman IJ, Prins JB, O’Moore-Sullivan T). This project is examining the link between cytokines, including adipokines, in chronic liver disease due to obesity and hepatitis C.

Pharmacodynamics in liver disease and in liver surgery (Roberts M, Weiss M, Macdonald GA, Fawcett J, Vitetta L, Fletcher L). Chronic liver disease and liver surgery can impact on drug metabolism. This has implications particularly in the preoperative period and also for patients undergoing liver transplantation. This project will examine the effect of liver disease and liver surgery on pharmacodynamics of a range of agents.

The role of adiponectin multimers and recptors in fatty liver disease (Nguyen T, Fletcher L, Murphy T, Lipka G, Macdonald GA, Whitehead J, Hickman I). HMW adiponectin multimers and adiponectin receptor expression are thought to play significant roles in the pathogenesis of liver disease. This project aims to correlate adiponectin multimer ratios and receptor expression in liver disease with a view to characterising their role in disease pathogenesis.

The pathogenesis if co-toxic liver disease (Fletcher L, Crawford D, Heritage M, Murphy T, Jaskowski L, Bridle K). Excess alcohol consumption, iron overload disease


and obesity are major public health issues which often lead to liver fibrosis and may progress to cirrhosis. Coexistence of more than one toxin may lead to accelerated disease. We aim to understanding the inter-dependent pathophysiological pathways in co-toxicity will allow us to move towards targeted therapeutic interventions to attenuate the fibrogenic process.

Rapamycin as an atifibrotic agent. Immunosuppression and the post-transplant hepatic fibrogenic response (Crawford D, Bridle K, Fletcher L, Sobbe A). This project explores the use of low dose rapamycin in novel animal models of liver disease to determine its value as an antifibrotic agent.

Industry Sponsored Clinical TrialsSchering Plough P02370 (Crawford DHG). Peg-Intron plus Rebetol for the treatment of subjects with chronic hepatitis C who failed to respond to previous combination therapy (any alfa Interferon treatment in combination with Ribavirin).

Schering Plough P02569 (Crawford DHG). Peg-Intron as maintenance therapy vs. an untreated control group in adults with compensated cirrhosis (METAVIR F4), secondary to chronic hepatitis C, who have failed to respond to therapy with any alfa Inteferon plus Ribavirin.

Schering Plough P02570 (Crawford DHG). Peg-Intron maintenance therapy vs. an untreated control group for the prevention of progression of fibrosis in adult subjects with chronic Hepatitis C with fibrosis (Metavir fibrosis score of F2 or F3), who failed therapy withPeg-Intron plus Rebetol (in protocol P02370).

ATAHC NCHECR (Crawford DHG). A prospective non-randomised dual arm longitudinal cohort within which all subjects will be given the option of undergoing treatment involving a 24 week course of pegylated interferon monotherapy (180mcg/weekly ) at entry to study.( Australian Trial of Acute Hepatitis C).

IDENIX NV-02B-022 (Crawford DHG). An open label trial of Telbivudine (LdT) in adults with chronic hepatitis B previously treated in Idenix-sponsored Telbivudine studies.

Roche CHARIOT STUDY ML17908 (Crawford DHG). A phase IV, randomised, multicentre, efficacy and safety study examining the effect of Induction dosing with the combination of Peginterferon alfa 2a and Ribavirin in patients with chronic hepatitis C infected with genotype 1.

Roche Transplant Study ML17235 (Crawford DHG). A phase III, randomised, multicentre, efficacy and safety study examining the efficacy of the combination of Peginterferon alfa 2a and Ribavirin versus Peginterferon alfa 2a monotherapy in liver transplant recipients with recurrent hepatitis C virus infection.

Sanofi Aventis EFC 4492 (Macdonald GA). Satavaptan cirrhotic ascites study: a double blind, randomised, parallel-group comparison of treatment with Satavaptan at 5 to 10mg daily versus placebo on top of conventional treatment in patients with ascites due to cirrhosis of the liver.

Sanofi Aventis EFC 4493 (Macdonald GA). Satavaptan in the prevention of ascites recurrence: a double-blind, randomised, parallel-group comparison of satavaptan at 5 to 10mg daily versus placebo with concomitant diuretics in patients with recurrent ascites due to cirrhosis of the liver.

Sanofi Aventis EFC 6682 (Macdonald GA). Satavaptan in the prevention of ascites recurrence: a double-blind, randomised, parallel-group comparison of satavaptan at 5 to 10mg daily versus placebo in the nascence of diuretics in patients with recurrent ascites due to cirrhosis of the liver.

Gilead GS-US-174-0102 (Crawford DHG). A randomised,double-blind controlled evaluation of Tenofovir DF versus Adefovir Dipivoxil for the treatment of presumed pre-core mutant chronic hepatitis C.

Gilead GS-US-174-0103 (Crawford DHG). A randomised, double-blind controlled evaluation of Tenofovir DF versus Adefovir Dipivoxil for the treatment of HBeAg positive chronic hepatitis B.

Bristol Myers Squibb AI463109 (Macdonald GA). Study of the antiviral activity of Entecavir in patients receiving liver transplant due to chronic hepatitis B virus infection.

Progen PR88302 (Macdonald GA). A prospective, randomised, double-blind, placebo controlled, parallel group , international, multicentre phase III trial of PI-88 in the adjuvant treatment of post- resection hepatocellular carcinoma.(PATHWAY).

Gilead GS-AU-103-0185 (Macdonald GA). Study of acquired viral mutations in chronic hepatitis B patients on antihepadnaviral therapy.

ACHOS NCHECR (Macdonald GA). Australian chronic hepatitis C observational study.


Vertex Advance study (Macdonald GA). A phase III study of 2 dose regimens of Telaprevir in combination with Peginterferon alfa 2a (Pegasys) and Ribavirin in treatment naïve subjects with genotype 1 chronic hepatitis C.

Boehringer Ingelheim BI201335 NA (Macdonald GA). Antiviral effect, safety and pharmacokinetics of once daily BI201335 NA in hepatitis C virus genotype 1 infected treatment naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon alfa-2a and ribavirin (double-blind, randomised, placebo-controlled, Phase II).

National & International PresentationsAssociate Professor Graeme Macdonald

American Transplant Congress, Toronto, Canada. “Insulin resistance: a metabolic pathway that contributes to chronic liver injury.”

Major Grants and Financial SupportTotal NHMRC funding: $ 554, 250

Other Competitive funding: $ 382, 000

Funding from Commercial studies: $ 147, 000



Hypertension

The PAH Hypertension Unit conducts internationally-recognised clinical research into the pathogenesis and

management of hypertension (HT), especially endocrine forms. Working with its sister unit at Greenslopes Hospital, it

is considered a world authority on primary aldosteronism (PAL), a specifically treatable and potentially curable form

of HT. Significant progress has been made in the quest to elucidate the genetic basis of PAL. Previous work identified a

small region on Chromosome 7 that demonstrated genetic linkage with PAL in two Australian, one South American and

two Italian affected families. In collaboration with Dr Kevin O’Shaughnessy (University of Cambridge, UK), sequencing

of the genes in this region is underway. This work has the potential to lead to better detection of PAL and increase

understanding of how PAL develops in the first place.

Other achievements have included:

The demonstration by Dr Sandie Staermose of elevated levels of the inflammatory marker, IL-6, in normotensive

subjects with familial PAL. This work adds to existing evidence that aldosterone excess causes cardiovascular damage

through inflammatory mechanisms that are not dependent on high blood pressure.

The development and further validation by Mr Paul Taylor, as part of his PhD, of a new, highly accurate method of

measuring aldosterone and cortisol hormones in clinical samples using high-performance liquid chromatography-

tandem mass spectrometry. This achievement has been critically important given the major problems that exist with

currently used methods of aldosterone measurement.

The demonstration by Dr Norlela Sukor as part of her PhD studies that

unilateral adrenalectomy can be highly beneficial and should not be

excluded as a treatment option in a selected subset of patients with

bilateral PAL.

The participation by Associate Professor Stowasser as a member of a task

force sponsored by the US Endocrine Society to develop clinical guidelines

for the diagnosis and management of PAL which were published in J Clin

Endocrinol Metab and have been widely distributed.

Associate Professor Michael StowasserDirector, Hypertension Unit; Co-director, Endocrine Hypertension Research Centre and Associate Professor, University of Queensland School of Medicine



Clinical ProjectsClinical, biochemical, morphological and management aspects of primary aldosteronism (Stowasser M, Gordon R, Sukor N, Ahmed A, Cowley D). Using meticulous new diagnostic approaches, the GHHU was first to demonstrate worldwide that PAL is approximately 10 times more common that previously thought. The combined PAHHU/GHHU has the largest number of patients (currently over 1400) with PAL worldwide who have been thoroughly studied and documented. This provides a unique resource for further research into the causes, diagnosis and treatment of mineralocorticoid hypertension. Ongoing projects in this area have included the demonstration by Dr Norlela Sukor as part of her PhD studies that unilateral adrenalectomy can be highly beneficial and should not be excluded as a treatment option in a selected subset of patients with bilateral PAL; and the assessment by Dr Ashraf Ahmed as part of his PhD of the effects of antidepressants and drugs containing female sex steroids (oral contraceptive agents and hormone replacement therapy) on the level of the aldosterone/renin ratio, used to screen patients for PAL.

Elucidating the molecular basis of familial hyperaldosteronism type II (Stowasser M, Gordon R, Sukor N, Dowling A, Jeske Y, O’Shaughnessy K, Mulatero P, Duffy D). The PAHHU is involved in collaborative research with the Queensland Institute of Medical Research, the University of Torino and the University of Cambridge (UK) in order to determine genetic mutations responsible for a new familial variety of PAL (FH-II) described by the GHHU in 1991. This has the potential to greatly facilitate detection of individuals with PALL through genetic testing while at the same time enhancing our understanding of the pathogenesis of this important, potentially curable and specifically treatable form of hypertension.

Non-BP dependent adverse cardiovascular effects of aldosterone excess II (Stowasser M, Gordon R, Staermose S, Dowling A, Marwick T). In 2008, the Unit’s previous findings in this area were extended by the demonstration that normotensive individuals with a familial variety of PAL (FH-I) had higher levels of the serum inflammatory marker IL-6 than matched normotensive controls.

A multi-centre, randomized, double-blind, placebo and active controlled, parallel group, dose finding study to evaluate the efficacy and safety of LCI699 compared to

placebo after 8 weeks treatment in patients with essential hypertension (Stowasser M, Cowley D, Staermose S)

The Unit was chosen to participate in this Novartis sponsored multicentre clinical trial which will evaluate the efficacy and safety of a new form of antihypertensive medication.

Other ProjectsThe development of a new, highly accurate method of measuring aldosterone using high performance liquid chromatography-mass spectrometry (Taylor P, Stowasser M, Gordon R, Cooper D). Mr Paul Taylor, as part of his PhD, has successfully developed this technique, which is a critical advance as other currently available methods of measuring aldosterone lack reliability. His work in 2008 served to further validate the method in the clinical setting. He also extended the application of this method to include measurement of cortisol, with the aim of using this technique to improve accuracy of results obtained during adrenal venous sampling procedures, in which both aldosterone and cortisol levels are measured in adrenal and peripheral venous blood in order to differentiate unilateral from bilateral forms of PAL. This is a vital part of the diagnostic workup for PAL as it helps guide definitive management (usually unilateral adrenalectomy for unilateral forms and aldosterone antagonist medications for bilateral forms).

Awards & PrizesAssociate Professor Michael Stowasser

Visiting Professorship, Tung Wah Eastern Hospital, Hong Kong.

National & International PresentationsStowasser M, Marwick TH, Sharman JE, Gordon R. Rediscovering aldosterone. 56th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, Adelaide, August.

Stowasser M, O’Shaughnessy K, So A, Jeske Y, Dowling A, Kelemen L, Duffy D, Gordon RD. Genetics of primary aldosteronism. Tung Wah Eastern Hospital, Hong Kong, November.

Associate Professor Michael Stowasser & Emeritus Professor Richard Gordon

Prevalence, diagnosis and genetics of primary


aldosteronism. 1st International Aldosterone Forum in Japan, Tokyo, May.

Diagnosis and management of primary aldosteronism. 22nd Scientific Meeting of the International Society of Hypertension, Berlin, June.

When and how to test for hyperaldosteronism. Scientific Sessions of the American Heart Association, New Orleans, November.

Primary aldosteronism: prevalence, diagnosis and management. Tung Wah Eastern Hospital, Hong Kong, November.

Associate Professor Michael Stowasser

Guidelines of the Endocrine Society for the diagnosis and treatment of primary aldosteronism. 5th Meeting of the Endocrine Hypertension Working Group of the European Society of Hypertension, Berlin, June.

Management of patients with “difficult” hypertension. Tung Wah Eastern Hospital, Hong Kong, November.

Case discussions: practical issues about primary aldosteronism. Tung Wah Eastern Hospital, Hong Kong, November.

Primary aldosteronism arrives: the new US Endocrine Society guideline for case detection, diagnosis and management. Chinese University of Hong Kong, Division of Endocrinology and Diabetes, Hong Kong, November.

Major Grants and Financial SupportTotal NHMRC funding: $ 400,000




Infection Management

Infection Management Services continues to provide clinical infectious diseases programmes, sexual health services,

provision of alternate site infusion services and infection control programmes at Princess Alexandra, Logan, Ipswich,

QEII and Redland Hospitals.

The Department provides undergraduate and post-graduate teaching in all areas of infectious diseases, infection

control, as well as some microbiology to Medical, Pharmacy and Science Students of the University of Queensland.

Post-graduate education and activities are undertaken with a range of professional groups including doctors, nurses,

pharmacists and laboratory scientists.

Research within the department primarily focuses on the epidemiology, prevention and therapy of healthcare

associated infection, particularly:

Healthcare acquired fungal nosocomial infection •

Healthcare acquired and community Staphylococcal infection •

Aspects of healthcare worker behaviour integral to the prevention of healthcare associated infection. •

Dr Michael WhitbyDirector


Clinical ProjectsA phase lll, double-blind, randomised study to evaluate the safety and efficacy of BAL8557 versus a caspofungin followed by Voriconazole regimen in the treatment of candidaemia and other invasive candida infections (Protocol No: WSA-CS-008).

A phase lll, double-blind, randomised study to evaluate the safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by aspergillus species or other filamentous fungi (Protocol No: WSA-CS-004).

Open Label Study of Isavuconazole In the Treatment of Patients with Aspergillosis and Renal Impairment

or of Patients with Invasive Fungal Disease caused by Rare Moulds, Yeasts or Dimorphic Fungi (Protocol WSA-CS-003).

Ethanol lock therapy for the prevention of tunnelled intravenous catheter-associated bacteraemias: a randomised controlled trial.

Prospective Surveillance of Invasive Fungal Infections in Australian Intensive Care Units.

A Phase 2 Randomised, Double-Blind, Double-Dummy Efficacy, Safety and Tolerability Study of IV Sulopenem with Switch to Oral PF-03709270 Compared to


Ceftriaxone with Step Down to Amoxycillin/Clavulanate Potassium in Subjects with Community Acquired Pneumonia requiring Hospitalisation (Protocol No: A8811020).

Awards & PrizesDr Kate McCarthy

Coviden Infection Control Scholarship: Rapid molecular detection of resistance mechanisms in Gram-negative bacilli. Awarded October 2008

National & International PresentationsDr David Looke

Whither glycopeptides? Currently available alternatives. Australian Society for Antimicrobials Annual Scientific Meeting. Sydney, February.

Atypical pneumonia: A review. Thoracic Society of Australasia. Queensland meeting July.

Dr Geoffrey Playford

Fungal pneumonia: a review. Thoracic Society of Australasia. Queensland meeting July.




Intensive CareThe Intensive Care Unit maintained its high level of research throughput the year. It has been an impressive year

which is reflected in the department’s involvement in an increasing number of national and international clinical

trials. Importantly, the research program has developed to reflect the multi-disciplinary nature of intensive care

practice.

Several clinical trials have been completed during whose results are eagerly awaited. Many trials are still ongoing

and several studies have progressed through to publication which demonstrates the high level of academic activity

and research that occurs in the ICU. The unit are the instigating centre for the NHMRC funded STATINS trial which is

recognised nationally, thanks to the hard work of our diligent research staff. The unit are proud of rising registrar

involvement in research and the number of successfully completed registrar projects. The Critical Care Endocrinology

and Metabolism Research Unit was also formarly recognised by The University of Queensland.

This continued success is the result of a good team effort.

Professor Bala VenkateshDirector of Research

Associate Professor Chris JoyceDirector of Intensive Care


Clinical TrialsDECRA (Decompressive craniectomy) study (Venkatesh B, Joyce C). Multi-centre prospective randomised trial of early decompressive craniectomy in patients with severe traumatic brain injury.

ENTERIC - The early Nasojejunal Tube to meet energy requirements in intensive care study (Joyce C, Fraenkel D). A multi-centre randomised controlled trial comparing early jejunal feeding (using a frictional nasojejunal tube) and standard feeding in critical illness.

RENAL (Joyce C, Kruger P). Multicentre, Unblinded, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuos Renal Replacement

Therapy (CRRT) on 90-day all-cause mortality of Intensive Care Unit Patients with Severe Acute Renal Failure (ARF).

CAS - The Continued Use of Atorvastatin in Sepsis Trial (Kruger P). A phase II randomised, controlled trial in patients on statin therapy who develop sepsis to evaluate the effect of continued atorvastatin use on the incidence of severe sepsis.

STATInS - Study of Atorvastatin therapy in Sepsis (STATInS) (Kruger P). A Phase II randomised Controlled Trial of Atorvastatin therapy in Intensive Care Patients with Severe Sepsis.


ART-123 (Venkatesh B, Nunnink L, Walsham J). Randomised, Double Blind, Placebo Controlled, Phase-2B Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated Intravascular Coagulation (PAH).

SAFE TBI II – (Venkatesh B, Joyce C). Fluid Resuscitation of Critically Ill Patients with Traumatic Brain Injury: potential mechanisms behind the detrimental effect of albumin resuscitation.

STRATIFY (Marwick T). Study of risk assessment to reduce cardiac events in patients following major surgery.

Other ProjectsChanges in Body fluid dynamics and drug behaviour in critically ill patients– currently looking at neuromuscular blocking drugs (Cisatracurium) and antibiotic dosing in sepsis.

Sepsis prognosis.

Fluid responsiveness in sepsis.

Vancomycin kinetics study.

Fluid responsiveness study – preload study in ventilated post-CABG patients

Comparison of brain natriuretic peptide and tissue Doppler imaging in the prediction of fluid responsiveness in septic shock

Comparison of predictive value of brain natriuretic peptide, troponin and tissue doppler imaging in the prognosis of septic shock.

Early PN - Early Parenteral Nutrition Versus Standard Care in the Critically Ill Patient: A Level I Randomised Controlled Trial.

Testing a home-based rehabilitation program for survivors of a critical illness: a randomised controlled trial.

Routine Methicillin-resistant Staphylococcus aureas (MRSA) swabbing of inter hospital transferred patients.

The Impact of Nursing Rounds on the Practice Environment, Nurse Satisfaction and Processes of Care.

HECTIC - Health and Economic Outcomes of Critical Trauma Intensive Care Patients Study.

Intestinal Flora, Enteral Nutrition and diarrhoea Study.

Awards & PrizesK Ranasinghe, B Venkatesh, M Roberts, S Cross, J Lipman

Tissue Antibiotics in Burns. Best Poster Prize, International Wound Conference, Canada.

National and International Presentations (invited only)Professor Bala Venkatesh

Adrenal dysfunction in critical illness- newer insights: International Congress of Critical Care and Emergency Medicine, Brussels, March.

Arterial PO2 : How low can you go? International Congress of Critical Care and Emergency Medicine, Brussels, March.

Tissue Doppler in critical illness. International Congress of Critical Care and Emergency Medicine, Brussels, March.

Have studies controlled for severity of illness in relation to high cortisol? 10th International Consensus Conference in Intensive Care Medicine Florence, Italy, 17-18 April.

Which dynamic testing can be performed in critically ill patients and how? 10th International Consensus Conference in Intensive Care Medicine Florence, Italy, 17-18 April.

Data interpretation in critical illness, Malaysian Intensive Care Society course, Kualalumpur, November.

Biochemical data sets in critical illness, Malaysian Intensive Care Society course, Kualalumpur, November.

Arterial blood gases, Malaysian Intensive Care Society course, Kualalumpur, November.

Microbiology data interpretation, Malaysian Intensive Care Society course, Kualalumpur, November.

Neurointensive care, Malaysian Intensive Care Society course, Kualalumpur, November.

The JFICM Primary and Fellowship Examination, Supervisor of Training Workshop, JFICM meeting, Melbourne, June.

Demystifying the JFICM exam, ANZICS registrar course, Melbourne, July.

PO2 – how low can you go? ANZICS registrar course,


Melbourne July.

Workshop on arterial blood gases? ANZICS registrar course, Melbourne July.

Strong ion difference – does it matter? ANZICS registrar course, Melbourne July.

Neuromonitoring - state of the art. Asia Pacific Critical Care Congress, Sydney November.

Evolution of a high stakes exam in intensive care. Asia Pacific Critical Care Congress, Sydney November.

Dr Peter Kruger

Observational Studies of Statins in Bacteraemia, 13th International Society of Infectious Diseases Annual meeting, Kuala Lumpur, Malaysia, June.

An update on the STATInS Trial - A multicentre phase II randomised controlled trial of atorvastatin therapy in intensive care patients with severe sepsis, ANZICS Clinical trials group meeting, Noosa, March.

An update on the STATInS Trial - A multicentre phase II randomised controlled trial of atorvastatin therapy in intensive care patients with severe sepsis, ANZICS Clinical trials group meeting, Sydney, October.

Dr David Cook

Control charts and Continuous Monitoring of Performance, Centre for Research Excellence in Patient Safety Registry Interest Group Meeting, Monash University, Melbourne, November.

Control Charts for Risk Adjusted Analysis, 2nd International Safety, Quality Audit and Outcomes Research in Intensive Care, Christchurch, 28-29 August.

Professor Leanne M Aitken

2008 Outcomes from trauma – what do we know? Invited paper presented at the Asia Pacific Critical Care 2008 Congress, Sydney, Australia.

2008 Creating an environment to implement and sustain evidence based practice, Invested paper presented at the Asia Pacific Critical Care 2008 Congress, Sydney, Australia.

Jane-Louise Cook

Pressures and pitfalls of starting in the ICU, Institute of Continuing Education (ICE) Conference, Brisbane, June 13-14, 2008.

Give a little – take a little: A respiratory trauma case study, Institute of Continuing Education (ICE) Conference, Brisbane, June 13-14, 2008.

Cheryl Buschel & Alison Juers

Current approaches to ventilation in the adult ICU patient, 13 June 2008. Presented at the Australian College of Critical Care Nurses Critical Care Nursing Continuing Education 9th Annual Meeting.

Alison Juers

Chest X-Rays – complexity, Institute of Continuing Education (ICE) Conference, Brisbane, June 13-14, 2008.




Internal Medicine & Clinical

EpidemiologyThe Department completed major literature reviews of: quality and safety improvement interventions targeting in-

hospital care; interpretation by clinicians of validity and utility of diagnostic tests; applicability of pay for performance

strategies to Australian healthcare settings; effectiveness of chronic disease management programs; value of ancillary

tests in predicting cardiovascular risk in asymptomatic persons; potential pitfalls involved in the conduct and reporting

of non-inferiority trials; assessment of need for an Australian registry in interventional cardiology; and prevalence,

types, causes and remediation of errors in reasoning by clinicians.

Associate Professor Ian ScottDirector

Current Research ActivitiesEvidence of effectiveness of acute medical units: a systematic review (Scott IA, Vaughan L, Bell D). A review of both peer-reviewed and non-peer-reviewed literature assessing the effectiveness on clinical outcomes of acute medical units within hospitals.

Survey of Australasian medical assessment and planning units comparing current practice with best-practice standards (O’Neill G, Jenkins P, Scott IA, Vaughan L, Brands C). A national web-based questionnaire survey of all known MAPUs in Australia and New Zealand aimed at assessing adherence of unit protocols and procedures with best practice standards.

Impact of hospital-wide process redesign on patient outcomes: a controlled study (Scott IA, Coory MD, Johnson V). A controlled interrupted time-series study of the changes in hospital access block, mortality, length of stay, and readmissions following implementation of a hospital-wide 6 month clinical process redesign program within 2 intervention hospitals compared to 3 control hospitals.

Validation study of use of c-codes within hospital administrative data in identifying potentially preventable adverse events related to healthcare of common medical conditions (Brand C, Scott IA, Jolley D, Sundararajan V). Study using Delphi consensus process involving randomly selected general physicians to identify candidate routinely coded ‘in-hospital’ complication (or c-code) diagnoses within casemix data as the basis for automated adverse event screening tools for acute myocardial infarction, chronic heart failure and pneumonia. Chosen codes will then be prospectively validated in an independent set of casemix data using expert review of clinical records.

Critical appraisal of validity and applicability of risk prediction and prognostication tools (Scott IA, Greenberg P for the Evidence-based Medicine Working Group of the Internal Medicine Society of Australia and New Zealand). Literature review aimed at identifying pitfalls in the design and interpretation of studies of risk prediction and prognostication.


National & International PresentationsAssociate Professor Ian Scott

New screening tests and biomarkers in assessing coronary risk. Do they help or hinder?; Pre-operative cardiac risk assessment. Presentations to the 6th Annual South-west Queensland Cardiovascular Scientific Meeting, Toowoomba, February.

Narrowing the gaps between best practice and routine care. Presentation to Internal Medicine Society of Australia and New Zealand (NZ) Annual Scientific Meeting, Tauranga NZ, March.

Pay-for-performance programs in healthcare. Proceed with caution. Presentation to the Australian College of Health Service Executives Victorian Annual Meeting, Melbourne, April.

Comparing risk-prediction methods using administrative or clinical data in assessing excess in-hospital mortality in patients with acute myocardial infarction. Presentation to QUT-St Andrew’s Medical Institute seminar Driving excellence in clinical outcomes: Methods for monitoring and influencing change. Brisbane, May.

Improving acute and chronic care of patients with cardiac disease. Presentation to National Heart Foundation Challenges in Cardiology Conference, Brisbane, May.

Cautionary tales in clinical decision-making: the role of cognitive error; Pre-operative cardiac assessment. Presentations to the Royal Australasian College of Physicians Annual Scientific Meeting, Adelaide, May.

Public reporting of healthcare performance data. Presentation to Symposium on Public Reporting of Health Data, University of Queensland and QUT, Brisbane, May.

The culture of reporting and change management. Presentation to 8th Annual Adverse Events management Conference, Melbourne, June.

Using evidence to optimise problem-solving in acute care settings. Presentation to Society of Acute Medicine Annual Scientific Meeting, London, September.

Putting evidence into practice within hospitals. Presentation to the Australasian Evidence-based Medicine Workshop, Bond University, Gold Coast, October.

Update on the management of acute coronary syndromes. Royal Australasian College of Physicians Queensland Annual Scientific Meeting, Mooloolaba, October.


Liver Research

The research laboratory is investigating mechanisms of hepatic fibrosis in response to chronic liver injury, where

normal liver cells are replaced by collagen-containing scar tissue which results in a deterioration of liver function.

Hepatic fibrosis can lead to cirrhosis and ultimately, liver transplantation may be required for patients with advanced

cirrhosis. For patients with chronic liver injury, hepatic fibrosis can be a very slowly progressing disease and while

some patients may develop cirrhosis within 10 years, for others it may take 30-40 years. One focus of the research is to

try to determine why there is such a great difference between patients in their rate of disease progression. In particular

the group is interested in (1) determining the relationship between body mass index, liver fat and fibrosis progression

and response to treatment in chronic HCV and other chronic liver diseases and (2) defining the role of hepatocyte

senescence, hepatic progenitor cells and the ductular reaction in promoting fibrogenesis in human liver disease.

Some key achievements during the year included:

Stuart McPherson, Winner, Young Investigator, Gastroenterology Society Annual Update, Coolum •

Elizabeth Powell, Invitation to chair ‘Meet the Professor Luncheon’ at the AASLD, San Francisco •

The continuation of international collaborations with Dr Herbert Tilg, University of Innsbruck (Austria), Dr •

Elizabeth Brunt, University of St Louis (USA) and Professor Derek Mann, University of Newcastle (UK).

Associate Professor Elizabeth PowellJoint Head

Associate Professor Julie JonssonJoint Head


Clinical ProjectsNon-invasive assessment of hepatic steatosis by magnetic resonance imaging (MRI) and spectroscopy (MRS) (Powell E, Cowin G, Galloway G, Volp A, Benson M, Clouston A, McPherson S, Jonsson J)

Effect of weight loss on liver protein expression and response to antiviral therapy in patients with chronic hepatitis C (Powell E, Jonsson J, Clouston A, McPherson S, Ward S)

Other ProjectsThe role of steatosis in promoting cellular injury and fibrogenesis in human liver (Powell E, Jonsson J, Clouston A)

Hepatocyte replicative arrest, hepatic progenitor cells and the ductular reaction in hepatic fibrogenesis (Jonsson J, Clouston A, Powell E, Olynyk J, Knight B)


Awards & PrizesStuart McPherson

Winner, Young Investigator, Gastroenterology Society Annual Update 2008, Coolum.

National & International PresentationsAssociate Professor Elizabeth Powell

Invitation to chair ‘Meet the Professor Luncheon’ at the AASLD, San Francisco, October.

Townsville Gut Club, August.

Associate Professor Andrew Clouston

Case Discussant – Liver Pathology, US-Canadian Academy of Pathology, 97th Annual Scientific Meeting, Denver USA, March.

Liver biopsy interpretation for the clinician, Johnson & Johnson Professional Practice Weekend for Gastroenterologists, Sydney, April.

Slide seminar – Gastrointestinal pathology, RCPA NSW Education Subcommittee, Sydney, May.

Infective liver diseases (slide seminar), International Academy of Pathology World Congress, Athens, Greece, September.

Inflammatory bowel disease – diagnosis, pitfalls and dysplasia (Colonic inflammatory lesions - Short Course), International Academy of Pathology World Congress, Athens, Greece, September.



Top (L-R): Dr Michelle Melino, Dr Richard Skoien, A/Prof Elizabeth Powell, A/Prof Julie Jonsson, Ms Luani Barge.

Bottom (L-R): Ms Cathy Moss, Ms Leigh Horsfall, Dr Shobha Mareddy, Ms Victoria Gadd, A/Prof Andrew Clouston


Medical Oncology

The Division of Cancer Services is a comprehensive, multidisciplinary adult cancer unit, incorporating the Departments

of Medical Oncology, Clinical Haematology, Radiation Oncology and Palliative Care. Unique features include an

established intellectual environment and research culture that brings together research scientists and clinicians across

disciplines, strong tradition of basic and clinical research. In addition there are a range of multidisciplinary cancer

clinics, a large clinical trials department and staff with national and international reputation.

The Medical Oncology Department is a tertiary-referral centre for cancer. Most clinics operate in a multi-disciplinary

format with radiation oncology, surgical and allied health services. The Department has an active clinical trials

program primarily in breast cancer, melanoma, gastroesophageal cancer, colorectal cancer, head and neck cancer,

pancreatic cancer and lung cancer. Participation in clinical trials conducted under the auspices of national and

international study groups such as the Australasian Gastro-Intestinal Trials Group (AGITG), the Australian New

Zealand Germ Cell Trials Group (ANZGCTG), the Australian New Zealand Breast Cancer Trials Group (ANZBCTG),

Eastern Cooperative Oncology Group (ECOG), National Surgical Adjuvant Breast and Bowel Group (NSABP), European

Organisation for Research and Treatment of Cancer (EORTC) has enabled the department access to and experience with

the latest developments in treatments regimens for cancer patients.

The unit has a significant history in the conduct of industry-initiated research trials allowing the hospital, and

ultimately the patient, access to potential cutting edge developments in cancer therapy. The department has a

considerable infrastructure of clinical trial research staff and shares research nurses and data managers with the

Haematology and the Radiation Oncology departments. New trials in sarcoma are due to start in 2009. Sadly, Dr

Guminski resigned to take up a position in Sydney.

Associate Professor Damien ThomsonDirector


Clinical Projects20050181 (Panitumumab): A Randomised, Multicentre Phase III Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Colorectal Cancer. Trial closed to accrual.

AGITG CO20: A Phase III Randomized Study of Brivanib Alaninate (BMS-582664) in Combination with Cetuximab (Erbitux®) versus Placebo in Combination with Cetuximab (Erbitux®) in Patients Previously Treated with Combination Chemotherapy for Metastatic Colorectal Carcinoma. Trial open to accrual.


AGITG CO7: A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin with 5-FU with LV for the Treatment of Patients with stages II and III Carcinoma of the Colon. Trial closed to accrual.

ALTTO: A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, their Sequence and their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer (BIG 2-06). Trial open to accrual.

ANZ0502 (NeoAdj Gem): A Phase II Trial Evaluating the Efficacy and Safety of Epirubicin and Cyclophosphamide (EC) followed by Docetaxel with Gemcitabine (DG) (+ Trastuzumab if HER2-positive) as Neoadjuvant Chemotherapy for Women with Large Operable or Locally Advanced Breast Carcinoma. Trial closed to accrual.

ANZGCTG 0106: Germ Cell CogState. Cognitive Function and Treatment for Testicular Cancer: Chemo and Cognition. Trial open to accrual.

ANZGCTG 0206: Accelerated BEP. A Feasibility Study of Accelerated BEP as First Line Chemotherapy for Advanced Germ Cell Tumours. (ANZGCTG 0206/ANZGOG0603). Trial open to accrual.

ATTAX (AG0603G): A Randomised Phase II Study Evaluating a Weekly Schedule of Docetaxel with Cisplatin and 5-FU (wTCF) or Capecitabine (wTX) in Advanced Oesohago-gastric Cancer. Trial closed to accrual.

ATTAX2: Phase II Study of Cetuximab (Erbitux) plus Weekly Docetaxel Chemotherapy in Docetaxel Refractory Patients with EGFR Positive Advanced Oesophago-gastric Cancer. PAH. Trial closed to accrual.

BCIRG 005: A Multicenter Phase III Randomized Trial comparing Docetaxel in combination with Doxorubicin and Cyclophosphamide (TAC) versus Doxorubicin and Cyclophosphamide followed by Docetaxel (AC-T) as Adjuvant Treatment of Operable Breast Cancer Her2neu Negative Patients with Positive Axillary Nodes. Trial closed to accrual.

BCIRG 006: Multicenter Phase III Randomized Trial comparing Doxorubicin and Cyclophosphamide followed by Docetaxel (AC-T) with Doxorubicin and Cyclophosphamide followed by Docetaxel and Trastuzumab (AC-TH) and with Docetaxel, Platinum salt and Trastuzumab (TCH) in the Adjuvant Treatment of Node Positive and High Risk Node Negative Patients with Operable Breast Cancer containing the Her2neu

Alteration. Trial closed to accrual.

CA184-029 (Ipilimumab): Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group. Trial open to accrual.

COMPLETE (EGF108919): A Randomised, Open Label, Phase III study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First Line Therapy for Women with HER2/neu Positive Breast Cancer “COMPLETE” (EGF108919). Trial open to accrual.

EFC6521 (SAVE-ONCO): A Multinational, Randomized, Double blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and who are undergoing Chemotherapy. Trial open to accrual.

EORTC 40983: Treatment with Chemotherapy Before and After Surgery versus Surgery in Liver Metastases from Colorectal Cancer. Trial closed to accrual.

EORTC 62005 (GIST): A Phase III Randomized, Intergroup, International Trial Assessing the Clinical Activity of STI-571 at two dose levels in patients with Unresectable or Metastatic Gastrointestinal Stromal Tumours (GIST) Expressing the KIT Receptor Tyrosine Kinase (CD117). Trial closed to accrual.

EORTC 62072 (PALETTE): A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy. PAzopanib ExpLorEd in SofT-Tissue Sarcoma - A phasE III study (EORTC 62072 -/ GSK VEG110727). Trial open to accrual.

IBCSG 18-98 (BIG 1-98): A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Receptor (ER and/or PgR) Positive Tumours. Trial closed to accrual.

IBCSG 20-98 (BIG 2-98): An Intergroup Phase III Trial to Evaluate the Activity of Docetaxel, Given Either Sequentially or in Combination with Doxorubicin, Followed by CMF, in Comparison to Doxorubicin Alone or in Combination with Cyclophosphamide, Followed by CMF, in the Adjuvant Setting Treatment of Node-Positive Breast Cancer Patients. Trial closed to accrual.

IFN β Vaccine: Therapeutic Human Melanoma Trial of Peptide Vaccine and Interferon Beta for Overcoming Melanoma Antigen Down-Regulation. Trial suspended.


INDY: A Phase II Study of Imatinib Mesylate in Patients with Neoplastic Diseases Involving Activated Tyrosine Kinases. Trial open to accrual.

LOTESS: The LOTESS Trial: A Clinical Study Investigating the Long Term Efficacy and Safety of Zometa® Treatment. (CZOL446EAU22). Trial closed to accrual.

Merkel Cell: Efficacy Study of Synchronous Weekly Carboplatin and Radiation in Merkel Cell Carcinoma of the Skin. Trial open to accrual.

P04720: A Study to Determine the Activity of SCH 717454 in Subjects with Osteosarcoma or Ewing’s Sarcoma That Has Relapsed After Standard Systemic Therapy (NCT00617890). Trial open to accrual.

PEG-Intron Melanoma: A Phase I Study of the Pharmacokinetics of PEG-Intron, Administered Weekly in Subjects with High Risk Melanoma (PO4831). PAH HREC Number: 2006/199. Trial closed to accrual

PI-88 w Dacarbazine: A Phase II Study of PI-88 with Dacarbazine in Patients with Metastatic Melanoma. Trial closed to accrual

QUASAR2: Multicentre International Study of Capecitabine +/- Bevacizumab as Adjuvant Treatment of Colon Cancer. Trial open to accrual.

STX 0206: Randomised comparative study of FOLFOX6m plus SIR-Spheres® versus FOLFOX6m alone as first line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma. 6. Trial open to accrual.

SYMMETRY: A Randomised, Double-blind, Phase 3 Trial of STA-4783 in combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects with State IV Metastatic Melanoma. SYMMETRY (Protocol # 4783-08). Trial closed to accrual.

TROG 03.02: A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer.. Trial closed to accrual.

TROG 03.07: A Randomised Phase II Study of Two Regimens of Palliative Chemoradiation Therapy in the Management of Locally Advanced Non Small Cell Lung Cancer. Trial closed to accrual.

TROG 05.01 (POST): Post-Operative Concurrent Chemoradiotherapy versus Post Operative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck. Trial open to accrual.

TROG 06.01 (EORTC 22033-26033): Primary chemotherapy with Temozolomide vs radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study. Trial open to accrual.

TROG 08.02: A Randomized Phase III Study of Temozolomide and Short-course Radiation versus Short-course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients. Trial open to accrual.

Major Grants & Financial SupportOther Competitive funding: $ 80,623



Nephrology

The Princess Alexandra Hospital Nephrology Department enjoys the best patient survival rates of any dialysis and

kidney transplant centre in Australia and New Zealand. The unit performs over 130 renal transplants per year (more

than any other unit in the southern hemisphere) and cares for approximately 650 established transplant patients and

500 dialysis patients. Each year, the unit provides over 20,000 occasions of outpatient service.

The department is the most productive Nephrology research unit in Australasia and is home to the University of

Queensland Centre for Kidney Disease Research (CKDR), the Australasian Kidney Trials Network (a multi-centre

Australasian renal clinical trials network endorsed by the NHMRC, Kidney Health Australia and the Australian and

New Zealand Society of Nephrology) and the NHMRC-endorsed Cardiovascular, Metabolic and Renal Centre of Clinical

Research Excellence. There are over 80 projects currently underway in the department, examining such diverse areas

as infection control, anaemia management, cardiac risk factor intervention, optimal timing of dialysis commencement,

obesity and kidney disease, enhancement of dialysis adequacy, novel prevention strategies for acute renal failure,

preservation of kidney function, monitoring healthcare delivery quality, optimization of the safety of anti-rejection

drug protocols in transplantation, immunosuppressive drug pharmacokinetic studies, and skin cancer and lymphoma

prevention in kidney transplant patients.

Over the last 5 years, several of the department’s research trials have earned national research awards and prompted

changes in clinical practice guidelines. The CKDR’s basic science research focus is the investigation of mechanisms

underpinning pathological kidney cell growth and fibrogenesis with a view to developing novel therapeutic strategies

for the management of acute renal failure, chronic renal scarring and failure, and renal cell carcinoma.

Professor David JohnsonDirector of Nephrology, Chair of Medicine, Professor of Medicine,

Professor of Population Health, Head of the Centre for Kidney Disease Research


Peritoneal DialysisThe balANZ trial - A multicentre randomised controlled trial of Balance in Australian and New Zealand PD patients (Johnson DW, Brown F, Woods F, Bali V).

Predictors of peritonitis in the Australian and New Zealand PD patient populations (Ghali J, Johnson DW, McDonald S, Bannister K).

Fungal Peritonitis in Australian Peritoneal Dialysis Patients: Predictors, Treatment and Outcomes in 162 cases (Miles R, McDonald S, Hawley CM, Rosman J, Brown F, Wiggins K, Bannister KM, Johnson DW).

Corynebacterium Peritonitis in Australian Peritoneal Dialysis Patients: Predictors, Treatment and Outcomes in 82 cases (Barraclough K, McDonald S, Hawley CM,


Rosman J, Brown F, Wiggins K, Bannister KM, Johnson DW).

Non-Pseudomonal Gram-Negative Peritonitis in Australian Peritoneal Dialysis Patients: Predictors, Treatment and Outcomes in 837 cases (Jarvis E, McDonald S, Hawley CM, Rosman J, Brown F, Wiggins K, Bannister KM, Johnson DW).

Polymicrobial Peritonitis in Australian Peritoneal Dialysis Patients: Predictors, Treatment and Outcomes in 359 cases (Barraclough K, McDonald S, Hawley CM, Rosman J, Brown F, Wiggins K, Bannister KM, Johnson DW).

Pseudomonas Peritonitis in Australian Peritoneal Dialysis Patients: Predictors, Treatment and Outcomes in 191 cases (Siva B, McDonald S, Hawley CM, Rosman J, Brown F, Wiggins K, Bannister KM, Johnson DW).

Staphylococcus aureus Peritonitis in Australian Peritoneal Dialysis Patients: Predictors, Treatment and Outcomes in 503 cases (Govindarajulu S, McDonald S, Hawley CM, Rosman J, Brown F, Wiggins K, Bannister KM, Johnson DW).

Streptococcal Peritonitis in Australian Peritoneal Dialysis Patients: Predictors, Treatment and Outcomes in 287 cases (O’Shea S, McDonald S, Hawley CM, Rosman J, Brown F, Wiggins K, Bannister KM, Johnson DW).

Peritoneal small solute clearance is non-linearly related to patient survival in the Australian and New Zealand peritoneal dialysis patient populations (Rumpsfeld M, McDonald SP, Johnson DW).

The effect of dialysis modality on decline of residual renal function (Hawley CM, Petrie J, Johnson DW).

The IMPENDIA trial – Multi-center, prospective, randomized trial to demonstrate Improved Metabolic Control of PPEN Vs DDDD in Diabetic CAPD patients (Johnson DW, Bali V).

Independent predictors of time to first peritonitis episode and peritonitis rate (and time to permanent catheter loss due to peritonitis) in the Australian and New Zealand PD patient populations (Johnson DW).

Outcomes following catheter removal for peritonitis (including outcomes upon recommencement of PD) (Barraclough K, Hawley CM, Johnson DW)

The impact of APD versus CAPD on peritonitis in the Australian and New Zealand PD patient populations (Barraclough K, Hawley CM, Johnson DW).

Predictors of recovery (and time to recovery) of dialysis-independent renal function in scleroderma renal crisis patients commencing PD or HD in Australia and New Zealand (Johnson DW).

The effect of dialysis modality on spontaneous recovery of dialysis-independent renal function in Australian and New Zealand dialysis patients with end-stage renal failure (Macdonald J, McDonald SP, Johnson DW).

A systematic review of the effects of biocompatible peritoneal dialysis solutions on patient outcomes (Wiggins K, Johnson DW).

The effect of dialysis modality on infectious mortality in the Australian and New Zealand PD patient populations (Johnson DW, Dent H, McDonald SP).

The effect of dialysis modality on cardiovascular mortality in the Australian and New Zealand PD patient populations (Johnson DW, Dent H, McDonald SP)

The effect of dialysis modality on the prevalence and incidence of hepatitis infections in the Asia-Pacific region (Johnson DW, Dent H).

Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients (Ghali J, McDonald SP, Bannister K, Johnson DW).

A randomised, controlled trial of exit site application of MedihoneyTM Wound Gel for the prevention of catheter-associated infections in peritoneal dialysis patients (HONEYPOT trial) (Johnson DW, Hawley CM, Isbel NM, Clark C, Bali V).

A randomised controlled trial of oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial) (Barraclough K, Johnson DW, Hawley CM, Leary DR)

Predictors of residual renal function decline in Australian and New Zealand peritoneal dialysis patients (Badve S, Johnson DW, McDonald S).

A retrospective observational cohort study assessing the clinical outcomes of amputation in dialysis patients (Hawley C, Isbel N, Campbell SC, Johnson DW).

Effect of dialysis modality on infectious hospitalisation and outcomes (Clark C, Hawley CM, Isbel NM, Johnson DW).


HaemodialysisTemporary vascular access in haemodialysis: reasons for process failure in incident dialysis patients (Hawley C, Nicholas P, Derhy A, Duke A for the Collaborative for Healthcare Improvement)

Ethanol lock therapy for the prevention of tunnelled catheter-related bacteraemia in haemodialysis patients (Broom J, Playford G, Johnson DW, Hawley CM)

A randomised, placebo-controlled trial of oxpentifylline on haemoglobin levels in patients with erythropoietin-resistant anaemia (The HERO trial) (Johnson DW, Hawley CM, Leary DR)

The impact of nocturnal home haemodialysis on patient outcomes (van Eps C, Hawley C, Isbel N, Campbell SB, Johnson DW).

Effects of Alternate Night Nocturnal Hemodialysis on Oxidative Stress and Antioxidant Enzymes (Van Eps C, Hawley C, Jeffries J).

Nutritional status and appetite regulation in alternate night nocturnal haemodialysis (Van Eps C, Hawley C, Jeffries J).

Bone mineral metabolism and histology in alternate nightly nocturnal haemodialysis (Van Eps C, Hawley C, Jeffries J).

Prognostic indices in post-transplantation lymphoproliferative disorders (PTLDs) after renal transplantation (Hourigan MJ, Mollee PN, Gill DS, Johnson DW, Gandhi MK).

Safety of immunosuppression cessation during chemotherapy for Post-Transplantation Lymphoproliferative Disorders (PTLD) in Renal Transplant Patients (Hourigan MJ, Mollee PN, Gill DS, Johnson DW, Gandhi MK).

A prospective trial of intradermal hepatitis B vaccination in dialysis patients who have failed to seroconvert following standard subcutaneous vaccination (Barraclough K, Wiggins K, Van Eps C, Hothersall E, Johnson DW, Campbell SB, Isbel N, Playford G, Hawley C).

A pure red cell aplasia surveillance program in haemodialysis patients receiving erythropoietin (Sudak J, Johnson DW).

A randomized, placebo-controlled study to assess the effects of Cholesterol-lowering therapy with a combination of simvastatin and Ezetimebe on the

Risk of Major Cardiovascular Complication Among Individuals with Chronic Kidney disease (SHARP trial) (Johnson DW, Sudak J).

The initiating dialysis early and late (IDEAL) study (Johnson DW, Martin A, Leary DR).

Quality of life and alternate nightly home haemodialysis (van Eps C, Hawley CM, Jeffries J, Johnson DW, Campbell SB, Isbel NM, Mudge DW).

A randomised, controlled, open-label, multi-centre, parallel-group study to demonstrate the efficacy and safety of RO0503821 when administered intravenously for the maintenance treatment of anaemia in patients with chronic kidney disease who are on dialysis (Johnson, DW, Sudak, J).

A randomized, controlled, open-label, multi-center, parallel-group study to compare the efficacy and safety of RO0503821 with that of darbepoetin alfa administered intravenously at extended dosing intervals for the maintenance treatment of anaemia in patients with chronic kidney disease who are on hemodialysis (Johnson, DW, Edmunds, J)

A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dise Vitamin D on Vascular Calcification in Subjects with Chronic Kidney Disease (CKD) Receiving Hemodialysis (Advance) (Hawley C, Sudak J).

Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) (Hawley C, Sudak J).

TransplantationOutcomes associated with live donor renal transplantation in Queensland (Kaisar MO, Campbell SB, Isbel N, Hawley CM, Nicol DL, Johnson DW).

Intravenous versus oral iron supplementation for the correction of post-transplant anaemia (Mudge DW, Tan K, Haley CM, Campbell SB, Isbel NM, Nicol DL, Johnson DW, Leary DR).

The role of tumourectomised kidneys as a potential source of allografts for renal transplantation (Nicol DL, Johnson DW, Campbell SB, Isbel N, Hawley C, Martin A).

Polycystic kidneys as a potential source of allografts for renal transplantation (Nicol DL, Johnson DW, Campbell SB, Isbel N, Hawley C).

Predictors of graft function in recipients of kidneys from live donors (Hawley CM, Kearsley J, Campbell SB,


Mudge DW, Isbel NM, Johnson DW, Hurst K, Preston J, Griffin A, Wall D, J Burke, McTaggart S, Frohloff G, Nicol DL).

Adiponectin in renal transplant recipients (Kaisar MO, Armstrong K, Prins J, Johnson DW, Isbel N).

Impact of Aggressive Intervention in RTR with impaired glucose tolerance on insulin resistance and atheroma burden (Kaisar MO, Armstrong K, Prins J, Johnson DW, Isbel N).

Assessment of exercise and dietary factors associated with abnormal glucose tolerance in renal transplant recipients (Orazio L).

Identification of cardiovascular risk markers in live donors post nephrectomy: longitudinal follow-up. Focus on endothelial dysfunction, inflammation and oxidative stress (Kaisar MO, Isbel NM, Johnson DW).

Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT) (Campbell, S, Leary DR).

A Randomized, Open-Label Study to Compare the Rate of New Non-melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen versus Continuation of a Calcineurin Inhibitor-based Regimen (Campbell S, Sonnenburg K).

Effectiveness of Dietician Involvement in a lifestyle intervention in renal transplant recipients with abnormal glucose tolerance (Orazio L, Isbel I, Armstrong K, Johnson D, Kaisar MO).

General NephrologyA randomised controlled trial comparing the impact of aggressive risk factor and lifestyle modification utilising nurse led co-ordinated care with standard care to limit the progression of cardiovascular disease in patients with chronic kidney disease (Isbel, N, Petchey, W, Sonnenburg, K).

The role of novel of novel biomarkers of cardiovascular disease in chronic kidney disease: focus on adiponectin and leptin (Kaisar MO, Johnson DW, Prins J, Isbel NM).

Opinions on the effect, content and structure of guidelines on CKD: Results of a national survey of nephrologists (Irving M, Walker R, Johnson DW).

Oxidative stress and cardiovascular disease in chronic kidney disease (Kaisar MO, Johnson DW, Isbel NM).

The use of Human Neutrophil Gelatinase-Associated Lipocalin as a predictor of contrast induced nephropathy in critical illness (Venkatesh B, Johnson DW).

The use of Human Neutrophil Gelatinase-Associated Lipocalin as a predictor of acute kidney injury in renal transplantation (Johnson DW).

A Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCI in Chronic Kidney Disease Subjects with Secondary Hyper-parathyroidism Not Receiving Dialysis Protocol 20000178 (Hawley C, Sudak J).

A Sequential Adaptive Phase II/III Multi-Centrer, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept versus Placebo on a Background of Mycophenolate Mofetil and glucocorticosteroids in Subjects with Active Proliferative Glomerulonephritis due to Systemic Lupus Erythematosus (SLE) (Mudge D, Edmunds J, Leary DR).

An Open-Label, PhaseIIIb, Multi-Centre, Randomised, Parallel-Group Study to Investigate the Efficacy and Safety of Three Dosing Schedules of Subcutaneous Dynepo in Adult Patients with Anaemia Associated with Chronic Kidney Disease who are Pre-Dialysis or Require Peritoneal Dialysis or Haemodialysis (Isbel N, Martin A, Bali, V).

An Open Label Tolerability and Safety Study of KRX-101 (Sulodexide Gelcaps) for the Treatment of Type 2 Diabetic Nephropathic Patients with Persistent Microalbuminuria in Australia, New Zealand and Hong Kong (Isbel N, Franzen K, Martin, A).

An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using once monthly subcutaneous injections of RO05030821 in patients with chronic kidney disease who are not on dialysis (Isbel N, Edmunds J).

A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (Mudge D., Edmunds J).

Randomised and Multi-Center Two-Group Clinical Trial to Assess the Best Treatment for Patients with High Blood Pressure and Renal Artery Stenosis: Stenting with Anti-Hypertensive Medical Therapy, Compared to Medical Therapy alone (Mudge D, Martin A).


PYR-210: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 2b Study to Evaluate the Safety and Efficacy of Pyridorin™ (pyridoxamine dihydrochloride) in Participants with Nephropathy Due to Type 2 Diabetes (Isbel N, Halbish S).

The prevalence of 25 hydroxy vitamin D deficiency in patients with CKD living in a subtropical climate (Siva B, Isbel N).

The high prevalence of obesity in the CKD population (Frazier J, Isbel N).

Basic Science ResearchErythropoeitin as a novel renoprotective agent in in vitro and in vivo models of acute ischaemic renal, brain and cardiac injury (Johnson DW, Vesey D, Gobe G, Endre Z).

Protective effect of Angelica sinensis on renal vascular endothelial cell damage induced by oxidative stress (Yamada M, Vesey DA, Gobe GC Johnson DW).

Effects of medicinal plant extracts on renal cells in vitro: Potential therapeutic and toxic effects (Wocjikowski K, Gobe G, Johnson DW).

Expression and phosphorylation of P66SHC in young and old rats subjected to oxidative stress (Percy C, Brown L, Johnson DW, Gobe GC).

Molecular pathways in age-associated chronic renal pathologies (Percy C, Brown L, Johnson DW, Gobe GC).

The role of protease activated receptors (PARs) in progressive renal scarring, inflammation and failure (Vesey D, Gobe G, Johnson DW).

Strategies for modifying acute renal ischemic injury: increasing the mobilisation and maturation of endothelial progenitor cells (Vesey D, Johnson DW, Gobe GC).

Apoptosis of tubulointerstitial chronic inflammatory cells in progressive renal fibrosis after cancer therapies (Johnson DW, Gobe GC).

The therapeutic application of adult mesenchymal stem cells in renal regeneration (Clark C, McTaggart S, Gobe GC, Johnson DW).

Awards & PrizesProfessor David Johnson

Queensland Finalist, Australian of the Year

Dr Katherine Barraclough

1st prize, Queensland Royal Australasian College of Physicians Medical Registrar Research Awards

Finalist, Young Investigator Awards, Australian and New Zealand Society of Nephrology Annual Scientific Meeting

Dr Sridevi Govindarajulu

Richard Kemp Prize, Qld RACP Advanced Trainees’ Annual Scientific Meeting 2008

Ms Linda Orazio

Nestle New Emerging Researcher Award, Dietitians Best new researcher at Dieticians Association of Australia National Conference, ASM

National & International PresentationsProfessor David Johnson

Erythropoietin and ischaemia-reperfusion injury, Amgen National Renal Weekend Symposium, Melbourne, 29 February – 2 March8.

HONEYPOT trial update, Amgen National Renal Weekend Symposium, Melbourne, 29 February – 2 March\.

What about down under? – ANZDATA Registry, 5th Asia-Pacific PD College, Bangkok, Thailand, March.

Automated peritoneal dialysis, 5th Asia-Pacific PD College, Bangkok, Thailand, March.

Clinicopathological case discussion, 5th Asia-Pacific PD College, Bangkok, Thailand, March.

Effect of dialysis modality on quality of life and infectious outcomes, Zhongshan Hospital, Guangzhou, China, March.

Dilaysis registry overview, Zhongshan Hospital, Guangzhou, China, March.

Effect of dialysis modality on infectious outcomes, Shanghai, China, March.

Automated peritoneal dialysis, Shanghai, China, March.

Biocompatible peritoneal dialysis solutions, Home Dialysis Therapies Symposium, Sydney, March.

APD versus CAPD, Home Dialysis Therapies Symposium, Sydney, March.

The contribution of chronic kidney disease to cardiovascular disease, GP Cardiovascular Symposia


Meetings, Brisbane, March.

Managing stage 3 Chronic Kidney Disease in General Practice, General Practice Conference, Cairns, May.

Hypertension Management, General Practice Symposium, Brisbane, May.

Management of stage 3 chronic kidney disease, General Practitioners’ Continuing Education Conference, Brisbane, September.

Cardiovascular care in chronic kidney disease, CKD Symposium, Prague, October.

Associate Professor Nicole Isbel

Diabetic Kidney disease 2008 GSK Gold Specialist and GP meeting, Sydney, May.

Circling around the problem – CKD and CVD ANZSN ASM, Newcastle, September

Associate Professor David Mudge

Management of Refractory Hypertension Sanofi-Aventis Hypertension Symposium, Brisbane, April.

Associate Professor Carmel Hawley

How to Get Blood into a Stone Renovascular Hypertension Symposium, Asia Pacific Forum in Nephrology, Melbourne, June.

eGFR: When To Refer Merck General Practice Education Meeting, Brisbane, July.

The Renaissance of Home Hemodialysis: Complications of Home Hemodilaysis. 28th Annual Dialysis Conference, March, Rosen Shingle Creek, Florida, USA.

PD Fundamentals: Metabolically Challenged PD Patients. 28th Annual Dialysis Conference, March, Rosen Shingle Creek, Florida, USA.

HDF – The Brisbane Experience: the fact, the fiction & the future. Hong Kong Society of Nephrology, Hong Kong, May.

Bone Disease in Recipients of Kidney and Kidney/Pancreas transplants - Is there evidence of efficacy Breakfast Symposium, XXII international Society of Transplantation Meeting, Sydney, August.

Home Haemodialysis- the promise, process and pitfalls. South Australian Nephrology Group, November.




Nursing Practice Development

The Nursing Practice Development Unit aims to increase the capacity for nurses to undertake research at the hospital.

During the year two joint appointments commenced within the hospital. Dr Alexandra McCarthy joined the Division

of Cancer Services as a Princess Alexandra Hospital /Queensland University of Technology Joint Senior Research Fellow

in Cancer Services. This role aims to support nursing research across the Southern Cancer Clinical Network. Mr Ramon

Shaban was appointed as a Princess Alexandra Hospital /Griffith University Joint Research Fellow in Infection Control.

Kerri HolzhauserActing Nursing Director, Research


Clinical ProjectsNational Emergency Care Pain Management Initiative (Huckson S, Bennetts S, Holzhauser K, Shaban R et al)

Improving pain management of abdominal pain in Paediatric Emergency patients using a pre-post: interventional study (Williams S, Bonney D, Gilhotra Y, Pitt R, Holzhauser K)

Regulatory systems for occupational exposures in emergency health care: Contemporary challenges for the emergency physician in prevention, control and management (Sinnott M, Shaban R, Devereux J)

An exploratory study to examine the phenomenon of ambulance ‘ramping’ at hospitals within the Queensland Southern Health Districts and Queensland Ambulance Service (Rose E, Shaban R, Holzhauser K, Fitzgerald G, Finucane J, Crilly J, Eeles D, Tippet V)

Prevalence and determinants of health promotion and risk-reduction practices of female survivors of breast cancer (McCarthy A, Yates P, Winch S, Shaban R, Clavarino A)

Fatuga’O Mania: Developing community capacity to prevent sick kidneys in the Samoan community of Logan (McCarthy A, Shaban R, Stone C, Martin-McDonald K)

A pilot study of the factors that influence the health promotion and risk-reduction behaviours of younger female survivors of breast and haematological cancers (McCarthy A, Shaban R, Winch S, Yates P, Clavarino A, Brunelli V)

Awards & PrizesKerri Holzhauser & Julie Finucane

College of Emergency Nursing Australasia 2008 Philippa Moore Publication Prize for manuscript entitled: Holzhauser K. & Finucane J. (2007) Part A: Staff Attitudes to Family Presence during Resuscitation, an intervention study. Australasian Emergency Nursing Journal, 10(3), 124-133.

Ramon Shaban

Appointment by invitation – Fellow, Royal College of Nursing Australia

Credentialed Infection Control Practitioner, Australian Infection Control Association




Nutrition and Dietetics

The department during the year presented three oral abstracts and five posters, and led three workshops at the

Dietitians Association of Australia conference in May. Linda Orazio received the Nestle Nutrition Institute Award for

Emerging Researcher at the conference.

There were a number of other staff achievements during the year. Winsome Abbott was awarded her PhD on ‘Fat

soluble vitamins and function in adults awaiting liver transplantation’, Maree Ferguson was appointed as Adjunct

Associate Professor at QUT and Griffith University, Angela Vivanti was appointed to Honorary Fellow at QUT and

Adjunct Lecturer at Griffith University.

The department received $65,000 in grants for research into malnutrition, falls, dehydration and nutritional status

of haemodialysis patients. The department partnered with Griffith University to provide eight research student

placements.

Dr Maree FergusonDirector


Clinical ProjectsManagement of patients with malnutrition at the Princess Alexandra Hospital (Ferguson M, Hedges K, O’Neill M, Vivanti A, Day S).

Nutrition as medicine for geriatric hospitalised patients with malnutrition (Ferguson M, Vivanti A Varghese P, Amin H, Dickson P).

Nutritional status, survivability and morbidity amongst haemodialysis patients (Vivanti, A Orazio L, Muller J, Campbell K).

Effect of plasma triglycerides on the central haemodynamic response to exercise (Sharman J, Marwick T, Kostner K, Vivanti A, Thomas S, Lambe K).

The effects of exercise as a nursing intervention to improve general physical health status in haemodialysis patients: a pilot study (Henson A, Finch L, Devlin J, Chatterton S, Gillispite B, Hawley C, McCarthy A, Orazio L).

Assessment of dietary factors and exercise associated with abnormal glucose tolerance in renal transplant recipients (Orazio L, Isbel N, Hickman I, Banks M).

National survey of hospital nutrition screening practices (Banks M, Bauer J, Ferguson M, Isenring E, Vivanti A, Capra S).


Exploring the relative risk of nutritional status of older people presenting to the emergency department upon falls and hospital admission (Vivanti A, MacDonald C, Haines T, Sinnott M).

Effect of weight loss in liver protein expression and response to antiviral therapy in patients with chronic hepatitis C (Powell L, Jonsson J, Clouston A, Power E, McPherson S, Benson M, Cowin G).

Swallowing management and radiotherapy trial (Riddle B, Cornwell P, Porceddu S, Ward E, Stuckey S, Davidson W).

Awards & PrizesLinda Orazio

Nestle Nutrition Institute award for Emerging Researcher, Dietitians Association of Australia Conference, 2008.

Major Grants and Financial SupportFunding from other sources: $ 65,000


Occupational Therapy

Princess Alexandra Hospital occupational therapists are health professionals working in partnership with adults to

overcome factors which limit their ability to function in their chosen ‘occupational roles’ and impact on their quality

of life. Injury or illness, environmental, psychological or emotional difficulties, or the effects of aging can cause

these limiting factors. Through developing research capacity and strength in a variety of clinical areas, occupational

therapists are a major contributor to the clinical knowledge base, creating a strong research profile nationally and

internationally, and enhancing evidenced based clinical decision making locally.

During the year research activity concentrated in the areas of brain injury rehabilitation, spinal cord injury research,

aged care assessment and management, hand and upper limb rehabilitation, cancer, and cardiac services. Highlights

included the commencement of an ARC Linkage grant for a multidisciplinary project on the transition from hospital

to home after brain injury. Research outcomes continue to be disseminated through publication in peer-reviewed

journals and by presentation at national rehabilitation and occupational therapy conferences. Currently, the

department supports eight postgraduate research students conducting research in the fields of brain injury, aged care,

cancer, and hand therapy.

Mary WhiteheadDirector


Clinical ProjectsEvaluation of rehabilitation strategies for prospective memory in individuals with traumatic brain injury (Fleming J, Shum D, Strong J). A NHMRC funded randomised controlled trial comparing remedial and compensatory approaches to rehabilitation. Findings indicate a compensatory approach is more effective in enhancing prospective memory performance and psychosocial outcomes, and a final manuscript of results is currently under preparation.

Community based rehabilitation after traumatic brain injury: a comparison of home and hospital based outpatient intervention (Doig E, Fleming J, Kuipers P). This PhD study compares goal attainment of individuals with TBI in two settings (outpatient clinic based rehabilitation and home/community based

rehabilitation) using a within-subjects design and qualitative methodology.

A randomised control trial investigating the effects of group education and support in reducing cancer-related fatigue and improving quality of life in patients undergoing radiotherapy (Purcell A, Fleming J, Haines T, Burmeister, B). This examines the effectiveness and timing of a multidisciplinary group intervention to assist patients to manage cancer-related fatigue and reduce its debilitating effects on quality of life during and following radiotherapy treatment.

Other ProjectsValidity of the Comprehensive Assessment of Prospective Memory (CAPM) for use with adults with


traumatic brain injury (Fleming J, Shum D, Gill H, Gullo M, Strong J, Fisher R, Kennedy S).

Predictors of prospective memory performance in adults with traumatic brain injury (Fleming J, Riley L, Gill H, Gullo M, Strong J, Shum D).

Helping people with traumatic brain injury and their families adjust to driving cessation (McKenna K, Fleming J, Liddle J, Turpin M, Weir N, Whitelaw P).

From hospital to home: transition experiences and outcomes for individuals with ABI (Turner B, Fleming J, Ownsworth T, Cornwell P).

Determinants of successful community transition for individuals with ABI and their families (Fleming J, Worrall L, Cornwell P, Haines T, Ownsworth T, Kendall M, Chenoweth L, Turner B, Nalder E).

A study of caregivers of adults with acquired brain injury: the impact of transition from hospital to home (Parry J, Vroomans M, Turner B, Fleming J).

Past and current leisure activities of individuals in a brain injury rehabilitation unit (Braithwaite H, Fleming J, Gustafsson L, Griffin J).

Wearing of splints post-discharge: factors contributing to sustainability of use following brain injury (Fleming J, Copley J, Worley L, Moes L, Griffin J, Kuipers K).

Does individualised hand splinting reduce spasticity after traumatic brain injury (Copley J, Fleming J, Griffin J).

Activities of daily living in clients with a dual diagnosis of spinal cord injury (SCI) and traumatic brain injury (TBI) (Price G, Fleming J, Gruss N, O’Connor T, Weir N).

Goal setting and attainment by individuals in spinal cord injury rehabilitation using the Canadian

Occupational Performance Measure (Mitchell G, Gustafsson L, Fleming J, Price G).

Cancer related fatigue: Contributing factors and effects in patients undergoing chemotherapy and radiotherapy treatment (Purcell A, McGuane K, Fleming J, Haines T).

Investigations of care requirements of people with brain tumour (Haines T, Cornwell P, Fleming J, Olsen S, Omerod A).

Evaluation of a multidisciplinary outpatient rehabilitation programme for patients with chronic heart failure (Gumley K, Shazad J, Fleming J, Coffey N).

Facilitation of self management of the upper limb following a stroke (Bower K, Hoffmann T, Gustafsson L).

Splinting to prevent forearm rotation – to what degree? (Slaughter A, Miles L).

The evaluation of multi-disciplinary goals and goal-setting: Processes in an adult rehabilitation setting (Cornwell P, Fleming J, Haines T, Leech E).

Effects of prism adaptation on space perception following chronic and reversible cortical lesions (Mattingly J, Eramudugolla R, Irvine D, Boyce A).

Clinical utility, reliability and validity of the Self-Perceptions in Rehabilitation Scale (SPIRS) in brain injury rehabilitation (Ownsworth T, Fleming J, Ross J, Collier AM, Ea Stewart).

Awards & PrizesDr Jennifer Fleming

School of Health and Rehabilitation Sciences Research Award for 2007 (Level C).



Older Persons Mental Health

The Older Persons Mental Health Service (OPMHS) is the psychogeriatric service within the Princess Alexandra Health

Service District.

A number of projects were undertaken within the Service to improve the quality of MH care provided by Queensland

Health across the state:

Standardisation of documentation used by OPMHS (Ms Jacinta Lipp). •

Work supporting the new statewide Mental Health Model of Service Delivery as it applies to older persons (Ms •

Leanne Izzard RN).

Literature review of OPMH service completed supporting the Model (Dr. Deidre McLaughlin- Senior Lecturer, UQ). •

Development of a model and trial of telegeriatric psychiatry in collaboration with the Geriatric Medicine •

Department (Susan Austin RN).

Development of a website for other OPMHS is allowing staff to access clinical information, tools and operating •

procedures in a user friendly format.

In collaboration with the Academic Unit of Geriatric medicine, the service has housed the Queensland node of the •

Dementia Collaborative Research Centre 2: Prevention, Promotion and Early Intervention since 2007 which has

resulted in a number of publications.

A multimedia website went live on the hospital intranet which is being evaluated by log file analysis assessing the •

utility of net-based dementia education in the hospital environment across 2008-2009.

Dr David LieDirector



Clinical ProjectsSTEADI (Streaming Technology as an Adjunct to Dementia Intervention) Project (Lie D, Austin S). Investigates the utility of web-based information in supporting clinical care and involved setting up a dementia related website on the PA server.

Other ProjectsKR1 Older Persons Mental health Documentation Project (Lie D, Lipp J). A state-wide standardised documentation suite was developed for use in Older Persons Mental health services. This entailed reviewing mental health assessment, risk assessment and treatment from the older patient perspective and allowing for local variation across Health Districts. Funding and supported from the Patient Safety Centre arising from the Achieving Balance Report.

Model of service Delivery (Lie D, Izzard L, McLaughlin D. A consultation was held to inform an updated model

of service delivery for OPMH to support the new Qld Plan for Mental Health 2007-2017. A literature review (author Dr. Deidre McLaughlin) and a summary of findings presented to the Statewide Mental Health Network. Protocols were developed to inform the use of telegeriatric psychiatry in QLD.

National & International PresentationsDr. David Lie

Dementia in acute care – Redesigning healthcare for the ageing population. Mecure Hotel, Brisbane, May.

Streamed technology as an adjunct to dementia interventions – Eastern Australian Dementia Training Study Centre Guest Lecture, Uni Wollongong, May.

Intranet Technology educates Acute Care on Dementia Interventions- Stirling Conference at the University of Stirling, September.



Pathology Queensland

Pathology Queensland established a new research facility, the Molecular and Clinical Pathology Research Laboratory

(MaCH R), on the campus of the Princess Alexandra Hospital.

The aims of the facility are:

To enable the translation of basic research into practical applications for the improvement of patient outcomes in

cancer, through the creation of a state-of–the-art translational support facility dedicated to providing a link between

basic science and clinical services for the direct benefit of cancer patients.

To facilitate the development of diagnostic/monitoring tests and novel predictive/prognostic biomarker assays to

improve patient outcomes in cancer and to facilitate the development of targeted therapy for cancer.

With the completion of the human genome project there have been major advances in the field of molecular

pathology with the identification of new therapeutic targets and biomarkers in cancer. Key technologies responsible

for these advances include microarray-based gene expression profiling, functional genomics, high-throughput

genetic profiling by single nucleotide polymorphism analysis,

tissue microarray technology, next generation sequencing, digital

slide scanning, computerised image analysis and automated

Immunohistochemistry and automated in-situ hybridisation.

Funding of $2.96 million has been received through the Smart State

Innovation Building Fund for purchasing of the required equipment.

Training and initial work-up of the instruments is proceeding and

the above technologies are being finalized at the facility.

A large database has been developed to integrate these biomarker

results with patient outcome.

Dr Glenn FrancisHead of Molecular and Clinical Pathology Research Laboratory


Other ProjectsPhenotypic / genotypic profiling and outcome in breast cancer (Francis G, Stein S, Wagner S). Aim of research project: The identification of biomarkers to determine outcome in breast cancer patients.

Prediction of lymph node status in breast cancer patients (Francis G, Stein S, Wagner S). Aim of research project: The prediction of the lymph node status from characteristics of the primary tumour.


Prospective assessment of patient response to treatment with the drug Trastuzumab (Francis G, Stein S, Wagner S). The aim of the research project is to determine biomarkers to predict response of HER2 positive patients to targeted therapy.

High-through-put tissue analysis of novel candidate biomarkers of breast cancer progression (Francis G, Stein S, Wagner S). The aim of the research project is to determine biomarkers to predict breast cancer progression in lymph node positive patients.

E-Health extraction of pathology data from text reports (Francis G, Stein S, Wagner S). The aim of the research project is to extract data from pathology reports into synoptic format.

Utilisation of biomarkers to determine outcome in HER2 positive breast cancer patients (Francis G, Stein S, Wagner S). The aim of research project is to determine biomarkers to predict response of HER2 positive patients to therapy.

Gene expression analysis of breast cancer cell populations and correlation with metastatic clones using immuno-laser capture microdissection (Francis G, Stein S, Wagner S). The aim of the research project is to identify gene expression profiles of breast cancer cell populations and correlation with metastatic clones.

Identification and analysis of non-coding RNAs that contribute to advanced breast cancer (Francis G, Stein S, Wagner S). The aim of research project is to identify non-coding RNAs that contribute to advanced breast cancer

An analysis of the Pathological Characteristics of a Proven Epidemiological Cluster of Breast Cancers (Francis

G, Stein S, Wagner S). The aim of the research project is to review the pathology of the tumours from the breast cancer patient cluster.

Novel Strategies for Prediction and Control of Advanced Breast Cancer via Nanoscaled Epigenetic-Based Biosensors (Francis G, Stein S, Wagner S). The aim of the research project is the identification of DNA methylation profiles using nanotechnology that enables prediction advanced breast cancer.

Novel nanoparticle-based biosensor technology for multiplexed detection of methylation profiles in breast cancer metastases (Francis G, Stein S, Wagner S). The aim of the research project is to identify methylation profiles in breast cancer

Translational pilot study of combined Androgen Receptor and ErbB2 inhibition in Molecular Apocrine subtype of Breast Cancer (Francis G, Stein S, Wagner S). Aim of research project: To identify androgen receptor status in apocrine type breast cancer

The affect of MYB and associated genes being expression on estrogen-receptor positive and negative breast cancer cells and lines (Francis G, Stein S, Wagner S). The aim of the research project is to identify genes associated with MYB in breast cancer

National & International PresentationsDr Glenn Francis

Molecular classification of breast cancer, Queensland Cancer Oncology Group, October.

Major Grants & Financial SupportCompetitive Funding: $ 2,960,000


Pharmacy

The Pharmacy department completed during the year both local and national Drug Use Evaluations (DUE). These have

been conducted by pharmacists, pharmacists completing postgraduate studies, undergraduate pharmacy students,

nursing and other clinical staff. The DUEs are co-ordinated by the Drug Use Evaluation pharmacist.

The department has a specialist pharmacist working in clinical trials who is involved in 90 Clinical trials, as well as

an infectious diseases specialist pharmacist who is involved in six clinical trials and oncology pharmacists who are

involved in 60 clinical trials.

Lynette LoyDirector


Clinical ProjectsEvaluation of the Impacts of a Doctor - Pharmacist Collaborative Supplementary Prescribing Model in a Multidisciplinary Elective Surgery Pre-Admission Clinic (Hale A)

Proposed Supplementary Prescribing Model - A randomised controlled study, following ethical approval, is proposed to investigate the outcome of extending the role of the senior pharmacist, in Pre-Admission Clinic only, to the prescribing of the inpatient medication chart for the administration of medications on the ward peri-operatively.

Other ProjectsWarfarin calculator – Clinicians views (Winckel K).

Potassium minibag trail in ICU (Badman B).

Evidence-Based Prescribing of Antiemetics in Chemotherapy Induced Nausea and Vomiting Sandhu G, Ng K, Yung E, Wojewoda D, Weir J).

Discharge Medications after Acute Coronary Syndrome (DMACS) a multicentre national study (Coombes J with Downie M and Slater K of cardiology research).

Audit of Medication Storage in ward refridgerators ( Allam L)

Rituximab use off label and associated outcomes (Horn B, Sturtevant J).

Evaluation of medications in patients attending PAH Heart Failure Service clinic and rehabilitation class (Chan K, Chuan F).

An Audit of Secondary Prevention for stroke (Lau E, Amin H).

An Audit of Benzodiazepine use in mental health (Wu F, Mould S).


National & International PresentationsJo Sturtevant

Invited speaker SHPA introductory seminar in clinical pharmacy practice, June.

Amgen Meeting, national Renal Symposium, Sydney.

Karl Winckel


Judith Coombes,


Badman B,

Invited Speaker SHPA seminar in critical care pharmacy.

Sean Unwin

Healthcare associated infection Antibiotic Stewardship Forum. Australian Commission on Safety and Quality in Healthcare, September.


Physiotherapy

The Physiotherapy Department had a very successful year with 10 publications in peer reviewed journals and in excess

of $1 million dollars received in grant funding. Three research higher degree students continued to make substantial

progress on their studies. The department farewelled Dr Terry Haines who returned to Melbourne to take up an

Associate Professor position at Monash University. He will be surely missed. His publication and funding track record

is substantial and the department wish him and his family well.

Kathy GrudzinskasDirector


Clinical ProjectsAbdominal Binder use in people with spinal cord injuries (Wadsworth B, Haines T, Cornwall P, Paratz J).

Validation of the acute brain injury physiotherapy assessment (Gesch J, Nascimento M, Passier L).

Advancing ankle fracture rehabilitation assessments (Haines T, McPhail S, Dunstan J, Schuetz M, Jasiewicz, Urry S, Cornwell P, Baxter B, Tonks P).

Treadmill walking to improve walking and fitness following stroke: a single blinded pilot randomized controlled trial. (Kuys SS, Brauer SG, Ada L).

Randomised controlled trial of multimedia patient education approaches to preventing in-hospital falls (Haines T, Hill K, Hoffmann T, Brauer SG, Oliver D, Hill A).

Evaluating health-related quality of life: new ideas for old problems (McPhail S, Beller E, Haines T).

Falling for misconceptions in hospital (Haines T, McPhail S, Varghese P).




Queensland Clinical Trials Centre

BiostatisticsThe Queensland Clinical Trials Centre was established in 2001 within The University of Queensland’s School of

Population Health. The Centre is based at the Princess Alexandra Hospital, in recognition of the need for Queensland

clinical trials to be methodological rigorous, properly conducted, ethical and feasible. The purpose of the Centre is

to design and manage clinical trials, provide statistical consulting services and related academic activities to improve

health through high-quality research for application in evidence-based practice locally and internationally.

The major research activity during the year included:

Further development of the Australasian Kidney Trials Network •

The continuation of the Centres as the statistical office for an NHMRC funded Centre for Clinical Research •

Excellence (which has been funded for a second term of five years)

Involvement in the statistical design and analysis of four Australasian trials in radiation oncology with the Trans- •

Tasman Radiation Oncology group

Involvement in the development of controlled trials with the Princess Alexandra Hospital Cancer Collaborative •

Group

Contribution to controlled trials in leukaemia (Australian Leukaemia and Lymphoma Group), physiotherapy, •

intensive care, emergency medicine, vascular surgery, diabetes, and renal medicine

Providing biostatistical advice on design, conduct and analyses of observational, cohort, case-series and •

case-control studies in clinical departments of hospitals including: Radiation Oncology, Medical Oncology,

Haematological Oncology, Orthopedics, Ent Surgery, Speech Therapy, Social Work, Physiotherapy, Cardiothoracic

Surgery, Nursing Research, Geriatrics, Palliative Care, Anaesthetics, Endocrinology, Radiology, Cardiology, Trauma

Surgery, Intensive Care, Emergency Medicine and The University of Queensland’s Diamantina Institute for Cancer,

Imunology and Metabolic Medicine.

Elaine BellerDirector



Clinical ProjectsThe HONEYPOT trial. A randmosied clinical trials to determine whether Medihoney™ Antibacterial Wound Gel, is an effective treatment for the prevention of infections that occur in patients requiring peritoneal dialysis (PD) for kidney failure. This trial has secured more than $800,000 in funding and has commenced recruitment. 370 patients will be recruited over 2 years.

The FAVOURED Trial. A randomised, placebo-controlled clinical trial to determine whether the anti-platelet agents aspirin and fish oil, either alone or in combination, will effectively reduce the risk of early thrombosis (blood clots) in arterio-venous fistulae (AVF). This trial has secured $1.79 million in funding and has commenced recruitment. Twelve-hundred patients requiring haemodialysis will be recruited over three years.

The HERO Trial. A randomised, placebo-controlled trial to determine whether Oxpentifylline (Trental®) administration will effectively treat erythropoitin-resistant or darbepoietin-resistant anaemia in chronic kidney disease patients. The trial has secured more than $310,000 in funding and will commence recruitment in May 2009. One-hundred and ten patients will be recruited over two years.

The BLOCADE Trial. Investigating whether carvedilol (beta-blocker) reduces the incidence of cardiovascular morbidity and mortality in patients receiving dialysis. A pilot study will initially be undertaken to determine recruitment rates, tolerability of carvedilol and event rates. The Pilot study has secured $755,000 and will commence recruitment at the end of 2009. One-hundred patients will be recruited over one year.

The Active Dialysis Trial. A prospective, randomised trial designed to provide definitive evidence on the benefits and costs of extending weekly haemodialysis hours beyond current standards, has recently received a National Health and Medical Research Council (NHMRC) Project Grant of $1.25 million. This trial is run from the George Institute and endorsed by the AKTN.

The POST Trial. A prospective randomised trial of post-operative concurrent chemo-radiotherapy versus post-operative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck. This trial is an initiative of the PAH Cancer Collaborative (Dr Sandro Porceddu), and run through the Trans-Tasman Radiation Oncology Group (TROG).

The TOAD Trial. A prospective randomised trial of the timing of intervention with androgen deprivation in prostate cancer patients with a rising PSA (TOAD). This TROG study is comparing early androgen deprivation treatment at PSA relapse, with standard treatment on clinical progression of disease.

TROG Advanced Oesophageal Trial. A randomised phase III study in advanced oesophageal cancer to compare quality of life and palliation of dysphagia in patients treated with radiotherapy versus chemo-radiotherapy.

TROG Bladder Cancer Trial. A randomised phase III study in advanced bladder cancer to compare relapse-free survival time in patients treated with radiotherapy versus chemo-radiotherapy. This study has closed to patient accrual, and will be analysed in 2010.

ALLG MM8 Amyloidosis Trial. A Phase II Study of Risk-Adapted IV Melphalan in patients with AL Amyloidosis. This is a national trial of the Australasian Leukaemia and Lymphoma Study Group, looking at a potential new treatment for this rare disease. It is an initiative of the PAH Cancer Collaborative (Dr Peter Mollee).

Other ProjectsADVANCE trial cost-effectiveness analysis (Glasziou P, Beller E, Alexander J, Clarke P, Rajmokan M) . This project is assessing the cost-effectiveness of strict blood glucose control and blood pressure lowering with a fixed combination of perindopril and indapamide in Type 2 diabetes mellitus: and is a substudy of the main ADVANCE trial coordinated by the George Institute for International Health.

National & International PresentationsAlan Cass

The Australasian Kidney Trial Network: Current and future trials. 18th Annual New Zealand Renal Physicians Conference, Auckland.

The Australasian Kidney Trial Network. NSW Paediatric Clinical Trials Research Roundtable. NSW Office for Science and Medical Research, Sydney.

Melissa Starfield

The Governance and Policies of the Australasian Kidney Trials Network. Clinical Research in Excellence Conference 08.


Introduction to the Australasian Kidney Trials Network. BioJapan Conference, Yokohama Tokyo.

The Australasian Kidney Trials Network. An approach using complementary medicine. Osaka Chamber of Commerce and Industry, Osaka, Japan.

Carmel Hawley

The Australasian Kidney Trials Network. Australia and New Zealand Society of Nephrology Conference, Newcastle.





Queensland Melanoma Project

The Queensland Melanoma Project was originally established in 1963 by Dr Neville Davies to investigate issues such

as the incidence of the disease and outcomes from treatment. The Project has developed over the years to include

a multi-disciplinary clinic that involves General Surgeons (Surgical Oncology), Plastic and Reconstructive Surgeons,

Medical Oncology, Radiation Oncology and Allied Health. This is the only specialist melanoma clinic in Queensland

and offers patient care and advice to clinicians in Queensland and Northern New South Wales. It is through this clinic

that a focus on clinical research has developed.

The Queensland Melanoma Project has been involved in local, national and international clinical trials. In 2008 the

Queenland Melanoma Project became one of two sites in Australia participating in the phase II PV-10 trial where Rose

Bengal is being injected directly into metastatic melanoma deposits. The project was also the first site in the world to

open to recruitment and enrol a patient in a new phase III vaccine trial. The project continues to collect prospective

data on all patients undergoing nodal surgery or isolated limb therapy. This data has been presented at National

conferences.

Associate Professor B Mark SmithersGeneral Surgeon, Senior Lecturer The University of Queensland Department of Surgery,

Chairman Queensland Melanoma Project Princess Alexandra Hospital, Chairman Upper GI and Soft Tissue Unit Princess Alexandra Hospital


Clinical ProjectsMulticenter Selective Lymphadenectomy for Melanoma Trial II (Smithers BM, Bayley G, Barbour A, Jones S, Allan C). A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in CutaneousMelanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node.

A Double blind, randomised, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma (Smithers BM, Barbour A, Burmeister B, Walpole W, Bayley G, Allan C).

A Phase II study of intralesional PV-10 in the treatment of metastatic melanoma (Multicentred trial) (Smithers BM, Barbour A, Bayley G, Burmeister B, Allan C).

A Phase I, open label cohort study of two doses of Cavatak (Coxsackievirus A21) given intra-tumourally in Stage IV Melanoma (Smithers BM, Thomson D, Barbour A, Bayley G, Walpole E, Guminski A, Joubert W, Atkinson V).

Phase I clinical trial of interferon modified B7 positive melanoma call vaccine in patients with Stage IV malignant melanoma (Smithers BM, Barbour A, Burmeister B, Walpole E, Bayley G, Allan C).


Prospective study of the natural history of subjects who were entered in the MMAIT-03-001 and MMAIT-04-001 trials and underwent post-operative therapy with BCG plus placebo or BCG plus Canvaxin (Smithers BM, Bayley G, Barbour A).

Follow-up Study of randomised double-blind phase II trial of NY-ESO-1 Iscomatrix vaccine and Iscomatrix adjuvant alone in patients with resected stage IIc, II or IV malignant melanoma. (Multicentred trial) (Smithers BM, Barbour A, Burmeister B, Walpole E, Bayley G).

The natural history of patients who were entered into the MRPQ0161A study (Smithers BM, O’Rourke M, Schmidt C).

Other ProjectsMelanoma Database – Nodal Dissection (Smithers BM, Jones S, Barbour A, Bayley G, Allan C). Established in

2004 data has been collected on all patients undergoing a sentinel lymph node dissection or complete lymph node dissection for metastatic melanoma. Retrospective data has been collected since 1997. There are currently 1117 patients.

Melanoma - Isolated Limb Infusion Database (Smithers BM, Jones S, Barbour A, Bayley G, Allan C). Data has been collected on all patients who have undergone an isolated limb infusion at the Princess Alexandra Hospital since 1997. The majority of these procedures have been for metastatic melanoma.

Major Grants & Financial SupportFunding from commercial studies: $ 264,167



Queensland

Spinal Cord InjuriesThe Queensland Spinal Cord Injuries Service consists of the Spinal Injuries Unit, the Transitional Rehabilitation

Program and the Spinal Outreach Team. All three services have active research programs.

Spinal Cord Injuries UnitResearch highlights in the Spinal Injuries Unit during the year have included; completion of the study “Autologous

olfactory ensheathing cell transplantation in human paraplegia: a 3-year clinical trial” with the final paper being

published in the journal Brain. Other ongoing research areas include studies related to Professional Boundaries, the

effectiveness of the Spinal Cord Injury Response program and use of abdominal binders in people with spinal cord

injury.

Dr Tim GeraghtyDirector Queensland Spinal Cord Injuries Service, Rehabilitation Physician


Clinical ProjectsThe effect of an abdominal binder on respiratory and speech function in people who have suffered a spinal cord injury (Wadsworth B). This study investigates the effect of an abdominal binder on breathing, speech and blood pressure in newly injured patients admitted to the Spinal Injuries Unit of the hospital. Subjects with damage to T5 level or above and presenting as a complete injury have been recruited and followed over a 1 year period. To date, full data is available for three subjects, with seven subjects approaching the final data collection point of one year.

Long-term Outcomes of the use of Intermittent Clean Self-Catheterisation (ICSC) following Spinal Cord Injury (Eugarde E, Kendall M, Urquhart S, Geraghty T).This study is investigating the outcomes of the long term use if intermittent clean self catheterisation (ICSC) in

people with spinal cord injury. Findings include that the majority of patients discharged using ICSC continue to do so in the long-term and despite the occurrence of complications and some inconvenience the majority not only persist with the technique but do not find it excessively demanding with respect to their daily living and quality of life.

Other ProjectsProfessional Boundaries: The design and evaluation of a psychoeducational intervention for the multidisciplinary team to improve knowledge, comfort, experience and ethical decision-making (Fronek P, Kendall M, Ungerer G, Eugarde E, Malt J and Geraghty T).Caring for Carers (Unger C, Vale E, Kwapil K, Fronek P)


National & International PresentationsGeraghty TJ, Mackay-Sim A, Féron F, Cochrane J, Bassingthwaighte L, Bayliss C, Davies, W, Fronek P, Gray C, Kerr G, Licina P, Nowitzke A, Perry C, Silburn PAS, Urquhart S.

Assessments and outcome measures in human spinal cord injury research – Reflections from a 3 year clinical trial of autologous olfactory ensheathing cell transplantation in human paraplegia. Australia and New Zealand Spinal Cord Society, Annual Scientific Meeting, Christchurch, New Zealand.

Patricia Fronek & Melissa Kendall

Professional Boundaries: Are they still relevant to contemporary practice? Invited workshop conducted at the Annual Scientific Meeting of the Australian and New Zealand Spinal Cord Society, Christchurch New Zealand.

Patricia Fronek

Invited to participate in a Delegation of Australian Social Workers to Beijing, Guilin and Shanghai, China.

Spinal Outreach TeamThe major research achievement for the Spinal Outreach Team was completion of the data collection phase of the Long Term Outcomes Study in Spinal Cord Injury. The study was conducted over five years and involved 270 participants. Data analysis has now commenced.

Kiley PershouseProgramme Manager


Clinical ProjectsOutcomes in long duration spinal cord injury: Documentation of multiple integrated trajectories of wellbeing and comparative analysis of outcome measures (Amsters D, Pershouse K, Barker R, Kuipers P,

Schuurs, S). The study utilises a wave panel design with the longitudinal aspect stretching over 5 years. Data collection was completed in 2008. Analysis of data has commenced.

Transitional Rehabilitation ProgramThe Transitional Rehabilitation Program (TRP) provides post-primary rehabilitation services for people with spinal cord injuries, who have undergone in-patient rehabilitation in the Queensland Spinal Injuries Unit. TRP forms an integral part of the Queensland Spinal Cord Injuries Service (QSCIS). Rehabilitation services are provided in the community in client’s homes or in the home-like setting of TRP accommodation.

In 2008, the Transitional Rehabilitation Program has continued its active research focus on the consolidation and finalisation of several projects. This activity has resulted in the acceptance and publication of several papers related to applied research that has been conducted over many years in the clinical setting and the submission of a doctoral research thesis. New research commenced to investigate the nature of the therapeutic relationship in community rehabilitation settings.

Greg UngererManager



Other ProjectsExploring the therapeutic relationship in transitional rehabilitation (Myburg M, Kendall M). This project commenced during 2008 and aims to examine the nature and scope of the therapeutic relationship between therapist and client in community rehabilitation settings such as transitional rehabilitation, from the perspective of both therapist and client. This project is continuing during 2009 and was presented at an international conference in 2008.

Social support following spinal cord injury: A qualitative examination of friendships (Kendall M, Kendall E). This project aimed to develop a theory of friendship following spinal cord injury and was completed during 2008 and a doctoral thesis was submitted based on the findings. Clinical guidelines are currently being developed from this project.

Professional boundaries: Development and evaluation of an intervention to address staff knowledge, comfort, attitudes and behaviour (Fronek P, Kendall M, Ungerer G, Malt J, Eugarde E, Geraghty T). This project evaluated an intervention to address professional boundaries in practitioner/client relationships. This project was completed in 2008 and two papers have been accepted for publication in 2009.

Spinal Cord Injury Response: Evaluating a cross-departmental government initiative (Ungerer G, Geraghty T, Fronek P, Bigby A, Rowe C, Shepherd C, Thorne CM, Dwyer P, Harre D). This collaborative project involved an evaluation conducted by Griffith University and contracted by Disability Services Queensland. The project was completed during 2008 and presented at an international conference.

Awards & PrizesGreg Ungerer

Best presentation, entitled Spinal Cord Injury: Breaking Down Barriers. Annual Scientific Meeting of the Australian and New Zealand Spinal Cord Society, Christchurch New Zealand.

National & International PresentationsPatricia Fronek & Melissa Kendall

Professional Boundaries: Are they still relevant to contemporary practice? Invited workshop conducted at the Annual Scientific Meeting of the Australian and New Zealand Spinal Cord Society, Christchurch New Zealand.


Radiation Oncology (Mater)

The department has continued to participate in a range of clinical research and is currently involved in 19 trials, 11

of which are still actively accruing patients. It has been pleasing to see increased participation of radiation therapy,

physics and nursing staff in research trials. With the introduction of two linear accelerators which are equipped with

on board imaging and Intensity Modulated Radiotherapy new protocols have been developed to allow the more

accurate delivery of treatment and reduced side effects to critical normal tissues.

Associate Professor Michael PoulsenDirector


Clinical ProjectsInvestigation of Image Guidance Methods for Improved lLocalisation in External Beam Radiotherapy of the Prostate. (Deagan T). This study prospectively investigates the use of two methods of image-guidance, kV imaging and cone beam CT imaging, for localisation of the prostate during radiation treatment.

Clinical TrialsTumour volume as an independent prognostic factor in patients with non-small cell lung cancer (TROG 99.05)

A randomised trial of preoperative radiotherapy for stage T3 adenocarcinoma of rectum (TROG 01.04)

A randomised clinical trial of surgery versus surgery plus adjuvant radiotherapy for regional control in patients with completely resected macroscopic nodal metastatic melanoma (TROG 02.01)

A randomised phase III study comparing radical chemo/radiotherapy versus radiotherapy alone in the definitive management of localised muscle invasive TCC of the urinary bladder (TROG 02.03)

A randomised phase III study in advanced oesophageal cancer to compare quality of life and palliation of

dysphagia in patients treated with radiotherapy versus chemo-radiotherapy (TROG 03.01)

A randomised trial investigating the effect on survival and PSA control of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate (RADAR) (TROG 03.04)

A phase III study of regional RT in early breast cancer (NCIC MA20) (TROG 03.05)

A phase III study of the Timing of Intervention with Androgen Deprivation in prostate cancer patients with a rising PSA (TOAD) (TROG 03.06)

A Phase III international randomised trial of Single vs. Multiple Fractions for Re-Irradiation of Painful Bone Metastases (TROG 03.08)

Post-operative Concurrent Chemo-Radiotherapy vs. Post-operative Radiotherapy in High-Risk cutaneous Squamous Cell Carcinoma of the Head and Neck (POST) (TROG 05.01)

QUARTZ – Quality of life after radiotherapy and/or steroids (MRC LU24) (TROG 07.02)


A phase I study of synchronous weekly carboplatin and radiation in Merkel Cell Carcinoma of the skin – a collaborative study between Brisbane, Melbourne and Newcastle departments (Merkel Cell)

Efficacy Study of Synchronous Weekly Carboplatin and Radiation in Merkel Cell Carcinoma of the Skin (Merkel Cell Ph II)

Dexamethasone for the Radiation-Induced for Pain Flare following Palliative Radiotherapy for Bone Metastases – A Phase II Study (Dex for Mets)

A multi-centre randomised trial of standard or higher targets for transfusion during chemo-radiation for cervix cancer (ANZGOG0401) (HOSTT)

A phase III multi-centre randomised trial comparing adjuvant radiotherapy (RT) with surveillance and early salvage RT in patients with positive margin or extraprostatic disease following radical prostatectomy (RAVES) (TROG 08.03)

Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma (PORTEC-3) (TROG 08.04)

Primary chemotherapy with Temozolomide vs radiotherapy in patients with low grade glioma after stratification for genetic 1 p loss: a Phase III study (EORTC 22033-26033) (TROG 06.01)

A randomised Phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (TROG 07.01)

National & International PresentationsMichael Poulsen, Jim Bishop, Kay Hull, Rhonda Coleman

Invited panel member. Building a cancer centre. Is there consensus about what constitutes a cancer centre? How are the needs of patients being met in a city, regional and rural areas? COSA November.

Kacy Baumann

Invited speaker. How to Engage All Disciplines Cancer Institute NSW Success in Clinical Trials: The Way Forward 2008 Workshop. November.




Radiation Oncology (Princess Alexandra Hospital)

The Princess Alexandra Hospital Radiation Oncology Department completed its seventh year of service. As in previous

years there have been significant increases in both workload and staffing. Activity in clinical research studies remains

high with 34 trials either recruiting patients or monitoring patients during the year. Eleven new trials are undergoing

review to commence in 2009 including three protocols initiated by investigators at this centre.

Following the commencement of service of the third linear accelerator, considerable progress has been made in the

use of new technology. Cone beam CT and the use of fiducial markers commenced in the management of prostate

cancer. Cone beam CT has also been used in the management of lung cancer and in abdominal lymphoma. Late in

2008 it was also identified that intensity modulated radiation therapy (IMRT) needed to become an integral part of

therapy PAH. With that in mind, a dedicated project officer has been appointed to streamline the development of IMRT

at PAH. The role out of the clinical information system, MOSAIQ continues to expand with more and more tasks being

managed electronically. There has been a steady move towards the development of technology –based clinical trials

both home-based and multi-centre which should continue in the future.

The Director of Radiation Oncology at the Princess Alexandra Hospital campus, Professor Bryan Burmeister, was

promoted to a full professor at The University of Queensland in November. Professor Burmeister was also the recipient

of an Australia Day Certificate of Achievement granted for his tireless efforts to improve the prognosis and quality of

life of patients with cancer through the enthusiastic involvement in TROG and other research activities. He was also

awarded a Certificate of Exemplary Service by Cancer Council Australia for his work in the development of Clinical

Guidelines for the Management of Melanoma in Australia and New Zealand.

Professor Bryan BurmeisterDirector


Clinical Projects20040118 (Palifermin) - A Phase III, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Reduction of Oral Mucositis in Subjects with Advanced Head and Neck Cancer Receiving Adjuvant Radiotherapy and Chemotherapy. [2004/209] (Porceddu S)

GOFURTGO - Phase II Study of Fixed Dose Rate Gemcitabine-Oxaliplatin Integrated with Concomitant 5FU and 3-D Conformal Radiotherapy for the Treatment of Localised Pancreatic Cancer. [2005/061] (Harvey J)

Merkel Cell - Efficacy Study of Synchronous Weekly Carboplatin and Radiation in Merkel Cell Carcinoma of the Skin. [2007/005] (Harvey J)


STARS (Pilot) - Pilot for a Randomised Comparison of Anastrozole Commenced Before and Continued During Adjuvant Radiotherapy for Breast Cancer versus Anastrozole and Subsequent Anti-Oestrogen Therapy Delayed Until After Radiotherapy. [2005/109] (Harvey J)

TROG 01.04 - A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of the Rectum. [2001/002] (Burmeister B)

TROG 02.01 - A Randomised Clinical Trial of Surgery versus Surgery plus Adjuvant Radiotherapy for Regional Control in Patients with Completely Resected Macroscopic Nodal Metastatic Melanoma. [2002/009] (Burmeister B)

TROG 03.01 - A Randomised Phase III Study in Advanced Oesophageal Cancer to Compare Quality of Life and Palliation of Dysphagia in Patients Treated with Radiotherapy versus Chemoradiotherapy. [2003/056] (Harvey J)

TROG 03.02 - A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer. [2003/035] (Harvey J)

TROG 03.04 (RADAR) - A Randomised Trial Investigating the Effect on Biochemical (PSA) Control and Survival of Different Durations of Adjuvant Androgen Deprivation in Association with Definitive Radiation Treatment for Localised Carcinoma of the Prostate. [2003/092] (Lehman M)

TROG 03.05 (MA.20) - A Phase III Study of Regional Radiation Therapy in Early Breast Cancer. [2003/101] (Harvey J)

TROG 03.06 (TOAD) - A Collaborative Randomised Phase III Trial: The Timing of Intervention with Androgen Deprivation in Prostate Cancer Patients with a Rising PSA. [2004/306] (Lehman M)

TROG 03.07 - A Randomised Phase II Study of Two Regimens of Palliative Chemoradiation Therapy in the Management of Locally Advanced Non Small Cell Lung Cancer. [2003/180] (Burmeister B)

TROG 04.01 (Cavilon) - A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream(CDBC) to 10% Glycerine (Sorbolene) Cream in the Prophylactic Management of Post Mastectomy Irradiation Skin Care. [2004/307] (Harvey J)

TROG 05.01 (POST) - Post-Operative Concurrent Chemoradiotherapy versus Post Operative Radiotherapy

in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck. [2004/218] (Porceddu S)

TROG 06.01 (EORTC 22033-26033) - Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low Grade Gliomas after Stratification for Genetic 1p Loss: A Phase III Study. [2007/043] (Lehman M)

TROG 06.02 (APBI) - A Multicentre Feasibility Study of Three-Dimensional Conformal Radiation Therapy for Accelerated Partial Breast Irradiation. [2007/098] (Lehman M)

TROG 07.01 (DCIS) - A Phase III Study of Radiation Dose Escalation and Fractionation in Women with Non-Low Risk Ductal Carcinoma In Situ (DCIS) Of The Breast. [2007/088] (Harvey J)

TROG 07.02 (QUARTZ) - A Phase III Multi-Centre Randomised Controlled Trial to Assess Whether Optimal Supportive Care Alone (Including Dexamethasone) is as Effective as Optimal Supporting Care (Including Dexamethasone) plus Whole Brain Radiotherapy in the Treatment of Patients with Inoperable Brain Metastases from Non-Small Cell Lung Cancer. (previously called OSCAR). [2007/079] (Mai T)

TROG 08.02 - A Randomized Phase III Study of Temozolomide and Short-course Radiation versus Short-course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients [2008/181] (Lehman M)

TROG 08.05 (WBRT) - Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma. [2008/179] (Burmeister B)

TROG 99.03 (ALLG NHLLOW5) - A Randomised Multicentre Trial of Involved Field Radiotherapy versus Involved Field Radiotherapy plus Chemotherapy for Stage I-II Low Grade Follicular Lymphoma. [2000/088] (Porceddu S)

TROG 99.04 - A Prospective, Non-Randomised Study of Chemotherapy and Radiotherapy for Osteolymphoma. [2000/022] (Mills A)

TROG 99.05 - Tumour Volume as an Independent Prognostic Factor in Non-Small Cell Lung Cancer. (Burmeister B)

Other ProjectsA Randomised Control Trial Investigating the Effects of Group Education and Support in Reducing Cancer-


Related Fatigue and Improving Quality of Life in Patients Undergoing Radiotherapy. (Purcell A; Fleming J; Haines T; Bennett S; Burmeister B)

The study has recruited 110 participants and data collection is due for completion in June 2009.

PET-guided Management of the Neck in Node Positive Head and Neck Cancer. Porceddu S; Pryor D; Burmeister L; Burmeister B; Poulsen M; Thomson D; Coman S; Coman W.

HPV H&N - Human Papillomavirus in Oropharyngeal Carcinoma: Prognostic Significance and Interaction with Radiation Therapy. (Porceddu S)

A Retrospective Study Comparing the Treatment Accuracy of Three Treatment Positions for Chest Irradiation. (Tran J)

A Project to Determine the Benefit / Use of Cone Beam CT During Treatment of Breast Cancer. (Mauro M)

Integration of Evidence Based Practice Culture into Radiation Therapy Work Practices. (Davidson K)

Comparative Study of Fixation Devices Utilized in Radiation Therapy Treatment of Breast Cancer at Princess Alexandra Hospital. (Van Den Bosch K)

Conformal External Beam Radiotherapy in the Treatment of Anal Canal Carcinoma. A Retrospective Study of Genital Sparing Technique. (Bui T; Harvey J; Brown E; Scott M; Haines T; Davidson K)

Hitting a Moving Target: Do Implanted Gold Seed Fiducial Markers Help? A Study of Prostate Motion and Accuracy of External Beam Radiation Therapy Delivery in Patients with Prostate Cancer [2007/136] (Brown S;

Lehman M; Ferrari J; Glyde A; Golding S; Davidson K)

Project to Develop an Implementation Plan for Intensity Modulated Radiation Therapy (Foley H)

Aims to Look at the Benefit / Use of 4D CT, Chest Immobilisation and Cone Beam CT During the Treatment of Lung Cancer. (Barnes N)

Patient Education Brochure to Increase Comfort and Ease of Positioning for Patients Undergoing Radiation Therapy for Breast Cancer. (O’Gorman H)

Awards & PrizesProfessor Bryan Burmeister

Queensland Health Australia Day award in January 2008 for research activity.

Associate Professor Sandro Porceddu

Elected President of the Australian Sarcoma Study Group

National & International PresentationsProfessor Bryan Burmeister

RANZCR ASM Adelaide, October

Associate Professor Sandro Porceddu

International Head and Neck Congress, San Francisco

General Surgeons of Australia, Coolum, September

ANZ Head and Neck Society, Melbourne, October




Clinical ProjectsInflammatory markers in COPD (Upham J, Smith D, Yerkovich S): This project has examined blood levels of an anti-inflammatory molecule, the soluble receptor for advanced glycation end products (sRAGE). Plasma sRAGE levels were significantly reduced in patients with COPD, but not in healthy subjects (both smokers and non-smokers). Ongoing work is examining the mechanisms behind this observation.

Host defence against virus infections in asthma. (Upham J, Yerkovich S): The project is examining anti-viral innate immunity in asthma, and has shown that people with asthma have a reduced capacity to respond to single stranded viral RNA.

Defining grass pollen allergy in sub-tropical regions of Australia (Davies J, Upham J): Most information regarding grass pollen allergy in Australia has been derived from cooler temperate regions of southern Australia. This project with define the role of sub-tropical grasses such as Bahia and Johnson grass in relation to grass pollen allergy in Queensland, and how this triggers asthma and allergic rhinitis.

Innate immune function in children with protracted bronchitis. (Upham J, Yerkovich S in collaboration with Dr Anne Chang, Royal Children’s Hospital): Recurrent

or protracted bacterial bronchitis is common clinical problem in children. The project is examining immune function in these children.

More efficient diagnosis of obstructive sleep apnoea. (C. Hukins): This project is looking at the using of automated snoring and EEG analysis to diagnose and manage obstructive sleep apnoea in a more cost-effective manner.

Other ProjectsUsing components of bacteria to treat asthma and allergies (Upham J, Davies J):Some components of the cell walls of bacteria have powerful immune modulating properties. This project exploits the use of bacterial lipoproteins to inhibit allergic immune responses in vitro. Initial studies show this to be effective for house dust mite allergy.

Effects of allergens on dendritic cell function in asthma (Upham J, Yerkovich S). The ability of allergens to trigger allergic inflammation is mediated partly via dendritic cells. This project is examining the molecular mechanisms involved. Thrombomodulin has been identified as a novel protein expressed in dendritic cells after allergen exposure.

Respiratory & Sleep Medicine

The department has an active research program focussing on the pathogenesis of inflammatory disorders of the lungs

and respiratory system, with a particular interest in the roles played by infections and allergy.

Professor John UphamHead


Awards & PrizesDr Daniel Smith

Best advanced trainee presentation, Thoracic Society of Queensland.

National & International PresentationsProfessor John Upham

Novel role of thrombomodulin expression on dendritic cells in the pathogenesis of human atopy and asthma. American Thoracic Society International Conference, Toronto, May.

PatentsNovel immunogenic molecules and uses thereof. Australian PCT No 30634847, Provisional, 2008, Australia (O’Hehir R, Davies J, Rolland J)

Novel immunogenic molecules and uses thereof. PCT/AU2008/001551, Provisional, 2008, Australia (O’Hehir R, Davies J, Rolland J)




The Rheumatology Department is actively involved in rheumatoid arthritis trials, mostly Phases II, III and IV. To date,

the majority have been biologic therapy of various types. We are also currently supporting the clinical work for a PhD

project in osteoarthritis.

Dr Phillip VecchioDirector


Clinical ProjectsLong-term extension study of safety during treatment with Tocilizumab (MRA) in patients completing treatment in MRA core studies.

A randomised, double-blind, parallel group,international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF alpha therapy.

Protocol No DE013: Prospective multi centre randomised, double blind, active comparator controlled parallel group study comparing the fully human monoclonal anti-TNFα antibody D2E7 given every second week with Methotrexate given weekly and the combination of D2E7 and Methotrexate administered over two years in patients with early rheumatoid arthritis (PREMIER)

A multi-centre, randomised, double-blind, placebo-controlled, parallel group, phase 2a clinical trial to

assess the efficacy and safety of Cpn10 administered as twice weekly subcutaneous injections in participants with rheumatoid arthritis.

A Multi-centre, long term follow-up, open label trial to assess the efficacy and safety of Cpn10 in subjects with Rheumatoid Arthritis.

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicentre Study to Evaluate the Efficacy, Safety, and Tolerability of BG00012 When Given with Methotrexate to Participants with Active Rheumatoid Arthritis who have had an Inadequate Response to Conventional Disease-Modifying Anti-Rheumatic Drug Therapy.

A Phase 2, Dose – Ranging Study of Multiple Subcutaneous Doses of LY2127399, and Anti – BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis despite ongoing Methotrexate Therapy.

Rheumatology


The department continues to maintain its interest in practice-based research with work being undertaken by social

workers primarily in the Rehabilitation and Disability as well as the Cancer Services Teams. Fundng from Queensland

Health and the Princess Alexandra Hospital Private Practice Grant have assisted in research projects and conference

attendances during the year.

Sue CummingDirector

Current Research ActivitiesSociodemographic and psychosocial profile of newly referred head and neck cancer patients (Wilson A, Mc Grath P).

A pilot study of social support and its effect on the quality of life of patients with advanced cancer and their care givers (Whelan J, Burns C, Burmeister B).

Clinical ProjectsSociodemographic and psychosocial profile of newly referred head and neck cancer patients (Wilson A, Mc Grath P).

The research proposal will involve a chart audit using a mixture of both quantitative and qualitative methods.

Social Work


De- identified sociodemographic information on patients along with clinical data on tumour location and staging data from the charts will be used.

A pilot study of social support and its effect on the quality of life of patients with advanced cancer and their care givers (Whelan J, Burns C, Burmeister B).

The project aims to identify the connection between the kind of social support available for patients and their care givers and the inter relationship of social support and its impact on the quality of life for patients with advanced cancer.

Other ProjectsProfessional Boundaries: The design and evaluation of a psychoeducational intervention for the multidisciplinary team to improve knowledge, comfort, experience and ethical decision-making (Fronek P, Kendall M, Ungerer G, Eugarde E, Malt J, Geraghty T).

Caring for Carers (Candice Unger, Elisabeth Vale, Karleigh Kwapil, Patricia Fronek).

National & International PresentationsPatricia Fronek and Melissa Kendall

Pre-conference workshop entitled ‘Professional Boundaries: Are they still relevant to contemporary practice?’ at ANZSCoS (The Australian and New Zealand Spinal Cord Society Annual Scientific Meeting) held in Christchurch, New Zealand, November.

Major Grants & Financial Support Other Competitive funding: $21,731

Funding from other sources: $40,553



Clinical ProjectsEvaluation of heat and moisture systems as a treatment option in pulmonary rehabilitation after total laryngectomy or pharyngectomy (K Hancock, L Cahill, P Cornwell, M Parkin & W Coman).

Determining the efficacy of the Lee Silverman Voice Treatment in the Treatment of Non-Progressive Dysarthria (R Wenke, D Theodoros & P Cornwell).

Other ProjectsInvestigating the link between global self-awareness and awareness of social communication skills in adults with traumatic brain injury (P.Cornwell, C. Newton, J. Fleming, C. Freebairn & K. Watter).

From hospital to home: transition experiences and outcomes for individuals with ABI (B. Turner B, J. Fleming, T. Ownsworth, P. Cornwell).

Determinants of successful community transition for individuals with ABI and their families (J. Fleming, L. Worrall, P. Cornwell, T. Haines, T. Ownsworth, M. Kendall, L. Chenoweth, E. Nalder).

Understanding the differential impact of acoustic speech parameters on the severity of motor speech disorders: effects on speech intelligibility and naturalness (P. Cornwell & M. McAuliffe).

The evaluation of multidisciplinary goals and goal setting processes in an adult rehabilitation setting (P. Cornwell, J. Fleming, T. Haines, & E. Leach).

Assessing acquired neurogenic communication disorders online: A telerehabilitation application (A. Hill, D. Theodoros, L. Ward & T. Russell) (sponsor – P. Addis & K. Clark).

Speech Pathology

The vision of the department is to further develop the evidence-base for clinical practice in the areas of

communication and swallowing caused by illness, injury, or treatment through research. Research activity within the

department has continued to expand. The areas of Acquired Brain Injury and Head and Neck Cancer remain strong

foci for research, but now sit alongside the emerging areas of Critical Care and Aging. While many projects focus on

speech pathology specific clinical practice, staff are also actively involved in a number of multidisciplinary research

projects.

The department’s research profile through its keen staff continues to develop both nationally and internationally.

Research outcomes have been disseminated in peer-reviewed publications and presentations at key national and

international conferences, while continuing to attract research funding. Currently, the department supports seven

postgraduate research students and one honours student conducting research, as well as assisting researchers from The

University of Queensland in conducting their projects.

Wendy McCallumDirector


Articulatory function in adults following cerebrovascular accident (Y. Chen, B. Murdoch & J. Goozee) (sponsor – P. Addis).

Formatting written health information for people with aphasia (T. Rose & L. Worrall) (Sponsor – W. McCallum).

State- of- the- art physiological and neurophysiological assessment of articulatory function in adults with apraxia of speech: Pathway to more efficacious treatment for speech disorders following left hemisphere stroke (J. Goozee, B. Murdoch, & C. Bartle) (sponsor - W. McCallum).

Hemispheric contribution to language: A divided visual field investigation of semantic processing following unilateral lesion (E. Smith, D. Copeland & H. Chenery) (sponsors – J. Lethlean & L. Smith).

Long-term swallowing outcomes in head and neck cancer patients: comparing non-surgical treatment regimens (B. Riddle, P. Cornwell, S. Porceddu, S. Stuckey, E. Ward, & W. Davidson).

Quality of life, cost effectiveness, survival and functional outcomes following differential management of laryngeal cancer (W. Coman, L. Cahill, K. Hancock, L. Ward & P. Cornwell).

Investigations of care requirements of people with brain tumour (T. Haines, P. Cornwell, J. Fleming, S Olsen, A. Omerod).

Abdominal Binders – giving breath and voice to people who have suffered a spinal cord injury (B. Wadsworth, T. Haines, J. Paratz, P. Cornwell).



Therapeutics Research

The Therapeutics Research Unit continued to study the spectrum of basic and clinical therapeutics, ranging from

theoretical mathematical modelling of drug disposition, through to very practical aspects such as drug trials in

seriously ill patients. A major highlight was the extensive use of our Multiphoton microscope by researchers across a

range of disciplines including topical drug ADMET studies and liver pharmacokinetics.

In targeted topical delivery, the unit succeeded in renewing its major support from NHMRC for a further three years.

Highlights were two papers and two invited presentations on nanoparticles, where the unit is establishing a reputation

as a world leader in a very controversial area. Important contributions to understanding the basic relationships

between physicochemical properties and skin transport were made, while clinical studies in skin cancer progressed

well.

In liver studies, NHMRC funding was secured for a further three years. Three publications and two invited international

presentations resulted from the work.

In clinical studies, important contributions to defining the correct dosing regimen in critically ill patients were made.

Key outcomes during the year were the award of a PhD to investigator, Jason Roberts and the publication of four peer-

reviewed papers. A phase II randomised controlled trial of atorvastatin therapy in intensive care patients with severe

sepsis progressed well, with the 100th patient being randomised. Chief Investigator Dr Peter Kruger has been invited

to a major European intensive care meeting in March 2009 as an invited expert on statin use in sepsis.

The Quality Medication Care

Team began a nationwide federal

government (Department of Veterans’

Affairs) project. The primary aim

of the project is Evaluation of the

Dose Administration Aids Service to

Veterans, to help the ageing veterans

better manage their medications; to

prevent any medical misadventures

and reduce any unnecessary or

earlier than required admission into

the hospital.

Professor Mike RobertsDirector



Clinical ProjectsAntibiotic dosing in the “at risk” critically ill patient (Roberts MS, Lipman J, Paterson D, Kirkpatrick C, Kruger P, Roberts JA).

A phase II randomised controlled trial of atorvastatin therapy in intensive care patients with severe sepsis (Roberts MS, Kruger P, Venkatesh B, Bellomo R, Kostner K, Cooper D).

Assessment of topically treated non melanoma skin cancers by sequential optical biopsies using multiphoton microscopy (Roberts MS).

Pharmacokinetics and liver vascularity (Roberts MS, Hung D, Crawford D).

Other ProjectsImproved quantification of spatial and temporal changes in plasma and tissue drug levels and tissue pathology (Roberts MS).

Targeted delivery by topical application (Roberts MS).

National Institute of Complementary Medicine Collaborative Centre for Transitional Preclinical and Clinical Research in Nutraceutics and Herbal Medicine (Vitetta L, Komesaroff P, James D, Linnane A, Roberts MS, Day R, Tiralongo E).

Micronanoprojection patches for minimally invasive and targeted delivery of genes and drugs to skin cells: from concept to technology platform (Kendall MA, Roberts MS).

Relationship between melanosome distribution and skin colour (Roberts MS, Zvyagin AV, Anissimov YG, Govindarajan R, Loy CJ).

Topical peptide delivery for cosmetic and therapeutic benefits (Roberts MS, Anissimov YG).

Dermal penetration of metal-based nanoparticles (Roberts MS)

Awards & PrizesKanchana Ranasinghe

Best Poster at the 14th Congress of the International Society for Burn Injuries, Montreal, Canada, 7-11 September, 2008, for her presentation entitled “The effect of thermal injury on interstitial tissue antibiotic distribution and the choice of resuscitation fluid”.

Co-authors were Venkatesh B, Lipman J, Dalley A, Robertson T, Roberts M, Cross S.

National & International PresentationsProfessor Mike Roberts

7th International Conference and Workshop, Biological Barriers and Nanomedicine – Advanced Drug Delivery and Predictive non vivo Testing Technologies, Saarbrücken February. (Quantum Dots)

1st International Conference on Drug Design and Delivery, Dubai February. (Targeted topical drug delivery)

8th International Symposium of Controlled Release Society, Ahmedabad February (Targeted topical drug delivery)

3rd Workshop on Advanced Multiphoton and FLIM Techniques (FLIM 2008), Saarbrücken June. (In vitro and in vivo imaging of xenobiotic transport in human skin and in the rat liver)

10th International Conference on Perspectives in Percutaneous Penetration, France March. (Skin Science)

BITS 6th Annual Congress of International Drug Discovery Science and Technology, Beijing, October (Drug Structure-Hepatic Pharmacokinetic Relationships in Normal and Diseased Livers)

19th Annual Conference of the Australian College of Pharmacy Practice and Management, Norfolk Island

Australasian Pharmaceutical Science Association Meeting, Canberra

10th Australian General Practice Network (AGPN) Forum, Darwin

Lions Q4 Convention, Hervey Bay

10th Australian General Practice Network (AGPN) Forum, Darwin

Controlled Release Society, Canberra







Clinical ProjectsIntermediate and high risk localized, completely resected, gastro-intestinal stromal tumours (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery. Intergroup study (EORTC 62024) (Smithers BM, Gotley D, Barbour A, Walpole E, Thomson D, Woodward N, Joubert W, Atkinson V) Protocol Number: 2005/108.

Basic Research ProjectsWhether inhibition of the shh pathway represents a potential therapeutic target in gastric cancer (Barbour A, Gotley D, Woodhall E).

The identification and characterisation of cancer stem cells in oesophagogastric cancer cell lines (Barbour A, Gotley D, Woodhall E).

Other ProjectsOesophageal Cancer Database and Quality of Life. Established in 1997 the database currently has 1535 patients who have been diagnosed with cancer of the oesophagus or OG Junction. Quality of Life has been conducted on all curative intent patients at baseline, 3, 6 9 12 18, 24, 36, 48 & 60 months. (Smithers BM, Gotley D, Martin I, Barbour A).

Upper Gastro-Intestinal

The Upper Gastro-Intestinal Unit treats patients with oesophagogastric disease, including oesophageal and gastric

cancer, and benign conditions such as gastro-oesophageal reflux, Barrett’s oesophagus and achalasia. It is the largest

referral unit for oesophagogastric cancer in Australia. A special interest of the unit is minimally invasive surgery, and

as a consequence the Department has the largest experience of minimally invasive oesophagectomy in the world,

totalling over 500 cases.

A large proportion of patients seen within the department have a malignant cancer. The department conducts a multi-

disciplinary meeting and clinic for these patients in conjunction with General Surgeons, Medical Oncologists, Radiation

Oncologists and Allied Health. All data on these patients are collected in a prospective database. The department is

involved in local, national and international clinical trials and in 2008 completed recruitment in the adjuvant GIST trial

in conjunction with the European Organisation for Research and Treatment of Cancer. In 2009 the department will

begin recruiting in a clinical trial in oesophageal cancer that has been initiated by one of the hospital clinicians.

The department is also experienced in laparoscopic surgery for gastro-oesophageal reflux, hiatus hernia and achalasia,

all of which is recorded (including progressive quality of life assessment) and stored. As of December 2008 there were

5080 patients whose data had been collected.

Associate Professor B Mark SmithersGeneral Surgeon, Senior Lecturer The University of Queensland Department of Surgery, Chairman Queensland Melanoma Project Princess Alexandra Hospital, Chairman Upper GI and Soft Tissue Unit Princess Alexandra Hospital


Gastric Cancer Database. Established in 2006 data has been collected both retrospectively and prospectively since 2000. The database currently has 293 patients who have been diagnosed with gastric cancer. (Barbour A, Smithers BM, Gotley D, Martin I).

Gastro-intestinal Stromal Tumour Database. Established in 2006 data has been collected both retrospectively and prospectively since 2000. The database currently has 78 patients diagnosed with GISTs. (Smithers BM, Gotley D, Martin I, Barbour A).

Laparoscopic Fundoplication Database. Established in 1991 data has been collected prospectively on all patients undergoing a Laparoscopic Fundoplication. The database currently has 3983 patients with quality of life on approximately 88% of patients. (Gotley D, Smithers BM, Martin I, Barbour A).

Para-oesophageal Hernia Repair Database. Established in 1991 data has been collected prospectively on all patients who have undergone a repair of a para-oesophageal hernia. The database currently has 627 patients with quality of life in over 88% of patients. (Gotley D, Smithers BM, Martin I, Barbour A).

Redo Hiatal Surgery Database. Established in 1991 data has been collected prospectively on all patients who have undergone a redo hiatus hernia repair. The database currently has 471 patients with quality of life in over 85% of patients. (Gotley D, Smithers BM, Martin I, Barbour A).

National & International PresentationsAssociate Professor Mark Smithers

Video presentation of Revision fundoplication, Seminars in Operative Surgery, Adelaide, Australia

The role of surgery for GIST, North Coast Cancer Conference, Kingscliff, Australia

Revision Fundoplication, International Society of Surgery conference, Townsville, Australia

Minimally invasive oesophagectomy, International Society of Surgery conference, Townsville, Australia

The outcomes form treating Achalasia, Combined Annual Scientific Congress – Royal Australasian College of Surgeons and College of Surgeons of Hong Kong

Quality of life of anti-reflux surgery, Combined Annual Scientific Congress – Royal Australasian College of Surgeons and College of Surgeons of Hong Kong

Minimally invasive surgery and mid oesophageal cancers, Combined Annual Scientific Congress – Royal Australasian College of Surgeons and College of Surgeons of Hong Kong. Hong Kong, China

Does surgical technique influence outcome in oesophageal cancer, Combined Annual Scientific Congress – Royal Australasian College of Surgeons and College of Surgeons of Hong Kong. Hong Kong, China

Oesophageal cancer: the last 20 years and 20 years into the future, Combined Annual Scientific Congress – Royal Australasian College of Surgeons and College of Surgeons of Hong Kong. Hong Kong, China

Minimally invasive oesophagectomy – A masterclass, Combined Annual Scientific Congress – Royal Australasian College of Surgeons and College of Surgeons of Hong Kong. Hong Kong, China

The role of neoadjuvant therapy for oesophageal cancer, 5th Sino-Australian Surgical Oncology Meeting. Guangzhou, China

The management of high grade dysplasia in Barrett’s oesophagus, Australian Gastroenterology Week, Brisbane, Australia

The diagnosis and management of Barrett’s oesophagus, 2nd Asia Pacific Gastroesophageal Cancer Congress, Hong Kong

High Grade Dysplasia in Barrett’s – EMR or Resection, 2nd Asia Pacific Gastroesophageal Cancer Congress, Hong Kong

Video Presentation – Minimally invasive oesophagectomy, 2nd Asia Pacific Gastroesophageal Cancer Congress, Hong Kong

The management of high grade dysplasia in Barrett’s Oesophagus, Sydney Upper GI Surgeons Society, Sydney

Oesophageal Cancer: Patterns of Care in Australia. Smithers BM, Doecke J, Corish T, Moore S, Whiteman D, Annual Scientific Meeting of the Clinical Oncological Society of Australia, Sydney

The epidemiology of oesophageal cancer. Whiteman D, Smithers BM, Gotley DC, Pandeya N, Sadeghi S, Green AC, Webb PM, Annual Scientific Meeting of the Clinical Oncological Society of Australia, Sydney

Professor David Gotley

Redo Fundoplications, Sydney Upper Gastrointestinal Surgeon’s Society. Sydney Australia


Minimally Invasive Oesophagectomy, Royal Adelaide Seminars. Adelaide Australia

Dr Ian Martin

Pre-operative weight loss and improved operative access, Combined Annual Scientific Congress – Royal Australasian College of Surgeons and College of Surgeons of Hong Kong. Hong Kong, China





Publications

Major Grants

People


Academic Unit in Geriatric Medicine

Acquired Brain Injury Outreach Services

Alcohol & Drug Assessment

Audiology

Cardiology


Cardiovascular Imaging


Dermatology

Diabetes & Endocrinology


Ear Nose Throat

Emergency

Gastroenterology & Hepatology

Hypertension

Infection Management

Intensive Care

Internal Medicine & Clinical Epidemiology

Liver Research

Medical Oncology

Nephrology


Nutrition & Dietetics




Pharmacy

Physiotherapy

Queensland Clinical Trials Centre - Biostatistics

Queensland Melanoma Project

Queensland Spinal Cord Injuries Service

Radiation Oncology Centre (Mater)

Radiation Oncology Centre (PAH)

Respiratory & Sleep Medicine

Social Work

Speech Pathology


Upper Gastrointestinal & Soft Tissue

Summary of Publications and Postgraduate Students

Publications

Journal Articles

Students #

Articles in Press

Postgraduate Students

AbstractsBook Chapters

10

0

3

1

5

1

39

6

16

19

51

4

5

10

4

12

22

11

4

6

13

18

7

10

0

2

2

10

8

1

2

13

16

8

2

7

21

8

4

0

1

0

0

1

13

4

2

2

0

2

2

4

5

0

8

4

0

0

21

9

1

12

2

2

0

5

1

0

2

4

3

7

1

5

0

4

0

2

0

0

0

0

0

0

0

0

8

1

2

1

0

0

8

0

0

0

5

13

0

6

0

0

0

1

0

1

2

0

2

3

1

0

13

1

4

0

0

0

0

0

0

6

0

18

25

0

2

0

4

14

1

11

0

0

7

0

11

2

1

0

0

5

0

2

0

0

0

4

0

1

12

5

3

3

4

0

5

0

12

0

1

6

42

0

11

4

4

2

11

1

0

0

21

6

1

11

0

0

0

3

1

0

1

2

6

1

1

7

11

1

Department

# Students supervised at the Princess Alexandra Hospital


Journal Articles

Abbott-Johnson W, Kerlin P, Abiad G, Clague A, Cuneo R: Dark adaptation impairment in vitamin A deficient adults awaiting liver transplantation-improvement with intramuscular vitamin A. Supplement to Transplantation 2008, 86(Suppl 2):657.

Abbott-Johnson W, Kerlin P, Clague A, Cuneo R: Severity of liver disease, rather than aetiology, reflects blood levels of fat soluble vitamins in adults awaiting liver transplantation. Supplement to Transplantation 2008, 86(Suppl 2):524.

Ahmed AH, Soyer HP, Saunders N, Boukamp P, Roberts MS. 2008. Non-melanoma skin cancers. Drug Discovery Today: Disease Mechanisms 5: e55-e62.

Aitken L.M, Pelter M.M, Carlson B, Marshall AP, Cross R, McKinley S, Dracup K. 2008. Effective strategies for implementing a multicenter international clinical trial, Journal of Nursing Scholarship, 40(2):101 – 108.

Aitken LM, Currey J, Marshall AP, Elliott D. 2008. Discrimination of educational outcomes between differing levels of critical care programmes by selected stakeholders in Australia: a mixed-method approach, Intensive and Critical Care Nursing, 24: 68 - 77.

Alenius H, Roberts DW, Tokura Y, Lauerma A, Patlewicz G, Roberts MS. 2008. Skin, drug and chemical reactions Drug Discovery Today: Disease Mechanisms 5: e211-e220.

Ali A, Murdock A, Pascoe A, Murrell K, Kruger P: Can Hypermanganesaemia occur without cholastasis in patients

receiving home parenteral nutrition (PN). Nutrition 2008, 24(5):511.

Anissimov Y, Roberts MS. 2008. Diffusion modelling of percutaneous absorption kinetics: 4. Effects of a slow equilibration process within stratum corneum on absorption and desorption kinetics. Journal of Pharmaceutical Sciences, 98:772-781.

Bansal M, Cho GY, Chan J, Leano R, Haluska BA, Marwick TH. 2008. Feasibility and accuracy of different techniques of two-dimensional speckle based strain and validation with harmonic phase magnetic resonance imaging. J Am Soc Echo; 21:1318-25.

Bansal M, Leano R, Marwick TH. 2008. Clinical assessment of left ventricular systolic torsion: Effects of myocardial infarction and ischemia. J Am Soc Echo; 21(8):887-894.

Bansal M, Marwick TH. 2008. Natriuretic peptides and filling pressure at rest and stress. Heart Fail Clin; 4: 71-86.

Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, Burmeister B, Smithers BM. 2008. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol;15 (10):2894-902.

Barbour AP, Lagergren P, Hughes R, Alderson D, Barham CP, Blazeby JM. 2008. Health-related quality of life among patients with adenocarcinoma of the gastro-oesophageal junction treated by gastrectomy or oesophagectomy. Br J Surg. Jan; 95(1):80-4.

Bardy GH, Lee KL, Mark DB, for the HAT Investigators. 2008. Home use of automated external defibrillators for sudden cardiac arrest. New Engl J Med. 358, 1793-1804.

Bardy GH, Lee KL, Mark DB, for the HAT Investigators. 2008. Rationale and design of the Home Automatic External Defibrillator Trial. Am Heart J;155:445-54. [3.6].

Barker R, Kendall M, Amsters D, Pershouse K, Haines T, Kuipers P. 2008. The relationship between quality of life and disability across the lifespan for people with spinal cord injury. Spinal Cord. Advanced Online Publication: 1-7.

Bauer J, Isenring M, Ferguson M. 2008. Dietary counselling: evidence in chemotherapy patients. Journal of Supportive Oncology, 6(8):354-355.

Baumgartner L, Vivanti A, Smithers M: 2008. Jejunally fed patients post oesophagectomy/ gastrectomy - are they getting all they need? An audit at the Princess Alexandra Hospital. Asia-Pacific Journal of Clinical Oncology, 4 (Suppl 2):A87-A182.

Baxi S, Burmeister B, Harvey JA, Smithers M, Thomas J. 2008. Salvage definitive chemo-radiotherapy for locally recurrent oesophageal carcinoma after primary surgery: a retrospective review. J Med Imaging Radiat Oncol; 52: 583 – 587.

Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Goldsmith D, Myburgh J, Norton R, Scheinkestel C. 2008. Design and challenges of the Randomized Evaluation of Normal


versus Augmented Level Replacement Therapy (RENAL) Trial: high-dose versus standard-dose hemofiltration in acute renal failure. Blood Purif, 26(5):407-416.

Bennett I, Johnson M, Kalkstein K, Gillespie G, Bellamy S, Fleischman J. 2008. Early abortion in primary care: Clinical outcomes. Contraception, 78(2):187-187.

Bhatt S, Bennett A, Young V, Riddle B, Davidson W. 2008. Characteristics associated with weight loss in head and neck cancer (HNC) patients receiving radiotherapy (RT). . Nutrition & Dietetics, 65 (S2 ):A11.

Boltz K, Halton K, Cook DA, Ramiritu P, Graves, N. 2008. Management of Central Venous Catheters in Adult Intensive Care Units in Australia: Policies and Practices. Healthcare Infection;13:48-55.

Brand CA, Ibrahim JE, Cameron PA, Scott IA. 2008. Standards for healthcare: A necessary but unknown quantity? Medical Journal of Australia 189: 257-260.

Brauer SG, Bew PG, Kuys SS, Lynch MR, Morrison G. 2008 Prediction of discharge destination following stroke using the Motor Assessment Scale on admission: a prospective, multi-site study. Archives of Physical Medicine and Rehabilitation 89: 1061-5. IF 1.8

Burmeister B, Zarate D, Colquist S. 2008 “Radiotherapy utilisation rates in Queensland public hospitals: is there a gap in treatment delivery?” Asia Pac J Clin Oncol; 4 Supp 2, A79.

Burmeister BH, Smithers BM, Thomas J, Burmeister E, Walpole E, Harvey J, Thomson D, Barbour A, Gotley D. 2008 “A randomised phase II trial comparing pre-operative chemotherapy with pre-operative chemoradiation therapy for localised carcinoma of the oesophagus.” Asia Pac J Clin Oncol; 4: Supp 2, A47.

Burmeister BH, Walpole ET, D’Arcy N, Burmeister EA, Cox S, Thomson DB, Harvey JA, Smithers BM. 2008. A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer.” Invest New

Drugs. 2009 Jun;27(3):275-9. Epub 2008 Oct 8.

Caldwell E, Whitehead M, Fleming J, Moes L. 2008. Evidence-based practice in everyday clinical practice: strategies for change in a tertiary Occupational Therapy Department. Australian Occupational Therapy Journal. 55: 79-84.

Callaway LK, Lawlor DA, McIntyre HD. 2008. Hypertensive disorders of pregnancy and long-term prognosis. Am J Obstet Gynecol; 199(1):e20; author reply e-1.

Callaway LK, Lawlor DA, McIntyre HD. 2008. Hypertensive disorders of pregnancy and long-term prognosis. Am J Obstet Gynecol; 199(1):e20; author reply e20-21.

Campbell-Lloyd A, Martin D, Martin I. 2008. Long-term outcomes after laparoscopic bile duct exploration: 15-year follow-up of 150 consecutive patients. ANZ Journal of Surgery;6:492-4.

Capp A, Ponta M, Bill D, Moscato P, Christie D, Lamb D, Turner S, Joseph D, Matthews J, Atkinson C, North J, Poulsen M, Spry N, Tai K, Wynne C, Duchesne G, Steigler A, Denham J. 2008. Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiotherapy and Oncology September. Radiother Oncol. 2009 Mar;90(3):400-7. Epub 2008 Oct 24

Celebi ME, Iyatomi H, Stoecker WV, Moss RH, Rabinovitz HS, Argenziano G, et al. 2008. Automatic detection of blue-white veil and related structures in dermoscopy images. Computerized Medical Imaging and Graphics, 32(8): 670-677.

Celermajer DS, Marwick T. 2008. Echocardiographic and right heart catheterization techniques in patients with pulmonary arterial hypertension. International Journal of Cardiology, 125(3):294-303.

Chaboyer W, Wallis M, Duffield C, Courtney M, Seaton P, Holzhauser K, Schluter J, Bost N. 2008. Comparison of activities undertaken by Enrolled and Registered Nurses on medical wards in Australia: an observational

study. International Journal of Nursing Studies, 45(9):127 - 1284.

Chan J, Khafagi F, Young AA, Cowan BR, Thompson C, Marwick TH. 2008. Impact of coronary revascularization and transmural extent of scar on regional left ventricular remodeling. Eur Heart J;29:1608-17.

Chang A, Haines T, Jackson C, Yang I, Nitz J, Low-Choy N, Darnell R, Vicenzino B. 2008. Rationale and design of the PRSM study: Pulmonary Rehabilitation or Self Management for chronic obstructive pulmonary disease (COPD), what is the best approach? Contemporary Clinical Trials 29:796-800.

Charles PG, Whitby M, Fuller AJ, Stirling R, Wright AA, Korman TM, Holmes PW, Christiansen KJ, Waterer GW, Pierce RJ, Mayall BC, Armstrong JG, Catton MG, Nimmo GR, Johnson B, Hooy M, Grayson ML. 2008. Australian CAP Study collaboration. The aetiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis:46:1513-21.

Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, Wright AA, Ramirez JA, Christiansen KJ, Waterer GW, Pierce RJ, Armstrong JG, et al; Australian Community-Acquired Pneumonia Study Collaboration, Grayson ML. 2008. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. Aug 1;47(3):375-84.

Chen SCA, Tong ZS, Lee OC, Halliday C, Playford EG, Widmer F, Kong FR, Wu C, Sorrell TC. Clinician response to Candida organisms in the urine of patients attending hospital. European Journal of Clinical Microbiology and Infectious Diseases;27:201-8.

Chen X, Prow TW, Crichton M, Fernando GJP, Roberts MS and MAF Kendall. 2008. Novel coating of Micro-nanoprojection patches for targeted vaccine delivery to skin. Proceedings of ICONN 2008, Melbourne, Australia, IEEE Press, Piscataway, pp. 105-108.

Clements A, Halton K, Graves N, Pettit A, Morton A, Looke D, Whitby M. 2008.


Overcrowding and understaffing in modern health-care systems: key determinants in Meticillin-resistant Staphylococcus aureus transmission. Lancet Infect Dis 8(7):427-434

Colley RC, Hills AP, O’Moore-Sullivan TM, Hickman IJ, Prins JB, Byrne NM. 2008. Variability in adherence to an unsupervised exercise prescription in obese women. Int J Obes (Lond). May; 32(5):837-44.

Collins N, Crossley K, Beller E, Darnell R, McPoil T, Vicenzino B. 2008. Foot orthoses and physiotherapy in the treatment of patellofemoral pain syndrome: randomized clinical trial. British Medical Journal. 337, a1735.

Connor JP, Jack A, Feeney GFX, Young RM. 2008. Validity of the obsessive compulsive drinking scale in a heavy drinking population. Alcoholism-Clinical and Experimental Research, 32(6):1067-1073.

Cook DA, Duke G, Hart GK, Pilcher D, Mullany D. 2008. Review of the Application of Risk Adjusted Charts to Analyse Mortality Outcomes in Critical Care. Critical Care and Resuscitation 10(3): 239 – 251.

Coombes I, Stowasser D, Coombes J, Mitchell C. 2008. Why do interns make prescribing errors? A qualitative study. Med J Aust; 188:89-94.

Corry J, Poon W, McPhee N, Milner AD, Cruickshank D, Porceddu SV, Rischin D, Peters LJ. 2008. Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo) radiation. J Med Imaging Radiat Oncol;52(5):503-10.

Courtney JM, Kelly MG, Watt A, Garske L, Bradley J, Ennis M, Elborn JS. 2008. Quality of life and inflammation in exacerbations of bronchiectasis. Chron Respir Dis; 5(3):161-8.

Cowin GJ, Jonsson JR, Bauer JD, Ash S, Ali A, Osland EJ, Purdie DM, Clouston AD, Powell EE, Galloway GJ. 2008. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. Journal of Magnetic Resonance Imaging, 28(4):937-945.

Cross SE, Roberts MS. 2008. Use of In vitro human skin membranes to model and predict the effect of changing blood flow on the flux and retention of topically applied solutes. J Pharm Sci 97:3442-50.

Cross SE, Russell M, Southwell I, Roberts MS. 2008. Human skin penetration of the major components of Australian tea tree oil applied in its pure form and as a 20% solution in vitro. Eur J Pharm Biopharm. 69:214-22.

Daly T, Hickey BE, Lehman M, Francis DP. 2008. Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Protocol). Cochrane Database of Systematic Reviews, Issue 3. Art. No: CD007234.

Dauber K, Kaye G2. 2008. High-pressure balloon angioplasty of coronary sinus vein. Europace, 10(9):1118-1120.

Daveson J, Macdonald G. 2008. A case of periportal fibrosis in a Sudanese refugee. Medical Journal of Australia, 188(11):677-678.

Davies JM, Mittag D, Dang TD, Symons K, Voskamp A, Rolland JM, O’Hehir RE. 2008. Molecular cloning, expression and immunological characterisation of Pas n 1, the major allergen of Bahia grass Paspalum notatum pollen. Mol. Immunol. 46; 286-293.

Davies JM, O’Hehir RE. 2008. Immunogenetic characteristics of IgE in allergic disease. Clin. Exp. Allergy, 38; 566-578.

Davies M, Lavalle-Gonzalez F, Storms F, Gomis R. 2008. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab, 10(5):387-399.

de Villiers L, Mackenzie S, Gibbs H, Leggett D, Neels M, Harper J. 2008. ‘Initial Australian experience with the recovery inferior vena cava filter in patients with increased risk of thromboembolic disease.’ Journal of Medical Imaging and Radiation Oncology. Apr; 52(2): 124-9.

Dendle C, Looke DFM. 2008. Review article: An update on the management

of animal bites. Emergency Medicine Australasia. 20:458-467.

Doig E, Fleming J, Kuipers P. 2008. Achieving optimal functional outcomes in community-based rehabilitation following acquired brain injury: a qualitative investigation of therapists’ perspectives. British Journal of Occupational Therapy 71: 360-370.

Doig GS, Simpson F, Finfer S, Delaney A, Davies AR, Mitchell I, Dobb G. 2008. Effect of evidence-based feeding guidelines on mortality of critically ill adults: a cluster randomized controlled trial. JAMA, 300(23):2731-2741.

Dorsett P, Geraghty T. Health-related outcomes of people with spinal cord injury--a 10 year longitudinal study. Spinal Cord. 2008 May;46(5):386-91. Epub 2008 Jan 8. PubMed PMID: 18180790.

Dracup K, McKinley, S, Doering LV, Riegel B, Meischke H, Moser DK, Pelter MM, Carlson B, Aitken L, Marshall A, Cross R. 2008. Acute Coronary Syndrome: What Do Patients Know? Archives of Internal Medicine, 168(10):1049 – 1054.

Du L, Redmond K, Johnstone S, De Leacy M, Harper J. 2008. Saphenous vein peripherally inserted central catheters: Technique, indications and safety issues. Journal of Medical Imaging and Radiation Oncology. Feb; 52(1): 68-71.

Dulay D, Gould PA, Leung A, Krahn AD. 2008. Images in cardiovascular medicine. A sensitive dissection: profound bradycardia complicating carotid dissection, Circulation. 9; 118 (11):e152-3.

Duncan EL, Brown MA. 2008. Genetic studies in osteoporosis--the end of the beginning. Arthritis Res Ther, 10(5):214.

Ebner C, Wurm EM, Binder B, Kittler H, Lozzi GP, Massone C, et al. 2008. Mobile teledermatology: A feasibility study of 58 subjects using mobile phones. Journal of Telemedicine and Telecare, 14(1): 2-7.

Erdine S, Ro YM, Tse HF, Howes LG on behalf of the Gemini AALA Investigators. 2008. Single-pill


amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). Journal of human hypertension:1-15

Feeney GFX, Connor JP. 2008. Wernicke-Korsakoff Syndrome (WKS) in Australia- no room for complacency. Drug and Alcohol Review 27: 388-392.

Ferguson M, Bauer J, Banks M, Capra S. 2008. Subjective Global Assessment is associated with objective nutrition parameters and length of stay. JPEN, 32(3):318-319.

Ferguson M, Host B, Day S. 2008. Implementation of a Better Choice Healthy Food and Drink Supply Strategy for Queensland Health Facilities. Nutrition & Dietetics, 65(Suppl 2):A30.

Ferguson M, Isenring E, Bauer J, Banks M, Capra S. 2008. Letter to the Editor. Nutrition in Clinical Practice, 23(6):658.

Fleming J, Riley L, Gill H, Gullo M, Strong J, Shum D. 2008. Predictors of prospective memory in adults with traumatic brain injury. Journal of the International Neuropsychological Society 14: 823-831.

Flora E, Wilson T, Martin I, O’Rourke N, Maddern G. 2008. A review of natural orifice translumenal endoscopic surgery (NOTES) for intra-abdominal surgery: experimental models, techniques and applicability to the clinical setting. Annals of Surgery; 247(4): 583-602.

Foot C, Host D, Campher D, Tomczak L, Ziegenfuss M, Cohen J, Nunnink L. 2008. Moulage in high-fidelity simulation-a chest wall burn escharotomy model for visual realism and as an educational tool. Simul Healthc. Fall;3(3):183-5.

Foote MC, Burmeister B, Burmeister E, Bayley G, Smithers BM. 2008. Desmoplastic melanoma: the role of radiotherapy in improving local control. ANZ J Surg; 78, 273 - 276.

Fox K, Ford I, Steg PG, Tendera M, Ferrari R. 2008. BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular

systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. Sep 6;372 (9641):807-16.

Freckleton I. 2008. Editorial. Multidisciplinary meetings: Patients expectations and Medical Liability. Journal of Medical Imaging and Radiation Oncology 52, 199-200.

Fronek P. 2008. The RAP in rehabilitation: The family conference in practice. SCI Psychosocial Process. 21(1):26-35

Fuentes H, Collier J, Sinnott M, Whitby M. 2008. Scalpel Safety: Modelling the effectiveness of different safety devices’ ability to reduce blade injuries. International Journal of Risk and Safety Medicine 2008, 20(1-2):83-89.

Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM. 2008. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 93:3266–3281.

Ghiculescu RA, Pillans PI. 2008. Australian reports of bleeding complications associated with antithrombotic drug combinations. J Pharm Pract Res 38: 32-34.

Ghosh P, Shimmon S, Wilson-Ghosh N, Whitehouse M. 2008. Cartilage Derived Peptacans: Novel Nutraceuticals with Immunomodulatory, Anti-inflammatory and Anti-arthritic activities. Current Topics in Nutraceutical Research, 6:83-98.

Gilmore SJ. 2008. Evaluating statistics in clinical trials: making the unintelligible intelligible. The Australasian Journal of Dermatology, 49(4):177-184.

Glasgow C, Tooth L, Fleming J. 2008. Which splint? Dynamic versus static progressive splinting to mobilise stiff joints in the hand. British Journal of Hand Therapy 13: 104-110.

Gould PA, Esler MD, Kaye DM. 2008. Atrial fibrillation is associated with decreased cardiac sympathetic response to isometric exercise in CHF in comparison to sinus rhythm,

Pacing Clinical Electrophysiology. Sep;31(9):1125-9

Gould PA, Gula LJ, Champagne J, Healey JS, Cameron D, Simpson C, Thibault B, Pinter A, Tung S, Sterns L, Birnie D, Exner D, Parkash R, Skanes AC, Yee R, Klein GJ, Krahn AD. 2008. Outcome of advisory implantable cardioverter-defibrillator replacement: one-year follow-up, Heart Rhythm. Dec; 5(12):1675-81. Epub 2008 Sep 23.

Gould PA, Klein GJ, Yee R, Skanes AC, Gula LJ, Krahn AD. 2008. Syncope, Handbook of Clinical Neurology; 90:247-63.

Graves N, Halton K, Doidge S, Clements A, Lairson D, Whitby M. 2008. Who bears the cost of healthcare-acquired surgical site infection? J Hosp Infect; 69:274-82.

Gray LC, Wootton R. 2008. Comprehensive geriatric assessment ‘online’. Australas J Ageing, 27(4):205-208.

Gray LC, Bernabei R, Berg K, Finne-Soveri H, Fries BE, Hirdes JP, Jonsson PV, Morris JN, Steel K, Arino-Blasco S. 2008. Standardizing assessment of elderly people in acute care: the interRAI Acute Care instrument. J Am Geriatr Soc, 56(3):536-541.

Gray LC, Travers CM, Bartlett HP, Crotty M, Cameron ID. 2008. Transition care: will it deliver? Med J Aust, 188(4):251-253.

Gunter JH, Thomas EC, Lengefeld N, et al. 2008. Characterisation of inosine monophosphate dehydrogenase expression during retinal development: Differences between variants and isoforms. International Journal of Biochemistry & Cell Biology 40(9): 1716-1728.

Haines T, Brown C, Morrison J. 2008. Public provision of four-wheeled walkers: Contingent valuation study of economic benefit. Australasian Journal on Ageing 27(3):161-164.

Haines T, Kuys S, Morrison G, Clarke J, Bew P. 2008. Balance impairment not predictive of falls in geriatric rehabilitation wards. Journals of Gerontology (Medical Sciences) 63: 523-28.


Haines TP, Cornwell P, Fleming J, Varghese P, Gray L. 2008. Documentation of in-hospital falls on incident reports: Qualitative investigation of an imperfect process. BMC Health Services Research 8: 254-261.

Haluska BA, Carlier Leano, R, Jeffriess L, Marwick TH. 2008. Influence of cardiovascular risk factors on total arterial compliance. J Am Soc Echo; 21(2): 123-28.

Haluska BA, Jeffriess L, Brown J, Downey M, Carlier SG, Marwick TH. 2008. Derivation of distensibility coefficient using tissue Doppler as a marker of arterial function. Clin Sci (Lond). 2008;114:441-7.

Haluska BA, Chan L, Jeffriess L, Shaw AA, Shaw J, Marwick TH. 2008. Correlates of preclinical cardiovascular disease in Indigenous and Non-Indigenous Australians: a case control study. Cardiovasc Ultrasound. 2008;6:36.

Hannawi S, Jenkins C, Marwick T, Thomas R. 2008. Coronary wall thickness is increased in recent onset rheumatoid arthritis. In: 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals: Oct 24-29 2008; San Francisco, CA; S275-S275.

Hare J, Brown J, Marwick TH. 2008. Association of myocardial strain with left ventricular geometry and progression of hypertensive heart disease. Am J Cardiol;102:87-91.

Hare J, Brown J, Marwick TH. 2008. Performance of conventional echocardiographic parameters and myocardial measurements in the sequential evaluation of left ventricular function. Am J Cardiol; 101(5):706-11.

Hare JL, Jenkins C, Nakatani S, Ogawa A, Yu CM, Marwick TH. 2008. Feasibility and clinical decision-making with 3D echocardiography in routine practice. Heart; 94(4):440-445.

Hawley CM, Jeffries J, Nearhos J, van Eps CL. 2008. Review. Complications of Home Haemodialysis. Haemodialysis International Suppl 1: S21-25.

Henderson A, Fox R, Armit L. 2008. Education in the clinical context: A strategic plan to ensure relevance. Collegian, 15(2):63-68.

Henderson A, Winch S. 2008. Managing the clinical setting for best nursing practice: A brief overview of contemporary initiatives. Journal of Nursing Management; 16(1):92-95.

Henderson A, Winch S. 2008. Staff Development in the Australian Context: Engaging with clinical contexts for successful knowledge transfer and utilization. Nurse Education in Practice, 8(3):165-169.

Henderson A. 2008. Commentary on Finfgeld-Connett, D. Meta-synthesis of caring in nursing. Journal of Clinical Nursing, 17(15):2098-2099.

Henderson A. 2008. Commentary on McCaughan E. & McKenna H. Never-ending making sense: towards a substantive theory of the information-seeking behaviour of newly diagnosed cancer patients. Journal of Clinical Nursing, 17(13):1817-1818.

Hickman IJ, Russell AJ, Prins JB, Macdonald GA. 2008. Should patients with type 2 diabetes and raised liver enzymes be referred for further evaluation of liver disease? Diabetes Research and Clinical Practice Journal. 21(6): 715-721.

Hickman IJ, Russell AJ, Prins JB, Macdonald GA. 2008. Should patients with type 2 diabetes and raised liver enzymes be referred for further evaluation of liver disease? Diabetes Res Clin Pract, 80(1):e10-12.

Hicks P, Cooper DJ, Webb S, Myburgh J, Seppelt I, Peake S, Joyce C, Stephens D, Turner A, French C et al. 2008. The Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. An assessment by the Australian and New Zealand intensive care society. Anaesth Intensive Care, 36(2):149-151.

Hirdes JP, Ljunggren G, Morris JN, Frijters DH, Finne-Soveri H, Gray L, Bjorkgren M, Gilgen R. 2008. Reliability of the interRAI suite of assessment instruments: A 12-country study of an integrated health information system. BMC Health Serv Res, 8(1):277.

Hirst LW, Pascual C, Madden P, Whitby M, McLaws ML. 2008. Potential effect of excluding variant Creutzfeldt-Jakob diseases on the eye donor pool in Australia. Cornea; 27:773-5.

Holt T, Bydder S, Bloomfield L, 2008. Survey of the learning activities of Australasian radiation oncology specialist trainees. J Med Imaging Radiat Oncol. Dec;52(6):605-10.

Holzhauser K, Cooke M, Winch S, Finucane J, Davis C. 2008. Developing a Research Active Clinical Environment: The Application of a Visiting Scholar Program within the Emergency Department. Journal of Professional Nursing, 24:36-41.

Holzhauser K, Finucane J. 2008. Part B: A Survey of Staff Attitudes Immediately Post Resuscitation to Family Presence during Resuscitation. . Australian Emergency Nursing Journal, 11(3):114-122.

Holzhauser K, Winch S, Henderson A. 2008. Response to Editorial: Watson, R. (2006) Editorial: Should studies without ethical permission be published in JCN? Journal of Clinical Nursing, 17(6):837-838.

Holzhauser K. 2008. Book Review: Andre, K. Heartfield, M. (2007). Professional Portfolios: Evidence of competency for nurses and midwives. Churchill Livingstone, Marrickville, NSW. Australasian Emergency Nursing Journal, 11(1):61.

Holzhauser K. 2008. Book Review: Qualitative Inquiry & Research Design: Choosing Among Five Approaches, second ed., John W Cresswell. . Australasian Emergency Nursing Journal, 11(2):100.

Hordern MD, Cooney LM, Beller EM, Prins JB, Marwick TH, Coombes JS. 2008. Determinants of changes in blood glucose response to short-term exercise training in patients with Type 2 diabetes. Clin Sci (Lond), 115(9):273-281.

Hourigan MJ, Doecke J, Mollee PN, Gill DS, Norris D, Johnson DW, Gandhi MK. 2008. The ‘renal-PTLD’ index: a new prognosticator for use in adults with Post-transplantation lymphoproliferative disorders after


renal transplantation. British Journal of Haematology 141(6)904-7.

Howard JR, O’Neil S, Travers C. 2008. Sexual interest, sexual arousal, relationships, and sexual distress in older Australian women. Journal of Sex Research, 45(2):94-94.

Hwang, Redfern & Alison. 2008. A narrative review on home-based exercise training in patients with chronic heart failure, Physical Therapy Reviews, 13(4): 227-236.

Irish A, Dogra G, Mori T, Beller E, Heritier S, Hawley C, Kerr P, Robertson A, Rosman J, Paul-Brent PA, Starfield M, Polkinghorne K, Cass A (2009). Preventing AVF thrombosis: The rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study. BMC Nephrol. 21; 10(1):1.

Isenring L, Hill J, Davidson W, Brown T, Baumgartner L, Kaegi K, Reeves M, Ash S, Thomas S, McPhee N et al. 2008. Evidence Based Practice Guidelines for the Nutritional Management of Patients Receiving Radiation Therapy (DAA Radiation Therapy Nutrition Steering Committee). Nutrition & Dietetics, 65(Suppl 1).

James ML, Lehman M, Hider PN, Jeffery M, Francis DP, Hickey BE. 2008. Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD003860.

Jenkins C, Monaghan M, Shirali G, Guraraja R, Marwick TH. 2008. An intensive interactive course for 3D echocardiography: Is ‘Crop Till You Drop’ an effective learning strategy? Eur J Echocardiogr; 9(3):373-380.

Jensen J, Gronning-Wang LM, Jebens E, Whitehead JP, Zorec R, Shepherd PR. 2008. Adrenaline potentiates insulin-stimulated PKB activation in the rat fast-twitch epitrochlearis muscle without affecting IRS-1-associated PI 3-kinase activity. Flugers Archiv-European Journal of Physiology, 456 5: 969-978.

Jeske WA, So A, Kelemen L, Sukor N, Willys C, Bulmer B, Gordon RD, Duffy D, Stowasser M. 2008. Examination of

chromosome 7p22 candidate genes RBaK, PMS2 and GNA12 in familial hyperaldosteronism type II. Clin Exper Pharmacol Physiol 35:380-385.

Johnson DW, Hawley CM, Rosser B, Beller E, Thompson C, Fassett RG, Ferrari P, McDonald SP, Pedagogos E, Cass A. 2008. Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. BMC Nephrology 9:8.

Johnson DW, Mathew T. 2008. How to treat proteinuria. Australian Doctor February 1:17-24.

Jones GRD, Mathew T, Johnson DW, Peake M. 2008. Implementation and routine reporting of eGFR in Australia and New Zealand. Scandinavian Journal of Clinical and Laboratory Investigation 68 (Suppl 241):23-29.

Jonsson JR, Barrie HD, O’Rourke P, Clouston AD, Powell EE. 2008. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology, 48(1):80-87.

Jonsson JR, Purdie DM, Clouston AD, Powell EE. 2008. Recognition of genetic factors influencing the progression of hepatitis C - Potential for personalized therapy. Molecular Diagnosis & Therapy, 12(4):209-218.

Kaisar MO, Isbel NM, Johnson DW. 2008. Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease. Recent Randomized Controlled Trials 3(2):79-98.

Kaisar MO, Kirwan R, Strutton G, Hawley C, Mudge DW, Campbell SB, Johnson DW, Isbel NM. 2008. Cutaneous manifestations of CMV disease in renal transplant recipients: a case series. Transplant Infectious Disease 10(3):209-13.

Karunajeewa AS, Abeyratne UR, Hukins C. 2008. Silenceβbreathingβsnore classification from snoreβrelated sounds. Physiol Meas. Feb;29(2):227-43.

Kendall BJ, Macdonald GA, Hayward NK, Prins JB, Brown I, Walker N, Pandeya N, Green AC, Webb PM, Whiteman DC. 2008. Leptin and the

risk of Barrett’s oesophagus. Gut, 57(4):448-454.

Khoo SK, O’Neill S, Travers C, Oldenburg B. 2008. Age-related changes relevant to health in women: design, recruitment, and retention strategies for the Longitudinal Assessment of Women (LAW) study. J Womens Health (Larchmt), 17(1):135-146.

Kosmala W, O’Moore-Sullivan TM, Plaksej R, Kuliczkowska-Plaksej J, Przewlocka-Kosmala M, Marwick TH. 2008. Subclinical impairment of left ventricular function in young obese women: contributions of polycystic ovary disease and insulin resistance. J Clin Endocrinol Metab;93(10):3748-3754.

Kosmala W, Wong C, Kuliczkowska J, Leano R, Przewlocka-Kosmala M, Marwick TH. 2008. Use of body weight and insulin resistance to select obese patients for echocardiographic assessment of subclinical left ventricular dysfunction. Am J Cardiol; 101(9):1334-40. [3.1]

Kruger P, Venkatesh B, Roberts M et al. 2009. Very high atorvastatin plasma concentrations are found in critically ill patients with sepsis. Intensive Care Medicine 2008 Nov 26. [Epub ahead of print] Intensive Care Med. 2009 Apr;35(4):717-21. Epub 2008 Nov 26

Kruger P. 2008. Statins in sepsis BJA, 100(6): 862.

Kuys SS, Brauer SG, Ada L, Russell TG. 2008. Immediate effect of treadmill walking practice versus overground walking practice on overground walking pattern in ambulatory stroke patients: a quasi- experimental study. Clinical Rehabilitation 22: 931-9.

Kuys SS, Brauer SG, Ada L, Russell TG. 2008. Increasing intensity of treadmill walking practice does not adversely affect walking pattern or reduce walking quality in newly-ambulating stroke patients: a quasi- experimental study. Australian Journal of Physiotherapy 54:49-54.

Lancellotti P, Marwick TH, Pierard LA. 2008. How to manage ischaemic mitral regurgitation. Heart 2008:94(11):1497-1502.


Langdahl BL, Uitterlinden AG, Ralston SH, Trikalinos TA, Balcells S, Brandi ML, Scollen S, Lips P, Lorenc R, Obermayer-Pietsch B et al. 2008. Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study. Bone, 42(5):969-981.

Laurie G.A, Venkatesh B, Kruger P.S, Morgan T.J and Pascoe R.L. 2008. Basic science research in Australian intensive care practice. Critical Care and Resuscitation, 10(1): 47-52.

Lehman M, Hickey BE, Francis DP. 2008. Partial breast irradiation for early breast cancer. (Protocol) Cochrane Database of Systematic Reviews 2008. Issue 2. Art. No.: CD007077.

Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB, Walpole ET, Haydon AM, Creese BR, Roberts KL, Zalcberg JR, Gonzalez R. 2008. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 2008;26:89-94

Li P, Wang GJ, Li J, Zhang Q, Liu X, Khlentzos A, Roberts MS. 2008. The prediction of the hepatic clearance of tanshinone IIA in rat liver subcellular fractions: accuracy improvement. Current Drug Metabolism. 9:39-45.

Lin C, Dickie G, Wiltshire K, Tripcony L, Jackson J, Keller J, Carr M, Poulsen M, Martin J. 2008. Perineural invasion of skin cancers of the Head and Neck: Outcomes and patterns of relapse of 280 patients treated with radiotherapy. Proceedings of 50th Annual ASTRO meeting. International Journal of Radiation OncologyBiologyPhysics, Volume 72, Issue 1, Pages S159-S159

Lyatomi H, Oka H, Celebi ME, Ogawa K, Argenziano G, Soyer HP, et al. 2008. Computer-based classification of dermoscopy images of melanocytic lesions on acral volar skin. Journal of Investigative Dermatology, 128(8): 2049-2054.

MacBean N, Ward E, Murdoch B, Cahill L, Solley M, GeraghtyT, Hukins C. 2008. Optimizing speech production in the ventilator-assisted individual following cervical spinal cord injury: a

preliminary investigation. Int. J. Lang. Comm. Dis, 40; 1-12.

Macdonald GA. 2008. Suspected Iron Overload or High Serum Ferritin. In: Pocket Clinical Gastroenterology. Edited by Talley N, Segal I, Weltmann M. Marrickville, NSW: Elsevier Australia; 389-396.Macfarlane PL, Nasser S, Coman WB, Kiss G, Harris PK, Carney AS. Tonsillectomy in Australia: an audit of surgical technique and postoperative care. Otolaryngol Head Neck Surg. 2008 Jul;139(1):109-114.

Mackay-Sim A, Feron F, Cochrane J, Bassingthwaighte L, Bayliss C, Davies W, Fronek P, Gray C, Kerr G, Licina P, Nowitzke A, Perry C, Silburn PAS, Urquhart S, Geraghty T. 2008. Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3-year clinical trial. Brain 2008; doi: 10.1093/brain/awn173.

Mackay-Sim A, Feron F, CochraneJ, Bassingthwaite L, Bayliss C, Davies W, Fronek P, Gray C, Kerr G, Licina P, Nowittzke A, Perry C, Silburn PAS, Urquhart S, Geraghty T. 2008. Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3 year clinical trial. Brain. 131:2376-86.

Martin J. 2008. Statins and congestive heart failure. Curr Atheroscler Rep. Oct;10(5):369-76.

Martin-Khan M, Flicker L, Wootton R, Loh P, Edwards H, Byrne G, Varghese P, Beller E, Gray L. 2008. Multicentre pilot for assessing the diagnostic accuracy of cognitive assessment via video consultation. Australasian Journal on Ageing, 27(S1):A21.

Martin-Khan M, Varghese P, Wootton R, Gray L. 2008. Physical examination and diagnosis of dementia for video consultation. J Am Geriatr Soc, 56(5):947-949.

Marwick TH, Schwaiger M. 2008. The future of cardiovascular imaging in the diagnosis and management of heart failure – Part 1: Tasks and Tools. Circulation Imaging; 1:58-69.

Marwick TH, Schwaiger M. 2008. The future of cardiovascular imaging in the diagnosis and management of heart failure – Part 2: Applications. Circulation Imaging; 1:162-170.

Marwick TH, Starling RC. 2008. The riddle of determining cardiac resynchronization therapy response a physiologic approach to dyssynchrony therapy. J Am Coll Cardiol; 52:1410-2.

Marwick TH. 2008. Assessment of subendocardial function with myocardial contrast echocardiography. J Am Coll Cardiol – Cardiovascular Imaging; 1(3):279-281.

Marwick TH. 2008. How dangerous is echocardiographic contrast? Heart;94:1522-3.

Marwick TH. 2008. Hype and hope in the use of echocardiography for selection for cardiac resynchronization therapy. Circulation;117:2573-6.

Marwick TH. 2008. Restrictive annuloplasty for ischemic mitral regurgitation: Too little or too much? J Am Coll Cardiol; 51(17):1702-03. [9.2]

Marwick TH. 2008. Strain without pain: Application of parametric imaging of strain rate response for the quantitation of stress echocardiography. J Am Soc Echo 2008;21:307-8.

Marwick TH: How dangerous is echocardiographic contrast? Heart 2008, 94(12):1522-1523.

Massey D, Aitken L, Chaboyer W. 2008. Care of the acutely ill ward patient, Australian Critical Care, 2008; 21(3): 127 – 140.

Massie BM, Carson PE, McMurray JJ. 2008. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. Dec 4;359(23):2456-67.

Massone C, Brunasso AM, Campbell TM, Soyer HP. 2008. State of the art of teledermatopathology. The American Journal of Dermatopathology, 30(5): 446-450.

Massone C, Soyer HP, Hofmann-Wellenhof R. 2008. A dermoscopic pitfall: Ancient melanocytic nevus. Journal of the American Academy of Dermatology, 59(2 SUPPL.): S42-S43.

Massone C, Wurm EMT, Hofmann-Wellenhof R, Soyer HP. 2008. Teledermatology: An update. Seminars in Cutaneous Medicine and Surgery, 27(1): 101-105.


Massone C, Wurm EMT, Soyer HP. 2008. Teledermatology. Giornale Italiano Di Dermatologia e Venereologia, 143(3): 213-218.

Mathew TH, Johnson DW, Jones GRD. 2008. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate. Medical Journal of Australia 188(7):429-30.

McAuliffe M, Cornwell PL. 2008. Intervention for lateral /s/ using electropalatography (EPG) biofeedback and an intensive motor learning approach: a case report. International Journal of Language and Communication Disorders 43: 219-229.

McCarthy KL, Looke DFM. 2008. Successful treatment of post-neurosurgical intracranial Mycoplasma hominis infection using Gatifloxacin. J Infect 57:344-346.

McFadyen L, Herlaar H, Smithers M. 2008. Melanoma Patients Australia – A focus on patient support and advocacy. Asia Pacific J Clin Oncol;4:Supp2, A147

McKinnon R, Christie D, Peres H, Bourke M, Le T, Lah M. The Prone Technique for Breast Irradiation – is it ready for clinical trials? The Breast. Epub 2008 Nov 17

McPhail S, Beller E, Haines T. 2008. Are pictures worth a thousand words: a pilot randomized trial of visual cues to improve speed of completion and comprehension of three surveys for older adults. The Open Geriatric Medicine Journal 1(6):50-55.

McPhail S, Beller, E, Haines T. 2008. Two perspectives of proxy reporting of health-related quality of life using the EQ-5D, an investigation of agreement. Medical Care 46: 1140-1148.

McPherson S, Jonsson JR, Barrie HD, O’Rourke P, Clouston AD, Powell EE. 2008. Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. Journal of Hepatology, 49(6):1046-1054.

Menzies SW, Kreusch J, Byth K, Pizzichetta MA, Marghoob A, Braun R, et al. 2008. Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. Archives of Dermatology, 144(9): 1120-1127.

Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD et al. 2008. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med, 358(19):1991-2002.

Mohanlal A, Erickson H, Ferguson M, Ramos N. 2008. New classifications of Texture Modified Foods and Fluids Nutrition & Dietetics, 65(Suppl 2):A38.

Mollah ZU, Pai S, Moore C, O’Sullivan BJ, Harrison MJ, Peng J, Phillips K, Prins JB, Cardinal J, Thomas R. 2008. Abnormal NF-kappa B function characterizes human type 1 diabetes dendritic cells and monocytes. J Immunol, 180(5):3166-3175.

Mor-Avi V, Jenkins C, Kuhl HP, Nesser H, Marwick TH, Franke A, Ebner C, Lang RM. 2008. Real-time 3-dimensional echocardiographic quantification of left ventricular volumes. Multicenter study for validation with magnetic resonance imaging and investigation of sources of error. JACC:Cardiovascular Imaging, 1(4):413-423.

Morgan TJ, Power G, Venkatesh B, Jones MA.Acid-base effects of a bicarbonate-balanced priming fluid during cardiopulmonary bypass: comparison with Plasma-Lyte 148. A randomised single-blinded study. Anaesth Intensive Care. 2008 Nov;36(6):822-9

Morton AP, Clements AC, Doidge SR, Stackelroth J, Curtis M, Whitby M. 2008. Surveillance of healthcare-acquired infections in Queensland, Australia: data and lessons from the first five years. Infect Control Hosp Epidemiol;29:695-701.

Munckhof WJ, Krishnan A, Kruger P, Looke DFM. 2008. Cavernous sinus thrombosis and meningitis from community acquired methicillin resistant Staphylococcus aureus. Internal Medicine Journal 38(4):283-287.

Munckhof WJ, Nimmo GR, Carney J, Schooneveldt JM, Huygens F, Inman-Bamber J, Tong E, Morton A, Giffard P. 2008. Methicillin-susceptible, non-multiresistant methicillin-resistant and multiresistant methicillin-resistant

Staphylococcus aureus infections: a clinical, epidemiological and microbiological comparative study. Eur J Clin Micro Infect Dis;27:355-64.

Myburgh JA, Cooper DJ, Finfer SR, Venkatesh B, Jones D, Higgins A, Bishop N, Higlett T. 2008. Epidemiology and 12-month outcomes from traumatic brain injury in Australia and New Zealand. J Trauma, 64(4):854-862.

Ng CS, Pillans PI, Johnson DW, Sturtevant JM. 2008. Acute renal failure in patients on diuretics and/or NSIAD, COX-2 inhibitors, ACEI, ARA. Journal of Pharmacy Practice and Research;38(4):274-276.

Nicol DL, Preston JM, Wall DR, Griffin AD, Campbell SB, Isbel NM, Hawley CM, Johnson DW. 2008. Kidneys from patients with small renal tumours – a novel source of kidneys for transplantation. British Journal of Urology; 102(2):188-92.

Noble E, Johnson DW, Gray N, Hollett P, Hawley CM, Campbell SB, Mudge DW, Isbel NM. 2008. The impact of automated eGFR reporting and education on nephrology service referrals. Nephrology Dialysis Transplantation; 23(12):3845-50.

Nohynek GJ, Dufour EK, Roberts MS. 2008. Nanotechnology, cosmetics and the skin: is there a health risk? Skin Pharmacol Physiol; 21:136-49.

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T. 2008. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet; 371:1007-16.

Nowittzke A, Perry C, Silburn PAS, Urquhart S, Geraghty T. 2008. Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3 year clinical trial. Brain. 131:2376-86.

Oakley F, Bataller R, Jonsson JR, Mann DA. 2008. Rela Serine 536


Phosphorylation Could Be a Biomarker for Fibrosis That May Be Susceptible to Regression Following Attenuation of Renin-Angiotensin Signaling. Hepatology, 48(4):111.

Ong C-LY, Ulett GC, Mabbett AN, Beatson SA, Webb RI, Monaghan W, Nimmo GR, Looke DF, McEwan AG, Schembri MA. 2008. Identification of Type 3 fimbriae in uropathogenic Escherichia coli reveals a role in biofilm formation. J. Bacteriol 190(3):1054-1063.

Orazio L, Hickman I, Armstrong K, Banks M, Johnson D, Isbel N. 2008. Higher levels of physical activity are associated with lower risk of abnormal glucose tolerance in renal transplant recipients. Nutrition & Dietetics, 65 (S2):A7.

Ownsworth T, Fleming J, Shum D, Kuipers P, Strong J. 2008. Comparison of individual, group and combined intervention formats in a randomized controlled trial for facilitating goal attainment and improving psychosocial function following acquired brain injury. Journal of Rehabilitation Medicine 40: 81-88.

Ownsworth T, Turpin M, Andrew B, Fleming J. 2008. Participant perspectives on an individualized self-awareness intervention following stroke: a qualitative case study. Neuropsychological Rehabilitation 18: 692-712.

Percy C, Pat B, Healy H, Waters MJ, Johnson DW, Gobe G. 2008. Phosphorylation of caveolin-1 is anti-Apoptotic and promotes cell attachment during oxidative stress. Pathology; 40(7):694-701.

Perkins J, Bartlett H, Travers C, Rand J. 2008. Dog-assisted therapy for older people with dementia: a review. Australas J Ageing; 27(4):177-182.

Petrie JJB, Ng Tsun, Hawley CM. 2008. Review. Is it time to embrace haemodiafiltration for centre-based haemodialysis. Nephrology; 13(4): 269-277.

Phillips LK, Prins JB. 2008. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep, 10(2):156-164.

Pillans PI. 2008. Clinical perspectives in drug safety and adverse drug reactions. Expert Rev Clin Pharmacol 1: 695-705

Pinto N, Hirst L, Whitby M. 2008. Conjunctival and episcleral Splendore-Hoeppli phenomenon. Clin Experiment Ophthalmol;36(9):865-7

Playford EG, Eggimann P, Calandra T. 2008. Antifungals in the Intensive Care Unit. Current Opinion in Infectious Diseases;21:610-9

Playford EG, Marriott D, Nguyen Q, Chen S, Ellis D, Slavin M, Sorrell TC. 2008. Candidemia in non-neutropenic critically ill patients: risk factors for non-albicans Candida spp., Critical Care Medicine, 36:2034-9

Pollock Ca, Johnson DW, Hörl WH, Rossert J, Casadevall N, Schellekens H, Delage R, De Francisco A, Macdougall I, Thorpe R, Toffelmire E. 2008. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clinical Journal of the American Society of Nephrology 3(1):193-9.

Porceddu S, Rosser B, Burmeister B, Jones M, Hickey B, Baumann K, Gogna K, Pullar A, Poulsen M, Holt T. 2008. Hypofractionated radiotherapy for advanced head and neck cancer in patients not suitable for curative treatment- Hypo trial. Author’s reply. Radiotherapy and Oncology 87 (2): 456-309.

Porceddu S, Sidhom M, Foote M, Burmeister E, Stonley A, El Hawwari B, Milross C, Kenny L, Poulsen MG, Coman WB. 2008. Predicting regional control based on nodal size in squamous cell carcinoma of the head and neck treated with chemoradiotherapy: a clinician’s guide. Journal of Imaging and Radiation Oncology 52(5): 491-496.

Porceddu SV, Burmeister BH, Hicks RJ. 2008. Role of functional imaging in head and neck squamous cell carcinoma: fluorodeoxyglucose positron emission tomography and beyond. Hematol Oncol Clin North Am. 22(6):1221-38.

Porceddu SV, Fogarty G 2008. Clinical Practice. Guide. Basal cell carcinoma, squamous cell carcinoma. (and related lesions) – a guide to clinical

management in Australia. Australian Cancer Network Publication Chapter 7 pp.64-76.

Poulsen M, Rischin D, Walpole E, Harvey J, Dickie G, O’Brien P, Keller J, Tripcony L. 2008. Weekly carboplatin reduces toxicity during synchronous chemo-radiotherapy for merkel cell carcinoma of skin. Int. J. Rad. Oncol. Biol. Phys; 72(4):1070-4.

Poulsen MG, Riddle B, Keller J, Porceddu SV, Tripcony L. 2008. Predictors of acute grade 4 swallowing toxicity in patients with stages III and IV squamous carcinoma of the head and neck treated with radiotherapy alone. Radiother Oncol;87(2):253-9.

Pring C, Tran V, O’Rourke N, Martin I. Laparoscopic versus open ventral hernia repair: a randomised controlled trial. ANZ Journal of Surgery. 2008;10:903-06

Prins JB. Experimental and clinical pharmacology - Incretin mimetics and enhancers: mechanisms of action. Australian Prescriber. 31(4): 102-104 2008

Pritchard M, Colditz P, Tudehope D, Gray P, Cartwright D, Wigg N, Beller E. 2008. Measuring sensorineural disability in preterm children using a public health screening strategy: A randomised controlled trial. Journal of Paediatrics and Child Health. 44, 424-431.

Pritchard M, Colditz PB, Beller E. 2008. Parental experiences and preferences which influence subsequent use of post-discharge health services for children born very preterm. Journal of Paediatrics & Child Health, 44 5: 281-284.

Prow TW, Chen X, Crichton M, Tiwari Y, Gradassi F, Raphelli K, Mahony D, Fernando G, Roberts MS, Kendall MAF. 2008. Targeted Epidermal Delivery of Vaccines from Coated Micro-Nanoprojection Patches. Proceedings of ICONN 2008, Melbourne, Australia, IEEE Press, Piscataway, pp. 125-128, 2008.

Pryor DI, Porceddu SV, Burmeister BH, Guminski A, Thomson DB, Shepherdson K, Poulsen M. 2008. Enhanced toxicity with concurrent cetuximab and radiotherapy in head


and neck cancer. Radiotherapy and Oncology; 90:172-6.

Rahimtoola SH, Dilsizian V, Kramer CM, Marwick TH, Vanoverschelde J.2008. Chronic ischemic left ventricular dysfunction. From pathophysiology to imaging and its integration into clinical practice. JACC:Cardiovascular Imaging. 1(4):536-555.

Ramiritu, P, Halton, K, Cook, DA, Whitby, M and Graves, N. 2008. A Review of Strategies to Prevent Central venous catheter-Related Bloodstream Infections in Intensive Care Units.Journal of Advanced Nursing 62(1):3-21.

Ramitru P, Halton K, Collignon P, Cook D, Fraenkel D, Battistutta D, Whitby M, Graves N. 2008. A systematic review comparing the relative effectiveness of antimicrobial intensive care units. Am J Infect Control;36:104-117.

Ramritru P, Halton K, Cook D, Whitby M, Graves N. 2008. Catheter-related bloodstream infections in intensive care units: a systematic analysis. J Adv. Nurs;62:3-21.

Rathnayake SI, Abeyratne UR, Hukins C, Duce B. 2008. Modelling of polysomnographic respiratory measurements for artefact detection and signal restoration. Physiol Meas. Sep;29(9):999-1021.

Rawlings AV, Matts PJ, Anderson CD, Roberts MS. 2008. Skin biology, xerosis, barrier repair and measurement. Drug Discov Today: Dis Mech, 5:e127-e136.

Roberts JA, Kruger PS, Patterson DL, Lipman JL. 2008. Antibiotic Resistance – What’s dosing got to do with it? Critical Care Medicine , 36(8): 2433-2440

Roberts JA, Roberts MS, Robertson TA, Cross SE, Lipman J. 2008. A novel way to investigate the effects of plasma exchange on antibiotic levels - the use of microdialysis. International Journal of Antimicrobial Agents.31:240-4.

Roberts MS, Roberts MJ, Robertson TA, Sanchez W, Thörling C, Zou Y, Zhao X, Becker W and Zvyagin AV. 2008. In vitro and in vivo imaging of xenobiotic transport in human skin and in the rat liver. J Biophoton 1: 478–493.

Salm P, Rooney F, Taylor PJ. 2008. Simultaneous measurement of cyclosporin and tacrolimus using HPLC-tandem mass spectrometry. Ther Drug Monit 30: 292-300.

Saunus JM, French JD, Edwards SL, Beveridge DJ, Hatchell EC, Wagner SA, Stein SR, Davidson A, Simpson KJ, Francis GD, Leedman PJ, Brown MA. 2008. Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR. Cancer Res. 68(22):9469-78.

Schluter J, Winch S, Holzhauser K. 2008. Nurses’ moral sensitivity and hospital ethical climate: A systematic review of the published literature 1980 - February 2007. Nursing Ethic, 15(3):304-321.

Scott IA, Greenberg PB, Phillips PA. 2008. Strengthening the scientific approach to clinical reasoning in the new physician training program. Internal Medicine Journal 38: 384-387.

Scott IA, Greenberg PB, Poole PJ. 2008. Cautionary tales in the clinical interpretation of studies of diagnostic tests. Internal Medicine Journal 38: 120-129.

Scott IA, Poole PJ, Jayathissa S. 2008. Improving quality and safety of hospital care: a reappraisal and an agenda for clinically relevant reform. Internal Medicine Journal 38: 44-55.

Scott IA, Thomson P, Narasimhan S. 2008. Comparing risk-prediction methods using administrative or clinical data in assessing excess in-hospital mortality in patients with acute myocardial infarction. Medical Journal of Australia 188: 332-336.

Scott IA. 2008. Acute coronary syndromes: Exploring the hest way forward in optimizing care. Medical Journal of Australia 188: 686-687.

Scott IA. 2008. Chronic disease management: a primer for physicians. Internal Medicine Journal 38: 427-437.

Scott IA. 2008. Interpreting risks and ratios in therapy trials. Australian Prescriber 31: 12-16.

Scott IA. 2008. Pay for performance in healthcare – a need for guiding principles. Australian Health Review 32: 740-749.

Scott IA. 2008. Reply to Laking and Ewald. Internal Medicine Journal 38: 615-616.

Scott IA. 2008. Why we need a national registry for interventional cardiology. Medical Journal of Australia 189: 223-228.

Scott JA, Coombes JS, Prins JB, Leano RL, Marwick TH, Sharman JE. 2008. Patients with type 2 diabetes have exaggerated brachial and central exercise blood pressure: relation to left ventricular relative wall thickness. Am J Hypertens, 21(6):715-721.

Scurr LL, Guminski AD, Chiew YE, Balleine RL, Sharma R, Lei Y, Pryor K, Wain GV, Brand A, Byth K, Kennedy C, Rizos H, Harnett PR, deFazio A. 2008. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer. Clin Cancer Res;14:6924-32.

Segedin J, Carige P, Vivanti A. 2008. Using BMI to improve nursing staff referrals in cardiac patients Nutrition & Dietetics, 65(Suppl 2):A43.

Sendra S, Vivanti A, Ferguson M. 2008. Weight changes in Geriatric and Rehabilitation Unit (GARU) patients and impact on hospital bistro food service system. Nutrition & Dietetics, 65(Suppl 2):A43.

Shaban RZ. 2008. Editorial: Emergency Nursing Specialist Standards for the Profession. Australasian Emergency Nursing Journal, 11(3):1-3.

Shaban RZ: Emergency Mental Health: Where are we now? Australasian Emergency Nursing Journal 2008, 11(2):1-2.

Shaban RZ: Inaugural Editorial. Australasian Emergency Nursing Journal 2008, 11(1):1-3.

Sharman JE, Holland DJ, Hare JL, Marwick TH. 2008. Contribution of Abnormal Arterial Function to Cardiac Syndrome X: A Study of Pressure Waveform Analysis and Exercise Haemodynamics. J Hum Hypertension;22(3):217-9.

Sharman JE, Moir S, Kostner KM, Haluska B, Marwick TH. 2008. Patients with coronary slow flow phenomenon demonstrate normal myocardial blood flow and arterial wave reflection


between acute episodes. Int J Cardiol;131:321–325.

Sharman JE, Stowasser M, Fassett RG, Marwick TH, Franklin SS. 2008. Central blood pressure measurement may improve risk stratification due to wide variation in central to peripheral systolic blood pressure amplification. J Hum Hypertens 22:838-844.

Sidhom MA, Kneebone AB, Lehman M. 2008 “Post-prostatectomy radiotherapy consensus guidelines of the Australia and New Zealand Radiation oncology genito-urinary group.” Radiotherapy and Oncology. 88(1):10-9.

Sidhom MA, Poulsen MG. 2008. Group decisions in oncology: Doctor’s perceptions of the legal responsibilities arising from multidisciplinary meetings. Journal of Medical Imaging and Radiation Oncology 52, 287-292.

Sims AM, Shephard N, Carter K, Doan T, Dowling A, Duncan EL, Eisman J, Jones G, Nicholson G, Prince R, Seeman E, Thomas G, Wass JAH, Brown MA. 2008. Genetic analyses in a sample of individuals with high or low BMD shows association with multiple Wnt pathway genes. J Bone Miner Res 23(4):499-506.

Sinnott M, Wall D: Scapel Safety. 2008. How safe (or dangerous) are safety scapels? International Journal of Surgery, 6(2):176-177.

Sinnott M: Thinking in Emergency Medicine, Thinking in Trauma and Designing an Emergency Department for the Future. In. Iran; 2008.

Smith E, DeYoung NJ, PAvey SJ, Hayward NK, Nancarrow DJ, Whiteman DC, Smithers BM, Rieszkewicz AR, Clouston AD, Gotley DC, Devitt PG, Jameison GG, Drewe PA. 2008. Similarity of abberant DNA methylation in Barrett’s oesophagus and oesophageal adenocarcinoma. Molecular Cancer;7:75 published online

Smithers BM, Couper GC, Thomas JM, Wong D, Gotley DC, Martin I, Harvey JA, Thomson DB, Walpole ET, Watts N, Burmeister BH. 2008. Positron emission tomography and pathological response to neoadjuvant therapy in

adenocarcinoma of the oesophagus. Dis Esophagus, 21:151-158.

Solares CA, Panizza B. 2008. Vestibular schwannoma: an understanding of growth should influence management decisions. Otol Neurotol. 29(6):829-34.

Spry N, Bydder S, Harvey J, Borg M, Ngan H, Millar J, Graham P, Zissiadis Y. 2009. “Accrediting radiation technique in a multicentre trial of chemoradiation for pancreatic cancer.” Journal of Medical Imaging and Radiation Oncology. 52, 598 – 604.

Spry N, Harvey J, MacLeod C, Borg M, Ngan SY, Millar J, Graham P, Zissiadis Y, Kneebone A, Carroll S, Davies T, Reece WH, Iacopetta B, Goldstein D. 2008. 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreas cancer: factors influencing outcome. Int. J. Rad. Oncol. Biol. Phys; 70(5):1438-46.

Stanley RJ, Stoecker WV, Moss RH, Rabinovitz HS, Cognetta AB. Jr, Argenziano G, Soyer, HP. 2008. A basis function feature-based approach for skin lesion discrimination in dermatology dermoscopy images. Skin Research and Technology, 14(4):425-35.

Stuckey SL, Wijedeera R. 2008. Multicentric/multifocal cerebral lesions: can fluid-attenuated inversion recovery aid the differentiation between glioma and metastases? Journal of Medical Imaging and Radiation Oncology. 52(2): 134-139

Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello C, Kelemen L, Jeske Y, Veglio F, Stowasser M. 2008. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J Hypertens 28:1577-1582.

Tate J, Ferguson W, Bais R, Kostner K, Marwick T, Carter A. The determination of the 99th centile level for troponin assays in an Australian reference population. Ann Clin Biochem 2008; 45: 275–288.

Taylor PJ, Cooper DP, Gordon R, Stowasser M. 2008 Semi-automated analysis of aldosterone by liquid chromatography-tandem mass

spectrometry: the new gold standard. Hypertension 52: 178-9.

Taylor PJ. 2008 Introduction to high-performance liquid chromatography-tandem mass spectrometry: The gold standard for monitoring immunosuppressive drugs. Annals of Transplantation 13 (Suppl 1): 18.

Thompson B, Austin R, Coory M, Aitken JF, Walpole E, Francis G, Fritschi L. 2008. Completeness of histopathology reporting of melanoma in a high-incidence geographical region. Dermatology. 218(1):7-14.

Thompson JF, Hersey P, Smithers BM, Coventry B, Ross MI, Wachter E. Chemoablation of cutaneous and subcutaneous metastatic melanoma using PV-10. Asia Pacific J Clin Oncol 2008;4:Supp2, A72

Thursky KA, Playford EG, Seymour JF, Sorrell TC, Ellis DH, Guy SD, Gilroy N, Chu J, Shaw DR. 2008. Recommendations for the treatment of established fungal infections. Internal Medicine Journal;38:496-520

Tong A, Sainsbury P, Carter S, Hall B, Harris D, Walker R, Hawley C, Chadban S, Craig JC 2008. Patients’ priorities for health research: focus group study of patients with chronic kidney disease. Nephrol Dial Transplant [Eur ahead of print] 23 (10): 3206-3214.

Travers C, Lie D, Martin-Khan M: Dementia risk reduction in primary care: Barriers & Enablers. Australasian Journal on Ageing 2008, 27(S1):A58.

Travers C, McDonnell G, Broe G, Karmel R, Anderson P, Duckett S, Gray L: The Acute-Aged Care Interface: Exploring the Dynamics of ‘Bed Blocking’. Australasian Journal on Ageing 2008, 27(3):116-120.

Treleaven NLC, Darnell R, Panizza B, Brown-Rothwell D, Jull G. 2008. Comparison of Sensorimotor Disturbance Between Subjects With Persistent Whiplash-Associated Disorder and Subjects With Vestibular Pathology Associated With Acoustic Neuroma. Julia Archives of Physical Medicine and Rehabilitation. Vol. 89, Issue 3, 522-530.

Tropea J, Slee JA, Brand CA, Gray L, Snell T: Clinical practice guidelines for


the management of delirium in older people in Australia. Australas J Ageing 2008, 27(3):150-156.

Turner B, Fleming J, Ownsworth T, Cornwell P. 2008. The transition from hospital to home for individuals with acquired brain injury: a literature review and research recommendations. Disability and Rehabilitation 30: 1153-1176.

Turner B, Ownsworth T, Turpin M, Fleming J, Griffin J. 2008. Self-identified goals and the ability to set realistic goals following acquired brain injury. Australian Occupational Therapy Journal 55: 96-107.

van Meurs JB, Trikalinos TA, Ralston SH, Balcells S, Brandi ML, Brixen K, Kiel DP, Langdahl BL, Lips P, Ljunggren O et al: 2008. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA, 299(11):1277-1290.

Velavan P, Bhat P, Kaye G, Nasir M, Clark AL, Cleland JGF: Predictors of appropriate shocks and mortality in recipients of implantable cardioverter defibrillators. In: Annual Scientific Conference of the British-Cardiovascular-Society: Jun 02-04 2008; Manchester, ENGLAND; 2008: A97-A98.

Venkatesh B, Morgan TJ. 2008. Unmeasured anions: the unknown unknowns.Crit Care;12(1):113. Epub 2008 Feb 5.

Vicenzino B, Collins N, Crossley K, Beller E, Darnell R, McPoil T. 2008. Foot orthoses and physiotherapy in the treatment of patellofemoral pain syndrome: a randomised clinical trial. BMJ 2008;337:a1735.

Vivanti A, Banks M, Aliakbari J, Suter M, Hannan-Jones M, McBride L: Meal and food preferences of nutritionally at-risk inpatients admitted to two Australian tertiary teaching hospitals Nutrition & Dietetics 2008 65:36-40.

Vivanti A, Harvey K, Ash S, Battistutta D. 2008. Clinical assessment of dehydration in older people admitted to hospital – what are the strongest indicators? Archives of Gerontology and Geriatrics, 47(340-355).

Vivanti A, Horgan N, Haines T. 2008. Nutritional status, functional performance and falls. Nutrition & Dietetics, 65((S2)):A22.

Vivanti A, Sharp S, Sukwa N: Mealtime absences and interruptions are uncommon in tertiary teaching hospital wards. Nutrition & Dietetics 2008, 65(Suppl 2):A46.

Wadsworth BM, Haines TP, Cornwell PL, Paratz JD. Abdominal binder use in people with spinal cord injuries: a systematic review and meta-analysis. Spinal Cord advance online publication, 21st October 2008;doi:10.1038/sc.2008.126

Ward E, Agius E, Solley M, Cornwell P, Jones C. 2008. Preparation, clinical support, and confidence of speech pathologists managing patients with a tracheostomy in Australia. American Journal of Speech-Language Pathology 17: 265-276.

Watt AM, Patkin M, Sinnott MJ, Black RJ, Maddern GJ: Scapel injuries in the operating theatre. British Medical Journal 2008, 336(7652):1031.

Weiss M, Hung DY, Poenicke K, Roberts MS. 2008. Kinetic analysis of saturable hepatic uptake of digoxin and its inhibition by rifampicin. European Journal of Pharmaceutical Sciences. European Journal of Pharmaceutical Sciences 34:345-350.

Wenke R, Theodoros D, Cornwell, P. 2008. The short- and long-term effectiveness of the LSVT® for dysarthria following TBI and stroke. Brain Injury 22: 339-352.

Wetzig N, Brown C, Gebski V, Coskinas X, Gill P, Stockler M: Relationship between clinicians’ measurements of arm volume and patients’ ratings of arm-swelling in the RACS SNAC trial of sentinel node based management for early breast cancer. In: 6th Biennial International-Sentinel-Node-Society Meeting: Feb 18-20 2008; Sydney, AUSTRALIA; 2008: 45-45.

Wetzig N, Wilcoxon H, Pearce A, Vagg R, Anderson K, Luxford K, Zorbas H: Best practice guidelines for sentinel node biopsy in early (operable) breast cancer. In: 6th Biennial International-Sentinel-Node-Society Meeting: Feb

18-20 2008; Sydney, AUSTRALIA; 2008: 14-14.

Whitby M, McLaws ML, Slater K, Tong E, Johnson B. 2008. Three successful interventions in healthcare workers that improve compliance with hand hygiene: is sustained replication possible? Am J Infect Control;36:349-55

Whitby M, McLaws ML, Slater K. 2008 .Needlestick injuries in a major teaching hospital: the worthwhile effect of hospital-wide replacement of conventional hollow-bore needles. Am J Infect Control;36:180-6.

White H, Cook DA, Venkatesh B. 2008.The role of hypertonic saline in neurotrauma.Eur J Anaesthesiol Suppl. 2008;42:104-9.

White H, Venkatesh B. 2008. Cerebral perfusion pressure in neurotrauma: a review. Anesth Analg. Sep;107(3):979-88.

Whiteman DC Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, Webb PM, Green AC for the Australia Cancer Study. 2008. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinoma of the oesophagus. Gut;57:173-80

Winckle G, Anissimov YG, Cross SE, Roberts MS. 2008. An integrated pharmacokinetic and imaging evaluation of vehicle effects on solute human epidermal flux and, retention characteristics. Pharm Res. 25(1):158-66.

Wojcikowski K, Wohlmuth H, Johnson DW, Gobe G. 2008. Dioscorea villosa (wild yam) induces chronic kidney injury via pro-fibrotic pathways. Food and Agricultural Toxicology 46(9):3122-31.

Wootton R, Krupinski E, Hailey D, Patterson V, Scott R, Whited J, Whitten P, Yoo S, Hui E, Ferguson J et al. 2008. Memorable telemedicine experiences. J Telemed Telecare, 14(1):50-54.

Wurm EMT, Campbell TM, Soyer HP. 2008. Teledermatology: How to start a new teaching and diagnostic era in medicine. Dermatologic Clinics, 26(2): 295-300.

Wurm EMT, Hofmann-Wellenhof R, Wurm, R, Soyer HP. 2008. Telemedicine


and teledermatology: Past, present and future. [Telemedizin und teledermatologie: Vergangenheit, gegenwart und zukunft] JDDG - Journal of the German Society of Dermatology, 6(2): 106-112.

Xia CH, Sun JG, Hao HP, Wang GJ, Yan B, Gu SH, Zheng CN, Shang LL, Roberts MS. 2008. Quantitative Determination of Ophiopogonin D by Liquid Chromatography/ Electrospray Ionization Mass Spectrometry and its Pharmacokinetics in Rat. Planta Med. 74:1832-6.

Yan L, Ropella GEP, Park S, Roberts MS, Hunt CA. 2008. Modelling and simulation of hepatic drug disposition using a physiologically based, multi-agent in silico liver. Pharm Res. 25:1023-36.

Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. 2008. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND).

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet.;372:1174-83

Yusuf S, Teo KK, et al. 2008. ONTARGET Investigators, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 358(15):1547-59.

Zalaudek I, Leinweber B, Hofmann-Wellenhof R, Scope A, Marghoob AA, Ferrara G et al. 2008. The epidermal and dermal origin of melanocytic tumors: Theoretical considerations based on epidemiologic, clinical, and histopathologic findings. The American Journal of Dermatopathology, 30(4): 403-406.

Zalaudek I, Marghoob A A, Scope A, Leinweber B, Ferrara G, Hofmann-Wellenhof R, et al. 2008. Three roots of melanoma. Archives of Dermatology, 144(10): 1375-1379.

Zeck W, McIntyre HD. 2008. Gestational diabetes in rural East Africa: a call to action. J Womens Health (Larchmt) 2008, 17(3):403-411.

Zeck W, Widberg C, Maylin E, Desoye G, Lang U, McIntyre D, Prins J, Russell A: Regulation of placental growth hormone secretion in a human trophoblast model--the effects of hormones and adipokines. Pediatr Res 2008, 63(4):353-357.

Zou YH, Yang Y, Li J, Wu Q, Li WP, Lu JT, Roberts M. 2008. Potential therapeutic effects of a traditional Chinese formulation, BJ-JN, on liver fibrosis induced by carbon tetrachloride in rats. J Ethnopharmacol. 120:452-7.

Zvyagin AV, Zhao X, Gierden A, Sanchez W, Ross JA, Roberts MS. 2008. Imaging of zinc oxide nanoparticle penetration in human skin in vitro and in vivo. J. Biomed. Opt., Vol. 13, 06403; doi:10.1117/1.3041492.


Book Chapters

Coman W. 2008. Chapter title: Vaccines and Immunotherapy in Head and Neck Cancer. Recent Advances in Otolaryngology 8. Keir J, Moffat D, Sudhoff H (eds). Royal Society of Medicine Press Ltd. London UK, pp. 111–120.

Dancik Y, Jepps OG, Roberts MS. Beyond stratum corneum. In Dermal absorption and toxicity assessment (Second Edition). Roberts MS, Walters KA. (eds.) Marcel Dekker, New York, pp. 209-250.

Dancik Y, Jepps OG, Roberts MS. Physiologically based pharmacokinetics and pharmacodynamics of skin. In Dermal absorption and toxicity assessment (2nd edn). Roberts MS, Walters KA. (eds.), Marcel Dekker, New York, pp. 179-207.

Dorsett P, Fronek P. (In press). Practitioner standards and skill development. In Moore E (ed) Case Management for Community Practice. Oxford University Press.

Elliott, D, Alison, J & Aitken L. Major key topics concerning physical rehabilitation programmes and psychological recovery for survivors of a critical illness after discharge from hospital, in Esquinas, A (ed) Yearbook: Respiratory Care Clinics and Applied Technologies, World Federation of Respiratory Care and Applied Technologies, Murcia, Spain.

Fleming J. Foster M, Taylor S. Contemporary health care practice. In S Taylor, M Foster, J Fleming (Eds). Health care practice in Australia:

Policy, context and innovations. Melbourne: Oxford University Press, pp. 161-181.

Fleming J. Health care workforce. In S Taylor, M Foster, J Fleming (Eds). Health care practice in Australia: Policy, context and innovations. Melbourne: Oxford University Press, pp. 103-130.

Foster M, Fleming J. 2008. The policy context of health care practice. In S Taylor, M Foster, J Fleming (Eds). Health care practice in Australia: Policy, context and innovations (pp.131-160). Melbourne: Oxford University Press

Foster M, Fleming J. The health care system in Australia. In S Taylor, M Foster, J Fleming (Eds). Health care practice in Australia: Policy, context and innovations. Melbourne: Oxford University Press, pp. 46-73.

Foster M, Fleming J. The policy context of health care practice. In S Taylor, M Foster, J Fleming (Eds). Health care practice in Australia: Policy, context and innovations. Melbourne: Oxford University Press, pp. 131-160.

Haines T. Economic evaluations and decision making in health care. In: Taylor S, Foster M and Fleming J, editors. Healthcare Practice and Policy in Australia: Oxford University Press.

Johnson DW, Excell L, Livingston B, Bannister K, McDonald SP. Peritoneal dialysis. In: 30th Annual Report of the ANZDATA Registry, Chapter 6, Adelaide.

Johnson DW. 2008. Managing anaemia of chronic disease. Check program on

anaemia. Royal Australasian College of General Practitioners, Melbourne.

Johnson DW. How to treat proteinuria. In Gavathas (ed) How to Treat Yearbook, Australian Doctor, Sydney.

Kanikkannan N, Bonner M, Singh J, Roberts MS. Iontophoresis. In Dermatologic, cosmeceutic, and cosmetic development: therapeutic and novel approaches. Walters KA and Roberts MS (eds.) 2008, Informa, New York, pp. 517-536.

Li,X Kruger, P; Roberts, M. (In press). Optimising drug dosing in the Intensive Care Unit. Yearbook of Intensive Care and Emergency Medicine - Edited by J. L. Vincent, Springer - Verlag. In press

Lu GW, Ciotti S, Valiveti S, Grice JE, Cross SE. Targeting the pilosebaceous gland. In Dermatologic, cosmeceutic, and cosmetic development: therapeutic and novel approaches. Walters KA and Roberts MS (eds.), Informa, New York, pp. 215-242.

Macdonald GA. Suspected Iron Overload or High Serum Ferritin. In: Talley N, Segal I, Weltmann M editors. Pocket Clinical Gastroenterology Marrickville, NSW: Elsevier Australia, pp. 389-396.

Martin D, Martin I. Flow Chart for the Treatment of Common Bile Duct Stones and Critical Comparison of Techniques. In Biliary lithiasis, Springer-Verlag Italia

Mathew T, Johnson DW. 2008. Kidney disease. In: Harris M, Bailey L, Bridges-Webb C, Furler L, Joyner B, Litt J,


Smith J, Zurynski Y (eds). Guidelines for preventive activities in general practice. 7th edition. Royal Australasian College of General Practitioners, Melbourne, Victoria.

Miles R, Johnson DW. Use of honey to prevent infections associated with medical devices. In: Cooper R, Molan P, White R (eds). Honey: A modern wound management product. Wounds UK Books, Dorset UK.

Morgan TJ, Venkatesh B. Monitoring oxygenation in Teik Oh’s Intensive Care Manual (in press).

Rate A, Upham JW. “The epithelium and immunoregulation.” Chapter 11 in The Pulmonary Epithelium in Health & Disease. Edited by David Proud, John Wiley Press, England, pages 201-224.

Rathbone MJ, Hadgraft J, Roberts MS, Lane ME. Modified Release Drug Delivery Technology, Second Edition, Volume 1, 499.

Rathbone MJ, Hadgraft J, Roberts MS, Lane ME. Modified Release Drug Delivery Technology, Second Edition, Volume 2, 699.

Roberts MS, Walters KA. Skin structure, pharmaceuticals, cosmetics, and the efficacy of topically applied agents. In Dermatologic, cosmeceutic, and cosmetic development: therapeutic and novel approaches. Walters KA and Roberts MS (eds.), Informa, New York, pp. 115-128.

Roberts MS, Bouwstra J, Pirot F and Falson F. Skin hydration – a key determinant in topical absorption. In Dermatologic, cosmeceutic, and cosmetic development: therapeutic and novel approaches. Walters K and Roberts MS (eds.), Informa, New York, pp1-10.

Roberts MS, Gierden A, Riviere JE, Monteiro-Riviere NA. Solvent and vehicle effects on the skin. In Dermal absorption and toxicity assessment (Second Edition). Roberts MS, Walters KA. (eds.) 2008, Marcel Dekker, New York, pp. 433-447.

Roberts MS, Walters KA (Eds.). Dermal absorption and toxicity assessment (Second Edition); Marcel Dekker, New York June, 678 pages.

Roberts MS, Walters KA. Human skin morphology and dermal absorption. In Dermal absorption and toxicity assessment (Second Edition). Roberts MS, Walters KA. (eds.) , Marcel Dekker, New York, pp. 1-15.

Shaban RZ, Henderson BC. Practice Standards for Community Infection Control and Prevention. In: Towbridge K, Kralik D editors. Community Nursing in Australia: A Practice Manual Oxford: Blackwell-Synergy.

Shaban RZ. Infection Control and Prevention in Community Settings. In: Van Loon A, Kralik D editors. Community Nursing in Australia Oxford: Blackwell-Synergy.

Shaban RZ. Paramedics and the mentally ill. In: Grbich C, O’Meara P editors. Paramedics in Australia: Contemporary Challenges Sydney: Pearson Education.

Taylor S, Foster M, Fleming J. 2008. Introduction. In S Taylor, M Foster, J. Fleming (Eds). Health care practice in Australia: Policy, context and innovations (pp.xiii-xix). Melbourne: Oxford University Press.

Upham JW, Stick SM, Moodley Y. “Lung Cell Biology.” Chapter in Pediatric Respiratory Medicine, 2nd Edition Edited by Taussig & Landau, Mosby 2008, pages 35-43.

Venkatesh B, Cohen J. Adrenocortical insufficiency in critical illness in Teik Oh’s Intensive Care Manual 2009; 6th edn. 647-653.

Venkatesh B, Cohen J. Disorders of the adrenal gland in Surgical Critical Care 2nd edn.

Venkatesh B. Acute calcium disorders in Teik Oh’s Intensive Care Manual 2009; 6th edn, pp 653-664.

Venkatesh B. Continuous intra-arterial blood gas monitoring in Mechanical Ventilation 2009; eds Papadakos and Lachmann pp 487-500.

Venkatesh B. Disorders of consciousness in Teik Oh’s Intensive Care Manual 2009; 6th edn. 525-540.

Walters KA, Roberts MS (Eds.). Dermatologic, cosmeceutic, and cosmetic development: therapeutic and novel approaches; Informa Health Care, New York, London, 628 pages.

Whitehouse MW, Sarkar M, Roberts MS. Drugs for pain and inflammation. In Dermatologic, cosmeceutic, and cosmetic development: therapeutic and novel approaches. Walters KA and Roberts MS (eds.) 2008, Informa, New York, pp. 215-242.

Yerkovich ST, Upham JW. “Interactions between allergens and DC: pattern recognition receptors and their function in the pathogenesis of allergic respiratory diseases”. Chapter in Allergens, pollutants and innate immunity. (In press – edited by Marc Williams; published by Research Signpost).


Published Abstracts and Conference Proceedings

Barbour A, Thompson I, Gotley DC, Jones M, Thomas J, Martin I, Smithers MB. Minimally invasive esophagectomy for esophageal cancer: analysis of recurrence patterns and prognostic factors of recurrence. Asia Pacific J Clin Oncol 2008;4:Supp2, A116

Barraclough K, Oliver K, Playford EG, Preston J, Campbell S, Johnson DW, Hawley C, Mudge D, van Eps C, Isbel N. Life threatening adenovirus infection in a kidney transplant recipient. Nephrol Dialysis Transpl Plus.

Baumgartner L, Vivanti A, Smithers M. Jejunally fed patients post oesophagectomy/gastrectomy – are they getting all they need? An audit at the Princess Alexandra Hospital. Asia Pacific J Clin Oncol 2008;4:Supp2,A107

Burmeister BH, Smithers BM, Thomas J, Burmeister E, Walpole E, Harvey J, Thomson D, Barbour A, Gotley D. A ranodomised phase II trial comparing pre-operative chemotherapy with pre-operative chemoradiation therapy for localized carcinoma of the oesophagus. Asia Pacific J Clin Oncol 2008;4:Supp2, A47

Chen S, Marriott D, Playford EG, Nguyen Q, Ellis D, Meyer W, Sorrell T, Slavin M and the Australian Candidemia Study. Candidemia with uncommon Candida species: risk factors, outcome, susceptibility and implications for management. 17th Congress of the International Society for Human and Animal Mycology, Tokyo, Japan, 25-29 May 2009.

Clark C, Johnson DW, Isbel NN, Hawley CM, Beller E, Heritier S, de Zoysa J,

McTaggart S, Playford EG, Smith A, Thompson C, Snelling P, Perkovic V and Cass A. Audit Of Previous Practice And Report Of Baseline Characteristics Of Initial Patients Enrolled To The Honeypot Trial: A RCT of Medihoneytm Antibacterial Wound Gel For The Prevention Of Catheter-Associated Infections In Peritoneal Dialysis Patients In Australia And New Zealand (ANZ). [Abstract 952859].World Congress of Nephrology. Milan, Italy, 22-26 May 2009

Connor JP. 2008. Future Directions in Alcohol Use Disorder Treatment Research. Conference Proceedings, 43rd Australian Psychological Society Annual Conference 2008:125-129

Cutler A, Wright O, Martin-Khan M, Varghese P, et al. Reliability of online geriatric consultation triage decisions: A pilot study. Internal Medicine Journal 38(s5): p A119-A137.

Duncan EL (2008) Calcium Disorders. Australian Doctor.

Duncan EL Addison K, M Brugmans, D Irwin, D Evans, J Eisman, G Jones, G Nicholson, R Prince, E Seeman_, A Uitterlinden, J Wark, S Ralston for FAMOS consortium, MA Brown (2008) “Phased Genome-Wide Association Study Identifies New Gene Affecting Bone Mineral Density” presented American Society for Bone and Mineral Research Meeting, Montreal, September 2008.

Duncan EL, F Rivadeneira, A-M Sims, A Dowling, T Doan, PP. Arp, P. Mila Jhamai, M Moorhouse, D Evans, J Eisman, G Jones, G Nicholson, R Prince, E Seeman, J Wass, A Hofman, HA. Pols,

MA Brown, AG Uitterlinden (2008) “Genome-Wide Association Study Identifies Klotho and Other Novel Loci as Contributors to BMD Variation in Postmenopausal Women. 33rd European Symposium Calcified Tissues, Barcelona, 2008.

Gill G, Gebski V, Wetzig N, Ung O, Campbell I, Collins J, Sourjina T, Coskinas X, Stockler M, Simes J. 2008. Sentinel node (SN) based management causes less arm swelling and better quality of life than routine axillary clearance (AC): 1 year outcomes of the SNAC trial. In: 6th Biennial International-Sentinel-Node-Society Meeting: Feb 18-20 2008; 46-46.

Gray L. Geriatric rounds by mobile videoconference. Annual Scientific Meeting of the ANZSGM, Melbourne, Australia, Internal Medicine.

Hackwood B, Carney D, Aitken L. Developing a sustainable implementation of practice change in the ICU (Abstract), Australian Critical Care, 21 (1): 55.

Haines T, McPhail S. Cost-benefit of falls prevention interventions – measuring more than just the benefit gained. Australian Health Outcomes Conference. Canberra.

Haines T, Sinnamon P, McPhail S. Response Shift or Recall Bias. Australian Health Outcomes Conference. Canberra.

Hearn C, Grudzinskas K. Physiotherapy recruitment and retention – determining strategies to develop and retain the physiotherapy workforce. Australian Physiotherapy Association National Congress. Perth.


Hickman, IJ; Sullivan, CM; Flight, S; Campbell, C; Crawford, DH; Masci, PP; O’Moore-Sullivan, TM; Prins, JB; Macdonald, GA. Obesity is linked with increased clot strength and impaired fibrinolysis in nonalcoholic fatty liver disease. International Journal of Obesity 32: S59-S59 Suppl. 1.

Hutley LJ. New Fat Cell Generation in Adult Humans – Regulation and Intervention. Australian Health & Medical Research Congress, Brisbane. Abs # ABSC3-JZ7LS-KX5HH-AH99X.

Ipavec-Levasseur S, Byrne NM, Cowin G, Hickman IJ, O’Moore-Sullivan TM, Prins JB. Obese men cannot utilise intramyocellular lipids or intrahepatic lipids during 1-hour of moderate intensity exercise. International Journal of Obesity, 32: S16-S16 Suppl. 1.

Ipavec-Levasseur, S; Byrne, NM; Cowin, G; Hickman, IJ; O’Moore-Sullivan, TM; Prins, JB. The effect of a lifestyle intervention on visceral fat, liver fat and intramyocellular lipids in obese men. International Journal of Obesity, 32: S72-S72 Suppl. 1.

Jack, L. Diarrhoea in Enterally Tube Fed Patients: A Retrospective Critical Care Chart Audit. ANZICS/ACCN. Australian Scientific Meeting 2008.

Jeske YW, So A, Kelemen L, Sukor N, Willys C, Gordon RD, Duffy D, Stowasser M. 2008. Genotyping and expression studies of 7p22 candidate genes in Familial Hyperaldosteronism Type II. Hypertension 52:169.

Lau A, Halliday C, Playford EG, Chen S, Stanley K, Sorrell T. Multiplex-tandem PCR (MT-PCR) for Rapid Diagnosis of Fungemia [Abstract M-699] 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Waashington DC 25-28 October 2008.

Lau A, Halliday C, Playford EG, Chen S, Stanley K, Sorrell T. Multiplex-tandem PCR (MT-PCR) for Rapid Diagnosis of Fungemia [Abstract M-699] 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC.

Lau A, Playford EG, Halliday C, Chen S, Sorrell T. Pattern of Candida colonisation and invasive candidiasis

in the ICU 17th Congress of the International Society for Human and Animal Mycology, Tokyo, Japan, 25-29 May 2009.

Lethlean J, Rhee J. Clinical application of “evidence” in aphasia: The PAH experience. Brain Impairment, 9(3), 305.

Li P, Weiss M, Khlentzos A, Roberts MS, Role of cellular binding and transporters on the processing of digoxin in the rat liver. Proceedings of the Australian Health and Medical Research Congress 2008. Brisbane, Poster 814.

Liu X, Kruger Peter, Roberts MS, Pharmacokinetic and Pharmacodynamics analysis of cistracurium in critically ill patients with sepsis. Proceedings of the Australian Health and Medical Research Congress 2008. Brisbane, Poster 434.

Martin-Khan M, Flicker L, Wootton R, Loh P, et al. Multicentre Pilot for assessing the diagnostic accuracy of cognitive assessment via video consultation. Australian Association of Gerontology Conference, Esplanade Hotel, Freemantle.

Martin-Khan M, Travers C, Lie D. Dementia risk reduction in primary care: barriers and enablers. National Dementia Research Forum, Sydney.

Martin-Khan M, Varghese P, Wootton R, Gray L. Research project to clinical service: the challenges of establishing a telegeriatric memory service. 7th National Conference of Emerging Researchers in Ageing, Freemantle, Western Australia.

McCall B, Slinko V, Smith G, Field H, Playford EG, Smith I, Heel K, Kung N. Public Health aspects of the Redlands Hendra Virus Outbreak July 2008 [Abstract 17.005]. International Meeting on Emerging Diseases and Surveillance 2009. Vienna, Austria, 13-16 February 2009

McCall B, Slinko V, Smith G, Field H, Playford G, Smith I, Heel K, Kung N. Public Health aspects of the Redlands Hendra Virus Outbreak July 2008 [Abstract 17.005]. International Meeting on Emerging Diseases and Surveillance 2009. Vienna, Austria, 13-

16 February 2009

McPhail S, Beller E, Haines T. Agreement between proxy-report and patient self-report of the EQ-5D amongst subacute elderly hospital patients: The interaction effects of perspective, timing and patient cognition. Australian Health Outcomes Conference. Canberra.

McPhail S, Beller E, Haines T. The effect of introducing detailed anchor-point descriptors on measurement of health-related quality of life using the EQ-5D. Australian Health Outcomes Conference. Canberra.

Munckhof WJ, Nimmo G, Schooneveldt J, Schlebusch S, Williams G, Huygens F. Nasal carriage of community-acquired methicillin-resistant Staphylococcus aureus in adults in a high prevalence population. Australian Society for Antimicrobials annual scientific meeting, Twin Waters, Queensland, April 2008.

Munckhof WJ, Nimmo G, Schooneveldt J, Schlebusch S, Williams G, Huygens F. Nasal carriage of community-acquired methicillin-resistant Staphylococcus aureus in adults in a high prevalence population. Australian Society for Antimicrobials annual scientific meeting, Twin Waters, Queensland, April.

Munckhof WJ, Nimmo GR, Schooneveldt J, Schlebusch S, Williams G, Huygens F. Nasal carriage of community-acquired methicillin-resistant Staphylococcus aureus in adults in a high prevalence population. 13th International Symposium on Staphylococci and Staphylococcal Infections, Cairns, Australia, September, abstract 602.

Munckhof WJ. MRSA in the community – review of generic and targeted strategies for control. Health care infection workshop, Australasian Society for Infectious Diseases Annual Scientific Meeting, Cypress Lakes resort, Hunter Valley, NSW, 25 – 29 March, 2009.

Ngo S, Barry J, Whitehead J. Dexamethasone inhibits insulin stimulated glucose uptake by reducing akt substrate of 160 kDa (AS160) phosphorylation in human adipocytes.


Diabetes Research and Clinical Practice, 79: S19-S19 Suppl. 1.

Ong CR; Ipavec-Levasseur S; Cowin G; Liu PY; O’Moore Sullivan TM; Prins JB. Androgen replete obese men are more insulin sensitive, store less intramyocellular lipids and have less intramyocellular lipids for use in acute exercise. International Journal of Obesity 32: S70-S70 Suppl. 1.

Ong CR; Lai J; Lloyd TB; Ipavec-Levasseur S; Liu PY; O’Moore Sullivan TM; Prins JB. Clinically achievable weight loss improves symptoms of androgen deficiency but does not increase Androgen Bioactivity or Testosterone concentrations in Obese men. International Journal of Obesity 32: S69-S69 Suppl. 1.

Ong, CR; Ipavec-Levasseur, S; Cowin, G; Liu, PY; O’Moore, STM; Prins, JB. Androgen replete obese men are more insulin sensitive, store less intramyocellular lipids and have less intramyocellular lipids for use in acute exercise. International Journal of Obesity 32: S70-S70 Suppl. 1 May 2008

Peel NM, Travers C, Gray L. Evaluation of a Statewide Area Falls Safety Officer Pilot Project. Australian and New Zealand Falls Prevention Conference, Melbourne.

Phillips LK, Prins JB. The link between abdominal obesity and the metabolic syndrome. Current Hypertension Reports 10 (2): 156-164.

Playford EG, Barraclough K, Wiggins K, Vann Eps C, Whitby M, Carpenter S, Johnson D, Hawley C. Intradermal versus Intramuscular Hepatitis B Virus Vaccination in Haemodialysis Patients: A Randomised Controlled Trial in Nonresponders to Primary Intramuscular Vaccination [Abstract G-396] 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC 25-28 October 2008

Playford EG, Lipman L, Kabir M, McBryde E, Lau A, Marriott D, Paterson D, Nimmo G, J. Iredell J, Sorrell T. Assessment of Risk Predictive Models for Invasive Candidiasis among a Multicentre Cohort of Australian ICU Patients [Abstract M-1854] 48th Interscience

Conference on Antimicrobial Agents and Chemotherapy. Washington DC, October.

Playford EG, McCall B, Allen G, Smith I, Slinko V, Smith G. Hendra Virus (HEV) Encephalitis: Two Further Cases Associated With An Equine Outbreak. Australasian Society for Infectious Diseases Annual Scientific Meeting Hunter Valley, NSW, 25-28 March 2009.

Playford EG, McCall B, Allen G, Smith I, Slinko V, Smith G. Hendra Virus (HEV) Encephalitis: Two Further Cases Associated With An Equine Outbreak. Australasian Society for Infectious Diseases Annual Scientific Meeting Hunter Valley, NSW, 25-28 March 2009.

Playford EG, Nimmo GR, Tilse M, Sorrell TC. The increasing incidence of candidaemia and the increasing importance of non-ICU/non-haematology patients: secular trends, Queensland, Australia 1999-2008. 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, 16-19 May 2009.

Playford EG. Candidaemia in the ICU – How does one predict? Australasian Society for Infectious Diseases Annual Scientific Meeting Hunter Valley, NSW, 25-28 March 2009.

Roberts MS, Quantum Dots. 7th International Conference and Workshop, Biological Barriers and Nanomedicine – Advanced Drug Delivery and Predictive non vivo Testing Technologies, Saarbrücken.

Roberts MS, Robertson TA, Roberts MJ, Sanchez W, Zhao X, Zyvagin AV, In vitro and in vivo imaging of xenobiotic transport in human skin and in the rat liver, 3rd Workshop on Advanced Multiphoton and FLIM Techniques (FLIM 2008), Saarbrücken.

Roberts MS, Targeted topical drug delivery. 1st International Conference on Drug Design and Delivery, Dubai.

Roberts MS, Targeted topical drug delivery. 8th International Symposium of Controlled Release Society, Ahmedabad.

Robertson TA, Zou Y, Thorling C, Roberts MS. In vivo imaging of xenobiotic transport in the rat liver. Proceedings of the Australian health

and medical Research Congress 2008. Brisbane 16-21 November, Poster 806.

Robertus LM, Konstantinos A, Wamsley M, Munckhof WJ. The Ipswich cluster: 5 years later. 2008 Australasian Tuberculosis Conference, Auckland, New Zealand, 27–29 November, 2008, abstract 3.

Sanchez WH, Zhao X, Charters C, Upton Z, Zvyagin AV, Roberts MS, Multiphoton imaging of zinc oxide nanoparticles penetration into human skin in vivo and in vitro and human skin equivalent comparison with human skin. Proceedings of the Australian health and medical Research Congress 2008. Brisbane 16-21 November, 2008, Poster 819.

Scott JA, Coombes JS, Prins JB, Leano RL, Marwick TH, Sharman JE. Patients with type 2 Diabetes have exaggerated brachial and central exercise blood pressure: Relation to left ventricular relative wall thickness. AMERICAN Journal of Hypertension. 2008 April 17 [Epub ahead of print].

Shum D, Banks M, Fleming J, Gill H. Performance of individuals with TBI on executive function testes and its relationship with psychosocial outcome. Abstracts of the 36th Annual International Neuropsychological Society Meeting, Waikoloa, Hawaii. In Journal of the International Neuropsychological Society, 14 (S1), 240.

Smithers BM, Doecke J, Corish T, Moore S, Whiteman D. Oesophageal Cancer: Patterns of Care in Australia. Asia Pacific J Clin Oncol 2008;4:Supp2, A30.

Smithers BM, Gotley DC Response to letter re: Comparison of outcomes between open and minimally invasive esophagectomy. Ann Surg 2008;247:397-8

Stowasser M, Gordon RD. Primary aldosteronism. In BMJ Point of Care. British Medical Journal Publishing Group, London. 2008.

Sukor N, Stowasser M, So A, Duffy D, Kelemen L, Jeske Y, Mulatero P, Gordon RD. 2008. Familial hyperaldosteronism type II - evidence for linkage at chromosome 7p22 in families from Australia, South America and Italy. Hypertension 52:178.


Tan HY; Rand JS; Morton JM; Fleeman LM; Coradini M; Armstrong PJ; Verkest KR; Ishioka K; Rose F; Richards A; Rawlings JM; Whitehead JP. Association of adiponectin multimers with dietary nutrient composition, body weight gain, meal feeding, and insulin sensitivity in cats. Journal of Veterinary Internal Medicine, 22 (3): 792-793 303.

Taylor PJ, Cooper DP, Gordon RD, Stowasser M. Semi-automated analysis of aldosterone by liquid chromatography-tandem mass spectrometry: the new gold standard. Hypertension 52:178.

Travers C, Martin-Khan M, Lie D. Dementia risk reduction in primary care: barriers and enablers. Australasian Journal on Aging Vol 27, Supp 1, Conference Abstract.

Turner B, Fleming J, Cornwell P, Haines T, Ownsworth T. 2008. Outcomes during the transition from hospital to home for individuals with ABI and their family caregivers. Abstracts of the International Brain Injury Association Congress, March 2008, Lisbon, Portugal. In Brain Injury, 22 (S1), 31.

Vela I, Gregory L, Clements JA, et al. Kallikrein related proteases and Wnt pathway interactions in prostate cancer. BJU International, 101: 24-24 Suppl. 1.

Verkest KR, Fleeman LM, Morton JM, Rand JS, Rose FJ, Richards AA, Whitehead JP, Ishioka K. Adiponectin concentration does not correlate with obesity-associated changes in fasting insulin sensitivity in dogs. Journal of Veterinary Internal Medicine 22 (3): 791-792 301.

Verkest, KR; Rand, JS; Fleeman, LM; Morton, JM; Rose, FJ; Richards, AA; Whitehead, JP. Lack of correlation between adiponectin multimers and obesity-related changes in insulin sensitivity in dogs. Journal of Veterinary Internal Medicine 22 (3): 792-792 302.

Wetzig N, Brown C, Gebski V, Coskinas X, Gill P, Stockler M: Relationship between clinicians’ measurements of arm volume and patients’ ratings of arm-swelling in the RACS SNAC trial of sentinel node based management for early breast cancer. In: 6th Biennial International-Sentinel-Node-Society Meeting: Feb 18-20 2008; Sydney, Australia; 2008: 45-45.

Wetzig N, Wilcoxon H, Pearce A, Vagg R, Anderson K, Luxford K, Zorbas H: Best practice guidelines for sentinel node biopsy in early (operable) breast cancer. In: 6th Biennial International-Sentinel-Node-Society Meeting: Feb 18-20 2008; Sydney, Australia; 2008: 14-14.

Whiteman D, SmithersBM, Gotley DC, Pandeya N, Sadeghi S, Green AC, Webb PM. The epidemiology of oesophageal cancer. Asia Pacific J Clin Oncol 2008;4:Supp2, A42.

Widberg CH, Newell FS, Bachmann AW, Ramnoruth SN, Spelta MC, Whitehead JP, Prins JB, Hutley LJ. Fibroblast Growth Factor-1 (FGF-1) and FGF Receptor-1 are Key Regulators of Adipogenesis in Human Preadipocytes. Australian Diabetes Society Annual Scientific Meeting. Melbourne. Abs # 159, Proceedings p 87.

Widberg CH, Newell FS, Bachmann AW, Ramnoruth SN, Spelta MC, Whitehead JP, Prins JB, Hutley LJ. Fibroblast Growth Factor-1 (FGF-1) and FGF receptor-1 are Key Regulators of Adipogenesis in Human Preadipocytes. Australian Health & Medical Research Congress, Brisbane. Abs # ABS6R-3U27P-ASGJL-3CNDF.

Willibald Z, Widberg C, Maylin E, Desoye G, Lang U, McIntyre D, Prins JB, Russell A. Regulation of placental growth hormone secretion in a human trophoblast model-t the effects of hormones and adipokines. Pediatric Research 63(4) 353-357, April 2008

Willys C, Gordon RD, Jeske YW, Kelemen L, So A, Stowasser M. Potassium channels, HERG mutations and hormonal secretion: possible involvement in primary aldosteronism. Hypertension 52:178.

Wright O, Pimm B, Gray L. Duplication of documentation amongst health professionals for frail, aged patients in an acute care setting. Annual Scientific Meeting of the ANZSGM, Melbourne, Australia, Internal Medicine.

Wu Y, Cross SE, Grice J, Bonner M. Quantitative estimation of vehicle effects on shunt route penetration by human skin sandwich system. Abstract, International Perspectives in Percutaneous Penetration.

Wu Y, Grice JE, Roberts MS, Effect of manipulating vehicle ratios in topical minoxidil penetration and hair growth stimulation. Proceedings of the Australian Health and Medical Research Congress 2008, Poster 499.

Yu XX, Watts LM, Hutley LJ, Whitehead JP, Prins JB, Wacher V, Monia BP, Bhanot S. Lowered Adiposity and Improved Insulin Sensitivity in Obese Mice after Suppression of Hepatic and Adipose Tissue FGFR4 Expression. American Diabetes Association 68th. San Francisco CA. Diabetes (Suppl) 2008, 57: A475 (1708-P).

Zhang Q, Grice JE, Li P, Wang GJ, Roberts MS.. Relationships between the physicochemical properties of phenolic compounds and their epidermal permeability. Proceedings of the Australian health and medical Research Congress 2008. Brisbane 16-21 November, 2008, Poster 817.

Zou Y, Liu X, Khlentzos P, Asadin P, Li C, Thorling C, Robertson T, Crawford HG, Roberts MS. Effect of Cirrohosis on the hepatic pharmacokinetics of the liver transplantation. Proceedings of the Australian health and medical Research Congress 2008. Brisbane 16-21 November, 2008, Poster 808.


Achong N, Wahi S, Marwick TH. Evolution and Outcome of Diastolic Dysfunction. Heart.

Ashley B Irish, Gursharan K Dogra, Trevor A Mori, Elaine M Beller, Stephane R Heritier, Carmel M Hawley, Peter G Kerr, Amanda J Robertson, Johan B Rosman, Peta-Anne Paul-Brent, Melissa R Starfield, Kevan R Polkinghorne and Alan Cass. Preventing AVF thrombosis: The rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study.

Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, Burmeister B, Smithers BM. Refining esophageal cancer staging after neoadjuvant therapy: Importance of treatment response. Ann Surg Oncol.

Barker A, Nitz J, Low-Choy N, Haines T. Clinimetric evaluation of the physical mobility scale supports clinicians and researchers in residential aged care. Archives of Physical Medicine and Rehabilitation.

Barker R, Kendall M, Amsters D, Pershouse K, Haines T, Kuipers P. The relationship between quality of life and disability across the lifespan for people with spinal cord injury. Spinal Cord.

Barraclough K, Oliver K, Playford EG, Preston J, Campbell S, Johnson DW, Hawley C, Mudge D, van Eps C, Isbel N. Life threatening adenovirus infection in a kidney transplant recipient. Nephrol Dialysis Transpl Plus.

Barraclough K, Staatz C, Isbel NM, Johnson DW. Therapeutic monitoring of mycophenolate in transplantation: is it justified? Current Drug Metabolism.

Brand CA, Cameron PA, Ibrahim JE, Scott IA. Process redesign: a solution or a useful tool for improving quality of care? Medical Journal of Australia.

Brennan S, Sly PD, Sturges N, Winfield K, Matt Wikstrom M, Palmer H, Gard S, and Upham JW. Alveolar macrophages and the CC chemokines MCP-1, MIP-1a, MIP-1b and MIP3a are increased in young children with cystic fibrosis. European Respiratory Journal.

Broome K, Worrall L, McKenna K, Fleming J. In press. Bus use and older people: A literature review applying the Person-Environment-Occupation model in macro practice. Scandinavian Journal of Occupational Therapy.

Brown J, Jenkins C, Marwick TH. Use of myocardial strain to assess global left ventricular function: a comparison with cardiac magnetic resonance and 3-dimensional echocardiography. Am Heart J.

Brown J, Shah P, Marwick T. Interaction and Prognostic Effects of Diastolic Dysfunction and Patient-Prosthesis Mismatch as Determinants of Outcome after Aortic Valve Replacement. Accepted in American journal of cardiology.

Brown J, Shah, P, Marwick TH. Interaction and prognostic effects of left ventricular diastolic dysfunction and patient-prosthesis mismatch

as determinants of outcome after isolated aortic valve replacement. Am J Cardiol.

Burmeister BH, Walpole ET, D’Arcy N, Burmeister EA, Cox S, Thomson DB, Harvey JA, Smithers BM. A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-flurouracil for esophageal cancer. Invest New Drugs 2008.

Butler N, Mundy J, Shah P: Aortic Complications of Giant Cell Arteritis: a diagnostic and management dilemma; A Case Series and review of recent literature. Under review in Heart, Lung and Circulation.

Butterly SJ, Pillans PI, Horn B, Miles R, Sturtevant JM. Off-label use of rituximab in a tertiary Queensland hospital. Intern Med J.

Campbell DJ, Nussberger J, Stowasser M, Jan Danser AH, Morganti A, Frandsen E, Fischli W, Ménard J. 2008. Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate information. Clin Chem.

Campbell-Lloyd AJ, Kanagalingam J, Bandi H, Coman S, 2008. Vertebral artery dissection after direct laryngoscopy: case report and literature review. J Laryngol Otol.

Capp A, Ponta M, Bill D, Moscato P, Christie D, Lamb D, Turner S, Joseph D, Matthews J, Atkinson C, North J, Poulsen M, Spry N, Tai K, Wynne C, Duchesne G, Steigler A, Denham J. 2008. Is there more than one


proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiotherapy and Oncology September. Radiother Oncol.

Cervin A, Wallwork B, Mackay-Sim A, Coman WB, Greiff L. Effects of long-term clarithromycin treatment on lavage-fluid markers of inflammation in chronic rhinosinusitis. Clin Physiol Funct Imaging. 2.

Cheung C, Gibbons N, Johnson DW, Nicol DL. Silibinin in Cancer - therapy and prevention. Anti-Cancer Agents in Medicinal Chemistry.

Cook DA, Flemming J. Understanding the Shared Responsibility in Assessing the Benefits and Risks of Research for the Vulnerable Critical Care Patient. Accepted to Critical Care Medicine Nov 2008.

Dalley A, Lipman J, Deans R, Venkatesh B, Rudd M, Roberts MS, Cross SE. Tissue accumulation of cephalothin in burns: a comparative study by microdialysis of subcutaneous interstitial fluid cephalothin concentrations in burn patients and healthy volunteers. Antimicrob Agents Chemother.

Davies J.M. Reduced IgE diversity and regulation of allergic inflammation in asthma. Clin. Exp. Allergy.

Doig E, Fleming J, Cornwell P, Kuipers P. Clinical utility of the combined use of the Canadian Occupational Performance Measure and Goal Attainment Scale. American Journal of Occupational Therapy.

Doig E, Fleming J, Kuipers P, Cornwell P. Qualitative exploration of a client-centered goal-directed approach to community-based occupational therapy for adults with traumatic brain injury. American Journal of Occupational Therapy.

Doig E, Fleming J, Cornwell P, Kuipers P. Exploring multiple perspectives of a client-centred goal-directed approach to community-based occupational therapy for adults with traumatic brain injury. American Journal of Occupational Therapy.

Erlich RB, Rickwood D, Coman WB, Saunders NA, Guminski A. Valproic acid as a therapeutic agent for head

and neck squamous cell carcinomas. Cancer Chemother Pharmacol.

Fanning KF, Anissimov YG, Roberts MS. Sulphonylurea Physicochemical-Pharmacokinetic Relationships in the Pancreas and Liver. Journal of Pharmaceutical Sciences.

Fleming J, Kennedy S, Fisher R, Gill H, Gullo M, Shum D. Validity of the Comprehensive Assessment of Prospective Memory (CAPM) for use with adults with traumatic brain injury. Brain Impairment.

Fleming JM, Kuipers P, Foster M, Smith S, Doig E. Evaluation of an outpatient, peer group intervention for people with acquired brain injury based on the ICF ‘environment’ dimension. Disability and Rehabilitation.

Foster M, Cornwell P, Fleming J, Tweedy S, Mitchell G, Hart A, Haines T. Better than nothing? Restrictions and realities of EPC for allied health professionals. Australian Journal of Primary Health.

Francis GD, Jones MA, Beadle GF, Stein SR. ‚Bright Field in-situ hybridization for HER2 gene amplification in breast cancer utilizing tissue microarrays: Correlation between chromogenic (CISH™) and automated silver enhanced (SISH) methods with patient outcome.’ Diagnostic Molecular Pathology.

Franjic B, Marwick TH. The Diabetic, Hypertensive Heart: Epidemiology and Mechanisms of a Very High Risk Situation. J Hum HT.

Fronek P, Kendall M, Ungerer G, Malt J, Eugarde E, Geraghty T. Towards healthy professional-client relationships: The value of an interprofessional training course. Journal of Interprofessional Care.

Ghiculescu RA, Pillans PI. Rare cause of dyspnoea.Intern Med J.

Haines T, Kuys S, Morrison G, Clarke G, Bew P. Cost-effectiveness analysis of screening for risk of in-hospital falls using physiotherapist clinical judgement. Medical Care.

Haines T, Massey B, Varghese P, Fleming J, Gray L. Inconsistency in classification and reporting of in-

hospital falls. Journal of the American Geriatrics Society.

Hamilton E, O’Callaghan C, O’Brien RM, Stowasser M, Gordon R, Zajac J, Grossmann M. Familial hyperaldosteronism type 1 in pregnancy. Intern Med J.

Irving MJ, Johnson DW, McDonald S, Walker RG, Frommer MS, Craig JC. Results of a national survey of Australian and New Zealand nephrologists: Opinions on the content and effects of clinical practice guidelines for chronic kidney disease. American journal of Kidney Diseases.

Jackson J, Dickie G, Wiltshire K, Poulsen MG, Hughes M., Keller J, Tripcony L, Allison R, Martin J. Radiotherapy for Perineural invasion in cutaneous head and neck carcinomas: towards a risk adaptive treatment approach. Head and Neck.

Jaksic AS, Nimmo GR, Dwyer BW. Laboratory diagnosis of Clostridium difficile-associated diarrhoea: microbiologists (should) do it with culture. Path.

Jenkins C, Haluska B, Marwick TH. Assessment of temporal heterogeneity and regional motion to identify wall motion abnormalities using treadmill exercise stress three-dimensional echocardiography. J Am Soc Echocardiogr.

Jenkins C, Moir WS, Chan J, Marwick TH. Left ventricular volume measurement with echocardiography: A comparison of left ventricular opacification, 3D echocardiography or both with magnetic resonance imaging. Eur Heart J.

Johnson DW, Clarke C, Isbel NM, Hawley CM, Beller E, Cass A, de Zoysa J, McTaggart S, Playford G, Rosser B, Thompson C, Snelling P. The Honeypot study protocol: A randomised controlled trial of exit site application of Medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients. Perit Dial Int.

Johnson DW, Dent H, Hawley CM, McDonald SP, Rosman JB, Brown FG, Bannister KM, Wiggins KJ. Associations of dialysis modality and infectious


mortality in incident dialysis patients in Australia and New Zealand. American Journal of Kidney Diseases.

Johnson DW, Dent H, Yao Q, Tranaeus A, Huang CC, Han DS, Jha V, Wang T, Kawaguchi Y, Qian J. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrology Dialysis and Transplantation.

Johnson DW, Jones GRD, Becker G, Mathew T. Automated laboratory reporting of eGFR – a useful tool for identifying and managing kidney disease. Medical Journal of Australia.

Kaisar MO, Armstrong K, Hawley C, Campbell S, Mudge D, Johnson DW, Prins J, Isbel N. Adiponectin is associated with cardiovascular disease in renal transplant recipients: baseline results from the LANDMARK 2 study. BioMed Central Nephrology.

Kaisar MO, Johnson DW, Prins J, Isbel N. The role of novel biomarkers of cardiovascular disease in chronic kidney disease: focus on adiponectin and leptin. Current Cardiology Reviews.

Kaisar MO, Nicol DL, Hawley CM, Mudge DW, Johnson DW, Preston J, Wall DR, Griffin AD, Campbell SB, Isbel NM. Change in live donor characteristics over the last 25 years: a single center experience. Nephrology.

Khan A, Gupta K, Stanley RJ, Stoecker WV, Moss RH, Argenziano G, Soyer HP, Rabinovitz HS, Cognetta AB. Fuzzy logic techniques for blotch feature evaluation in dermoscopy images. Computerized Medical Imaging and Graphics.

Kruger PS, Freir NM, Venkatesh B, Robertson TA, Roberts MS, Jones M. A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med. Volume 35 (4) April, 10.1007/s00134-008-1358-3.

Kuipers K, Copley J, Rassafiani M, Ashburner J, Griffin J, Worley L, Moes L, Fleming J. Do clients with acquired brain injury use the splints prescribed by occupational therapists? A descriptive study. Neurorehabilitation.

Kuipers P, Foster M, Smith S, Fleming J. Using ICF-Environment factors to enhance the continuum of outpatient ABI rehabilitation: An exploratory study. Disability and Rehabilitation.

Lin C, Dickie G, Tripcony L, Wiltshire K, Jackson J, Evans J, Poulsen M, Martin J, Allsion R. Pathological Perineural infiltration of cutaneous head and neck carcinoma. Int J Rad Oncol Biol Phys 2008

Lin C, Dickie G, Wiltshire K, Tripcony L, Jackson J, Keller J, Carr M, Poulsen M, Martin J, Allison R. Clinical perineural infiltration in cutaneous head and neck carcinoma: Squamous cell carcinoma and high risk locations predict worse outcome. Int J Rad Onc Biol Phys.

Marwick TH, Branagan H, Venkatesh B, Stewart S. Strategies for reduction of cardiac events after major noncardiac surgery: comparison of a uniform and selective beta-blockade. Am Heart J.

Marwick TH, Hordern M, Miller T, Chyun D, Bertoni AG, Blumenthal RS, Philippides G, Rocchini A. Exercise Training for Type 2 Diabetes Mellitus – Impact on Cardiovascular Risk. AHA Scientific Statement. Circulation.

Marwick TH, Leano RL, Brown J, Sun JP, Hoffmann R, Lysyansky P, Becker M, Thomas JD. 2008. Myocardial strain measurement using two-dimensional speckle tracking echocardiography: definition of normal range. J Am Coll Cardiol – Cardiovascular Imaging.

Marwick TH, Venkatesh B et al. Use of a nurse led intervention to optimize beta blockade for reducing cardiac events after major non-cardiac surgery In press American Heart Journal

Marwick TH. Ischaemic mitral regurgitation: mechanisms and diagnosis. Heart.

Marwick TH. The deconvolution of diastole. J Am Coll Cardiol.

Marwick TH. The future of echocardiography. Eur J Echo.

Marwick TH. Straining the guidelines with dyssynchrony imaging. J Am Soc Echo.

Matelebe M, Mundy J, Shah P: Cardiac Tumours in Adults: Case series and

review of literature. Under review in Heart Lung and Circulation.

McDonald SP, Marshall MR, Johnson DW, Polkinghorne K. Relationship of dialysis modality with mortality. Journal of the American Society of Nephrology.

McKinnon R, Christie D, Peres H, Bourke M, Le T, Lah M. The Prone Technique for Breast Irradiation – is it ready for clinical trials? The Breast.

Mooney O, Doig E, Fleming J. Risk assessment and management for providers of community-based rehabilitation to people with acquired brain injury: Health professionals’ perspectives. Disability and Rehabilitation.

Morgan TJ, Vellaichamy M, Venkatesh B et al. The acid-base effects of colloid haemodilution – an in vitro investigation. In press Anaesthesia and Intensive care

Ng CS, Pillans P, Johnson DW, Sturtevant J. Diuretic, non-steroidal antiinflammatory drug (NSAID), cyclooxygenase-2 inhibitor (COX-2 inhibitor), angiotensin converting enzyme inhibitor (ACE-I), angiotensin receptor antagonist (ARA) related acute renal failure. Journal of Pharmacy Practice Research.

O’Shea S, Duffull S, Johnson DW. Aminoglycosides in hemodialysis patients: is the current practice of post-dialysis dosing appropriate? Seminars in Dialysis.

O’Connor E, Walsham J. Indications for Thoracolumbar Imaging in Blunt Trauma Patients: A Review of Current Literature. Emergency Medicine Australasia

Ong B, Bergin P, Hefferan T, Stuckey S. Transient seizure related MRI abnormalities. Journal of Neuroimagimg.

Panchabhai TS, Dangayach NS, Krishnan A, Kothari VM, Karnad DR. Effect of oropharyngeal cleansing with 0.2% chlorhexidine in critically ill patients:an open-label randomized trial with 0.01% potassium permanganate as control. Chest.

Percy CJ, Pat B, Healy H, Johnson DW, Gobe G. Phosphorylation of caveolin-1


is anti-apoptotic and promotes cell attachment during oxidative stress of kidney cells. Journal of Pathology.

Percy CJ, Brown L, Power D, Johnson DW, Gobe GC. p66Shc and AMPK as markers of age-associated chronic renal pathologies linked to hypertension and obesity. Mechanisms of Aging and Development.

Percy CJ, Brown L, Power DA, Johnson DW, Gobe GC. Obesity and hypertension have differing oxidant handling molecular pathways in age-related chronic kidney disease. Mechanisms of Ageing and Development.

Peters P, Butler N, Mundy J, Shah P: Non Hodgkin’s lymphoma presenting as a isolated soft tissue chest wall mass. Case report under review in Annals of thoracic surgery.

Pizzichetta MA, Canzonieri V, Massone C, Soyer HP. Clinical and dermoscopic features of porokeratosis of Mibelli. Archives of Dermatology, 145(1): 91-2.

Pryor D, Porceddu S, Gumisnski A, Thomson D, Sheperdson K, Poulsen MG. Enhanced toxicity with cetuximab and radiation in head and neck cancer- the Queensland Experience. Radiotherapy and Oncology.

Purcell A, Fleming J, Haines T, Bennett S. In press. Cancer-related fatigue: A review and a conceptual model to guide therapist understanding. British Journal of Occupational Therapy

Rajandram R, Pat BK, Li J, Johnson DW, Gobe GC. Expression of apoptotic tumour necrosis factor receptor-associated factor, caspase recruitment domain and cell death-inducing DFF-45 effector genes in therapy-treated renal cell carcinoma.. Nephrology.

Johnson DW, Clark C, Isbel NM, Hawley CM, Beller E, Cass A, de Zoysa J, McTaggart S, Playford G, Rosser B, Thompson C, Snelling P; HONEYPOT Study Group. The honeypot study protocol: randomised, controlled trial of exit site application of Medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients. Peritoneal Dialysis International.

Rate A, Upham JW, Bosco A, McKenna KL, Holt PG. Airway epithelial cells regulate the functional phenotype of locally differentiating dendritic cells: implications for the pathogenesis of infectious and allergic airway disease. J Immunology.

Rumpsfeld M, McDonald SP, Johnson DW. Peitoneal small solute clearance is non-linearly related to patient survival in the Australian and New Zealand peritoneal dialysis patient populations. Peritoneal Dialysis International.

Salm P, Taylor PJ, Roberts D, Dawson A. Liquid chromatography-tandem mass spectrometry method for the simultaneous quantitative determination of the organophosphate pesticides dimethoate, fenthion, diazinon and chlorpyrifos in human blood. J Chrom B.

Scott IA. Evaluating the usefulness of ancillary tests in predicting cardiovascular risk in asymptomatic persons. British Medical Journal.

Scott IA. Non-inferiority trials – determining when alternative treatments are good enough. Medical Journal of Australia.

Scott IA. What are the most effective strategies for improving quality and safety of healthcare? Internal Medicine Journal

Scott IA. Errors in clinical reasoning: causes and remedial strategies. British Medical Journal.

Senior R, Monaghan M, Main ML, Zamorano JL, Tiemann K, Agati L, Weissman NJ, Klein AL, Marwick TH et al. Detection of coronary artery disease with perfusion stress echocardiography using a novel ultrasound imaging agent: two Phase 3 international trials in comparison with radionuclide perfusion imaging. Eur J Echo 2009;10:26-35

Serginson JG, Yang I, Armstrong JG, Cooper DM, Matthiesson AM, Morrison SC, Gair J, Cooper B, Zimmerman PV Variability in the rate of of prescription and cost of domiciliary oxygen therapy in australia Med J Aust .

Sharman JE, Stowasser M. 2009. Australian Association for Exercise and Sports Science position statement on exercise and hypertension. J Sci Med Sport.

Shenfine J, Barbour AP, Wong D, Thomas J, Martin I, Gotley DC, SmithersBM. Quantitative fluro-deoxyglucose positron emission tomography values predict prognosis in respectable adenocarcinoma of the oesophagus treated by surgery alone. Dis Esophagus.

Singh MP, Armstrong J, Murphy MA, Coucher J, Ong B. Is this really pneumothorax? Thorax.

Smith E, DeYoung NJ, PAvey SJ, Hayward NK, Nancarrow DJ, Whiteman DC, Smithers BM, Rieszkewicz AR, Clouston AD, Gotley DC, Devitt PG, Jameison GG, Drewe PA. Similarity of abberant DNA methylation in Barrett’s oesophagus and oesophageal adenocarcinoma. Molecular Cancer 2008;7:75.

Staermose S, Marwick TH, Gordon RD, Cowley D, Dowling A, Stowasser M. 2009. Elevated serum interleukin 6 levels in normotensive individuals with familial hyperalodsteronism type 1. Hypertension.

Tan KS, Johnson DW. Managing the cardiovascular complications of renal disease. Australian Prescriber

Taylor PJ, Cooper DP, Gordon R, Stowasser M. Measurement of aldosterone in human plasma by semi-automated high performance liquid chromatography-tandem mass spectrometry. Clin Chem

Thompson B, Austin R, Coory M, Walpole E, Francis G, Fritschi L. ‘Histopathology reporting of breast cancer in Queensland: The impact on the quality of reporting as a result of the introduction of recommendations’ Pathology.

Timpson NJ, Tobias JH, Richards JB, Soranzo N, Duncan EL, Sims AM, et al. Common variants in the region around Osterix are associated with bone mineral density and growth in childhood. Hum Mol Genet.

Turner B, Fleming J, Cornwell P, Haines T, Ownsworth T. Outcomes during the


transition from hospital to home for individuals with ABI and their family caregivers. Brain Injury.

Turner B, Ownsworth T, Cornwell P, Fleming J. Re-engagement in meaningful occupations during the transition from hospital to home for individuals with acquired brain injury and their family caregivers. American Journal of Occupational Therapy.

Turner B, Cornwell P, Haines T, Ownsworth T, Fleming J. Profiling early outcomes during the transition from hospital to home after brain injury. Brain Injury.

Turner B, Ownsworth T, Cornwell P, Fleming J. A prospective longitudinal study of re-engagement in meaningful occupations during the transition from hospital to home for individuals with acquired brain injury. American Journal of Occupational Therapy.

Venkatesh B, Kennedy P, Kruger P, et al. Changes in serum PCT following antimicrobial therapy as a guide to antibiotic duration in the critically ill: A prospective evaluation. In press Anaesthesia and Intensive care

Venkatesh B, Kennedy P, Kruger P, Looke D, Jones M, Ray Burrell G. The utility of serial concentrations

of serum procalcitonin and CRP as a guide to the duration of of antimicrobial therapy in the critically ill: A prospective evaluation. Anaesthesia and Intensive Care.

Wadsworth B, Haines T, Cornwell P, Paratz J. Abdominal Binder use in people with Spinal Cord Injuries: A Systematic Review. Spinal Cord.

Wadsworth BM, Haines TP, Cornwell PL, Paratz JD. Abdominal binder use in people with spinal cord injuries: a systematic review and meta-analysis. Spinal Cord advance online publication.

Walters D, Connor JP, Feeney GFX, Young RMcD. The Cost Effectiveness of Naltrexone added to Cognitive-Behavioural Therapy (CBT) in the Treatment of Alcohol Dependence. Journal of Addictive Diseases.

Welsh A, Kruger P, Faogali J. Antimicrobial action of statins.Pathology.

Wenke R, Theodoros D, Cornwell, P. The short and long term effectiveness of the LSVT® on hypernasality in non-progressive dysarthria. International Journal of Language and Communication Disorders.

Wiggins KJ, Strippoli GFM, Craig JC, Johnson DW. Biocompatible dialysis fluids for peritoneal dialysis. (Cochrane Review Protocl). In: The Cochrane Library. Chichester, UK, John Wiley & Sons, Ltd.

Wojcikowski K, Wohlmuth H, Johnson DW, Rolfe M, Gobe G. An in vitro investigation of herbs traditionally used for kidney and urinary system disorders: Potential therapeutic and toxic effects. Nephrology.

Yerkovich ST, Roponen M, Smith ME, McKenna K, Bosco A, Subrata LS, Mamessier E, Wikström ME, Le Souef P, Sly PD, Holt PG, Upham JW. Allergen-enhanced thrombomodulin (blood dendritic cell antigen 3, CD141) expression on dendritic cells is associated with a Th2-skewed immune response. J Allergy Clin Immunology.

Yerkovich ST, Upham JW. “Reply: Thrombomodulin expression on multiple DC subsets: an emerging story in allergic asthma” J Allergy Clin Immunology.


Major Grants

ARC/ARC Discovery

$245,000 Micronanoprojection patches for minimally invasive and targeted delivery of genes and drugs to skin cells: from concept to technology platform (Kendall MA, Roberts MS)

$107,692 Designing robust reactive scheduling system for emergency medical services (Kozan E, Collier J, Sinnott M)

$88,000 Function and regulation of the Schlafen gene family: Novel regulators of blood cell proliferation and function (Gonda, T)

$88,000 The function of truncated MEK1 in a G2 phase cell cycle delay an in mitosis (Gabrielli, B)

$86,000 Topical peptide delivery for cosmetic and therapeutic benefits (Roberts MS, Anissimov YG, Govindarajan R, Loy CJ)

$74,230 Relationship between melanosome distribution and skin colour (Roberts MS, Zvyagin AV, Anissimov YG, Govindarajan R, Loy CJ)

$51,871 Determinants of successful community transition for individuals with acquired brain injury and their families (Fleming J, Worrall L, Cornwell P, Haines T, Ownsworth T, Kendall M, Chenoweth L)

NHMRC Grants

$640,000 Immunological therapies for cancer and autoimmunity (Frazer I, Thomas, R)

$509,700 A trial of aspirin and fish oil for the prevention of thrombosis in dialysis access (Irish A, Dogra G, Hawley C, Beller E, Polkinghorne K, Kerr P, Cass A, Mori T)

$438,750 Retroviral Expression Cloning using an Arrayed Full-Length cDNA Gene Set –ARVEC. (Gonda T, Gabrielli B)

$413,450 Australian Genomewide Association study in Osteoporosis (Brown, M)

$400,000 CCRE in Cardiovascular and Metabolic Diseases (Marwick T, Prins J, Macdonald G, Isbel N, Hegney D, Stowasser)

$351,000 Predicting the risk of invasive candidiasis in critically ill patients (Sorrell TC, Lipman J, Playford EG, Jones M, Iredell JR, Paterson D, Marriott D)

$258,000 Australian Kidney Trials Network (Hawley C, Beller E, Hoy W, Johnson D, Cass A, Craig J, McDonald S, Perkovic V, Chadban S, Kerr P, Dogra S, Wang Z, McTaggart S, Nicol D, Pilmore H, Polkinghorne K, Becker G)

$245,000 NHMRC Health Research Partnership in Type 2 diabetes (Prins, J)

$239,813 Targeted delivery by topical application National Institute of Complementary Medicine Collaborative Centre for Transitional Preclinical and Clinical Research in Nutraceutics and Herbal Medicine (Vitetta L, Komesaroff P, James D, Linnane A, Roberts MS, Day R, Tiralongo E)

$226,625 Interaction between PTH and Y2 bone anabolic pathways (Gardiner, E)

$218,000 Antibiotic dosing in the ‘at risk’ critically ill patient (Lipman,J; Robers, M; Paterson, D; Kirkpatrick, C; Kruger, P; Roberts, J)

Funds received in 2008, over $50,000 per grant


$200,000 GEFOS - Genetic Factors for Osteoporosis (Brown, M)

$198,450 Transition Care: Innovation and Evidence (Cameron I, Crotty M, Gray L.)

$190,000 Can the needs of caregivers of patients with advanced cancer be improved by using a GP Caregiver Needs Toolkit? (Mitchell G, Poulsen M, Walpole E))

$185,888 Randomised controlled trial of multi-media patient education approaches to preventing in-hospital falls (Haines T, Hill K, McKenna K)

$174,500 Non-viral vectors for targeted delivery of RNAi nucleotides to cervical cancers (McMillan, N)

$172,500 Role of obesity in impaired treatment response in chronic hepatitis C: mechanisms and therapeutic strategies (Powell E, Jonsson J, Clouston A, Ward S)

$170,500 CDK4 activity in S/G2 phases influences mitotic fidelity (Gabrielli, B)

$169,000 Hepatocyte replicative arrest, hepatic progenitor cells and the ductular reaction in hepatic fibrogenesis (Jonsson J, Clouston A, Powell E, Olynyk J, Knight B)

$167,336 Pharmacokinetics and liver vascularity (Roberts MS, Hung D, Crawford D A)

$159,250 Identification and characterisation of the way erythropoietin protects tissue from oxidant stress (Johnson DW, Gobe GC, Colditz P)

$155,250 The role of mycophenolate mofetil therapeutic drug monitoring in renal transplant recipients (Staatz CE, Johnson DW, Tett S, Taylor P, Lynch S)

$155,250 Improved patient outcomes through dosage individualisation of the newer immunosuppressant drugs (Staatz CE, Tett SE, Taylor PJ, Johnson DW, Lynch SV.)

$154,250 IMPDH and lipid accumulation (Whitehead, J)

$154,250 Adiponectin multimerisation, secretion and action (Whitehead J, Macdonald G, Prins J)

$152,125 Identification of clinically significant subtypes of head and neck cancer cells (Saunders, N)

$140,875 FGF-1 in human adipgenesis (Hutley, L)

$130,250 Research Fellowship (Brown, M)

$123,122 Study of HPV 6L1 virus like particles as therapeutic vaccine for genital warts and recurrent respiratory papillomatosis. (Frazer, I)

$113,500 Obesity-related inflammation and insulin resistance in chronic liver disease. Exercise and diet as treatment options (Hickman, I)

$110,000 Improved quantification of spatial and temporal changes in plasma and tissue drug levels and tissue pathology (Roberts M et al)

$109,150 Validation of Cognitive Assessment using Telecommunication (Gray L, Flicker L, Wootton R, Poh-Kooi L, et al)

$107,500 NHMRC Research Fellowship (Whitehead, J)

$107,250 Mechanisms of tolerance in memory T cells (Steptoe, R)

$103,500 NHMRC Research Fellowship (Gabrielli, B)

$102,500 Mechanisms of dendritic cell-induced T-cell tolerance (Steptoe, R)

$102,250 Tolerance induction by antigen-presenting cell-targeted antigen (Steptoe, R)

$100,000 Sun Exposure, Vitamin D and the outcomes of Prostate Cancer (Armstrong B, Nelson, C, Smith D, Steginga S, Kricker A, Kimlin M, Clements M)

$97,500 The role of post translationally modified antigen in rheumatoid arthritis (Capini, C)

$93,500 Investigation into the alternative splicing of steroid hormone regulated genes in breast cancer (Dowhan, D)

$80,850 Practitioner Fellowship (Upham J)

$76,842 Mechanisms regulating cell cycle progression in response to UV radiation (Lee, W)

$75,000 IDEAL Trial (Pollock CA, Vesey DA, Gobe G, Endre Z)

$69,750 Identification and function analysis of novel post-translational modifications of CDC25B (Boutros, R)

$68,500 The role of RelB in atopic asthma (Street, S)

$67,250 Sensitise cervical cancer cells to shRNA-medicated gene silence (Gu W)

$66,000 Type 2 Diabetes and chronic liver disease: An emerging relationship between co-morbid diseases of obesity (Hickman, I)

$56,625 Practitioner Fellowship (Powell E)


Cancer Council Queensland

$600,000 Novel nanoparticle-based biosensor technology for multiplexed detection of methylation profiles in breast cancer metastases NBCF/Cancer Council, (Trau M, Brown M. AI: Francis G.) Collaborative

$400,000 QCF Collaborative Research Grant funds Cancer Collaborative Group. (Gill D, Beller E, Burmeister B, Frazer I, Gotley D, Saunders N, Thomson D)

$80,000 Histone Deacetylase Inhibitors can inhibit tumour growth via induction of an anti-tumour immune response (Gabrielli B; Leggatt G)

$80,000 Is the heterochromatin checkpoint a useful anti-cancer drug target? (Gabrielli B)

$80,000 RNA Interference to Boost Immune Responses against Cancer (McMillan N)

$80,000 The role of MYB oncogene in mammary carcinogenesis (Gonda T)

$80,000 Codon modifications redirect expression of HPV16 E7 oncogene and human oncosuppressor genes (p53 & Rb) in keratinocytes (Zhao K-N)

$80,000 Assessment of topically treated non melanoma skin cancers by sequential optical biopsies using multiphoton microscopy (Roberts M)

$78,000 Development of models to study human papillomavirus and its involvement in non-melanoma skin cancer (Antonsson, A)

$78,000 Clinical measures of obesity and risk of Barrett’s oesophagus (Macdonald GA, Whiteman DC, Kendall BJ

$100,000 Chronic respiratory diseases (Upham J)

$50,000 Arthritis complicating inflammatory bowel disease-Prevalence and genetic predictors (Brown, M)

$50,000 Do human papillomaviruses participate in breast cancer genesis (Saunders, N)

$50,000 A randomised trial of intravenous versus oral iron supplements for post-transplant anaemia in renal transplant recipients (Mudge DW, Johnson DW, Tan K, Hawley CM, Campbell SB, Isbel N)

$50,000 Management of patients with malnutrition (Ferguson M, Day S, O’Neill M. Vivanti A)

$50,000 Investigation of an epidemiologically proven cluster of breast cancer cases (Bennett I, Brown M, Chenevix-Trench G, Francis G, Gonda T, Lakhani S, McMillan N, Newman B, Saunders N)

$50,000 Identification of biomarkers for indolent vs aggressive prostate cancer (Nelson, C)

$50,000 Obesity-related inflammation and insulin resistance in chronic liver disease (Macdonald GA, Hickman IJ, Prins JB, O’Moore-Sullivan T)

$600,000 A pilot study of the value of multidisciplinary chronic kidney disease clinics (Isbel NM, Johnson DW)

$230,000 Smart State Clinical Research (Upham J)

$174,250 Cofactors in Liver Disease (Crawford D, Fletcher L, Bridle K)

$110,000 A randomised controlled trial of exit site application of Medihoney for the prevention of catheter-associated infection in peritoneal dialysis patients (Hawley C, Johnson DW, Beller E, De Zoysa, Playford EG, Cass A).

$160,800 A randomised controlled trial of exit site application of Medihoney (TM) for the prevention of catheter associated infections in peritoneal dialysis patients (Hawley C)

$100,000 QLD Government New Initiatives Fund (Powell E)

$88,818 Developing an electronic ACAP module to supplement comprehensive geriatric assessment in acute care (Gray, L.)

$87,000 Report for QH (Bartlett H, Gray L, Hegney D)

$60,000 Evaluation of low-low beds to prevent in-hospital falls (Haines T, Bell R, Varghese P)

Queensland Government and Queensland Health

PA Foundation and Private Practice Fund


Other Grants and Funding

$5,000,000 Novel Strategies for Prediction and Control of Advanced Breast Cancer via Nanoscaled Epigenetic-Based Biosensors. NBC. (Trau M, Forbes J, Clark S, Francis G, Brown M, Dobrovic A, Scott R.)

$3,200,000 Comprehensive Cancer genomics Facility. Australian Cancer Research Foundation. (Gonda T, Brown M, Nelson C, Frazer I, Saunders N. AI: Gabrielli S, Grimmond S, McMillan N, Clements J, Leo P, Francis G, Roe .)

$2,960,000 Smart State Innovation Building Fund (Francis G, Nelson C, Gonda T, Beadle G, Marlton P.)

$2,000,000 Smart State NIRAP Prostate Collaboration (Nelson C, Clements J, Nicol D, Collaborator, Francis G )

$634,953 Confocal microscopy. University of Queensland (Gabrielli, B)

$550,000 Innovation Skills Fund Smart State Premier’s Fellowship 2005-06 QLDGOV (Frazer, I)

$500,000 PO1-A Genome wide Association Study of Ankylosing Spondylitis Susceptibility (National Institute of Arthritis and Musculoskeletal Skin Diseases (USA and Uni Texas). NIHUSA (Brown, M)

$438,000 Evidence Based Practice in Residential Aged Care – Falls Prevention. Department of Health & Ageing (Hill K, Black K, Haines T)

$318,223 HONEYPOT (A randomised controlled trial evaluation of antibacterial Honey verses Nasal Eradication of staphylococci for the prevention of Tenckhoff infections in PD) Sponsored by Baxter Extramural Grant (Johnson D, Isbel N)

$263,669 Innovations in Clinical Education for Physiotherapy Students. ARC – Linkage / Physiotherapists Registration Board of Queensland (Jull G, Peterson R, O’Connor V)

$220,723 Interleukin 1 and tolerance in type 1 diabetes. Juvenile Diabetes Research Foundation (International) (Thomas, R)

$210,756 PV-10 Clinical Trial. Sponsored by Provectus Commercials (Smithers BM)

$179,200 Are hospitals providing quality care for people with dementia? Sponsored by JO and JR Wicking Trust (Gray L, Byrne G, Jones R, Martin-Khan M, et al.)

$178,600 The HONEYPOT Trial Sponsored by Baxter Extramural Grant (Johnson, DW Clark C, Isbel NM)

$168,500 Professorial Chair - Sponsored by Arthritis Queensland (Thomas, R)

$166,582 Respiratory rehabilitation or self management for Chronic Obstructive Pulmonary Disease: What is the best management approach? Sponsored by MBF Foundation (Vicenzino B, Chang A, Haines T)

$165,000 Developing E2F inhibitors as a potential therapeutic strategy for the treatment of head and neck squamous cell carcinoma. Garnett Passe and Rodney Williams Memorial Foundation (Saunders, N)

$156,289 Induction of tolerance in memory diabetogenic T cells. Juvenile Diabetes Research Foundation (Steptoe, R)

$150,000 Liposomal formulation as a cell free therapy to treat Rheumatoid Arthritis in an antigen specific manner QLDGOV + ARTHFA (Capini, C)

$145,000 Application of a human bone engineering platform to an in vivo prostate cancer model. Prostate Cancer Foundation of Australia (Hutmacher, DW, Clements, J, Nelson, C, Nicol, D)

$143,286 Phenotypic/Genotypic profiling in Breast Cancer. Study Education and Research Trust Fund (Francis GD)

$126,031 Study of HPV 6L1 virus like particles as therapeutic vaccine for genital warts and recurrent respiratory papillomatosis. Wellcome Trust. (Frazer, I)

$101,818 A randomised placebo-controlled trial of Oxpentifylline (Trental) in erythropoitin-resistant anaemia (ERA) in chronic disease kidney disease. Sponsored by Amgen (Johnson D, Hawley C, Cass A)

$100,000 The role of human papillomaviruses in the development of prostrate cancer. PCFA (Antonsson, A)

$100,000 New therapies for bone and joint disease through identification of novel disease causing genes. Queensland & Northern NSW Lions Medical Research Foundation (Thomas,G)

$100,000 Fellowship. Sasakawa Foundation, Royal Children’s Hospital (Jonsson J)


$100,000 The HERO trial. Roche Foundation for Anemia Research (RoFAR) (Johnson DW, Hawley CM, Beller E)

$100,000 The HERO trial. Amgen (Johnson, DW. Hawley, CM. Beller E)

$94,027 Purchase of Tissue Microarrayer. Golden Casket Foundation (Francis GD)

$89,732 Anti-viral immunity in asthma Asthma Foundation of Queensland (J Upham, S Yerkovich)

$85,500 UQPO1 Department of Health & Ageing (Lie, D.)

$81,000 Fellowship University of Queensland (Ward S)

$77,907 A randomised placebo-controlled trial of Oxpentifylline (Trental) in erythropoitin-resistant anaemia (ERA) in chronic disease kidney disease. Roche Anemia Foundation Grant (Johnson D, Hawley C, Cass A)

$74,000 Postdoctoral Research Fellowship University of Queensland (Kherrouche Z)

$72,300 Prediction of lymph node status in breast cancer. Study Education and Research Trust Fund. (Francis GD)

$70,391 Postdoctoral Research Fellowship. University of Queensland (Danoy, P)

$70,000 Identifying the molecular basis for osteosarcoma metastasis. WESLEY (Saunders, N)

$70,000 Slide Path Distiller software. Study Education and Research Trust Fund, (Francis GD)

$60,000 Developing sustainable community-based rehabilitation approaches for Aboriginal and Torres Strait Islander Queenslanders with Acquired Brain Injury: identifying and strengthening resources with two remote Aboriginal communities. Health Practitioners Research Scheme: Princess Alexandra Hospital. (Gauld S, Smith S, Kendall M.)

$60,000 Study on Changes in Stress and Strain in the Left Atrium and Cardiac Neurohormonal Function Post Ablation for Paroxysmal Atrial Fibrillation. Sylvia and Charles Viertel (Doneva S, Marwick T, Gould, PA)

$60,000 The HONEYPOT Trial. Baxter CEC funding (Johnson, DW. Hawley, CM. Beller E)

$60,000 Improved quantification of spatial and temporal changes in plasma and tissue drug levels and tissue pathology. University of Queensland Major Equipment and Infrastructure Grant.

$57,744 Elucidating genetic mechanisms responsible for familial hyperaldosteronism type II. US Endocrine Society (Stowasser, M; O’Shaughnessy, K; Gordon, R)

$56,509 Determinants of successful community transition for individuals with acquired brain injury and their families. ARC – Linkage / QH (Fleming J, Worrall L, Cornwall P, Haines T)

$52,000 In Vivo Examination Of Neoplastic And Inflammatory Skin Diseases by Reflectance Confocal Microscopy. Epiderm (Soyer, HP)

$50,000 Targeting liver macrophages to prevent diabetes. Queensland Government (O’Sullivan, B)

$50,000 Investigation into the functional role of novel AdipoR interacting proteins. Diabetes Australia Research Trust (Whitehead, J)

$50,000 The role of FOXO transcription factors in Glucocorticoid-induced insulin resistance. Diabetes Australia Research Trust (Barry, J)

$50,000 The Australasian Kidney Trials (AKT) Network. University of Queensland. (Johnson DW, Hawley CM, Beller E, Hoy W)

$50,000 University Of Queensland (Barbour A)


Committees

Allied Health Research Committee

Dr Jennifer Lethlean, Chair; Speech Pathologist

Delena Amsters, Spinal Outreach Team

Annette Broome, Psychology

David Brown-Rothwell, Audiology

Julie Connell, Executive Director, Clinical Support Services

Judith Coombes, Pharmacy

Dr Petrea Cornwell, Conjoint Research Position in Speech Pathology PAH/UQ

Sue Cumming, Director, Social Work

Kirsty Davidson, Radiation Therapy

Dr Maree Ferguson, Director, Nutrition and Dietetics

Dr Jenny Fleming, Conjoint Research Position in Occupational Therapy PAH/UQ

Sue Foss, Prosthetics & Orthotics

Melissa Kendall, Transitional Rehabilitation Program & Acquired Brain Injury Outreach Service

Steve McPhail, Researcher, Physiotherapy

Kiley Pershouse, Spinal Outreach Team

Angela Vivanti, Research & Development Dietician

Cancer Collaborative Group

Associate Professor Devinder Gill, Chair; Director, Clinical Haematology

Elaine Beller, Director, Queensland Clinical Trials Centre (Biostatistics)

Maree Ferguson, Director, Nutrition and Dietetics

Professor Ian Frazer, Director, Diamantina Institute for Cancer, Immunology & Metabolic Medicine

Areti Gavrilidis, Director, Research Development and Ethics, Centres for Health Research

Professor John Prins, Chair, Centres for Health Research

Associate Professor Nicholas Saunders, Diamantina Institute for Cancer, Immunology & Metabolic Medicine

Associate Professor Mark Smithers, Director, Upper Gastro-Intestinal & Soft Tissue Unit

Associate Professor Damien Thomson, Director, Medical Oncology

Alexandra McCarthy, Senior Research Fellow, SAHSCCN; Senior Lecturer, QUT

Dr Peter Mollee, Haematologist

Dr Terry Haines, Conjoint Research Fellow

Associate Professor Sandro Porceddu, Radiation Oncology


Dr Jennifer Fleming, Chair

Jan Maxwell, Lay Woman (Until May)

Bev Ryan, Lay Woman (From June)

Colin Sutcliff, Lay Man

Denzil Scrivens, Lay Man

Dr John North, Surgeon

Dr Robert Zubershaw, Medical Practitioner

Dr Richard Roylance, Physician

Dr Daniel Varghese, Research

Dr Karam Kostner, Physician & Researcher

Rev Father Bernard Thomas, Minister of Religion

John Bennett, Lawyer

Associate Professor Carl Kirkpatrick, Pharmacist

Dr Eleanor Milligan, Ethicist

PA Foundation

Board of Directors

Michael T Wille OAM, Chairman, Chair Executive Committee and Company Director

William Deutrom OAM, Deputy Chairman, Chair, Marketing Committee and Company Director

Richard Bowly, Queensland Hotels Association

Dr Richard Ashby, Executive Director of Medical Services, PAH

Gareth Evans, Retired Newspaper Executive

Professor Ian Frazer, Director, Diamantina Institute for Cancer, Immunology & Metabolic Medicine

Andrew Griffiths, Company Director

Lenore Guthrie, Former CEO

Linda Lavarch MP, State Member for Kurwongbah

Professor John Prins, Chair, Research Committee; Chair, Centres for Health Research

Professor David Theile (Snr) AO, Clinical CEO, PAH

Heather Tyrrell, Company Secretary; Manager, Governance, PAH

Michael Back, Honorary Solicitor

Phillip Sciacca, Honorary Accountant

Research Committee

Professor John Prins, Chairman

Professor Leanne Aitken

Professor Thomas Marwick


Associate Professor Mark Smithers

Human Research Ethics Committee

The Committee is constituted in accordance with the National Statement on Ethical Conduct in Human Research (2007), section 5.1.29-5.1.33


Research Staff by Department

Academic Unit in Geriatric Medicine

Professor Len Gray, Director

Professor Steven Counsell, Visiting Geriatrician, Illinois, USA

Dr Salih Salih, Lecturer and Geriatrician

Dr Alison Cutler, Senior Geriatric Registrar

Dr Catherine Travers, Research Fellow

Dr Olivia Wright, Research Officer

Sue Austin, Project Officer

Nadine Krueger, Research Assistant

Rochelle Vincent, Research Assistant

Catherine Beverly, Research Nurse

Bonnie Pimm, Research Nurse

Vivian Cheung, PhD student

Prabha Lakhan, PhD student

Melinda Martin-Khan, PhD student

Acquired Brain Injury Outreach Service

Raymund Quinn, Manager

Melissa Kendall, Research and Development Officer

Jessica Staskiewicz, Research Assistant

Areti Kennedy, Project Officer, Pathways Home

Diane Clarke, Project Officer, Pathways Home

Elissa Morriss, Rehabilitation Co-ordinator

Judy Roser, Rehabilitation Co-ordinator

Susan Gauld, Rehabilitation Co-ordinator

Gina Black, Rehabilitation Co-ordinator

Clarissa Wilson, Rehabilitation Co-ordinator

Claire Schirrman, Rehabilitation Co-ordinator

Sharon Smith, Rehabilitation Co-ordinator

Ann Lancaster, Rehabilitation Co-ordinator

Suzanne Wright, Rehabilitation Co-ordinator

Marie Hollingworth, Rehabilitation Co-ordinator

Alcohol and Drug Assessment

Dr Gerald Feeney, Medical Director

Sr Annie McPherson, Nurse Unit manager

Jane Tucker, Social Worker

Professor Ross Young, Visiting Senior Clinical Psychologist

Associate Professor Jason Connor, Visiting Senior Clinical Psychologist


Audiology

Evelyn Towers, Director

David Brown-Rothwell, Audiologist

Megan Haynes, Audiologist

Tracey Ross, Audiologist

Jillian Sellars, Audiologist

Katie Stapleton, Audiologist

Julie-Anne Ross, Senior Occupational Therapist

Dale Fogarty, Neuropsychologist

Julie Worner, Acting Nursing Unit Manager

Cardiology

Dr Paul Garrahy, Directory

Professor Tom Marwick, Professor of Medicine, University of Queensland

Dr John Hill, Director of Cardiac Pacing and Electrophysiology

Dr Gerald Kaye, Staff Cardiologist

Dr Richard Lim, Staff Cardiologist

Dr Sudhir Wahi, Staff Cardiologist

Dr Dariusz Korczyk, Staff Cardiologist

Dr Paul Gould, Staff Cardiologist

Dr William Wang, Staff Cardiologist

Cindy Hall RN, Manager Clinical Research Co-ordinator

Ruth Calvert RN, Clinical Nurse - Clinical Trials

Clare O’Neill RN, Clinical Nurse - Clinical Trials

Desiree Gifford EN, Enrolled Nurse - Clinical Trials

Dr Robert Fathi, Visiting Cardiology Interventionalist

Dr Stephen Cox, Visiting Cardiology Interventionalist

Dr Jeffrey Franco, Visiting Cardiology Interventionalist

Dr Daljeet Gill, Visiting Cardiology Interventionalist

Dr Bennett Franjic, Visiting Consultant Cardiologist

Dr Harry Gibbs, Visiting Cardiovascular Consultant

Dr Johannes Moolman, Visiting Consultant Cardiologist


Associate Professor Julie Mundy

Paul Peters, Senior Lecturer

Pallav Shah, Senior Lecturer

Annabel Wood, Research Nurse

Rayleene Griffin, Research Administrative Assistant

Cardiovascular Imaging Group

Professor Tom Marwick, Director

Associate Professor Karam Kostner, Leader – Lipid Research group

Dr Sudhir Wahi, Leader – Valve Research

Dr Matt Hordern, Post-Doctoral Fellow

Dr Bruno Jesuthasan, Post-Doctoral Fellow

Dr Sandhir Prasad, Post-Doctoral Fellow

Brain Injury Rehabilitation

Dr Ron A Hazelton, Medical Director

Dr W Chan, Senior Specialist

Paula Addis, Senior Speech Pathologist

Janelle Gesch, Senior Physiotherapist


Dr Chai-Keat See, Post-Doctoral Fellow

Dr James Sharman, Post-Doctoral Fellow

Dr Tony Stanton, Post-Doctoral Fellow

Brian Haluska, Senior Research Officer, Sonographer

Rodel Leano, Research Officer, Sonographer

Carly Jenkins, Research Officer, Sonographer

Leanne Jeffriess, Research Officer, Sonographer

Joseph Brown, Research Assistant / Database Supervisor

Ryan Thwaites, Database Manager

Helen Branagan, Research Nurse

Melody Downey, Research Nurse

Jill Duncan, Research Nurse

Deborah Gilroy, Research Nurse

Julie Holliday, Research Nurse

Azette Rafei, Research Nurse


Associate Professor Peter Pillans

Paul Taylor, Senior Scientist

Michael Franklin, Scientist

Dr Christine Staatz, Research Fellow

Lucy Goodman, Research Assistant

Dermatology

Professor H. Peter Soyer, Chair and Professor of Dermatology

Associate Professor Stephen Gilmore, Associate Professor of Dermatology

Dr Graham Stephenson, Senior Lecturer

Nicole Lin, Personal Assistant to Professor Soyer

Terri Campbell, Research Assistant

Dr Cathy Xu, Senior Research Fellow

Dr Kate De Ambrosis, Clinical Research Assistant

Dr Philip Singh, Clinical Research Assistant

Dr Corinne Yoong, Clinical Research Assistant

Diabetes and Endocrinology

Dr Anthony Russell, Director

Dr Ross Cuneo, Endocrinologist (Part Time)

Dr Emma L Duncan, Endocrinologist (Part Time)

Dr Emily Mackenzie, Endocrinologist (Part Time)

Professor David McIntyre, Endocrinologist (Part Time)

Dr Trisha O’Moore-Sullivan, Endocrinologist (Part Time)

Professor John Prins, Professor of Endocrinology; Chair, Centres for Health Research

Dr Clair Sullivan, Endocrinologist (Part Time)

Dr Margaret Williamson, Senior Visiting Endocrinologist

Dr Michelle Leong, Endocrinologist (Visiting Consultant)

Dr Brian Hirschfeld, Diabetologist (Visiting Consultant)

Dr Alan Stocks Emeritus, Physician (Visiting Consultant)

Dr Merryn Thomae, Advanced Endocrine Trainee

Dr Amanda Love, Advanced Endocrine Trainee

Dr Judy Hadwen, Chief Medical Registrar

Dr Janelle Nisbet, Research Fellow, PhD Student

Dr Cynthia Ong, Research Fellow, PhD Student

Dr Liza Phillips, Research Fellow, PhD Student

Stephanie Ipavec Levasseur, PhD Student

Sally Skuthorpe, Nurse Unit Manager

Denise Bennetts, Diabetic Educator

Roisine Warwick, Diabetic Educator


Dr Bevan Lowe, Locum Staff Specialist

Dr James Collier, Staff Specialist

Dr Andrew Staib, Staff Specialist

Dr Iain McNeill, Staff Specialist

Dr Tina Stathakis, Staff Specialist

Dr Darren Powrie, Staff Specialist

Dr Hector Fuentes, Staff Specialist

Dr Sean Lawrence, Staff Specialist

Dr Ellen Burkett, Staff Specialist

Julie Finucane, Nurse Unit Manager, Adj Senior Lecturer UQ, Executive Director College of Emergency Nursing Australasia

Collette Owens, Nurse Manager

Jan Gehrke, Clinical Nurse Consultant

Nicole Mitchell, Clinical Nurse Consultant

Cathy Davis, Acting Clinical Nurse Consultant (Chair Research Portfolio - Nursing)

Trina Cambourne, Acting Nurse Educator

Dr Roy Mulcahy

Dr Marianne Cannon

Dr Andrew Parkin

Dr John Isoardi

Dr Peter McSweeney

Dale Mason, Acting CNC, Trauma Registry (Part-Time)

Kerri Holzhauser, Nurse Researcher

Eleanor Hammond (Rose), Acting Nurse Researcher

Nicola Melton, Research Officer

Therese Murphy, Scientific Research Staff

Amy Sobbe, Scientific Research Staff

Dr Lara Kane, Senior Gastrology Registrar / Clinical Hepatology Fellow

Dr Dinesh Jothimani, Fellow in Hepatology and Medical Education

Dr Griff Walker, Interventional Endoscopy Fellow

Dr Paul Clark, Advanced Trainee

Dr Caroline Tallis, Advanced Trainee

Fiona Giddens, Clinical Trials

Alison Cunnington, Clinical Trials

Leigh Horsfall, Clinical Trials

Cathy Moss, Clinical Trials

Sid Siddle, Clinical Trials

Leanne Foxcroft, Nurse Unit Manager Endoscopy Unit

Jo Sexton, Hepatitis C Shared Care Co-Ordinator

Eshter Drommel, Queensland Bowel Cancer Screning Program

Gastroenterology and Hepatology

Associate Professor Graeme Macdonald, Director

Dr Luke Hourigan, Clinical Director Endoscopy

Dr Leisa Barrett, Consultant Physician

Professor Darrell Crawford, Consultant Physician

Dr James Daveson, Consultant Physician

Dr Bradley Kendall, Consultant Physician

Dr Elizabeth Powell, Consultant Physician

Dr Rebecca Ryan, Consultant Physician

Dr Katherine Stuart, Consultant Physician

Dr Peter Whiting, Consultant Physician

Dr Linda Fletcher, Senior Scientist

Dr Kim Bridle, Scientific Research Staff

Dr Mandy Heritage, Scientific Research Staff

Dr Ingrid Hickman, Scientific Research Staff

Lesley Jaskowski, Scientific Research Staff

Dianne Jones, Scientific Research Staff

Geraldine Lipka, Scientific Research Staff


Hypertension

Associate Professor Michael Stowasser, Director, Hypertension Unit; Co-director, Endocrine Hypertension Research Centre and Associate Professor, University of Queensland School of Medicine

Diane Cowley, Hypertension Nurse

Christine Ossenberg, Hypertension Nurse

Dr Norlela Sukor, PhD Student

Paul Taylor, PhD Student

Dr Ashraf Ahmed, PhD Student

Dr Sandie Staermose, Hypertension Registrar / Clinical Research Fellow

Yvette Jeske, Research Assistant

Alison Dowling, Research Assistant

Corwin Willys - MBBS Hons Student, Research Assistant

Emeritus Professor Richard Gordon, Honorary Research Consultant, Endocrine Hypertension Research Centre, University of Queensland School of Medicine, Greenslopes and Princess Alexandra Hospitals

Dianne Robson, Hypertension Nurse, Hypertension Unit, Greenslopes Private Hospital

Cynthia Kogovsek, Hypertension Nurse, Hypertension Unit, Greenslopes Private Hospital

Kylie Selwood, Acting Nurse Unit Manager, Ward 5D

Belinda Henderson, CNC – Infection Control

Catherine Watson, CNC – Infection Control

Rebecca Adams, CNC – Infection Control

Peter Gallagher, Nurse Unit Manager, Alternate Site Infusion Service

Dee Archbold, Nurse Unit Manager, Sexual Health

Dr Margaret Lindsay, Scientific Co-ordinator, Infection Control

David McDougall, Pharmacist, ASIS

Barbara Johnson, Quality Co-ordinator, Infection Management Services

Sean Unwin, Pharmacist, Infection Management Services

Intensive Care

Associate Professor Chris Joyce, Director

Dr Peter Kruger, Deputy Director

Professor Bala Venkatesh, Director of Research

Professor Leanne Aitken, Chair Critical Care Nursing

Dr David Cook, Senior Staff Specialist

Dr David Fraenkel, Senior Staff Specialist

Dr Anand Krishnan, Staff Specialist

Dr Ros Purcell, Staff Specialist

Dr Leo Nunnink, Staff Specialist

Dr James Walsham, Staff Specialist

Dr Gordon Laurie, Staff Specialist

Dr Wayne Kelly, Visiting Medical Officer

Infection Management Services

Dr Michael Whitby, Director

Dr David Looke, Consultant

Dr Wendy Munckhof, Consultant

Dr Geoffrey Playford, Consultant

Dr Kate McCarthy, Consultant

Dr Brian Dwyer, Consultant

Dr Jennifer Broom, Visiting Medical Officer

Dr David Jardine, Senior Medical Officer, Sexual Health

Dr Cheryn Palmer, Senior Medical Officer, Sexual Health

Dr Tony Morton, Consultant Statistician

Dr Keat Choong, Advanced Trainee

Dr Trent Yarwood, Advanced Trainee


Dr David Sturgess, Research Fellow, Intensive Care

Samantha Clayton, Nurse Unit Manager

Jennifer Robertson, Acting Nurse Unit Manager

Michael Abbey, Clinical Nurse Consultant

Sharon Wetzig, Clinical Nurse Consultant

Danielle Griffiths, Acting Clinical Nurse Consultant

Fiona Jennings, Acting Clinical Nurse Consultant

Alison Juers, Nurse Educator

Cheryl Buschel, Nurse Educator

Jane-Louise Cook, Nurse Educator

Associate Professor Ian Scott, Director

Dr Golam Khadem, Senior Medical Officer

Dr Graham Hall, Senior Visiting Medical Officer

Dr Su Mien Yeoh, Visiting Medical Officer

Dr Catherine Yelland, Senior Staff Specialist, GARU

Associate Professor Peter Pillans, Director, Clinical Pharmacology

Liver Research

Associate Professor Elizabeth Powell, Head

Associate Professor Julie Jonsson, Head

Associate Professor Andrew Clouston, Senior Staff

Dr Scott Ward, Senior Staff

Helen Barrie, Research Staff

Karli McSweeney, Research Staff

Luani Barge, Research Staff

Dr Dinesh Jothimani, Research Staff

Leigh Horsfall, Research Staff

Cathy Moss, Research Staff

Medical Oncology

Associate Professor Damien Thomson, Director

Associate Professor Euan Walpole, Senior Medical Oncologist, Director of Cancer Services, Metro South

Dr Natasha Woodward, Medical Oncologist

Dr Alex Guminski, Medical Oncologist

Dr Elizabeth McCaffrey, Medical Oncologist

Dr Warren Joubert, Medical Oncologist

Dr Victoria Atkinson, Medical Oncologist

Dr Keith Horwood, Senior Medical Oncologist, Visiting Medical Officer

Dr Maree Colosimo, Senior Medical Oncologist, Visiting Medical Officer

Adam Stoneley, Research Unit Co-ordinator

Susan Arnold, Research Nurse

Mary Ashmead, Research Nurse

Paul Baxter, Research Nurse

Sharon Cox, Data Manager

Internal Medicine and Clinical Epidemiology

Leanne Jack, Clinical Nurse Researcher

Regina Boyce, Clinical Nurse Researcher

Meg Harward, Research Coordinator

Anne Hughes, Research Coordinator

Jean Helyar, Research Assistant

Liz Burmeister, Research Assistant

Jennie Abbey, Research Assistant

Professor Wendy Chaboyer, Visiting Scholar, Griffith University

Dr Marion Mitchell, Visiting Scholar, Griffith University


Nancy D’Arcy, Data Manager

Nicky Gill, Data Manager

Tanya Graham, Research Nurse

Steven Ivanhoe, Data Manager

Louise Knop, Data Manager

Josephine Logan, Data Manager

Janelle Meakin, Data Manager

Leah Peut, Research Nurse

Jenny Suffolk, Research Nurse

Kim Wright, Data Manager

Nephrology

Professor David Johnson, Director of Nephrology, Chair of Medicine, Professor of Medicine, Professor of Population Health, Head of the Centre for Kidney Disease Research

Dr Scott Campbell, Deputy Director of Nephrology

Associate Professor Carmel Hawley, Consultant Nephrologist, Chair of the Australasian Kidney Trials Network Operations Secretariat

Associate Professor Nicole Isbel, Consultant Nephrologist, Co-Chair of the Cardiovascular, Metabolic and Renal Centre of Clinical Research Excellence

Associate Professor David Mudge, Consultant Nephrologist

Dr Carolyn van Eps, Consultant nephrologist

Dr David Vesey, Senior Research Scientist, Renal Research Laboratory

Dr Jeremy Frazier, Chief Renal Registrar

Dr Katherine Barraclough, Chief Renal Registrar

Dr Rhianna Miles, Renal Registrar

Dr Sridevi Govindarajulu, Renal Registrar

Dr Brian Siva, Renal Registrar

Dr Omar Kaisar, Renal Research Fellow

Dr Will Petchey, Renal Research Fellow

Dr Carolyn Clark, Renal Research Fellow

Alison Martin, Nurse Unit Manager, Renal Clinical Research Unit

Joanna Sudak, Research Nurse

Kirsten Franzen, Research Nurse

Kylie Hurst, Data Manager, Renal and Renal Transplant Unit

Rachel Pidcock, Research Nurse

Diana Leary, Research Nurse

Venita Bali, Research Nurse

Suzanne Halbish, Clinical Nurse

Natasha Old, Research Nurse

Jennifer Edmunds, Research Nurse

Karen Sonnenburg, Research Nurse

Linda Orazio, Dietician

Bettina Douglas, Research Nurse, Dialysis & Transplantation Nurse Practitioner, Adjunct Senior Lecturer, School of Nursing and Midwifery, University of Queensland

Dr John Burke, Visiting Consultant Nephrologist

Dr James Petrie, Visiting Consultant Nephrologist

Dr Troy Kay, Visiting Consultant Nephrologist

Dr Steven McTaggart, Visiting Consultant Nephrologist

Dr Omar Kaisar, Visiting Consultant Nephrologist

Dr Robyn Caterson, Visiting Consultant Nephrologist

Dr James Swao, Visiting Consultant Nephrologist

Dr Jenny Wong, Visiting Consultant Nephrologist


Dr Sarah Winch, Nursing Director, Research

Kerri Holzhauser, Acting Nursing Director, Research

Dr Amanda Henderson, Nursing Director, Education

Eleanor Milligan, Clinical Ethics Co-ordinator


Ramon Shaban, Joint Research Fellow Infection Control

Eleanor Hammond, Nurse Researcher

Gillian Ray-Barruel, Nurse Researcher

Vikki Tomlinson, Nurse Researcher

Jean Hellyar, Nurse Researcher

Emma Eaton, Nurse Educator

Alison Trivella, Nurse Educator

Michelle Twentyman, Nurse Educator

Tim Michaux, Executive Support Officer

Elaine Bull, Executive Support Officer

Nutrition and Dietetics

Dr Maree Ferguson, Director

Dr Angela Vivanti, Research and Development Dietitian

Dr Winsome Abbott, Senior Advanced Level Dietitian

Azmat Ali, Acting Team Leader

Wendy Davidson, Acting Team Leader

Helen Porteous, Acting Team Leader

Nora Ramos, Foodservice Dietitian

Linda Orazio, Dietitian Nutritionist, Research Staff


Mary Whitehead, Director, Occupational Therapy Department

Ruth Cox, Acting Director, Occupational Therapy Department

Geoff Lau, Acting Director, Occupational Therapy Department

Dr Jenny Fleming, Conjoint Senior Research Fellow, UQ and PAH

Suzanne Stirling, Evidence-Based Practice Champion

Jodie Carolan, Evidence-Based Practice Champion

Nicole Weir, Rehabilitation

Janelle Griffin, Rehabilitation

Kylie Bower, Rehabilitation

Julie-Anne Ross, Rehabilitation

Glenda Price, Spinal Injuries Unit

Mary Little, Hands and Plastics

Amanda Purcell, Cancer Services

Nicole Coffey, Cardiology

Cecile Prescott, Acute services

Penny Whitelaw, Researcher

Annette Fisher, Researcher

Adrienne Slaughter, Researcher

Angela Boyce, Researcher

Laura Worley, Researcher

Ann Maree Collier, Researcher

Emily Nalder, Researcher

Emmah Doig, Researcher

Ben Turner, Researcher

Hannah Gill, Researcher

Celeste Glasgow, Researcher

Ea Stewart, Researcher


Dr David Lie, Director

Carolyn Coombes, Team Leader

Janet Meadows, Nursing Unit Manager

Rebecca Parker, Policy Officer

Susan Austin, Node Manager



Dr Glenn Francis, Head of Molecular and Clinical Pathology Research Laboratory

Sandra Stein, Research Assistant

Sarah Wagner, Research Assistant

Amy Chiang, Research Scientist

Helen McCosker, Student

Kathryn Salkield, Student

Pharmacy Department

Lynette Loy, Director

Lee Allam, Assistant Director

Frank Czajkowski, Assistant Director

Bryson Swan, Assistant Director

Robyn Hurley, Clinical Trials Pharmacist

Tina Patterson, DUE Pharmacist

Julia Bates, Senior Pharmacist Sterile Production Centre

Janet Weir, Oncology / Haematology Unit

David Wojewoda, Oncology / Haematology Unit

Vivien Chan, Oncology / Haematology Unit

Trang Le, Oncology / Haematology Unit

Judith Coombes, Senior Pharmacists Education, Conjoint Lecturer School of Pharmacy, University of Queensland

Karl Winckel, Senior Pharmacists Education, Conjoint Lecturer School of Pharmacy, University of Queensland

Jo Sturtevant, Senior Clinical Pharmacist Renal and Transplant

Cathy Lynch, Senior Clinical Pharmacist

Libby Donegan, Senior Clinical Pharmacist

Sean Unwin, Senior Pharmacist Infectious Diseases

Physiotherapy

Kathy Grudzinskas, Director

Cherie Hearn, Assistant Director

Suzanne Kuys, Research Fellow

Urszula Dolecka, Senior Physiotherapist - Acute Aged Care and Cancer Services

Janelle Gesch, Senior Physiotherapist - Neurosciences

Tony Cassar, Senior Physiotherapist - Critical Care

Sharon Chatterton, Senior Physiotherapist - Cardiac Sciences and Respiratory

Josh Simmons, Senior Physiotherapist – Acting Spinal Injuries

Brett Baxter, Senior Physiotherapist - Musculoskeletal Inpatients

Peter Tonks, Senior Physiotherapist - Musculoskeletal Outpatients

Louise Matthews, Senior Physiotherapist - Specialised Spinal Physiotherapy Clinics and Multidisciplinary Service

Greg Morrison, Senior Physiotherapist - Geriatric Assessment and Rehabilitation

Queensland Clinical Trials Centre - Biostatistics

Elaine Beller, Director

Dr Melissa Starfield, Manager

Charles Thompson, Junior Statistician

Dr Conrad Leonard, Data Manager

Mohana Rajmokan, Data Manager

Jan Alexander, Data Manager


Donna Reidlinger, Administration Assistant

Alicia Smith, Study Co-ordinator

Peta-Anne Paul-Brent, Study Co-ordinator

Fiona Rogers, Study Co-ordinator

Queensland Melanoma

Associate Professor B Mark Smithers, General Surgeon, Senior Lecturer The University of Queensland Department of Surgery, Chairman Queensland Melanoma Project Princess Alexandra Hospital, Chairman Upper GI and Soft Tissue Unit Princess Alexandra Hospital

Dr Stan Jones, General Surgeon

Dr Andrew Barbour, General Surgeon, Senior Lecturer The University of Queensland Department of Surgery, Specialist Surgeon Upper GI and Soft Tissue Unit Princess Alexandra Hospital.

Dr Gerard Bayley, Plastic and Reconstructive Surgeon, Visiting Medical Officer Plastic and Reconstructive Surgery Unit Princess Alexandra Hospital

Dr Christopher Allan, General Surgeon, The University of Queensland Department of Surgery, Visiting Medical Office Melanoma Unit Princess Alexandra Hospital.

Janine Thomas, Clinical Trials Co-ordinator

Ben Shea, Research Nurse

Sharan Burton, Research Nurse

Queensland Spinal Cord Injuries Service

Dr Tim Geraghty, Director Queensland Spinal Cord Injuries Service, Rehabilitation Physician

Dr Susan Urquhart, Senior Medical Officer, Rehabilitation Medicine

Dr Wilbur Chan, Part-Time Staff Specialist, Rehabilitation Physician

Alison New, Nurse Unit Manager

Tricia Fronek, Senior Social Worker

Josh Simmons, Senior Physiotherapist

Glenda Price, Senior Occupational Therapist

Karleigh Kwapil, Clinical Neuropsychologist

Rachael Jones, Clinical Nurse Consultant

Brooke Wadsworth, Physiotherapist

Spinal Outreach Team

Kiley Pershouse, Programme Manager

Delena Amsters, Research Officer

Sarita Schuurs, Research Officer

Dr Ruth Barker, Honorary Associate

Dr Pim Kuipers, Honorary Associate

Transitional Rehabilitation Program

Greg Ungerer, Manager

Melissa Kendall, Research and Development Officer

Michelle Myburg, Occupational therapist

Sue Booth, Social Worker

Jennifer Campbell, Physiotherapist

Melissa Wallace, Occupational Therapist

Jodie Harper, Clinical Nurse

Radiation Oncology Centre (Mater)

Associate Professor Michael Poulsen, Director

Dr Guy Bryant, Oncologist

Associate Professor Jonathan Ramsay, Radiation Oncologist

Dr Kumar Gogna, Radiation Oncologist


Dr Jennifer Harvey, Radiation Oncologist

Dr Judy Cox

Dr Tanya Holt, Registrar

Dr Andrew Pullar

Dr Tiffany Daly, Medical Officer

Dr Helen Peres, Radiation Oncologist

Dr Matthew Foote, Registrar

Dr Pat Dwyer, Registrar

Dr Nicolle Buddle, Medical Officer

Dr Caroline Round

Simon McQuitty, Director - Radiation Therapy Services

Timothy Deegan, Radiation Therapist

Adrian Gibbs, Principal Physicist

Pauline Rose, Nurse Unit Manager

Sally Whiting, Registered Nurse

Jennifer Donoghue, Registered Nurse

Kacy Baumann, Clinical Trials Co-ordinator

Adrienne See, Clinical Trials Co-ordinator

Narelle Wallace, Clinical Trials QA Co-ordinator

Radiation Oncology Centre (PAH)

Professor Bryan Burmeister, Director of Radiation Oncology

Dr Andrew Pullar, Radiation Oncologist

Dr Jennifer Harvey, Radiation Oncologist

Dr Margot Lehman, Radiation Oncologist

Associate Professor Sandro Porceddu, Radiation Oncologist

Dr Tao Mai, Radiation Oncologist

Jennie Baxter, Director of Radiation Therapy

Alan Glyde, Lead Research Radiation Therapist

Elizabeth Brown, Lead Research Radiation Therapist

Heath Foley, Lead Research Radiation Therapist

Helen O’Gorman, Lead Research Radiation Therapist

Janet Ferrari, Lead Research Radiation Therapist

Jenny Tran, Lead Research Radiation Therapist

Kirsty Davidson, Lead Research Radiation Therapist

Kylie Van Den Bosch, Lead Research Radiation Therapist

Melissa Scott, Lead Research Radiation Therapist

Michelle Mauro, Lead Research Radiation Therapist

Natalie Barnes, Lead Research Radiation Therapist

Shona Barry, Lead Research Radiation Therapist

Simon Brown, Lead Research Radiation Therapist

Thanh Bui, Lead Research Radiation Therapist

Susan Golding, Radiation Oncology Nurse

Amanda Purcell, Occupational Therapist

Jenny Fleming, Occupational Therapist

Adam Stoneley, Research Unit Co-ordinator

Janelle Meakin, Research Co-ordinator

Jen Suffolk, Research Co-ordinator

Josephine Logan, Research Co-ordinator

Kim Wright, Research Co-ordinator

Mary Ashmead, Research Co-ordinator

Nancy D’Arcy, Research Co-ordinator

Respiratory and Sleep Medicine

Professor John Upham, Head

Dr Stephanie Yerkovich, Senior Scientist

Dr Janet Davies, Senior Scientist

Alisa Poh, Research Staff


Melanie Hunt, Research Staff

Darren Kirkegard, Research Staff

Hongzhuo Li, Research Staff

Michelle Towers, Clinical Research

Dr Daniel Smith, Clinical Research

Dr John Armstrong, Clinical Research

Dr Craig Hukins, Clinical Research

Social Work

Sue Cumming, Director

Margo Newman, Aged Care

Patricia Fronek, Rehabilitation and Disability

Sherryl Searles, Cancer, Oncology and Cardiac

Angela Tonge, Trauma and Critical Care

Patricia Harrower, Aged Care

Associate Professor Cheryl Tilse, Director Postgraduate Research Studies, School of Social Work and Human Services, The University of Queensland

Dr Margaret Shapiro (retired), School of Social Work and Human Services, The University of Queensland

Speech Pathology

Wendy McCallum, Director Speech Pathology

Dr Petrea Cornwell, Research Fellow, Speech Pathology – The University of Queensland / PAH

Kathy Clark, Senior Speech Pathologist, GARU

Kelli Hancock, Senior Speech Pathologist, Acute, and Advanced Clinician

Bena Riddle, Acting Senior Speech Pathologist, Acute

Paula Addis, Advanced Clinician, Rehabilitation

Dr Jenny Lethlean - Advanced Clinician, Stroke and Senior Lecturer

Kelly Beak (nee Read), Speech Pathologist

Brooke Duggan, Speech Pathologist

Carly Freebairn, Speech Pathologist

Joanna Rhee, Speech Pathologist

Leanne Smith, Speech Pathologist

Kerrin Watter, Speech Pathologist


Professor Mike Roberts, Director

Dr Jeff Grice, Group Leader & Research Officer

Dr Tom Robertson, Group Leader & Research Officer

Dr Washington Sanchez, Research Officer

Dr Owen Jepps, Research Officer

Dr Xin Liu, Research Officer

Dr Yuri Dancik, Research Officer

Jenny Ordonez, Research Assistant

Dr Yuhong Zou, Research Officer

Dr PengTjun Choy, Group Leader & Research Officer

Dr Greg Medley, Research Officer

Camilla Thorling, Research Assistant

Dr Andrew Dalley, Research Officer

Dr Julijana Nikolovski, Research Officer

Dr Lingling Ren, Research Assistant

Genevieve Staines, Executive Support Officer

Ya-Ting Wu, Research Student

Dr Kanchana Ranasinghe, Research Student

Dr Peter Kruger, Research Student

Sukhpreet Kaur, Research Student


Peng Li, Research Student

Dr Ken Newton, Research Student

John Chapman, Research Student

Damon Judges, Research Student

Upper Gastro-Intestinal

Associate Professor B Mark Smithers, General Surgeon, Senior Lecturer The University of Queensland Department of Surgery, Chairman Queensland Melanoma Project Princess Alexandra Hospital, Chairman Upper GI and Soft Tissue Unit Princess Alexandra Hospital

Professor David Gotley, General Surgeon, Professor The University of Queensland Department of Surgery, Specialist Surgeon Upper GI and Soft Tissue Unit Princess Alexandra Hospital.

Dr Ian Martin, General Surgeon, Visiting Medical Officer Upper GI and Soft Tissue Unit Princess Alexandra Hospital.

Dr Andrew Barbour, General Surgeon, Senior Lecturer The University of Queensland Department of Surgery, Specialist Surgeon Upper GI and Soft Tissue Unit Princess Alexandra Hospital.

Dr Justin Greenslade, General Surgeon, Visiting Medical Officer Upper GI and Soft Tissue Unit Princess Alexandra Hospital

Dr Cuong Duong, Senior Fellow

Dr Iain Thomson, Research Fellow

Emma Woodhall (PhD), Scientist

Janine Thomas, Clinical Trials Co-ordinator


Postgraduate Students

PhD Completions

Abbott, Winsome

De Kluyver, Rachel

Fanning, Kent

Haluska, Brian

Hannawi, Dr Suad

Hordern, Matt

Jenkins, Carly

Lang, Carolyn

Marshall, Andrea

Narayan, Sharmal

Neumann, Brent

Newell, Felicity

Pegum, Nell

Richardson, Michelle

Rumpsfeld, Markus

Su, Hua

van Eps, Dr Carolyn

Walsh, Meagan

Wenke, Rachel

PhD Commencements

Ahmed, Ashraf

Bower, Kylie

Brooks, Kelly

Davidson, Stuart

Gannon, Orla

Iain, Thomson

Kaur, Sukhpreet

Nalder, Emily

Oakes, Vanessa

Pattabiraman, Diwakar

Petchey, Will

Pyne, John

Rahayu, Mustaffa Kamal

Rollo, Megan

PhD in Progress

Abd Warif, Nor Malia

Astuti, Puji

Bennett, Nigel

Brancato, Tania

Broom, Jennifer

Calleja, Pauline

Cameron, Sarina

Chan, Dora

Chapman, John

Charlton, Hayley

Cheung, Vivian

Clark, Carolyn

Cohen, Dr Jeremy

Davidson, Stuart

Dissanayka, Nadeeka

Doig, Emmah

Drabsch, Yvette

Fronek, Patricia

Gill, Hannah

Glasgow, Celeste

Hare, Dr James

Harrison, Matthew

Holland, David

Ipavec Levasseur, Stephanie

Irving, Aaron

Jack, Leanne

Jellis, Dr Christine

Kaisar, Dr Omar

Kanagarajah, Ash

Kendall, Melissa


Khairuddin, Norliana

Kruger, Peter

Kuys, Suzanne

Lakhan, Prabha

Li, Jun

Li, Pengchen

Martin-Khan, Melinda

Massey, Debbie

McErlean, Michael

McNally, Alice

McPhail, Steven

Morais, Christudas

Neilson, Gail

Newton, Ken

Ngo, Sherry

Nguyen, Thien

Nisbet, Janelle

O’Moore-Sullivan, Dr Trisha

Ong, Cynthia

Percy, Christine

Phillips, Liza

Pike, Tanya

Poth, Kim

Purcell, Amanda

Rahimpour, Azad

Ranasinghe, Dr Kanchana

Rate, Angela

Riddle, Bena

Rose, Pauline

Sacre, Julian

Smith, Ian

Smith, Louise

Statham, Dixie

Stephenson, Matthew

Sturgess, Dr David

Sukor, Norlela

Sweet, Allison

Symons, Martyn

Taylor, Paul

Thomas, Elaine

Thorberg, Fred

Turner, Benjamin

Warrener, Robyn

Wigan, Matthew

Wocjikowski, Ken

Worton, Leah

Wu, Michelle (Ya-Ting)

Wu, Sherry

Yamada, Miko

Zhe, Yang

Zhou, Fang

Masters Completions

Brown, Elizabeth

Cable, Prue

Colless, Melanie

Giles, Nichole

Hopley, Shane

Lamprecht, Brock

Mills, Karen

Orazio, Linda

Page, Colin

Staskiewicz, Jessica

Stone, Cassandra

Usriansyah

Chang, Tina

Chih-Ling, Lin

Daveson, James

Gordon, Lisa

Jeffries, Janine

Mauro, Michelle

Oliver, Veronica

Overlack, Regan

Rahathungoda, Nimai

Schreiweis, Nadia

Stewart, Ea

Cannon, Dr Marianne

Chen, Yueh

Eugarde, Ellen

Franjic, Dr Bennett

Masters Commencements

Masters In Progress

Becker, Jillian

Best, Jennifer


Hamilton, Melissa

Ingham, Karen

Jenkins, Kelly

Kendall, Bradley

McErlean, Deanne

McPherson, Stuart

Mitchell, Nicole

Nguyen, Thien

O’Gorman, Helen

Peters, Robyn

Robinson, Rosemary

Saxon, Robyn

See, Adrienne

Swan, Bryson

Taurima, Karen

Wadsworth, Brooke

Weir, Janet

Other

Bryce, Vivian (Graduate Diploma in Cardiac Nursing)

Fiorenza, Salvatore Padget, Michelle (Graduate Certificate in Health Management)

Contact Us

Mailing Address: Princess Alexandra Hospital Centres for Health Research 2nd Floor, Building 35 Ipswich Rd Woolloongabba QLD 4102

Phone: +61 7 3240 7663

Fax: +61 7 3240 7667

E-mail: [email protected]

Web: www.health.qld.gov.au/pahospital/research/default.asp


health • care • people

annual research report 2008 - princess alexandra hospital...4 centres for health research annual...

Documents